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Summary
Methicillin-resistant Staphylococcus aureus is a leading cause o f hospital infections 
world-wide. Consecutive S. aureus wound isolates (n=561) were collected from PHW 
Microbiology ABM Laboratory, Swansea (PHW-ABM); 137 (24.4%) were mecA- 
positive; 424 (75.6%) were mecA-negative using real-time PCR. Audit revealed that 15 
(10.9%) mecA-positive strains were not reported as MRSA. Genotyping was performed 
using pulsed-field gel electrophoresis (PFGE), spa typing and SCCmec typing. MRSA 
predominantly belonged to EMRSA-15 (89.1%) and EMRSA-16 (5.8%) clones. All S. 
aureus strains were included in an evaluation of three SCCmec-orfX  PCR assays. The 
assays had high diagnostic sensitivity (>95%) and specificity (>94%) but false negative 
and false positive results were obtained. A deletion at the SCCmec-orjX  right junction 
was proposed as the probable cause of false negative results. SCCmec-associated loci 
ccrABl, ccrAB4, ccrC, and dcs were detected in four false positive MSS A, respectively. 
MALDI Biotyper mass spectrometry was evaluated for identification of S. aureus.
Nineteen (3.4%) o f the PHW-ABM wound isolates were Panton Valentine-Leukocidin 
(PVL)-positive S. aureus. The molecular epidemiology o f these and PVL-positive S. 
aureus (n=61) from Specialist Antimicrobial Chemotherapy Unit, Cardiff (SACU) was 
investigated using mecA and arginine catabolic mobile element PCRs, PFGE, spa and 
SCCmec typing. The PHW-ABM strains were predominantly MSSA belonging to the 
CC159 (n=5; 26.3%), CC275 (n=4; 21.1%) and CC005 (n=2; 10.5%) ^a-B U R P 
clusters, affiliated to the ST121, ST30 and ST22 lineages. Within the SACU cohort the 
USA300 clone (n=16; 26.2%) was predominant, other genotypes included: t044- 
MRSA-IVc (n=5; 8.2%); t002-MRSA-IVc (n=3; 4.9%) and tl27-MRSA-IVa (n=2; 
3.3%), affiliated to the European (ST80), USA800 (ST5) and USA400 (ST1) clones. 
Susceptibility testing demonstrated statistically significant differences between the 
SACU and PHW-ABM cohorts for oxacillin 57%/5%, gentamicin 2%/16%, and 
tetracycline 10%/42% resistance (p<0.05). These observed differences highlight the 
importance o f including unselected strains in addition to referred reference laboratory 
isolates in epidemiological investigations.
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Chapter One: Introduction
1.1 Staphylococci
The Staphylococcus genus comprises bacteria that are Gram-positive cocci (0.5 to 1.5 
pm in diameter) which occur singly, in pairs, tetrads, short chains of three to four cells 
and grape-like clusters (Bannerman and Peacock, 2007, Gotz et al., 2006). They are 
non-motile, non-spore forming, usually catalase positive and are typically 
unencapsulated or have limited capsule formation under laboratory conditions 
(Bannerman and Peacock, 2007, Gotz et al., 2006). Until the early 1970’s the 
Staphylococcus genus comprised three species: the coagulase-positive species S. aureus 
and coagulase-negative species S. epidermidis and S. saprophyticus but currently 44 
species and 24 subspecies have been described (http://www.bacterio.cict.fr/) (see Table 
1.1). The members o f the Staphylococcus genus are facultative anaerobes except for S. 
saccharolyticus and S. aureus subsp. anaerobius, which initially grow anaerobically but 
may become increasingly aerotolerant on subculture (Bannerman and Peacock, 2007, 
Gotz et al., 2006).
The genomes o f several Staphylococcus species have been published, particularly S. 
aureus strains and some coagulase-negative staphylococci including S. epidermidis, S. 
saprophyticus, S. haemolyticus, S. camosus and others (see Table 1.2). Currently there 
are 21 published complete genomes o f S. aureus strains, twenty S. aureus genome 
sequencing projects are in progress and 48 are in draft assembly 
(http://www.ncbi.nlm.nih.gov/genomepij/). The genome of S. aureus has a guanine- 
plus-cytosine (G+C) content of approximately 30 to 39% (Bannerman and Peacock, 
2007, Gotz et al., 2006). These comprise a single chromosome which is approximately
2.5 Mb and carry 2,400 to 2,500 coding sequences (Bannerman and Peacock, 2007, 
Gotz et al., 2006). The Micrococcus and Macrococcus genera are also Gram-positive 
cocci and were initially regarded as staphylococci however these genera are 
distinguished from staphylococci by their G+C content and certain phenotypic 
characteristics. The Micrococcus genus comprises bacteria which are Gram-positive 
cocci (0.7 to 1.8 pm in diameter) occurring in clusters, tetrads or pairs and they are 
obligate aerobes (Bannerman and Peacock, 2007). Both the staphylococci and 
micrococci may reside on mucosal surfaces and may be present in clinical and 
veterinary specimens however, micrococci are less prevalent and are largely regarded as 
saprophytic contaminants (Bannerman and Peacock, 2007).
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Table 1.1. Staphylococcus species and subspecies (http://www.bacterio.cict.fr/)
No. Staphylococcus species and subspecies
1. S. arlettae
2. S. aureus
S. aureus subsp. anaerobiu s; S. aureus subsp. aureus
3. S. auricularis
4. S. capitis
S. capitis subsp. capitis; S. capitis subsp. urealyticus
5. S. caprae
6. S. camosus
S. camosus subsp. camosus; S. camosus subsp. utilis
7. S. caseolyticus
8. S. chromogenes
9. S. cohnii
S. cohnii subsp. cohnii; S. cohnii subsp. urealyticus
10. S. condimenti
11. S. delphini
12. S. epidermidis
13. S. equorum
S. equorum subsp. equorum; S. equorum subsp. linens
14. S. felis
15. S. fleurettii
16. S. gallinarum
17. S. haemolyticus
18. S. hominis
S. hominis subsp. hominis; S. hominis subsp. novobiosepticus
19. S. hyicus
S. hyicus subsp. chromogenes; S. hyicus subsp. hyicus
20. S. intermedius
21. S. kloosii
22. S. lentus
23. S. lugdunensis
24. S. lutrae
25. S. massiliensis
26. S. microti
27. S. muscae
28. S. nepalensis
29. S. pasteuri
30. S. pettenkoferi
31. S. piscifermentans
32. S. pseudintermedius
33. S. pulvereri
34. S. rostri
35. S. saccharolyticus
36. S. saprophyticus
S. saprophyticus subsp. bovis; S. saprophyticus subsp. saprophyticus
37. S. schleiferi
S. schleiferi subsp. coagulans; S. schleiferi subsp. schleiferi
38. S. sciuri
S. sciuri subsp. camaticus; S. sciuri subsp. lentus; S. sciuri subsp. rodentium; S. sciuri subsp. sciuri
39. S. simiae
40. S. simulans
41. S. succinus
S. succinus subsp. casei; S. succinus subsp. succinus
42. S. vitulinus
43. S. wam eri
44. S. xylosus
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Table 1.2. Completely sequenced S. aureus genomes (http://www.ncbi.nlm.nih.gov/genomeprj/)
No. Strains Accession no. Reference
1. S. aureus 04-02981 CP001844 (Nubel et al., 2010)
2. S. aureus ED98 NC 013450 (Lowder et al., 2009)
3. S. aureus RF122 AJ938182 (Herron-Olson et al., 2007)
4. S. aureus COL CP000046 (Gill et al., 2005)
5. S. aureus ED 133 CP001996 (Guinane et al., 2010)
6. S. aureus JH1 CP000736 (Mwangi et al., 2007)
7. S. aureus JH9 CP000703 (Mwangi et al., 2007)
8. S. aureus JKD6159 CP002114 (Chua et al., 2010)
9. S. aureus MRSA252 BX571856 (Holden et al., 2004)
10 S. aureus MSSA476 BX571857 (Holden et al., 2004)
11. S. aureus MW2 BA000033 (Baba et al., 2002)
12. S. aureus Mu3 AP009324 (Neoh et al., 2008)
13. S. aureus Mu50 BA000017 (Kuroda et al., 2001)
14. S. aureus N315 BA000018 (Kuroda et al., 2001)
15. S. aureus NCTC 8325 CP000253 (Gillaspy et al., 2006)
16. S. aureus ST398 S0385 AM990992 (Schijffelen et al., 2010)
17. S. aureus TW20 FN433596 (Holden etal., 2010)
18. S. aureus US A3 00 FPR3757 CP000255 (Diep et al., 2006)
19. S. aureus US A3 00 TCH1516 NC 010079 (Highlander et al., 2007)
20. S. aureus JKD6008 CP002120 Stinear, T. P., Seemann, T. & Howden, B. P*
21. S. aureus Newman AP009351 (Baba et al., 2008)
* ST239 S. aureus strain associated with intermediate level vancomycin resistance (unpublished) (http://www.ncbi.nlm.nih.gov/)
Micrococcus luteus is the most common micrococcal species found in nature 
(Bannerman and Peacock, 2007). Furthermore they have a higher G+C genome content, 
66 to 75% versus 30 to 39% in staphylococci and they are oxidase positive whereas 
staphylococci are oxidase negative, with the exception of S. lentis, S. sciuri, S. vitulus, 
S.fleurettii (Bannerman and Peacock, 2007, Gotz et al., 2006). Macrococci are marginal 
facultative anaerobes and they grow optimally under aerobic conditions. Members of 
this genus include Macrococcus bovicus, Macrococcus caseolyticus, Macrococcus 
carouselicus and Macrococcus equipercicus. They have a smaller genome size (1.5 to
1.8 Mb) than staphylococci but have a higher G+C genome content (38 to 45%) and a 
larger cell size diameter (1.3 to 2.5 pm) (Bannerman and Peacock, 2007, Kwok and 
Chow, 2003, Kloos et al., 1998). They can also be distinguished from staphylococci by 
virtue o f being oxidase positive (Bannerman and Peacock, 2007, Kwok and Chow,
2003). The clinical significance o f macrococci is yet to be established and these bacteria 
are largely associated with aquatic animals and some hoofed animals (Bannerman and 
Peacock, 2007).
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1.2 Natural habitats of staphylococci
Staphylococcus species are widespread in nature and represent a major group of the 
bacteria inhabiting the skin and mucous membranes o f mammalian and avian hosts 
(Bannerman and Peacock, 2007). Generally they have a symbiotic relationship with 
their hosts but can become pathogenic after gaining entry into host tissue (Bannerman 
and Peacock, 2007). Staphylococcus species which are affiliated with humans and other 
primates include S. epidermidis, S. aureus, S. capitis, S. caprae, S. saccharolyticus, S. 
warneri, S. pasteuri, S. haemolyticus, S. hominis, S. lugdunensis, S. schleiferi, S. 
auricularis, S. saprophyticus, S. cohnii, S. xylosus and S. simulans (Bannerman and 
Peacock, 2007).
Some of the species have particular niches on their hosts, for instance S. aureus 
primarily resides in the anterior nares o f humans especially adults and other sites 
include the axilla, pharynx and perineum. On the other hand S. epidermidis is the most 
prevalent and persistent Staphylococcus species on human skin (Bannerman and 
Peacock, 2007, Gotz et al., 2006). It is especially present in greater populations in areas 
with high moisture content e.g. axillae, the inguinal perineal areas, anterior nares and 
between the toes. Infrequently this species may be found on other hosts such as 
domestic animals but this may be the result of human to animal transfer (Bannerman 
and Peacock, 2007, Gotz et al., 2006). S. hominis is also prevalent on the human skin 
and together with S. haemolyticus these species are found in greater populations in 
regions comprising numerous apocrine glands e.g. axillae and pubic areas (Bannerman 
and Peacock, 2007). S. capitis subsp. capitis is commonly present on the human head 
where sebaceous glands are numerous e.g. the scalp and forehead (Bannerman and 
Peacock, 2007). S. auricularis and S. cohnii are primarily isolated from the external 
auditory meatus and human feet, respectively, whereas S. saprophyticus is commonly 
present in the female genitourinary tract (Bannerman and Peacock, 2007). Other 
staphylococci rarely inhabit humans and primarily reside on animal hosts, such as S. 
intermedius and S.felis  which are major species o f domestic dogs and cats, respectively. 
Whereas S. xylosus, S. kloosii and S. sciuri are common residents on rodents (Gotz et 
al., 2006). S. hyicus, S. chromogenes, S. sciuri, S. lentus and S. vitulus are frequent 
residents of ungulates and have also been isolated from food products (Bannerman and 
Peacock, 2007).
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1.3 Clinical relevance of Staphylococcus aureus
Staphylococcus aureus is the most common cause of staphylococcal infections in 
humans and these range in severity from self-limiting to life-threatening. Normally it 
colonises the anterior nares and carriage varies within the population: 10 to 35% of 
individuals are persistently colonised whereas 70% of the population are transiently 
colonised, however, colonisation is a risk factor for infection (Kooistra-Smid et al., 
2009, Miller et al., 2009). S. aureus primarily causes skin and soft tissue infections 
(SSTIs) but it can also cause invasive infections and toxin-mediated diseases 
(Bannerman and Peacock, 2007). The latter include food poisoning, scalded skin 
syndrome and toxic shock syndrome whereas SSTIs include boils, ulcers, abscesses, 
cellulitis, furunculosis, wound infections and necrotizing fasciitis (Bannerman and 
Peacock, 2007). Invasive infections include bacteraemia, osteomyelitis, pneumonia and 
infective endocarditis. S. aureus also causes hospital-acquired infections including 
surgical wounds, ventilator-associated pneumonia and infections associated with 
intravenous devices and prosthetic materials e.g. prosthetic joints and vascular grafts 
(Bannerman and Peacock, 2007).
The success o f S. aureus in clinical pathogenesis is attributed to its expression of 
virulence factors and the acquisition of antibiotic resistance determinants. Currently the 
most notorious resistance determinant is mecA which confers resistance to all beta (P)- 
lactam antibiotics i.e. methicillin resistance. Methicillin-resistant S. aureus (MRSA) 
have become a leading cause o f hospital-acquired infections in the UK and in many 
countries world-wide. S. aureus can also express resistance to non P-lactam antibiotics 
via the acquisition o f plasmids and transposons harbouring diverse resistance 
determinants. These include plasmid based tet(K) and tet(L) genes which confer 
resistance to tetracycline and ermC which confers resistance to macrolides 
(erythromycin), lincosamides (clindamycin) and streptogramin B. The ileS and 
aac(6’)/aph(2”)  genes are also acquired via the acquisition o f plasmids and these genes 
confer resistance to mupirocin, an antibiotic which is essential for MRSA de­
colonisation and aminoglycosides, gentamicin, respectively (Diep et al., 2006). In cases 
o f treatment failure glycopeptides (vancomycin, teicoplanin), linezolid and daptomycin 
are used as the last lines o f antibiotic therapy however since 2002, reports describing 
clinical MRSA with decreased susceptibility to vancomycin have been published 
(Lindsay, 2009, Sung and Lindsay, 2007).
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Vancomycin resistance is attributed to the acquisition of vanA via conjugative 
transposition from vancomycin resistant enterococci and it has also been suggested that 
this resistance may arise from chromosomal mutations resulting in the disruption o f the 
accessory gene regulator. (Grundmann et al., 2006). Threats to linezolid and 
daptomycin treatment have also been reported through resistance to linezolid due to 
expression of the plasmid-mediated cfr gene, although daptomycin resistance has also 
been observed, where the mechanism o f resistance is not yet clearly understood 
(Woodford and Livermore, 2009, Hayden et al., 2005, Qi et al., 2005).
1.4 Synthesis of the staphylococcal cell wall
1.4.1 Peptidoglycan
Staphylococci are gram-positive bacteria and therefore their cell walls are composed of 
peptidoglycan (murein), teichoic acids and cell-wall associated proteins (Dmitriev et al.,
2004). Peptidoglycan is a heteropolymer comprising alternating 0-1,4 linked amino 
sugars namely V-acetylglucosamine (GlcTVac) and V-acetylmuramic acid (Mur/Vac) 
which are cross-linked by short peptides (Bannerman and Peacock, 2007, Gotz et al., 
2006). The latter comprise: L-alanine, D-isoglutamine, L-lysine, D-alanyl-D-alanine 
and this pentapeptide is linked via an amide bond to the D-lactyl moiety o f MurVac. 
The pentaptides are also cross-linked in a 2nd dimension by bridges consisting o f five 
glycines extending from the carboxy-terminal D-alanine to the e-amino group o f the L- 
lysine in position 3 of the adjacent pentapeptide (Bannerman and Peacock, 2007, Gotz 
et al., 2006, Stapleton and Taylor, 2002). Therefore the GlcTVac-MurNac glycan strands 
and the cross-linked peptides create a three-dimensional macromolecule which gives 
rigidity to the cell wall (Bannerman and Peacock, 2007, Gotz et al., 2006).
The first stage o f peptidoglycan synthesis occurs within the cytoplasm and concerns the 
assembly o f the glycan strand precursor: UDP-MurTVac-pentapetide from UDP-GlcTVac, 
this involves six cytoplasmic steps mediated by MurA to MurF (see Figure 1.1.) 
(Bannerman and Peacock, 2007, Gotz et al., 2006). The second stage involves the 
transfer of UDP-MurVac-pentapeptide by the transferase MraY, to a membrane attached 
lipid carrier (undecaprenyl phosphate, C55-P) and this yields lipid I (Bannerman and 
Peacock, 2007, Gotz et al., 2006) (see Figure 1.1).
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Figure 1.1. Pathway of peptidoglycan synthesis in staphylococci (Gotz et al., 2006). 
Red, antibiotics inhibiting specific stages of synthesis; Grey, enzymes mediating 
specific stages of synthesis; Blue, peptides added at different stages.
Subsequently GlcA^ac is added to the Css-UDP-MurAfac-pentapeptide/ lipid I, forming 
the C5 5 -PP-disaccharide-pentapeptide/ lipid II. Subsequently the synthesis of the 
pentaglycine interbridge occurs by the sequential addition of glycine to s-amino group 
of the L-lysine (position 3) on the stem pentapeptide. This is mediated by enzymes 
termed the Fern factors (Bannerman and Peacock, 2007, Gotz et al., 2006).
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Figure 1.2. Synthesis of pentaglycin bridge between pentapeptide chains of 
peptidoglycan in S. aureus (Gotz et al., 2006).
The FemX (FmhB), FemA and FemB factors mediate the addition of the first glycine, 
then the second and third, and finally the fourth and fifth glycines, respectively (see 
Figure 1.2). The last stage of peptidoglycan synthesis involves the transportation of the 
subunits to the outside of the cytoplasmic membrane, incorporation of the subunits to 
the nascent peptidoglycan and the cross linking of peptidoglycan (Bannerman and 
Peacock, 2007, Gotz et al., 2006). The latter involves transpeptidation reactions which 
are catalysed by membrane bound penicillin-binding proteins (PBPs). S. aureus has four 
intrinsic PBPs: PBP1, PBP2, PBP3, PBP4, the first three are high molecular mass PBPs 
(HMM-PBPs) whereas PBP4 is a low molecular mass PBP (LMM-PBP). HMM-PBPs 
have multifunctional roles, the C-terminal has transpeptidase activity and the N-terminal 
has transglycosylase activity (Navratna et al., 2010). Interestingly most LMM-PBPs are 
monofunctional but PBP4 is unique as it is multifunctional, exhibiting transpeptidase 
and D,D-carboxypeptidase activities (Navratna et al., 2010). Transglycosylation 
involves the attachment of the last glycine residue of the pentaglycine bridge to the 
penultimate D-alanine residue on another stem pentapeptide. This is followed by the 
removal of the terminal D-alanine by the activity of D,D-carboxypeptidases (Kong et 
al., 2009).
1.4.2 Antim icrobials inhibiting peptidoglycan synthesis
Several antimicrobials have been developed for the inhibition of peptidoglycan 
synthesis at different stages. These include phosphonomycin (fosfomycin), cycloserines, 
bacitracin, glycopeptides and (3-lactam antibiotics (see Figure 1.1) (Kong et al., 2009, 
Gotz et al., 2006).
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Fosfomycin binds to the cysteine residue o f the transferase which mediates the transfer 
o f enolpyruvate from phosphoenolpyruvate to UDP-GlcVac, thus it inhibits the earliest 
stage o f peptidoglycan synthesis (Kong et al., 2009, Gotz et al., 2006). The cycloserines 
inhibit D-alanine metabolism by irreversibly binding to the alanine racemase and this 
hinders the incorporation of D-alanine into peptidoglycan (Kong et al., 2009, Gotz et 
al., 2006). Bacitracin inhibits the dephosphorylation o f undecaprenyl pyrophosphate 
(C55-PP) thus preventing further transfer o f the muramylpentapeptides across the 
cytoplasmic membrane to the nascent peptidoglycan (Kong et al., 2009, Gotz et al.,
2006). Vancomycin binds to the terminal D-alanyl-D-alanine moiety o f  pentapeptide 
thus preventing transglycosylation and cross linkage o f the stem-pentapeptides (Kong et 
al., 2009, Gotz et al., 2006).
Penicillins are a group of natural and semisynthetic antibiotics which contain a (3-lactam 
ring fused to a thiazolidine ring. These antibiotics are the most widely used antibiotic in 
the treatment o f most Gram-positive and some Gram-negative bacteria. They are 
structural analogues o f D-alanyl-D-alanine which irreversibly bind to the Ser40 3  residue 
within the active site o f PBPs. This inhibits the transpeptidase activity o f the PBPs and 
it is also thought that the activity of (3-lactam antibiotics triggers the activation of 
membrane associated autolytic enzymes which destroy the cell wall (Bannerman and 
Peacock, 2007). However, resistance to penicillins is widely exhibited by S. aureus 
strains by the expression of penicillinases which hydrolyse the p-lactam ring. These 
enzymes are encoded and regulated by the blaZ operon which is frequently located on 
transposon Tn552 (McKinney et al., 2001, Rowland and Dyke, 1990). Methicillin is a 
semi-synthetic P-lactam antibiotic which was introduced in clinical practice in 1960 but 
later replaced by less toxic derivatives e.g. flucloxacillin and dicloxacillin (Cunha,
2005). These antibiotics are poorly hydrolysed by penicillinases as they contain an 
ortho-dimethoxyphenyl group attached to a side chain carbonyl group and this sterically 
hinders the activity o f penicillinases. However, MRSA express a fifth type o f PBP 
termed PBP2a which is encoded by mecA and works cooperatively with PBP2. Beta- 
lactam antibiotics irreversibly bind to the transpeptidase domain o f PBP2 but its 
transglycosylation domain continues its function o f cross linking the stem pentapeptides 
o f peptidoglycan. PBP2a which has very low affinity for p-lactam antibiotics then 
continues the transpeptidation o f peptidoglycan (Berger-Bachi and Rohrer, 2002).
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1.5 Regulation of PBP2a expression
Transcription o f mecA is regulated by the regulatory genes mecRl and mecl which are 
located upstream and transcribed divergently from mecA. It can also be regulated by the 
homologous blaRl and blal regulatory genes of blaZ. The mecRl gene encodes MecRl, 
a membrane bound p-lactam-sensing signal-transducer and mecl encodes Mecl, a 
transcriptional repressor (Deurenberg and Stobberringh, 2008, Berger-Bachi and 
Rohrer, 2002, Stapleton and Taylor, 2002). In the absence o f a p-lactam antibiotic, Blal 
and Mecl bind to the operator region and repress transcription of blaZ; blciRl-blal and 
mec A', mecRI-mecI, respectively. When an inducing p-lactam antibiotic binds to the 
extracellular sensor domain of M ecRl, cleavage of the sensor transducer is triggered, 
followed by the subsequent activation of an intracellular metalloprotease domain (see 
Figure 1.3). This protease cleaves the repressor (Blal or Mecl) enabling the transcription 
of the b/aZ; blaRl-blal and mecA; mecRl-mecl transcripts and subsequent expression of 
PBP2a (Deurenberg and Stobberringh, 2008, Berger-Bachi and Rohrer, 2002, Stapleton 
and Taylor, 2002, Katayama et al., 2001).
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Figure 1.3 Schematic diagram of regulation of PBP2a and penicillinase expression 
(Berger-Bachi & Rohrer, 2002)
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1.6 Phenotypic expression of methicillin resistance
Even though MRSA strains may exhibit high minimum inhibitory concentrations 
(MICs) for P-lactam antibiotics it is relatively rare that all the cells in the culture of a 
MRSA strain have identical high levels of resistance (Tomasz et al., 1991). Different 
MRSA strains may exhibit homogeneous or heterogeneous forms of methicillin 
resistance. With homogeneous strains all the cells of a single culture exhibit uniform 
high MICs in vitro whereas heterogeneous strains comprise two or more subpopulations 
of cells with varying MICs in vitro. There are different degrees of heterogeneous 
expression, at one end of the spectrum there are strains with up to 99.9% cells with 
MICs just above susceptibility and a very low frequency of highly resistant cells, 
whereas other strains may comprise multiple populations with intermediate degrees of 
resistance ranging from low MICs to very high MICs (Finan et al., 2002, Tomasz et al., 
1991). Tomasz et al. (1991) defined four arbitrary classes of methicillin resistance 
expression in staphylococci (see Figure 1.4). In class 1 strains, the majority of cells had
• * 7 8low methicillin MICs (1.3 to 3 pg/ml) and a very small population (10" to 10' ) 
depicted MICs >25 pg/ml. In class 2 strains most cells had more substantial MICs (6 to 
12pg/ml) and more cells (10‘6 to 104) could grow at higher concentrations of 
methicillin.
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Figure 1.4. Growth curves of four MRSA strains with different degrees of expression of 
methicillin resistance (Tomasz et al., 1991)
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In class 3 strains the majority o f cells (99%) exhibited considerably high MICs (50 to 
200 }ig/ml) and a small population was highly resistant (see figure 1.4). Class 4 strains 
contained cells with uniform high resistance to methicillin (MICs o f 400 to 1000 fig/ml) 
thus displaying homogenous methicillin resistance. In spite o f the low frequency o f cells 
with high MICs in heterogeneous strains, under conditions o f antibiotic pressure these 
highly resistant subpopulations can grow extensively in culture (Balslev et al., 2005, 
Venezia et al., 2001, Tomasz et al., 1991).
Some MRSA strains may depict oxacillin susceptible phenotypes due to the strong 
suppression o f mecA by the repressor Mecl as has been observed in the MRSA N315 
strain which was consequently referred to as a pre-MRSA strain. The de-activation o f 
Mecl by deletion or promoter mutations subsequently de-represses PBP2a production 
(Berger-Bachi and Rohrer, 2002, Kondo et al., 2001). Furthermore despite the carriage 
o f mecA by all MRSA strains, the constitutive expression o f PBP2a does not necessarily 
correlate with high MICs because other genetic determinants affect the expression and 
regulation o f methicillin resistance e.g. the fem  or aux factors (de Lencastre and 
Tomasz, 1994). The roles of the Fem factors in the synthesis o f pentaglycine cross 
bridge during peptidoglycan synthesis are unique and there are no alternate pathways to 
compensate for them. Therefore mutations in the fem  genes have significant impacts on 
resistance and ultimately compromise cell wall synthesis. The activity o f PBP2a is 
dependent on the complete pentaglycine bridge, so modifications hinders its function 
and leads to hypersusceptibility to P-lactam antibiotics (Berger-Bachi and Rohrer,
2002). Many other chromosomal genetic determinants or auxiliary genes have been 
identified and these have varying effects on the expression o f methicillin resistance (see 
Table 1.3) (de Lencastre and Tomasz, 1994, Hartman and Tomasz, 1986).
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Table 1.3. Some of the genetic determinants with effects on the expression of 
methicillin resistance (Berger-Bachi and Rohrer, 2002)
Factor Function and effect on methicillin resistance
fmhB (femX) Addition of the first glycine to pentapeptide stem; inactivation lethal
femA Addition of the 2nd and 3rd glycine to pentapeptide stem; inactivation abolishes 
methicillin resistance
femB Addition of the 4th and 5th glycine to pentapeptide stem; inactivation reduces 
methicillin resistance
femC  (glnR) Glutamine synthetase repressor; inactivation reduces amidation of the D- 
glutamate of the pentapeptide; inactivation reduces methicillin resistance
femD  (glmM) Phosphoglucosamine mutase; catalyzes the interconversion of glucosamine-6-
(femR315) phosphate to glucosamine-1-phosphate; a cytoplasmic peptidoglycan 
precursor; inactivation reduces methicillin resistance
femE Function unknown; inactivation slightly reduces methicillin resistance
femF  (murE) Catalyzes incorporation of lysine into peptidoglycan pentapeptide stem; 
inactivation reduces methicillin resistance
fmtA Membrane protein; inactivation decreases cross-linking and amidation of 
peptidoglycan, and reduces methicillin resistance
fmtB (mrp) Cell surface protein; function unknown; inactivation reduces pentaglycyl- 
substituted monomer of the cell wall fraction while increasing the amount of 
unsubstituted pentapeptide and reduces methicillin resistance
fmtC (mprF) Membrane-associated protein; inactivation reduces modification of 
phosphatidyl-glycerol with L-lysine, and reduces methicillin resistance
llm Function unknown; inactivation increases Triton-X-100-induced autolysis and 
reduces resistance
lytH Homologous to lytic enzymes; inactivation increases methicillin resistance
pbp2 Penicillin-binding protein 2; functional transglycosylase domain of PBP2 is 
needed for methicillin resistance
sigB Alternate transcription factor; inactivation reduces methicillin resistance
hmrA Putative aminohydrolase; over expression increases methicillin resistance
hmrB Homologue of acyl carrier protein; over expression increases methicillin 
resistance
dlt operon Transfer of D-alanine into teichoic acids; inactivation increases methicillin 
resistance
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1.7 Identification of staphylococci at species level
The differentiation o f Staphylococcus species is performed with a range o f tests 
investigating the activity o f diverse enzymes and the capacity o f the strains to produce 
acid from carbohydrate substrates. The evaluation of colony morphology and pigment 
production is also used as a measure o f identification. The ability to clot rabbit plasma 
due to the expression o f coagulase is a major criterion for the identification of 
pathogenic staphylococci i.e. S. aureus in humans and S. intermedius and S. hyicus in 
animals (Bannerman and Peacock, 2007). Most o f the other staphylococcal species do 
not produce coagulase and the term coagulase-negative staphylococci (CoNS) is used as 
a general reference for all o f these species. Other key biochemical tests for the 
identification of Staphylococcus species include detecting the activity o f the following 
enzymes: phosphatase, pyrrolidonyl arylamidase, ornithine decarboxylase, urease, p- 
galactosidase and acetoin production (Bannerman and Peacock, 2007). In addition the 
identification o f novobiocin resistance differentiates a group containing S. 
saphrophyticus from the other CoNS species (Bannerman and Peacock, 2007). 
Polymixin B resistance is also used to differentiate staphylococci, as only a few are 
resistant namely S. aureus, S. epidermidis, S. hyicus and S. chromogenes (Bannerman 
and Peacock, 2007). The tests for the detection of acid production involve the use o f the 
following carbohydrate substrates: D-Trehalose, D-Mannitol, D-Mannose, D-Turanose, 
D-Xylose, D-Cellobiose, maltose and sucrose (Bannerman and Peacock, 2007).
1.8 Identification of S. aureus
1.8.1 Phenotypic tests
S. aureus is the most common cause o f staphylococcal infections in humans however 
certain CoNS species such as S. epidermidis can also cause severe infections, 
particularly bacteraemia and biomedical device-associated infections. In routine clinical 
testing the identification of S. aureus is based on the identification of certain distinct 
phenotypic characteristics. These include the examination o f colony morphology, in 
contrast to the CoNS species, S. aureus typically produce staphyloxanthin, an orange 
carotenoid which confers a yellow colour to the colonies (Forbes, 2009). The 
production o f coagulase is a major phenotypic determinant o f S. aureus and the 
detection o f this enzyme is an integral part of S. aureus identification. Other tests 
include the detection o f specific cell wall-associated proteins i.e. clumping factor and
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protein A and the secreted DNase enzyme (Kateete et al., 2010, Forbes, 2009, Brown et 
al., 2005, Goldstein and Roberts, 1982, Menzies, 1977).
Conventional detection o f coagulase is performed with the tube test and the principle is 
based on the property o f this enzyme to cause clumping o f rabbit plasma. Coagulase 
binds to prothrombin in rabbit plasma and activates it via conformational change, the 
resultant coagulase:prothrombin complex binds to fibrinogen and triggers the cleavage 
of fibrinogen forming fibrin which causes the clotting o f the plasma (Cheng et al., 
2010). However false negative results are possible with some S. aureus strains due to 
the production o f staphylokinase which may cause lysis of the clots, furthermore some 
CoNS species can generate false positive results i.e. S. delphini, S. intermedius, S. 
lutrae, S. pseudointermedius and S. schleiferi but these staphylococci are rarely 
implicated in human infections (Forbes, 2009, Jin et al., 2008, Lijnen et al., 1991). The 
detection o f clumping factor and protein A is done with slide agglutination tests 
comprising latex particles coated with fibrinogen and immunoglobulin G which bind to 
clumping factor and protein A, respectively, leading to the clumping o f the latex beads. 
Generally agglutination tests are rapid, generating results within several seconds and are 
frequently performed as S. aureus identification tests rather than the conventional 
coagulase tube tests which may take up to 24 hours (Davies et al., 2008, Weist et al., 
2006, van Griethuysen et al., 2001). However, some CoNS species can cause false 
positive results and some MRSA strains express capsular type 5 and 8 antigens which 
mask clumping factor and protein A, causing false negative results with the 
agglutination tests (Forbes, 2009, Smole et al., 1998, Brakstad et al., 1993, Croize et al., 
1993). Accordingly several agglutination tests have been developed for the detection of 
the capsular type 5 and 8 antigens and these are often used for the verification of 
presumptive S. aureus strains e.g. the Prolex Staph Xtra Latex Kit (Pro-Lab 
Diagnostics), MastaStaph (Mast Diagnostics), S. aureus Latex test (Denka-Seiken) 
(Forbes, 2009). The DNase enzyme depolymerizes deoxyribonucleic acid and its 
expression is detected with agar that contains DNA. Following growth o f a presumptive 
S. aureus isolate on the DNase test agar the plate is flooded with hydrochloric acid, 
which precipitates the DNA making the medium opaque. If DNase has been expressed 
by the isolate a clear zone manifests around the growth of the isolate, signifying the area 
where the DNA has been degraded.
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In routine clinical analysis testing for coagulase or clumping factor/ protein A and 
DNase will recognize most S. aureus strains but some strains may remain undetected. 
There are further commercially available diagnostic tests for the identification o f 
staphylococcal species e.g. API / ID32 Staph range and RAPIDEC Staph strips by 
BioMerieux and the BBL crystal identification system Gram-positive ID kit (Becton 
Dickinson). These tests contain micro-tubes with dehydrated biochemical substrates for 
the detection o f enzymes which are typically produced by staphylococci allowing 
identification. There are also automated microbial identification systems which are also 
designed for susceptibility testing o f microorganisms e.g. Vitek 2 (BioMerieux), BD 
Phoenix (Becton Dickinson) and MicroScan Walk-Away (Siemens) (Forbes, 2009, 
Carroll et al., 2006). Alternative identification systems include the resolution o f fatty 
acids with gas chromatography e.g. the MIDI Sherlock identification system (MIDI, 
Inc.) and the matrix assisted laser desorption ionization time-of-flight (MALDI-TOF) 
system which combines the ionization o f ribosomal proteins and the resolution o f 
resultant mass ions with mass spectrometry (Rajakaruna et al., 2009, Forbes, 2009, 
Leonard et al., 1995).
1.8.2 Polymerase Chain Reaction
The polymerase chain reaction (PCR) is a molecular technique based on the 
amplification o f nucleic acids and due to its low limit of detection it is a powerful 
method for the identification o f bacterial isolates from clinical specimens. PCR 
comprises three main temperature dependant stages: denaturing, annealing and 
extension. Denaturing is the separation of a double stranded DNA sequence into single 
strands and this occurs at high temperatures. At a lower temperature the primers (or 
oligonucleotides) anneal to complementary regions within the separated DNA 
sequences. An optimal temperature is vital at this stage because it determines the 
specificity (or stringency) o f the reaction. During the subsequent stage the annealed 
primers are extended by the thermostable DNA polymerase as it synthesizes a DNA 
sequence which is complementary to the region o f interest using the four 
desoxyribonucleotide triphosphates. In an efficient PCR reaction at the end o f each 
cycle the quantity of generated DNA is double the amount o f the preceding cycle. 
However, the successful amplification of nucleic acid sequences requires the 
optimisation of factors which affect the efficiency o f the PCR i.e. the concentration of 
magnesium ions which is essential for robust activity o f the DNA polymerase, the
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annealing temperature, the DNA template concentration, the concentration o f the 
primers and the number of cycles performed.
1.8.2.1 Real-time PCR
Conventionally at the end of the PCR the products are resolved in an agarose gel using 
electrophoresis and then visualised with Ultra-Violet transillumination. The 
development of real-time PCR has enabled the quantitative detection of the products as 
the reaction progresses and this also decreases the duration of the assay. Real-time PCR 
involves the use of fluorescent dyes which bind to the minor grooves of the DNA hybrid 
structure and fluoresce upon light excitation e.g. SYBR Green, Syto 9 or EvaGreen 
(Kubista et al., 2006, Monis et al., 2005). Since these bind to double-stranded DNA, as 
the reaction progresses the dye binds to each new copy o f double-stranded DNA and the 
fluorescence increases in proportion to the quantity of generated DNA per cycle. The 
cycle number at which the fluorescence signal indicates progression of the reaction 
above the background noise is used as an indicator of successful target amplification 
and this is commonly referred to as the threshold cycle (Ct) or crossing point (CP) (see 
Figure 1.5). In quantitative real-time PCR the Ct values are vital for the quantification 
of the PCR products, as determined by generated standard curves. Baustin et al. (2009) 
recently published guidelines for the ‘Minimum Information for Publication of 
Quantitative Real-Time PCR Experiments (MIQE) in which they have recommended 
the universal use of the term ‘Cp value’ (Bustin et al., 2009).
S2.C-
Plateau phase
40 -
3 0 -
20 - ^Exponential phaseo
1 0 -
Threshold line
0 10 20  30
Cycle number
40 50
Figure 1.5. An amplification curve from a PCR reaction (adapted from Kubista et al., 
2006) and a melt curve showing similar Tm peaks of several specific PCR products
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The chemistry of DNA-intercalating dyes is effective and simple but the disadvantage is 
that they also bind non-specific PCR products. Therefore the analysis of the dissociation 
or melting curves of the PCR products is important for the verification of specific 
fragments (see Figure 1.5). For instance melting curves with peaks at melting 
temperatures (Tm) lower than that of the specific PCR product indicate the formation of 
primer-dimers, while diverse peaks with different Tm values indicate production of non­
specific products (Espy et al., 2006, Mackay, 2004, Cockerill, 2003).
DNA probes which are labelled with fluorophores are used in real-time PCR and the 
application of these enhances the specificity of the reaction. Several fluorescent probe 
technologies have been developed based on two modes of action: the hydrolysis probes 
e.g. Taqman probes and the hybridization probes e.g. the dual hybridization 
fluorescence resonance energy transfer (FRET) probes, which are also referred to as 
LightCycler probes (Bustin et al., 2009, Espy et al., 2006, Mackay, 2004, Cockerill,
2003). Fluorophores are excited and emit fluorescence at different wavelengths and this 
property is incorporated into the chemistry of the probes used in real-time PCR. For 
instance the Taqman probe is labelled at the 5’ end with a reporter dye and at the 3’ end 
with a quencher dye and these are in close vicinity, so the fluorescence of the reporter 
dye is suppressed by the quencher dye (see Figure 1.6). However during the extension 
stage the 5’ to 3 ’ exonuclease activity of the DNA polymerase causes cleavage of the 
annealed probe (Espy et al., 2006, Mackay, 2004, Cockerill, 2003, Holland et al., 1991).
Figure 1.6. Real-time PCR technologies of the Taqman and dual hybridization FRET 
probes [adapted from Espy et al. (2006).]
Taqman probe Dual hybridisation FRET probes
Fluorescence quenched
Excitation Emission
Fluorescence emitted
Donor
probe
Taq pol
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This releases the reporter dye from its close proximity to the quencher dye and the 
fluorescence is freely emitted. The intensity increases in proportion to the generated 
product at each cycle. In the dual hybridization FRET probe system a donor and 
receptor probe anneal in close proximity to adjacent regions on the target sequence. The 
donor probe is labelled with fluorophore at the 3' end and the acceptor probe is labelled 
with fluorophore at 5' end (see Figure 1.6). When the fluorophore o f the donor probe is 
excited at a specific wavelength the energy is transmitted to the fluorophore o f the 
acceptor probe and this mechanism o f transfer is referred to as FRET. The excited 
acceptor fluorophore then emits fluorescence at a different wavelength which is 
detected and measured. In contrast to the hydrolysis probes which are destroyed by the 
exonuclease activity o f the polymerase, the FRET hybridization probe technology 
enables the annealing o f the probes at the end o f the reaction and therefore melt curve 
analysis o f the amplified product is possible. There are various automated systems 
which have been developed for real-time PCR reactions, including the Rotor-gene RG- 
6000 (Corbett), the Light Cycler (Roche) and the iQ5 real-time PCR detection system 
(Bio-Rad). These instruments comprise thermo-cycling platforms, channels for 
fluorescence detection and in-built software for the analysis and graphical 
representation o f results.
Several conventional PCR methods have been developed for the amplification o f target 
sequences in S. aureus-specific genes and these have greatly contributed to the accurate 
identification o f S. aureus isolates e.g. 16S rRNA, the thermonuclease gene (nuc), 
coagulase (coa), protein A {spa), femA, femB, sa442, clfA and clfB (Kilic et al., 2010, 
Ghebremedhin et al., 2008, Riyaz-Ul-Hassan et al., 2008, Maes et al., 2002, Martineau 
et al., 2001).
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1.9 Susceptibility test methods: broth dilution and disc diffusion methods
The gold standard for antibiotic susceptibility testing is the determination o f minimum 
inhibitory concentration (MIC) with broth or agar dilution methods (Forbes, 2009, 
Brown et al., 2005, Brown, 2001b). The MIC is the fundamental measurement that 
forms the basis o f most susceptibility testing methods. In dilution methods antimicrobial 
agents are usually tested at log2 (two-fold) dilutions and the lowest concentration that 
inhibits visible growth o f the microorganism is regarded as the MIC (Jorgensen and 
Tumidge, 2007). The general approaches for the dilution method include broth 
macrodilution in which the broth is in volumes o f >1.0 ml in test tubes and broth 
microdilution whereby the antimicrobial dilutions are in volumes o f <0.1 ml in wells of 
microdilution trays. The recommended inoculum in dilution testing is 5 x 105 CFU/ml 
and growth in the antimicrobial-containing tubes/ wells is indicated by turbidity or 
sedimented buttons o f bacterial growth (Jorgensen and Tumidge, 2007). The lowest 
concentration that completely inhibits visible growth o f the organism as detected by the 
unaided eye is defined as the MIC (Jorgensen and Tumidge, 2007).
Under standardized conditions MIC values provide a fixed reference point for the 
formulation o f pharmacodynamic breakpoints with the power to predict efficacy in vivo. 
These can be applied directly to routine dilution testing methods and they are also used 
as a reference value for deriving breakpoints for disc diffusion methods (Tumidge et al.,
2007). Breakpoints or interpretative criteria are the values that determine the categories 
for susceptible, intermediate and resistant. The approach to establishing these is 
established by national testing committees or institutes and these bodies also review 
them regularly e.g. British Society for Antimicrobial Chemotherapy (BSAC, UK), 
Clinical Laboratory Standards Institute (CLSI, USA), Comite de 1’Antibiogramme de la 
Societe Francaise de Microbiologie (France) and Swedish Reference Group for 
Antibiotics (SRGA, Sweden). Since 2002 there have been on-going efforts by the 
European Committee on Antimicrobial Susceptibility Testing (EUCAST) to harmonize 
guidelines and antimicrobial breakpoints across European countries (Brown and 
MacGowan, 2010). Regardless o f the different testing committees the establishment of 
breakpoints requires the inclusion o f certain essential data like the distribution o f MIC 
values exhibited by a population o f strains; the pharmacokinetic/ pharmacodynamic 
properties of the antibiotic and the clinical and bacteriological response rates o f the 
organism for which the MICs o f the novel antimicrobial agents have been determined
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(Tumidge et al., 2007). Broth dilution methods represent a standardized reference 
method for susceptibility testing, however, they are laborious and commercially 
prepared microdilution testing panels and automated systems are alternatively used in 
most routine clinical laboratories (Tumidge et al., 2007).
Susceptibility testing is also performed with agar diffusion tests and these involve filter 
paper discs impregnated with a single concentration o f an antimicrobial agent, placed on 
the surface o f an agar medium that has been inoculated with the test organism 
(Jorgensen and Tumidge, 2007). The drug diffuses through the agar and as the distance 
from the disk increases, the concentration of the antimicrobial agent decreases 
logarithmically (Jorgensen and Tumidge, 2007). This creates a gradient o f drug 
concentrations in the agar medium surrounding each disk. However, in areas where the 
concentration o f the drug is inhibitory to the test organism, no bacterial growth occurs, 
resulting in a clear zone around each disk, which are o f varying size depending on the 
susceptibility o f the test organism (Jorgensen and Tumidge, 2007). The breakpoints for 
disc diffusion tests are determined from the MICs predetermined by broth dilution 
methods. These are calculated by plotting the inhibition zone diameters against the 
MICs derived from testing o f a large number o f strains o f various species. Statistical 
evaluations are then used to determine the appropriate zone diameters for categorization 
in susceptible, resistant and intermediate/indeterminate (Tumidge et al., 2007).
1.10 Detection of methicillin resistance in S. aureus
1.10.1 Detection of methicillin resistance in S. aureus with phenotypic tests
According to the BSAC March 2010, version 9.1 susceptibility testing guidelines, the 
detection of methicillin resistance in S. aureus can be performed with either oxacillin or 
cefoxitin. Both these antibiotics are penicillinase resistant p-lactam antibiotics, however 
cefoxitin is a cephamycin, a cephalosporin that has a broader spectrum of activity 
against Gram-positive and Gram-negative bacteria. The accuracy o f antibiotic 
susceptibility testing is challenged by the variability o f mecA expression and certain 
mecA-positive strains may depict low-level resistance phenotypes, whilst some mecA- 
negative S. aureus strains depict borderline oxacillin resistance phenotypes due to 
mutations in their existent PBP genes or the hyper-production o f penicillinase (Skinner 
et al., 2009, Keseru et al., 2005, Varaldo, 1993, Chambers et al., 1989). Furthermore
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susceptibility tests are affected by test conditions and it is difficult to implement 
standard conditions for the unambiguous detection o f heterogeneous MRSA strains and 
at the same time clearly distinguish mecA-negative penicillinase hyper-producers 
(Brown et al., 2005, Berger-Bachi and Rohrer, 2002, Berger-Bachi, 1995). Nevertheless 
test conditions have been modified to augment the expression o f methicillin resistance 
and these include the addition o f NaCl (2-5%) and the lowering o f incubation 
temperatures. The benefits o f increased NaCl concentrations are dependent on the type 
o f growth media, inoculum size, the incubation temperature and duration of incubation 
(Skov et al., 2009, Brown et al., 2005, Berger-Bachi and Rohrer, 2002, Berger-Bachi, 
1995, Madiraju et al., 1987). For instance the incorporation o f 2% NaCl into Mueller- 
Hinton (MH) or Columbia agar has been shown to improve the detection o f methicillin 
resistance, however, in Iso-Sensitest agar this is less beneficial (Forbes, 2009). With 
heterogeneous strains the smaller population o f cells with higher MIC may grow more 
slowly and may be missed at higher incubation temperatures. Thus the reduction o f the 
incubation temperature to 30°C rather than 35°C has been recommended in order to 
enhance the growth o f the highly resistant subpopulation. However, a higher NaCl 
concentration in the growth medium i.e. 5% NaCl, may inhibit the growth of some 
MRSA. Slow growing MRSA strains may require up to 48 hours for accurate detection 
o f methicillin resistance and if tests are read earlier the strains may be falsely regarded 
as MSSA. These represent some o f the challenges of developing standardised methods 
which detect all MRSA strains with excellent accuracy.
In the UK the BSAC March 2010 version 9.1 susceptibility testing guidelines are used 
and these recommend 2% NaCl in either MH or Columbia agar for the oxacillin disc 
diffusion test and an incubation at 30°C for 24 hours, whereas Iso-Sensitest agar with no 
added NaCl and incubation at 35°C for 18 to 20 hours is recommended for the cefoxitin 
disc diffusion test. The loading amounts for the antimicrobial discs are 1 pg for 
oxacillin and 10 pg for the cefoxitin. However the option o f oxacillin or cefoxitin and 
the concentrations vary depending on the guidelines o f the respective national 
committees. For instance the CLSI M100-S17 performance standards for antimicrobial 
susceptibility testing recommend cefoxitin (30 pg) instead o f oxacillin for disc diffusion 
or a plate containing 6 pg/ml of oxacillin in MH agar supplemented with NaCl (4% 
w/v) as alternative methods o f testing for MRSA ( http://www.cdc.gov/mrsa/).
2 2
Automated susceptibility systems are frequently employed especially in the high 
volume clinical laboratory environments such as the VITEK 2 system and the BD 
Phoenix. Several studies have investigated the diagnostic performance o f these systems 
for the detection o f methicillin resistance in S. aureus and CoNS strains which may also 
exhibit heterogeneous expression o f methicillin resistance (Junkins et al., 2009, 
Horstkotte et al., 2004, Horstkotte et al., 2002). With S. aureus strains these systems 
have been shown to have improved diagnostic sensitivity for the detection o f methicillin 
resistance when both the oxacillin and cefoxitin MICs were included in the 
interpretation o f the results (Junkins et al., 2009). With the CoNS strains the BD 
Phoenix was shown to have excellent diagnostic sensitivity but lower diagnostic 
specificity (Horstkotte et al., 2004, Horstkotte et al., 2002).
Automated susceptibility systems generally comprise micro-dilution broth panels and 
serve the dual purpose o f antibiotic susceptibility testing and species identification 
(Junkins et al., 2009, Kaase et al., 2009). For instance the BD Phoenix automated 
microbiology system is intended for the rapid identification and determination o f MICs 
for isolates from pure cultures. It uses cassettes comprising an identification (ID) test 
panel and an antimicrobial susceptibility test (AST) panel. The ID panel comprises 
micro-wells containing lyophilized biochemical substrates based on microbial 
utilization and the degradation o f the substrates which are detected with various 
chromogenic or fluorogenic indicator systems e.g. acid production from the hydrolysis 
o f carbohydrates is detected with a phenol red indicator which changes to a yellow 
colour. The AST panel comprises micro-wells with various antimicrobial agents in two­
fold doubling concentrations and a redox indicator is used for the detection o f bacterial 
growth in the presence o f the antimicrobial agent. In the Public Health Wales Abertawe 
Bro Morgannwg (PHW ABM) Microbiology Laboratory the BD Phoenix PMIC/ID-67 
panel is used for identification and susceptibility testing o f bacteria including 
presumptive MRSA strains. The AST panel includes a range o f antibiotics including 
oxacillin and cefoxitin, the dilution range is 0.25 to 2 pg/ mL for oxacillin and 2 to 8 
pg/ mL for cefoxitin. The determined species identification o f the tested isolate is then 
used in the interpretation o f the MIC values for evaluation o f susceptibility or resistance 
to the respective antimicrobial agents. In the BSAC March 2010 version 9.1 
susceptibility testing guidelines the MIC breakpoints for methicillin resistance in S. 
aureus are >2 pg/ mL for oxacillin and >4 pg/ mL for cefoxitin. There are several
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commercially available latex agglutination tests which detect PBP2a, and these are often 
used for verification o f presumptive MRSA strains in routine clinical laboratories e.g. 
PBP2’ latex test (Oxoid), MRSA latex test (Denka-Seikin), Mastalex-MRSA test (Mast 
Diagnostics) and Slidex MRSA test (BioMerieux) (Horstkotte et al., 2001, Louie et al., 
2000, Marriott et al., 1999).
1.10.2 Detection of methicillin resistance in S. aureus with molecular methods
The specificity o f MRSA identification is based on the detection of the mecA gene and a 
S. aureus-specific gene. The application of real-time PCR methods has been particularly 
valuable in MRSA detection, whereby DNA-probes labeled with fluorophores have 
been used for the simultaneous detection o f mecA and a S. aureus-specific gene e.g. nuc, 
fem A ,fem B  or Sa442 and mecA (Pasanen et al., 2010, Thomas et al., 2007, Costa et al., 
2005, Hope et al., 2004, Fang and Hedin, 2003, Francois et al., 2003, Jonas et al., 2002, 
Reischl et al., 2000a, Perez-Roth et al., 2001, Vannuffel et al., 1995). For instance 
Pasanen et al. (2010), Thomas et al. (2007), Hope et al. (2004) and Fang et al. (2003) 
used Taqman probe-based duplex real-time PCR methods for the detection o f mecA and 
nuc to expedite the screening o f MRSA from clinical specimens. Alternatively Francois 
et al. (2003) and Perez-Roth et al. (2001) targeted the femA  and fem B  genes respectively 
in their methods. Real-time PCR has also been used for the detection o f additional 
antibiotic resistance markers in MRSA e.g. ermA (erythromycin resistance), aacA-aphD 
(aminoglycoside resistance) and ileS-2 (mupirocin resistance) (Sabet et al., 2007a, Sabet 
et al., 2007b, Perez-Roth et al., 2001). However, the application o f PCR assays which 
target mecA and a S. aureus-specific gene is limited to clinical isolates or typically 
sterile clinical specimens e.g. blood cultures because in non-sterile or mixed flora 
clinical specimens e.g. wound swabs, contaminating CoNS species may also be present 
and since mecA may also be acquired by these staphycloccci, false positive results are 
possible with these duplex PCR assays.
A novel concept for the identification o f MRSA from clinical specimens which 
potentially harbour mixed flora such as MRSA and methicillin resistant CoNS was 
pioneered by Huletsky et al. (2004). This method is based on the location o f the mecA 
gene on a mobile genetic element termed the SCCmec element and the orfiC locus which 
is unique to S. aureus. They developed a PCR method comprising oligonucleotides for 
the amplification o f a sequence spanning from the right extremity of the SCCmec
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element to orfiC. Ideally the amplification o f the SCCmec-orJX junction provides a 
surrogate marker for MRSA and allows unambiguous detection from non-sterile clinical 
specimens. Further SCCmec-orJX PCR methods were developed by Cuny and Witte
(2005) and Hagen et al. (2005) and the original Huletsky et al. (2004) method was 
subsequently used in the development o f a commercial test for detection o f MRSA from 
clinical nasal swabs i.e. the BD GeneOhm MRSA test. Amplification o f the SCCmec- 
orfX junction has been shown to be robust for MRSA detection and this concept serves 
as the principle of other commercial tests for MRSA detection in screening nasal swabs 
i.e. the GeneXpert MRSA (Cepheid), the GenoQuick MRSA test (Hain LifeScience) 
and the LightCycler MRSA Advanced test (Roche) (Kolman et al., 2010, Snyder et al., 
2010, Bishop et al., 2006, Prere et al., 2006, Cuny and Witte, 2005, Hagen et al., 2005, 
Huletsky et al., 2004).
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1.11 The Staphylococcal Cassette Chromosome mec (SCCmec)
The mecA gene is located on a mobile genetic element termed the Staphylococcal 
Cassette Chromosome mec (SCC/wec) (Zhang et al., 2009, Berglund et al., 2008, Ito et 
al., 2004). These elements have characteristic features:
i) The mec gene complex and the ccr gene complex
ii) Direct and inverted repeats at the chromosome-SCCmec boundaries
The mec gene complex comprises mec A, its regulator genes and insertion sequences 
while the ccr gene complex contains ccr genes and surrounding open reading frames 
(Arakere et al., 2009).
1.11.1 The different mec gene complex classes
Presently there are five classes o f mec gene complexes (A, B, C l, C2 and D):
i) Class A is the prototype and is structured as follows: mecI-mecRl-mecA-lS43J. 
It comprises mecA, complete mecRl and m ecl regulatory genes upstream of 
mecA, the hypervariable region (HVR) and an insertion sequence IS431 
downstream of mecA. Variants have also been described including those 
containing IS437 or IS 1182 upstream of mecl (IWG-SCC, 2009, Ito et al., 2004, 
Katayama et al., 2001).
ii) Class B is structured as follows: \j/IS7272-Amec7?7-/wec^-IS431, whereby there 
is a deletion of m ecl and the deletion of the penicillin binding domain o f mecRl 
due to the insertion of pseudo-IS7272. A variant has been described with an 
insertion of Tn4001 upstream of mecA (IWG-SCC, 2009)
iii) Class C comprises two types (Cl and C2) which are structured as follows: 
\S431-AmecRl-mecA-lS431, whereby mecRl is truncated by the insertion of 
IS457. In class C l the IS457 upstream of mecRl is in the same orientation as 
IS431 downstream of mecA whereas in class C2 the orientation o f IS431 
upstream of mecRl is reversed. Also class C2 has a larger deletion o f the 
penicillin binding domain in mecRl (IWG-SCC, 2009, Hanssen and Sollid, 
2006, Katayama et al., 2001).
iv) Class D: AmecRl-mecA-lS431 has a truncated mecRl (lacking an insertion 
sequence) due to a deletion of the penicillin binding domain. Shore et al. (2005) 
have also described class E which is similar to class D except, it has a 976 bp 
deletion in the membrane-spanning domain o fm ecR l (IWG-SCC, 2009).
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1.11.2 The ccr gene complex
The ccr genes encode site-specific recombinases which mediate the chromosomal 
integration and excision of the SCCmec element in the S. aureus chromosome at a 
specific site termed attB which is located in orflC (Wang and Archer, 2010, Deurenberg 
and Stobberringh, 2008, Hanssen and Sollid, 2006). There are five allotypes o f the ccr 
gene complex, the first four types are pairs o f homologous ccrAB genes: type 1 
(containing ccrA lB l), type 2 (containing ccrA2B2), type 3 (containing ccrA3B3), type 4 
(containing ccrA4B4) and type 5 contains one recombinase gene, ccrC (IWG-SCC, 
2009, Hanssen and Sollid, 2006, Ito et al., 2004). These have homology to integrases 
and recombinases of other bacteria e.g. an integrase of Lactococcus lactis acquired from 
bacteriophage TP901-1 and a putative integrase o f Bacillus cereus acquired from 
bacteriophage TP21ply21. They also have homology to recombinase SpoIVCA of 
Bacillus subtilis and transposase TnpX o f Clostridium perfringens but the S CCmec 
elements do not carry genes encoding bacteriophage head and tail proteins or the tra 
genes which are essential for conjugative transfer (Hanssen and Sollid, 2006).
1.11.3 The junkyard regions
Outside o f the mec and ccr gene complexes, the SCCmec elements comprise three 
regions termed the junkyard (J) regions J l, J2 and J3. These may harbour additional 
antibiotic resistance genes, virulence genes, pseudogenes, non-coding regions, insertion 
sequences, plasmids or transposons (see Figure 1.7). J l is the region between the left 
chromosomal junction and the ccr gene complex, J2 is between the ccr and mec gene 
complexes and J3 is between the mec gene complex and the right chromosomal junction 
(IWG-SCC, 2009).
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Figure 1.7. Schematic diagram of SCCmec type I to VI elements (not drawn to scale) 
[adapted from (de Lencastre et al., 2007, Hanssen and Sollid, 2006)]
1.11.4 Classification of SCCmec elements in MRSA
SCCmec types I to VIII have been described in MRSA and they range in size from 
approximately 21 to 67kb (see Figure 1.7). Recent recommendations by the 
International Working Group on the Classification of Staphylococcal Cassette 
Chromosome Elements (IWG-SCC) state that the nomenclature of the elements should 
reflect the combination of the ccr and mec gene complexes within the elements. 
Therefore SCCmec type I would be termed ‘IB’ to signify the type 1 ccr gene complex 
and the class B mec gene complex harboured by this element (see Figure 1.7). Similarly 
the other SC Cmec types would be: type II (2A), type III (3A), type IV (2B), type V 
(5C2) and type VI (4B) (see Figure 1.7). SCCmec subtypes are defined by the presence 
of characteristic loci in the junkyard regions (see Table 1.4).
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S. aureus especially MRSA strains can carry several copies of insertion sequences e.g. 
IS431 and these are implicated in the trapping and clustering of resistance markers by 
homologous recombination. For instance the SCCmec type II and III elements contain 
plasmids pUB770, pT7#7 and pL256 respectively which are flanked by IS431 (Hanssen 
and Sollid, 2006) (see Figure 1.7). The SC Cmec type I, IV and V elements are typically 
smaller than SCCmec type II and III elements and usually only harbour the methicillin 
resistance genetic determinant, mecA. However, some variants o f these elements carry 
additional resistance determinants such as the SC Cmec 1.2 and IVA subtypes which 
elements also harbour the pUB770 plasmid (see Table 1.4). This plasmid carries 
aadD/ble which encodes kanamycin, tobramycin and bleomycin resistance (see Table 
1.3). SCCmec type V is the only known SCCmec element which has a complete set of 
genes encoding the type I restriction-modification system i.e. hsdR, hsdS, and hsdM  
genes. These are also thought to be involved in the stabilisation o f this element in the S. 
aureus chromosome (see Figure 1.7).
Pairs of SCCmec elements arranged in tandem, possibly arising from recombination 
events, have been described in S. aureus such as the ZH47, TSGH17 and PM1 strains. 
Strain ZH47 contains a composite element comprising a SCC element with ccrC and an 
additional SCCmec with a type 2 ccr gene complex and a class B2 mec complex (a class 
B mec complex with Tn4001 integrated within it) (IWG-SCC, 2009). In these cases the 
composite elements are classified by the SCCmec element present within the 
combination i.e. the element o f the ZH47 strain is designated SC Cmec 2B&5 and 
regarded a type IV variant (IWG-SCC, 2009).
There is more structural diversity o f SCCmec elements in methicillin resistant CoNS 
than in MRSA and CoNS species are postulated to harbour the reservoir o f SCC 
elements. Unique ccr and mec gene classes and complex combinations i.e. one mec gene 
complex and up to three ccr gene complexes have been described in CoNS species. 
Therefore it has also been proposed that the classification o f SC Cmec elements should 
reflect the copy number o f ccr genes (Ruppe et al., 2009, Hanssen and Sollid, 2006).
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1.11.5 SCC elements that do not contain mecA
Several SCC elements lacking mecA have been described in S. aureus e.g. SCCcapl, 
SCCHg, SCCfur and these carry genes for capsular polysaccharide 1 involved in the 
evasion o f phagocytosis, a mercury resistance operon and fusidic acid resistance genes, 
respectively (IWG-SCC, 2009, Hanssen and Sollid, 2006). The SCC elements have 
characteristic features o f SCC mec elements i.e. carriage o f a ccr gene complex, 
integration at orjX  and flanking direct repeats. The SCC47 6  element which is carried by 
the MSSA476 strain carries a gene encoding a protein similar to the plasmid-borne 
fusidic acid-resistance determinant (Holden et al., 2004). Is also has two site-specific 
recombinases which are homologous to the ccr A and ccrB genes of the non-mecA SCC 
element, SCC12263 which is harboured by a S. hominis strain (Holden et al., 2004). Other 
non-mecA SCC elements in CoNS strains include a large composite non-mecA element 
(57kb) termed SCCcomposite island, which is carried by the S. epidermidis ATCC 
12228 strain. It comprises a SCC element carrying a type 2 and type 4 ccr complex and 
an additional element in tandem termed SCCpbp4. The latter element carries a homolog 
of the gene encoding PBP4, which is involved in peptidoglycan synthesis (Hanssen and 
Sollid, 2006).
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1.12 The typing of S. aureus isolates
A comprehensive understanding o f the epidemiology and evolution o f S. aureus is 
enhanced by the application o f typing techniques which enable the discrimination o f 
unrelated isolates and discernment o f clonal lineages. The discrimination of strains may 
be based on phenotypic or genetic factors but it is important that the techniques have 
robust discriminatory power and reproducibility in order to be effective methods.
1.12.1 Phenotypic typing methods
The earliest phenotypic typing methods included the analysis o f antibiograms and phage 
typing which were based on the susceptibility o f the isolates to antibiotics and 
bacteriophages (Weller, 2000, Gillepsie et al., 1990). However, antibiotic resistance 
patterns are influenced by environmental selective pressures and unrelated isolates may 
eventually have similar profiles. Phage typing involves the application of a selection o f 
phages to a bacterial isolate on an agar plate and the examination o f developed plaques. 
This method was commonly used and was the earliest method to be standardised by an 
international committee, however, inherent problems include the lack of susceptibility 
o f certain strains to phages and poor reproducibility (Strommenger et al., 2008, 
Devriese, 1984, Blair and Williams, 1961). Other methods include cellular protein 
analysis after lysis o f the bacterial isolate with lysostaphin. The proteins are then 
separated with polyacrylamide gel electrophoresis and the resultant patterns exhibit 
multiple bands. This method was further refined with immunoblotting, a process 
involving the further addition o f anti-staphylococcal antibodies and the visualisation o f 
resultant patterns labeled secondary antibodies (Weller, 2000, Pagani et al., 1991, 
Mulligan et al., 1988). However, in some outbreaks the use o f these protein-based 
patterns did not adequately distinguish strains. Multi-locus enzyme electrophoresis 
(MLEE) has also been applied to S. aureus isolates. It involves the extraction o f cell 
associated enzymes and their separation by electrophoresis. Since mutations in the 
genes encoding the enzymes can affect the amino acid composition o f the enzymes, this 
can affect the electrophoretic mobility o f the products and thus result in diverse MLEE 
patterns for respective test isolates (Weller, 2000, Tenover et al., 1994). However, the 
discriminatory power o f MLEE is partly dependant on which enzymes are included and 
some have been found to be monomorphic across respective S. aureus isolates thus 
limiting the discriminatory capacity o f the method.
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1.12.2 M olecular typing methods
A plethora of molecular typing techniques have been developed and the earliest 
technique was plasmid analysis which differentiated strains by virtue o f the number and 
size o f harboured plasmids, as determined by plasmid extraction and subsequent 
electrophoresis. However, the success o f this method is limited to strains which carry 
plasmids and since these are mobile elements they may be lost by certain strains and 
this affects the discriminatory power and reproducibility o f this method (Weller, 2000). 
The digestion o f chromosomal DNA with restriction enzymes e.g. BglII and EcoKl was 
found to be an alternative means o f discriminating S. aureus isolates. This method is 
referred to as restriction enzyme analysis (REA) and produces multiple fragments but 
conventional electrophoresis is not able to separate large fragments (>20kb), thus there 
is a likelihood of these overlapping and this masks existent differences between strains. 
The combination o f REA and Southern blotting enabled the use o f probes for the 
detection o f different loci which are found in multiple copies in the chromosome e.g. 
16S and 23S ribosomal proteins (ribotyping) and insertion sequences such as IS437, 
IS256 and IS1181 (Deplano et al., 1997, Derbise et al., 1994, Jensen et al., 1993). 
However, there will always be strains lacking insertion sequences making them 
untypeable with this method (Weller, 2000, Richardson et al., 1994, Jordens, 1991). 
Some unrelated MRSA strains have been shown to exhibit identical rRNA gene 
restriction fragment patterns, indicating that ribotyping is not a highly discriminatory 
typing tool for S. aureus (Prevost et al., 1992).
The analysis o f restriction enzyme patterns has been enhanced by the application of 
pulsed field gel electrophoresis. This technique involves continual changes in the 
direction of the electric field during electrophoresis and this frequent re-orientation 
enables efficient separation o f large chromosomal DNA fragments, resulting in patterns 
which have proved highly effective for the discrimination o f strains. For S. aureus the 
use o f the Smal restriction enzyme has been found to produce the most discriminatory 
and reproducible PFGE patterns. Efforts have been undertaken to standardize this 
method and it is currently regarded as the gold standard for S. aureus typing (Murchan 
et al., 2003). However it is technically demanding, the results are inclined to subjective 
interpretation and inter-laboratory comparison o f the results is difficult (Conceicao et 
al., 2009, Schouls et al., 2009, Faria et al., 2008, Strommenger et al., 2006).
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As such molecular techniques are still being developed and advocated as alternative 
methods to expedite S. aureus typing. This has included the development o f methods 
involving various PCR applications. For instance random amplified polymorphic DNA 
(RAPD) analysis involves a low stringency PCR with a pair or several pairs o f short 
primers (Weller, 2000). The low stringency conditions enable the primers to anneal to 
random regions in the chromosome and the resulting fragments are resolved in an 
agarose gel. However although it is more rapid than PFGE it has been found to lack 
reproducibility in some studies (Reinoso et al., 2004, Telecco et al., 1999, Tambic et al., 
1997).
The sequencing o f several S. aureus genomes revealed the presence o f polymorphic 
regions comprising variable numbers o f highly similar repeated DNA sequences 
arranged consecutively, which are alternatively termed variable-number tandem repeats 
(VNTRs) (Hardy et al., 2006, Hardy et al., 2004). The amplification o f VNTRs of 
several S. aureus-specific loci including the sdr, e lf A, clfB, ssp, coa and spa genes, has 
been used as the basis for the differentiation o f strains (Hardy et al., 2006, Harmsen et 
al., 2005, Hardy et al., 2004, Shopsin et al., 1999, Schwarzkopf and Karch, 1994, Goh 
et al., 1992). For instance sdr, clfA, clfB encode cell-surface proteins and contain a 
region with repeated Ser-Asp dipeptides encoded by an 18 bp sequence at the 3’- region 
o f the genes. Whereas the coa and spa genes contain regions comprising a series o f 
approximately 81 and 24 bp repeats which vary in number across S. aureus strains 
(Weller, 2000, Shopsin et al., 1999). In coa typing the PCR products are subsequently 
digested with a restriction enzyme e.g. Alu\ and the patterns are used to discriminate 
strains (Goh et al., 1992). Although spa typing also initially involved restriction enzyme 
digestion, this method has since been modified and currently involves the sequencing o f 
the amplified polymorphic region (Harmsen et al., 2003). This has increased the 
discriminatory capacity o f this approach and it has been found to be comparable to the 
PFGE typing in several studies (Faria et al., 2008, Strommenger et al., 2006, Koreen et 
al., 2004, Harmsen et al., 2003). The DNA sequence between \S431mec and mecA is 
referred to as the hypervariable region (HVR) and is composed o f direct repeat units 
(DRUs) each of which are approximately 40 bp in size (Nishi et al., 1995). Initially the 
HVR-PCR product sizes were used as the basis for discriminating S. aureus strains, 
however, sequencing o f the products and the comparison o f the variable dru sequences 
has been found to be a more discriminatory approach (Goering et al., 2008). Since the
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dru locus is located on SC Cmec elements this method is limited to MRSA and may be 
more appropriate as a subtyping technique. In several studies the DNA sequence 
analysis o f multiple VNTR loci (MVLA) has been shown to be comparable to PFGE 
and is advocated as a potential alternative to this method (Pourcel et al., 2009, Schouls 
et al., 2009, Tenover et al., 2007, Sabat et al., 2003).
DNA sequencing-based methods are increasingly the preferred means o f typing S. 
aureus because they offer the advantage o f rapid, unambiguous, exportable data 
(Deurenberg and Stobberringh, 2008, Faria et al., 2008, Hallin et al., 2007, Aires-de- 
Sousa et al., 2006). Multi locus sequence typing (MLST) involves the generation of 
allelic profiles based on sequencing o f 500 bp internal fragments o f seven housekeeping 
genes, for S. aureus these are: arc (carbamate kinase), aro (shikimate dehydrogenase), 
glp (glycerol kinase), gmk (guanylate kinase), pta  (phosphate acetyltransferase), tpi 
(triosephosphate isomerase) yqi (acetyl-coenzyme A-acetyltransferase 
(http://saureus.mlst.net/). MLST has become the gold standard for long-term 
epidemiological studies, however, it is too expensive and labour-intensive for routine 
surveillance or outbreak investigations (Faria et al., 2008, Mellmann et al., 2008, 
Enright et al., 2002, Enright et al., 2000). Alternatively, spa typing has been 
recommended as a potentially effective technique for long-term epidemiological studies. 
A further advantage o f DNA sequence based genotyping, is the availability of 
accessible internet databases e.g. http://saureus.mlst.net/ and 
http://www.spaserver.ridom.de/. This facilitates data comparison and the monitoring o f 
clone dissemination world-wide (Faria et al., 2008, Strommenger et al., 2008, 
Strommenger et al., 2006, Koreen et al., 2004).
The discrimination of SCC mec elements is integral to the nomenclature o f MRSA 
strains and there are various SCCmec typing methods which have been developed for 
the discrimination of these elements into diverse types (Kondo et al., 2007, Milheirico 
et al., 2007b, Milheirico et al., 2007a, Oliveira and de Lencastre, 2002). The 
combination of the MLST sequence type and the SC Cmec type is fundamental to the 
nomenclature of MRSA clones e.g. ST8-MRSA-IVa (USA300 clone), ST22-MRSA-IV 
(EMRSA-15 clone).
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DNA hybridisation microarray technology is basically miniaturised DNA detection 
assays based on the hybridisation o f a DNA target sequence to its complementary probe 
on a solid support. The number o f oligonucleotide sequences which are used as the 
DNA probes on the microarray plate varies according to the application of the assay. 
This is a powerful molecular technique which has been used for the analysis of bacterial 
genomes (Lindsay et al., 2006, Witney et al., 2005) and also for the characterization o f 
S. aureus strains, MRSA and PVL-positive S. aureus (Tissari et al., 2010, Garch et al., 
2009, Goering et al., 2009, Monecke et al., 2009, Monecke et al., 2008, Monecke et al., 
2007, Lindsay et al., 2006). Since this method enables the detection o f multiple genetic 
determinants in a single test, e.g. virulence genes, pathogenicity related determinants, 
and antibiotic resistance markers, large volumes o f data are obtained for the comparison 
and typing o f strains. Thus with a larger population o f test strains genes that are 
affiliated with particular clones can be identified.
In previous studies the cluster analysis o f the data generated with whole genome 
microarrays has been shown to be concordant with the clonal lineages predetermined by 
MLST (Lindsay et al., 2006, Witney et al., 2005, Lindsay and Holden, 2004, Fitzgerald 
et al., 2001). Furthermore whole genome microarray analysis has granted insights into 
the structural composition o f the S. aureus genome, revealing that a large proportion 
(>50%) is composed of the core genome which comprises genes that are highly 
conserved within clonal lineages (Lindsay and Holden, 2006). It is also composed of the 
accessory genome which is represented by mobile genetic elements (MGEs) such as 
bacteriophages, pathogenicity islands, genomic islands, plasmids and transposons. 
These vary extensively across the different strains and clonal lineages (Lindsay and 
Holden, 2006, Lindsay and Holden, 2004). Therefore strains from the same lineage 
have remarkably conserved genomes (with the exception o f their MGEs) despite having 
diverse geographic, temporal and selective diversity. This has been shown by the 
comparison of whole genome sequences o f the USA CA-MRSA MW2 strain and the 
UK MSSA476 strain which belong to the same lineage, CC1. Even though the former is 
an MRSA, only 285 point mutations were identified among approximately 2,500 genes 
that do not encode MGEs (Lindsay, 2010, Holden et al., 2004). Therefore, since 
microarrays provide a comprehensive analysis o f the core and accessory genes, they can 
enable the elucidation o f which genes are important in invasive infection and also 
identify genes that can serve as ideal targets for candidate antimicrobial therapies.
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1.13 Em ergence of methicillin resistant Staphylococcus aureus 
In 1960 MRSA were first reported in the UK and were implicated in three cases in a 
Southern England hospital (Deurenberg and Stobberringh, 2008, Deurenberg et al., 
2007, Grundmann et al., 2006). The causative strain (NCTC 10442), also referred to as 
the archaic clone, was later found to contain SCCmec type I (Deurenberg and 
Stobberringh, 2008, Grundmann et al., 2006, Ito et al., 2001). By 1967 MRSA which 
were resistant to multiple classes of antibiotics e.g. streptomycin, tetracycline and 
erythromycin, were reported from Switzerland, France, Denmark, England, Australia 
and India. From 1967 to 1971 approximately 15% o f all S. aureus isolates in Denmark 
were methicillin resistant and belonged to the phage type 83A clone (Grundmann et al., 
2006). Even though the rates o f MRSA declined in the 1970s in Europe the 1980’s 
brought a surge of MRSA in many countries including the UK where there was an 
increase in the prevalence o f gentamicin-resistant strains (Grundmann et al., 2006). The 
New York/ Japan clone containing SC Cmec type II also spread to various countries 
worldwide, followed by the discovery o f the MRSA 85/ 2082 strain in New Zealand 
which harbours SC Cmec type III (Deurenberg et al., 2007, Grundmann et al., 2006). In 
the UK a numerical prefix classification system based on phage typing was initiated in 
the 1980s and based on this definition sixteen epidemic types (EMRSA-1 to EMRSA- 
16) were identified in England and Wales until 1995 (Grundmann et al., 2006). In the 
early 1990s, EMRSA-3 was prevalent but then EMRSA-15 emerged in hospitals in the 
Midlands o f England and in 1992 the EMRSA-16 strain was identified as the causative 
pathogen o f an outbreak affecting 400 patients and 27 staff in a hospital in 
Northamptonshire, England (Murchan et al., 2004). EMRSA-17 emerged in hospitals 
along the south coast o f England during the late 1990s but it remained largely restricted 
to this area (Aucken et al., 2006).
Currently the EMRSA-15 and EMRSA-16 clones are the predominant causes of 
hospital-acquired infections (HAIs) in the UK (Ellington et al., 2009, Lindsay, 2009, 
Aucken et al., 2006, Grundmann et al., 2006, Moore and Lindsay, 2002). 
Characteristically HA-MRSA exhibit multiple-antibiotic resistance and carry SCCmec 
type II and III elements, however the EMRSA-15 and EMRSA-16 clones exhibit 
resistance solely to ciprofloxacin and variable resistance to erythromycin and 
clindamycin, and EMRSA-15 harbours the SCC mec type IV element (Amorim et al., 
2007, Aucken et al., 2006, Aucken et al., 2002, Shukla et al., 2004, Okuma et al., 2002).
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The earliest reports of community-acquired MRSA (CA-MRSA) was in the 1980s, 
when MRSA strains were implicated in infections amongst intra-venous drug users in 
Michigan, USA (Millar et al., 2007a). In 1993 novel strains were isolated from skin and 
soft tissue infections o f healthy individuals o f the aboriginal community in Western 
Australia. The infected individuals had no known HAI risk factors and the MRSA had 
exclusively originated in the community (Boucher and Corey, 2008, Grundmann et al., 
2006). In 1999, unanticipated deaths of four previously healthy children were reported 
in Minnesota and North Dakota in the USA. These cases also lacked any HAI risk 
factors and the causative virulent strain was designated the Midwest/MW2 clone 
(Shukla et al., 2004, Ma et al., 2002). Since these early reports CA-MRSA have become 
highly prevalent in the USA but variably present in other countries e.g. Australia and 
Asia (Boyle-Vavra and Daum, 2007, Millar et al., 2007b).
The Centers for Disease Control (CDC) drafted the initial demographic, clinical and 
epidemiologic factors for the differentiation o f HA-MRSA from CA-MRSA (see Table
1.5). CA-MRSA are primarily associated with young healthy individuals or community 
populations with no HAI risk factors i.e. school children, sport athletes especially those 
in team or contact sports, military personnel and incarcerated individuals (see Table
1.5). Generally CA-MRSA cause self-limiting skin and soft tissue infections but certain 
virulent strains like US A300 and the European clone have been affiliated with severe 
infections e.g. necrotizing pneumonia and infective endocarditis. These cases exhibit 
rapid deterioration and are frequently fatal (Boyle-Vavra and Daum, 2007, Millar et al., 
2007b, Maltezou and Giamarellou, 2006). CA-MRSA were originally susceptible to 
non-p-lactam antibiotics, however, the resistance profile of CA-MRSA is evolving and 
some strains express now resistance to several classes of antibiotics e.g. tetracycline, 
erythromycin and clindamycin, chloramphenicol, aminoglycosides and trimethoprim.
CA-MRSA primarily carry S CCmec type IV and some isolates carry SCC mec type V. It 
has been suggested that the carriage o f these smaller SCCmec elements rather than the 
larger type II and III elements, imparts some dissemination advantage to CA-MRSA, 
enabling them to successfully outcompete other MRSA clones and colonise hosts 
(Ellington et al., 2009, Kobayashi and DeLeo, 2009, Boyle-Vavra and Daum, 2007, 
Maltezou and Giamarellou, 2006, Okuma et al., 2002).
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1.14 Prevalent HA-MRSA and CA-MRSA clones
The molecular typing o f S. aureus strains with MLST revealed that this species is highly 
clonal consisting o f about ten dominant human lineages (CC1, CC5, CC8, CC12, CC15, 
CC22, CC25, CC30, CC45 and CC51) and many minor lineages (Feil et al., 2003, 
Enright et al., 2002, Enright et al., 2000). The lineages are often referred to by their 
clonal complex (CC) numbers which are identified by MLST but can also be identified 
with microarray analysis and spa typing (Lindsay, 2010). A selected number o f HA- 
MRSA and CA-MRSA clones associated with specific clonal lineages have become 
established as the leading cause o f infections worldwide (Lindsay, 2010, Deurenberg 
and Stobberringh, 2008, Diep and Otto, 2008, Tristan et al., 2007, Enright et al., 
2002).It is suggested that the success o f these clones is due to the horizontal transfer o f 
MGEs encoding virulence and resistance genes into a lineage that can establish in a 
given environment. The acquired MGEs remain stable within the genome and they 
provide some selective advantage to enable the transmissibility and dissemination o f the 
clone (Lindsay, 2010)
The common names o f HA-MRSA and CA-MRSA clones often reflect the region or the 
communities in which they caused adverse or extensive infections (see Table 1.6 and 
1.7). For instance the Midwest/MW2/USA400 clone (ST1-MRSA-IV) was originally 
prevalent in Western Australia. However, it was later implicated in fatal infections in 
the USA and became well known with reference to this region. McDougal et al. (2003) 
initially defined MRSA in the USA according to their PFGE patterns. They identified 
eight distinct clusters and designated them USA100 to USA800. PFGE types USA300 
and USA400 were from CA-MRSA outbreaks, while the others were from HA-MRSA 
infections (Seybold et al., 2006, McDougal et al., 2003). The Southwest Pacific clone 
(ST30-MRSA-IV) has been frequently implicated in community outbreaks in Australia 
and the USA whereas the European clone (ST80-MRSA-IV) is largely restricted to 
sporadic community associated infections in some European countries i.e. France, 
Denmark, Norway. The Pacific clone or Taiwanese clone (ST59-MRSA-Vt) is highly 
prevalent in paediatric infections in Taiwan and is becoming established as a HA- 
MRSA clone in this country (Chen et al., 2009, Takano et al., 2008).
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Table 1.7. Major CA-MRSA clones identified worldwide (Diep and Otto, 2008, 
Deurenberg and Stobberringh, 2008)_____________________________________________
Clone MLST profile STa CCb SC Cmec spa type0
Midwest/MW2/ l - l - l - l - l - l - l 1 1 IV t!27 ,tl 28,tl 74,tl 76
USA400 t386,t558
Southwest 2-2-2-2-6-3-2 30 30 IV tO 12,t018 ,t019,t021
pacific/Oceania t038,t268
European 1-3-11-14-11-51-10 80 80 IV t044,tl 31 ,t376,t416 
t436 t455,tl 109
Pacific 19-23-15-2-19-20-15 59 59 IV or Vy t216,tl99,t444
US A3 00 3-3-1-1-4-4-3 8 8 IV t008,t024,t064,t 190 
t206,t211
“Sequence type; Clonal complex, cspa types according to the Ridom SpaServer (most prevalent spa types in bold)
The most notorious CA-MRSA clone is USA300 (ST8-MRSA-IVa) because o f its high 
prevalence in the USA. It is characterised by the PFGE profile designated US A300- 
0114 and first came to the attention of CDC in 2000 during an outbreak among football 
players in Pennsylvania, USA. In subsequent years it showed high transmissibility 
causing a series of outbreaks throughout the country e.g. among prisoners in California, 
Texas and Georgia, children in Texas, Illinois and Arkansas and athletes in Colorado 
and Indiana (Tenover and Goering, 2009, King et al., 2006).
In the UK, MRSA remain primarily associated with HAIs and the leading HA-MRSA 
clones belong to the ST22-MRSA-IV (EMRSA-15) and ST36-MRSA-II (EMRSA-16) 
clonal lineages. CA-MRSA represent <1% o f MRSA but due to the high transmissibility 
o f certain CA-MRSA clones, there is a possibility that some could be imported and 
established into the UK (Ellington et al., 2009, Elston and Barlow, 2009, Tenover and 
Goering, 2009).
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1.15 Virulence factors of S. aureus
A plethora o f secreted and cell-surface associated virulence factors have been described 
in S. aureus and these function at different stages o f infection such as the adhesion to 
host cells and the evasion o f innate and acquired immune responses (Foster, 2005, 
Rooijakkers et al., 2005). Adhesion to extracellular matrix proteins is mediated by 
Microbial Surface Components Recognising Adhesive Matrix Molecules which are 
convalently anchored to peptidoglycan by sortase (Otto, 2010, Foster, 2005). These 
include clumping factors A, B and Efb which bind fibrinogen and SdrC, SdrD and SasG 
which promote adhesion to squamous cells (Foster, 2005). On establishment during 
invasive infection within the host tissues formylated peptides are secreted by the 
growing bacterium. In addition the C3a and C5a peptide fragments are released by 
complement activation and these are recognised with high affinity by receptors on the 
surface o f neutrophils (Foster, 2005). Consequently S. aureus strains can express 
chemotaxis inhibitory proteins which bind C5a- and formyl peptide-receptors on the 
surface o f neutrophils, thus inhibiting the attraction o f these phagocytes to the growing 
bacteria (Foster, 2005). Staphylococci complement inhibitor is also involved in the 
inhibition of complement activation. S. aureus strains also express protein A, which is 
cell-surface associated protein. It binds to the Fc region o f IgG resulting in a coat of 
non-specific antibodies around the bacterium, thus inhibiting the recognition of the 
bacteria by phagocytes (Otto, 2010, Foster, 2005). Some strains also express a capsular 
polysaccharide to prevent phagocytosis and many strains also carry the icaADBC 
operon which encodes the polysaccharide intercellular adhesion (PIA) in S. epidermidis. 
PIA is a major mechanism of intercellular adhesion which is essential for the 
accumulation of multilayered biofilms. It has also been shown to confer virulence to S. 
epidermidis strains and also grant reduced susceptibility to certain combinations of 
antibiotics (Mack et al., 2006). Similarly, in S. aureus the icaADBC operon may confer 
similar properties.
S. aureus also harbours pathogenicity islands that encode several virulence genes, 
including genetic determinants for superantigens, toxic shock syndrome toxin-1 {tst) 
and enterotoxins B and C (seb, sec). These can elicit a non-specific T-cell response, 
leading to massive cell expansion and shock. Other S. aureus toxins include exfoliative 
toxins A and B, encoded by eta, etb, which cause scalded skin syndrome (Lindsay and 
Holden, 2006).
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Toxins that lyse immune cells represent some of the most crucial weapons that S. 
aureus strains use in the evasion of the immune response. S. aureus exotoxins are 
involved in the lysis o f erythrocytes or leukocytes, many are p-channel pore forming 
leukotoxins and are monomeric or have a bi-component structure. The archetype is a - 
toxin/a-haemolysin (Hla) which forms pores in the cytoplasmic membrane o f several 
cell types including monocytes, platelets and erythrocytes. Panton-Valentine 
Leukocidin (PVL) also belongs to the pore-forming leukotoxin family. It is a bi­
component toxin comprising LukF-PV and LukS-PV subunits encoded on an operon. S. 
aureus strains acquire PVL genes via various PVL-encoding bacteriophages OSa2958, 
OSa2mw, OPVL, O108PVL, OSLT, and OSa2USA (Boakes et al., 2010, Otto, 2010, 
Kobayashi and DeLeo, 2009). There is variability in the prevalence of virulence factors 
in S. aureus strains; while a-toxin is expressed by most strains, PVL is expressed by a 
much lower proportion o f strains i.e. 2-3% (Loffler et al., 2010, Otto, 2010).
1.15.1 Role of PVL in Staphylococcus aureus pathogenesis
PVL genes are frequently present in established CA-MRSA clones and absent in the 
leading HA-MRSA clones. As such it has previously been used as an epidemiological 
marker for CA-MRSA. Furthermore since certain CA-MRSA clones have been 
implicated in severe necrotising infections e.g. necrotising pneumonia, necrotising 
fasciitis and sepsis, it has been considered that PVL could contribute directly to the 
virulence o f these clones (Li et al., 2009, Boyle-Vavra and Daum, 2007). Several 
studies have employed in vitro cell culture experiments and different animal infection 
models to investigate the specific role of PVL in CA-MRSA pathogenesis, however, 
these have generated conflicting results and the role o f PVL remains a point of 
contention (Loffler et al., 2010, Otto, 2010, Li et al., 2009, Kobayashi and DeLeo, 2009, 
Diep et al., 2008a).
In a recent study by Brown et al. (2009) mice were infected with lx l0 8 CFUs o f PVL- 
positive USA300 or with isogenic PVL-negative strains and examined for 8 days. 
Seventy two percent of the mice infected with the PVL-positive strains died 2 days post 
infection, compared to only 19% mortality of the mice infected with the isogenic PVL- 
negative mutant strains. Furthermore the PVL-positive strains caused more aggressive
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lung damage and severe myositis beneath the site of infection on the skin. Similarly, 
Labandeira-Rey et al. (2007) used purified PVL and isogenic PVL-positive and 
negative S. aureus strains in murine pneumonia models. They determined that PVL had 
a key role in pulmonary infections and the expression of lukF/lukS-?V genes interfered 
with global regulatory factors (Labandeira-Rey et al., 2007). Diep et al. (2008) used 
isogenic USA300 PVL-positive and PVL-negative strains in a bacteraemia rabbit model 
and investigated bacterial densities in vital organs i.e. lungs, spleen and kidney. They 
found higher densities of the PVL-positive strain in the kidney at 24 and 48 hours but at 
72 hours the densities o f the isogenic PVL-positive and negative strains were 
comparable. So the they deduced that PVL has a minor and transient role in 
pathogenesis (Diep et al., 2008a).
Even though the former studies illustrate the virulence potential o f PVL they are 
ardently contested by other studies with contrasting results. For instance Voyich et al.
(2006) compared PVL-positive USA300 and USA400 strains to their isogenic PVL- 
negative mutants in sepsis and abscess mouse models and found that the wild type and 
the mutants caused comparable skin conditions (Voyich et al., 2006). Similarly, 
Wardenburg et al. (2007, 2008) used a USA300 strain and its isogenic PVL-negative 
mutant in murine models o f staphylococcal skin infection and pneumonia. They also 
found that PVL did not increase the virulence o f staphylococcal infection in mice 
(Wardenburg et al., 2008, Wardenburg et al., 2007). Furthermore Otto (2010) discusses 
these former studies in a comprehensive review and determines that PVL does not have 
a key role in S. aureus pathogenesis (see Table 1.8).
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1.16 The Arginine Catabolic Mobile Element
The arginine catabolic mobile element (ACME) was initially identified in S. aureus by 
Diep et al. (2006) when they sequenced the complete genome o f the USA300 FPR3757 
strain (Montgomery et al., 2009, Diep and Otto, 2008, Ellington et al., 2008). The 30.9 
kb genetic island was integrated into orjX  at the same attachment site as the SCCmec 
element. As it was flanked by repeat sequences characteristic o f SCC mec elements they 
postulated that it uses the SCC mec recombinase genes for integration and excision from 
the core genome. The ACME element comprises diverse genes and Diep et al. (2006) 
characterised two interesting gene clusters: arc and Opp-3. The arc gene cluster 
comprises six genes which encode a complete arginine deiminase pathway which 
mediates the conversion of L-arginine to carbon dioxide, ATP and ammonia. The 
generated ammonia could enable the strain to maintain pH homoeostasis on the acidic 
human skin (pH 4.2-5.9). As the ATP was induced under anaerobic conditions it could 
be important for energy production in wound environments which are low in oxygen 
(Diep et al., 2006). Therefore the ACME element could facilitate colonization and 
persistence within a host (Montgomery et al., 2009). All S. aureus strains carry a native 
arc cluster on the core genome which is induced under biofilm and mild acid conditions 
but it is different from the ACME-arc cluster by virtue o f gene sequence and 
orientation. The second gene cluster identified in ACME, was the Opp-3 operon which 
comprises five genes encoding a putative oligopeptide permease pathway (Diep et al., 
2006). It was termed number three to differentiate it from the native Opp-1 and Opp-2 
operons present in the core genome. Homologues o f these operons are present in group 
A Streptococcus species and other gram positive and gram negative bacteria. They 
encode various functions including peptide nutrient uptake, quorum sensing, pheromone 
transport, chemotaxis, eukaryotic cell adhesion, binding o f serum components and 
expression of virulence determinants (Podbielski et al., 1996).
Outside o f the USA300 genome, ACME has been infrequently detected in other S. 
aureus genetic backgrounds. Diep et al. (2008) discovered variant allotypes in MRSA 
strains belonging to ST5 and ST59 lineages whereas Ellington et a l  (2008) detected 
ACME in MRSA belonging to ST1 and ST97 lineages (Diep et al., 2008b, Ellington et 
al., 2008).
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Many o f the antibiotic resistance and virulence determinants harboured by S. aureus 
strains originate in S. epidermidis and other coagulase-negative staphylococci. 
Similarly, S. haemolyticus strains and many S. epidermidis strains also carry diverse 
ACME allotypes, including the allotype specifically found in the US A300 clone. It is 
thought that ACME was horizontally acquired by US A300 from S. epidermidis and that 
this transfer was central to the evolution o f the US A300 clone (Miragaia et al., 2009, Pi 
et al., 2009).
The role of ACME in S. aureus pathogenesis has been investigated in several studies 
but with conflicting results (Montgomery et al., 2009, Diep et al., 2008b). In co- 
infection studies involving a rabbit bacteraemia model, Diep et al. (2008b) inoculated 
rabbits with both the wild type US A300 and isogenic ACME-deletion mutants and they 
found greater numbers o f the wild type strain in the lungs, spleen and blood o f the 
rabbits and concluded that the deletion o f ACME attenuates the fitness o f the USA300 
strain. Montgomery et al. (2009) used murine models o f necrotizing pneumonia and 
skin infection to investigate the role of ACME. They used isogenic ACME positive and 
deletion mutants o f USA300 strains and also clinical isolates containing ACME and 
lacking the element. They found no significant difference between the virulence of the 
wild type US A300 and its isogenic deletion mutant in the murine models. There were 
also no differences between the clinical isolates containing or lacking ACME. So the 
role o f ACME in the USA300 clone pathogenicity and the significance o f its presence 
in the genetic background o f some other S. aureus backgrounds remain unclear.
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1.17 MRSA infections: societal effects and infection control measures
MRSA infections are a health-care problem in the UK and many countries worldwide so 
the control of these infections is essential (Grundmann et al., 2006). Surveillance 
systems such as the European Antimicrobial Resistance Surveillance System and the 
National Nosocomial Infection Surveillance System sponsored by the CDC in the USA, 
serve to monitor HAIs and provide national prevalence rates of MRSA. In the UK, a 
compulsory surveillance system was undertaken by acute National Health Service 
(NHS) Trusts from April 2001 requiring the reporting o f MRSA causing bacteraemia 
(Pearson et al., 2009).
The MRSA prevalence rates in S. aureus bacteraemia peaked at 40-45% during 2001 - 
2005 in the UK but decreased to 37% in 2007 and these rates continue to decline (see 
Figure 1.8) (Pearson et al., 2009, Woodford and Livermore, 2009, Gould, 2005). For 
instance recent data from the voluntary reporting scheme shows that there were 11,115 
S. aureus bacteraemia reports in 2009, comprising 10,039 from England, 585 from 
Wales and 491 from Northern Ireland indicating a 10.8% decrease from rates in 2008 
(www.hpa.org.uk/hpr/infections/bacteraemia.htm#saur).
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Figure 1.8. Trends in S. aureus bacteraemia laboratory reports (voluntary reporting 
scheme): England, Wales and Northern Ireland 2000-2009 
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In certain other countries the prevalence rates o f MRSA are considerably higher, e.g. in 
the USA MRSA accounts for >60% of S. aureus isolates in hospital intensive care units 
and >50% of S. aureus bacteraemia isolates (Boucher and Corey, 2008, Shukla et al., 
2004). In European countries the prevalence varies considerably, for instance the 
Netherlands and Scandinavian countries have exceptionally low prevalence rates <1% 
but this is in contrast to other countries e.g. Italy, Spain, Greece and Portugal which 
have reported high rates (>30%) (van Rijen and Kluytmans, 2009, Boucher and Corey, 
2008, Zetola et al., 2005).
Societal costs o f MRSA infections accrue directly from extended hospital stays and 
additional antibiotic use or indirectly from reduced productivity, long-term disability 
and cases o f mortality. Other financial repercussions include costs for the containment 
o f outbreaks and changes o f empirical antibiotic prescriptions (Grundmann et al., 2006). 
The economic burden of MRSA infections is not readily available in many countries but 
studies in the USA suggest that patients with MRSA infections have up to three times 
increased hospital stay; three times total charges and five times the risk o f in-hospital 
mortality. National hospital costs are between $1.5 billion and $4.2 billion (Gould, 
2006). In the UK, the results of a study conducted in an England NHS trust district 
hospital revealed an estimated 320 994 patients per annum have one or more infections 
presenting during the in-patient period, costing the hospital sector approximately £1 
billion per annum and the hospital costs resulting from a MRSA outbreak have been 
estimated at £400 000 (Plowman et al., 2001).
In an effort to reduce the burden o f MRSA infections, the UK Department of Health 
introduced the target to reduce MRSA bacteraemia in all acute and foundation trusts by 
50% by 2008 (NAO Report: Reducing Healthcare Associated Infections in Hospitals in 
England, 2009). This was pursued by the implementation o f several strategies including 
the robust training on infection control procedures (NAO Report: Reducing Healthcare 
Associated Infections in Hospitals in England, 2009). In May 2008 reports indicated 
that the NHS had attained a 57% reduction of MRSA bacteraemia against the initial 
target o f 50%, indicating that the reduction o f infections is attainable (NAO Report: 
Reducing Healthcare Associated Infections in Hospitals in England, 2009).
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Rapid laboratory diagnosis is an important part o f infection control but routine 
phenotypic assays involving the growth o f cultures in media, biochemical and antibiotic 
susceptibility tests have long turnaround times of up to 24 to 48 hours, whereas 
molecular real-time PCR-based methods are more rapid (2 to 4 hours) and generally 
more sensitive. From a laboratory perspective the development and implementation of 
rapid and accurate screening methods is essential as this can benefit a more rapid 
implementation of infection control procedures and consequently facilitate the reduction 
o f MRSA transmission.
In light o f this the objectives o f this study were the following:
i. To investigate the concordance of the mec A and femA  real-time PCR results of 
S. aureus isolates to the reported results by the Public Health Wales (PHW) 
Microbiology ABM Swansea Laboratory.
ii. To determine the genotypic characteristics of the MRSA isolates with the 
following molecular typing techniques: PFGE, spa typing and SCCmec typing.
iii. To compare the diagnostic performance o f three SCC/wec-o/yX PCR methods by 
determining the sensitivity, specificity and predictive values with a collection of 
MRSA and MSSA isolates.
iv. To further investigate the genotypic characteristics of false negative and false 
positive isolates o f the SCCmec-orjX PCR methods by PFGE, spa typing and 
SCCmec typing.
v. To investigate the prevalence o f PVL in unselected consecutive S. aureus 
isolates and to characterize the PVL-positive strain by PFGE, spa typing, 
SCCmec typing and detection of ACME.
vi. To compare the molecular epidemiology of two collections of PVL-positive S. 
aureus strains from PHW Microbiology ABM Swansea Laboratory and the 
Specialist Antimicrobial Chemotherapy Unit, Cardiff.
vii. To explore the discriminatory capacity o f the Matrix Associated Laser 
Desorption Ionisation-Time O f Flight mass spectrometry technique with a 
collection 137 S. aureus isolates.
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Chapter Two 
Materials and Methods
2.1 Media
Media was prepared with distilled water (dH^O) and sterilised at 121 °C for 15 min in 
bench-top pressure vessels (Prestige Medical) or the front loading autoclave 
(Priorclave).
2.1.1 Tryptose Soy media (TSB)
TSB powder 30 g/ L
15g/ L Oxoid Bacteriological Agar was used for TSB agar
Make up to 1L with d tkO
2.1.2 Oxoid ready-to-use agar plates (90 mm)
The following were obtained from PHW Microbiology ABM Laboratory.
2.1.2.1 Columbia Blood Agar with horse blood (CBA)
2.1.2.2 2% NaCl Columbia Salt Agar (CSA)
2.1.2.3 Iso-Sensitest Agar
2.2 Buffers and stock solutions
2.2.1 50X TAE Buffer
Tris Base 242 g
Glacial acetic acid
EDTA 22.6 g
57 ml
Make up to 1L with dH20, adjust to pH 8.0
2.2.2. DNA Enzymatic lysis buffer
Tris-HCl (pH8) 
EDTA 
Triton X-100
20 mM 
2m M
1.2%  (w/v)
100 pg/ml RNAse 
100 |ig/ml Lysostaphin
10 pi 
10 pi
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2.2.3 Buffers and stock solutions for Pulsed field gel electrophoresis (PFGE)
2.2.3.1 0.5M EDTA (stock)
Na-EDTA 93.06 g
dH20  400 ml
Adjust pH to 7.5 with NaOH. Make up to 500ml.
2.2.3.2 5M NaCl (stock)
NaCl 146.1 g
dH20  to 500ml
2.2.3.3 Tris-HCl, pH 7.5 (stock)
Tris Base 2.36 g
Tris-HCl 12.70 g
dH20  89 ml
Make up to 100ml. Autoclave and check pH before use.
2.2.3.4 SE Buffer (75mM  NaCl, 25mM EDTA, pH 7.5)
5M NaCl 15 ml
0.5M EDTA 50 ml
dH20  to 1000ml
2.2.3.5 1.6% Low-melting point (LMP) agarose
LMP agarose (BIO RAD) 80 mg
SE buffer 5 ml
Melt in microwave oven and equilibrate to 50°C in a water bath before use. 2ml aliquots 
stored at -20°C.
2.2.3.6 TE Buffer (10mM  Tris-HCl, lOmM Na-EDTA)
1M Tris-HCl (pH 7.5) 10 ml
0.5M Na-EDTA (pH 7.5) 20 ml
dH20  970 ml
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2.23.1  Lysis Buffer (6mM Tris-HCl, 1M NaCl, lOOmM EDTA, 0.2% Na-deoxycholate,
1% Na-lauryl sarcosine)
1M Tris-HCl (pH 7.5) 1.2 ml
5M NaCl 40 ml
0.5M EDTA (pH 7.5) 40 ml
Na-deoxycholate 400 mg
Na-lauryl sarcosine 2.0 g
dH20  to 200ml
2.2.3.8 Lysis solution
Lysis Buffer 1 1 ml
Lysostaphin (5mg/ml) 10 pi
2.2.3.9 Proteinase K buffer (pH 9)
Na-lauryl sarcosine 10 g
0.5M EDTA (pH 7.5) 1000 ml
Add 40-50 drops of NaOH to pH 9, make up to 1L
2.2.3.10 Proteinase K lysis solution
Proteinase K buffer 1ml
Proteinase K 2pl
2.2.3.11 Buffer J(10X )
T r i s  HC1 (pH 7.5) lOOmM
MgCl2 70 mM
KC1 500 mM
D L - D i t h io t h r e i t o l  ( D T T )  10 mM
2.2.3.12 0.5X TBE
1 OX TBE (bought stock) 100 ml
dH20  1900 ml
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2.3 Agarose gels and gel staining solutions
2.3.1 2%Agarose gel
Agarose 1.5 g
lx  TAE 75 ml
2.3.2 PFGE small agarose certified megabase gel
Agarose (BIO RAD) 1.2 g
0.5XTBE 120 ml
Melt at 60°C in microwave
2.3.3 PFGE large agarose certified megabase gel
Agarose (BIO RAD) 1.6 g
0.5XTBE 160 ml
2.3.4 Ethidium Bromide DNA staining solution
Ethidium bromide 20 jil
dH20  400 ml
2.3.5 SYBR safe DNA gel stain (Invitrogen)
SYBR safe DNA gel stain 1 pi 
Melted agarose 10 pi
2.4 QIAGEN Buffers
2.4.1 Buffer AL
Supplied in QIAamp DNA Mini Kit (Qiagen, UK), details not provided
2.4.2 Buffer AW1
Supplied in QIAamp DNA Mini Kit as a concentrate and the appropriate volume of
ethanol was added as stated on the label of the bottle.
2.4.3 Buffer AW2
Supplied in QIAamp DNA Mini Kit as a concentrate and the appropriate volume of
ethanol was added as stated on the label o f the bottle.
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2.4.4 Buffer PBI
Supplied in QIAquick PCR Purification kit, details not provided.
2.4.5 Buffer PE
Supplied in QIAquick PCR Purification kit, details not provided.
2.5 Enzymes
Analytical grade enzymes and chemicals were obtained from Promega, Sigma, Fisher 
BioReagents and Qiagen:
• Protease (supplied in QIAamp DNA Mini kit)
• Lysostaphin (Sigma)
•  lOOmg/ ml Proteinase K (Fisher BioReagents)
• lOOmg/ ml RNAse A (Qiagen)
• 10 U/ mg Smal (Promega)
Lyophilised lysostaphin (Sigma, UK) was dissolved in dlUO to 5 mg/ ml and stored at 
-20°C. DTT (DL-Dithiothreitol) (Sigma) was dissolved in dlUO to 100 mM and stored in 
the dark at -20°C.
2.6 Bacterial growth conditions
S. aureus cultures were grown under aerobic conditions at 37°C (unless otherwise 
stated) in laboratory incubators: the stationary incubator (Genlab, UK), the Lab Therm 
LT-X incubator with an inbuilt Kuhner shaker, the HT Inforse Minitron incubator and 
the Sartorius Certomat BS-1 incubator.
2.7 Storage and preparation of bacterial stocks
S. aureus isolates were preserved on Protect™ cryopreservation beads (Technical 
Service Consultants Ltd, UK) and stored at -80°C in an ultra low temperature freezer 
(New Brunswick Scientific, UK). Isolates were also preserved in glycerol stocks (0.7ml 
TSB and 0.3ml 50% glycerol) in 1.5 ml microcentrifuge tubes (Fisherbrand, UK) and 
stored at -20°C in freezers (Liebherr-Profiline, Germany). Fresh media plates and 
cultures were stored at 2 to 8°C in separate refrigerators (LEC, UK and Liebherr- 
Profiline, Germany) or in the laboratory cold room.
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2.8 Vortex and centrifugation
Genie-2 vortexes (Scientific Industries Inc.) were used for the vigorous mixing of 
suspensions and solutions. Cells were harvested from liquid cultures or from 
suspensions by spinning at high speeds in the laboratory centrifuges: the Sanyo MSE 
MicroCentaur,the Eppendorf centrifuge 5418, the Eppendorf centrifuge 5415R and 
Eppendorf Mini Spin centrifuge.
2.9 Bacterial strains
The bacterial reference strains included MRSA strains: NCTC10442 (SCCmec type 1/ 
accession number AB033763), N315 (SCCmec type II/ accession number D86934) and 
85/2082 (SCCmec type III/ accession number AB037671), as described by (Ito et al.,
2001). CA05 (SCCmec type IVa/ accession number AB063172) and JCSC1978 or 8/6- 
3P (SCCmec type IVb/ accession number AB063173) as described by (Ma et al., 2002). 
MR108 or 81/108 (SCCmec type IVc/ accession number AB096217) as described by 
(Ito et al., 2003) and WIS (SCCmec type V/ accession number A B121219) as described 
by (Ito et al., 2004) were kindly provided by T. Miethke, Munich, Germany. The UK 
epidemic MRSA strains, EMRSA-1 to EMRSA-17 were kindly provided by J. A. 
Lindsay, St. Georges Hospital Medical School, London, UK (Moore and Lindsay,
2002).
The MRSA reference strains which carried genes for Panton-Valentine Leukocidin 
(PVL) were: MW2 (provided by T. Miethke), the USA300 SF8300 and USA300 
FPR3757 strains (provided by B. A. Diep, UCLA, Los Angeles, USA). The PVL- 
positive MSSA reference strains were: the Oxford strain (provided by the PHW 
Microbiology ABM Laboratory) and the MSSA476 strain (provided by J. A. Lindsay).
2.10 Clinical isolates
S. aureus isolates were initially identified from wound swabs in the PHW Microbiology 
ABM Laboratory and were collected as pure cultures on Iso-Sensitest agar plates. 
Colonies were collected directly from these cultures or were sub-cultured onto CBA 
plates and incubated at 37°C for 24 hours. Fresh cultures were prepared by inoculating 
isolates from frozen stocks onto CBA plates (or other media), these were then incubated 
at 37°C for 24 hours.
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2.11 Extraction of genomic DNA
2.11.1 Crude genomic DNA
Colonies were picked directly from cultures and a bacterial suspension o f two to three 
colonies in 400jnl nuclease free water was prepared in 1.5 ml micro-centrifuge tubes and 
heated at 95°C for 10 min in a dry heat block (Techne, UK). The suspension was 
centrifuged at 8000 xg for 3 min and then 2 pi of the supernatant was transferred to 
23 pi PCR reaction mix.
2.11.2 Purified genomic DNA
Purified genomic DNA was extracted from S. aureus isolates with the QIAamp DNA 
Mini kit (QIAGEN, UK). Isolates were inoculated onto CBA plates from frozen stocks 
and incubated overnight at 37°C, a single colony was then suspended in 5 ml TSB broth 
and grown overnight at 37°C. Then 1.0 ml o f bacterial culture was pipetted into a 1.5ml 
micro-centrifuge tube and centrifuged for 5 min at 13000 xg. The supernatant was 
discarded and the bacterial pellet was suspended in 180 pi o f the enzymatic lysis buffer, 
with lOpl lysostaphin and lOpl RNase. The mixture was incubated for at least 30 min at 
37°C (solution should go clear) and then 20 pi Proteinase K and 200 pi Buffer AL was 
added and mixed by vortexing. The mixture was incubated at 56°C for 30 min. The 
mixture was then briefly centrifuged and 200 pi ethanol was added, pulse-vortexed for 
15 sec and briefly centrifuged to remove droplets from the inside o f the lid. The mixture 
was carefully transferred to the QIAamp Spin Column (in a 2.0 ml collection tube) 
without wetting the rim and centrifuged at 6,000 xg (8000 rpm) for 1 min. The 
collection tube containing the flow through was discarded and the QIAamp spin column 
was placed in a clean 2 ml collection tube provided. 500 pi Buffer AW1 was carefully 
added into the QIAamp spin column and centrifuged at 6000 xg for 1 min. The 
collection tube containing the flow through was discarded and the QIAamp spin column 
was placed in a clean 2 ml collection tube. 500pl Buffer AW2 was carefully added into 
the QIAamp spin column and centrifuged at 20,000 xg (14000 rpm) for 3 min. The 
collection tube containing the flow through was discarded and the QIAamp spin column 
was placed in a clean 1.5 ml micro-centrifuge tube. 200 pi sterile dlUO was carefully 
added into the QIAamp spin column and incubated at room temperature for 5 min and 
then centrifuged at 6,000 xg for lmin. The eluted DNA was stored at -20°C for long­
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term storage and in subsequent PCR assays 1 pi was transferred to 24 p.1 PCR reaction 
mix.
2.12 Calculation of DNA concentration
The concentration (ng/ pi) o f DNA in extracts or amplification products was ascertained 
with the Nanodrop ND-1000 spectrophotometer (Thermo Scientific, USA) which was 
performed according to the manufacturer’s instructions. Only 2 pi of the samples was 
required and the concentrations were determined by the in-built software and were 
shown on the viewer display screen. On completion the system was shut down 
according to the manufacturer’s instructions.
2.13 Polymerase Chain Reaction methods
The Sensimix No Ref (Quantace, UK) reaction mix was used for all the polymerase 
chain reaction (PCR) assays i.e. conventional and real-time PCR methods. The ready- 
to-use heat activated 2 x reaction mix containing: heat-activated DNA polymerase; 
dNTPs and M gCk (6 mM). Separate vials o f SYBR Green and 50 mM MgCl2 were also 
provided. All the reactions were performed in a total volume o f 25 pi in detached 0.2 
mL thin-walled, flat capped tubes (StarLab, UK).
With the conventional PCR methods the reactions were performed in the DNA Engine 
Tetrad 2 Thermal cycler (BIO-RAD, UK) and products were resolved by 
electrophoresis in an agarose gel. They were prepared by dissolving agarose powder in 
1 X TAE buffer by boiling in a 900W or 1200W microwave oven (Sanyo, UK). Then 
SYBR safe DNA gel stain (Invitrogen) was added (1 pi/ ml) and the mixture was gently 
swirled to mix it in the stain. The mixture was poured into a casting tray, the required 
sized comb was set in and the gel was cooled at room temperature. The agarose 
concentration was dependant on the size o f the PCR products: <1000 bp products were 
resolved in a 2% gel and >1000 bp products were resolved in a 1% gel. Electrophoresis 
was performed in mini tanks (Mini Subcell GT, BIO-RAD) with 1 X TAE buffer used 
as the running buffer for 40 to 50 min at 110V. Visualisation and imaging o f the PCR 
products was done with the BIO-RAD Molecular Imager Gel Doc XR system and the 
Quantity One 4.6.3 Basic software (BIO-RAD, UK).
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With the real-time PCR methods the PCR products were detected with SYBR Green 
which was provided in the Sensimix No R ef kit. The reactions were performed in the 
Rotor-Gene RG-6000 (Corbett Life Science, Australia).
2.13.1 Amplification of target sequences in the mecA and femA  genes
The amplification o f target sequences in mec A, femA  o f S. aureus (femAsf) and femA  of 
S. epidermidis {femAs e )  was done with singleplex real-time PCR methods which were 
adapted from Francois et al. (2003). Since S. epidermidis is a common contaminant of 
staphylococci wound infections the femAsE PCR was included to detect the presence of 
S. epidermidis (see Table 2.1).
2.13.2 Amplification of sequences of the SCCmec-orJX right junction
Three methods: PCR-A, PCR-B and PCR-C were employed for the amplification o f the 
SCCmec-orfX  junction. The PCR-A method was adapted from the Huletsky et al. 
(2004) method, the PCR-B method was adapted from the Hagen et al. (2005) method 
and the PCR-C method adapted was from the Cuny and Witte (2005) assay (see Table 
2 .1).
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The real-time PCR cycles were performed as following: 
mecA, femAsA and fem ASE PCR methods __________
Singleplex PCR reaction mix PCR cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
Forward primer 200nM S2 95°C / 15s (denature)
Reverse primer 200nM 60°C / 20s (anneal)
SYBR Green 0.75pl 72°C / 20s (extension)
Crude DNA supernatant 2.0 pi Repeat cycle S2 50 times
Make up to 25pi with Nuclease free water Melt
PCR-A SCCm ec-orfX  method
M ultiplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
Forward primer (DM6) 200nM S2 95°C /15s
Forward primer (DM7) 200nM 60°C / 20s
Forward primer (DM8) 200nM 72°C / 20s
Forward primer (DM9) 200nM Repeat cycle S2 50 times
Forward primer (DM10) 200nM Melt
Reverse primer (DM11) 200nM
SYBR Green 0.75pl
Crude DNA supernatant 2.0 pi
Make up to 25pi with Nuclease free water
Key: S l-step l, S2-step 2.
PCR-B SCCm ec-orfX  method
M ultiplex PCR (M aster Mix) PC R  cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
Forward primer (DM3) 200nM S2 95°C /15s
Forward primer (DM4) 200nM 56°C / 20s
Reverse primer (DM5) 200nM 72°C / 20s
SYBR Green 0.75pl Repeat cycle S2 50 times
Crude DNA supernatant 2.0 pi Melt
Make up to 25pi with Nuclease free water
Sl-step l, S2-step 2
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PCR-C SCCmec-orfX  method
Singleplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
Forward primer (DM1) 200nM S2 95°C /15s
Reverse primer (DM2) 200nM 55°C / 20s
SYBR Green 0.75pl 72°C / 20s
Crude DNA supernatant 2.0 pi Repeat cycle S2 50 times
Make up to 25pl with Nuclease free water Melt
Sl-step l, S2-step 2.
2.14 Amplification of Panton-Valentine Leukocidin
The amplification of a sequence in the Panton-Valentine Leukocidin (PVL) gene was 
done with a real-time PCR method which was adapted from Deurenberg et al. (2004) 
(see Table 2.2).
2.15 Amplification of arcA-ACM E  sequence
The amplification of a sequence in the arcA gene o f the arcRADBC locus located in the 
Arginine Catabolic Mobile Element (ACME) was performed with a conventional PCR, 
performed in a DNA Engine Tetrad 2 Thermal cycler (BIO-RAD, UK). The method 
which was adapted from Zhang et al. (2008) (see Table 2.3).
Table 2.2. Oligonucleotides for the PVL RT-PCR
Label Sequence (5’-3 ’) Position Reference
PVL-F
PVL-R
GCT GG AC AA AACTT CTT GG A AT AT 
GATAGGACACCAATAAATTCTGGATTG
2666-2690° 
2749-2723 °
(Deurenberg et al., 2004) 
(Deurenberg et al., 2004)
aS.aureus V 8/A T C C 49775
Table 2.3. Oligonucleotides for the arcA-ACME  PCR
Label Oligonucleotide sequence (5’-3’) Position Reference
arc A- F 
arc A- R
GC AGC AG AATCT ATTACT G AGCC 
TGCTAACTTTTCTATTGCTTGAGC
74075-74053°
73563-73586“
(Zhang et al., 2008) 
(Zhang et al., 2008)
° Staphylococcus aureus subsp. aureus USA300, TCH1516, CP000730.1
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The PVT PCR method
Singleplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
Forward primer 200nM S2 95°C /15s
Reverse primer 200nM 60°C / 20s
SYBR Green 0.75pl 72°C / 20s
Crude DNA supernatant 2.0 pi Repeat cycle S2 40 times
Make up to 25pi with Nuclease free water Melt
The arcA-ACM E  PCR method
Singleplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi SI 95°C / lOmin
arc A- Forward 400nM S2 95°C / 30s
arc A- Reverse 400nM 60°C / 30s
Genomic DNA 1.0 pi 72°C / 45s
Make up to 25pi with Nuclease free water S3 72°C / 4min
Hold at 4°C
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2.16 Purification of PCR products
2.16.1 QIAquick PCR purification
The purification of the PCR products for subsequent DNA sequencing was done with 
the QIAquick PCR purification kit (QLAGEN, UK) according to the manufacturer’s 
instructions. Five times the volume of Buffer PBI was added to one volume of the PCR 
reaction before mixing. The mixture was applied to the QIAquick column and 
centrifuged at 13000 rpm for 1 min, the flow through was discarded and the QIAquick 
column was placed back into the same collection tube. Then 0.75 ml Buffer PE was 
added to the QIAquick column and centrifuged at 13000 rpm for 1 min. The flow 
through was discarded and the QIAquick column was placed back in the same 
collection tube. The column was centrifuged again for 1 min at 13000 rpm in order to 
remove any remaining traces of Buffer PE. The QIAquick column was placed in a clean
1.5 ml micro-centrifuge tube and 30 pi sterile dFLO was added. The column was left to 
stand for 1 min and then centrifuged for at 13000rpm for 1 min and the eluate was 
stored at -20°C.
2.16.2 Sequencing of PCR products
DNA sequencing was done by an external company, Eurofins MWG Operon (London, 
UK). The concentrations o f the purified PCR products were prepared according to the 
size of the products as per the company’s criteria:
• <300bp: 2ng/ pi in a minimum volume of 15 pi
• 300 to lOOObp: 5ng/ pi in a minimum volume of 15 pi
• > lOOObp: 10ng/ pi in a minimum volume of 15 pi
• Oligonucleotide concentration: 2 pmol/pl in a minimum volume o f 15 pi 
Generally the PCR product sizes ranged within 300-1000 bp therefore they were 
prepared at a concentration of 5 ng/pl in a volume of 15 pi, duplicate samples were 
prepared for sequencing o f forward and reverse sequences. Aliquots o f the forward and 
reverse oligonucleotides (2 pmol/pl in a minimum volume o f 15 pi) were also prepared. 
The samples and the olignucleotides were then dried in the Eppendorf Vacufuge 
Concentrator 5301 centrifuge (Cambridge, UK) or in the Vacuum Centrifuge Maxi Dry 
Plus (Heto, Allerod, Denmark) for 30 min to 1 hour, these were packaged and sent by 
normal mail. The DNA sequences were aligned and assessed with the Clustal X 1.81 
and BioEdit sequence alignment programmes.
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2.17 Identification of S. aureus Matrix Assisted Desorption/ ionization-time of 
flight mass spectrometry
The Matrix Assisted Desorption/ ionization-time of flight (MALDI-TOF) mass 
spectrometry assay was performed with the Bruker Daltonics Microflex LT system. 
(Bruker Daltonics, Germany). For S. aureus identification either colonies from pure 
cultures were tested directly or extracts were prepared with the ethanol formic acid 
method
2.17.1 Preparation of Matrix solution
The saturated solution o f matrix solution was prepared in a 1.5 mL micro-centrifuge 
tube in a fume cupboard due to the potent vapours and corrosive nature o f acetronitrile 
(ACN) and tri-fluor-acetic acid TFA. 500 pi o f ACN was carefully added to 15 to 20 
mg o f alpha-4-cyano-hydrocycinnamic acid (HCCA), then 475 pi o f sterile Millipore 
dEbO and 25 pi TFA were carefully added. The solution was then ultra-sonicated for 
10-15 min, until the HCCA had dissolved. The matrix solution was protected from light 
in order to keep it stable for several days.
2.17.2 Direct smear preparation
Pure cultures of S. aureus isolates were prepared on CBA plates (37°C for 24 hours) 
and a sterile loop was used to carefully touch and spread part o f a single colony within a 
well of a clean steel target plate. The smears were dried at room temperature, overlaid 
with 0.5 to 1 pi matrix solution, then again dried at room temperature prior to analysis.
2.17.3 Protein extraction with the ethanol formic acid procedure
One or two colonies from a pure S. aureus culture were suspended in 100 pi o f sterile 
Millipore dH20  in a sterile 1.5 ml micro-centrifuge tube then 450pl o f absolute ethanol 
was added and the suspension was centrifuged at 12000 xg for 2 min. The supernatant 
was decanted taking care to completely remove the supernatant. The pellet was 
vigorously re-suspended in 30 pi o f formic acid (at least 70%) followed by the addition 
o f 30 pi pure ACN and the suspension was vortexed. The suspension was centrifuged at 
12,000 xg for 2 min and then 0.5 to 1 pi o f the supernatant was placed onto a spot o f a 
clean steel target plate; each extract was placed onto six successive spots on the target 
plate. These were dried at room temperature and then overlaid with 0.5 to 1 pi matrix
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solution and then again dried at room temperature. The target plate was then loaded into 
the Bruker Daltonics Microflex LT system.
2.17.4 M ALDI-TOF data analysis
The spectra were recorded within a positive linear mode o f range 2000 to 20000Da and 
analysed with the MALDI Biotyper 2.0 software (Bruker Daltonics, Germany). 
Generated mass-ion peaks of the mass spectra profiles were automatically analysed 
against reference strains in the in-built MALDI Biotyper reference library. The software 
provides a log-score classification system for the identification o f isolates whereby:
>2.3 highly probable species identification
<2.299 to >2.0 secure genus identification, probable species identification
<1.999 to >1.7 probable genus identification
<1.699 no reliable identification
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2.18 Typing methods
2.18.1 Pulsed Field Gel Electrophoresis
Pure cultures o f S. aureus isolates were prepared on CBA plates from frozen stocks and 
incubated 37°C for 24 hours. A single colony was suspended in 5 mL TSB broth and 
grown overnight at 37°C. The overnight cultures were vortexed and 800 pi was 
aliquoted into respective sterile micro-centrifuge tubes. The bacterial cultures were 
centrifuged at 12000 rpm for 2 min, the supernatant was discarded and the pellet was re­
suspended in 1.0 ml SE Buffer (this step was repeated twice). Then 125 pi o f the 
suspension was transferred to a clean micro-centrifuge tube, 125 pi LMP agarose was 
added to the suspension and mixed by vortexing. Approximately 100 pi o f the mixture 
was then transferred into a plug mould (BIORAD) and these were placed at 4°C for at 
least 30 min.
The plugs were removed from the moulds, placed into 15.0 ml tubes and 1.0 ml of lysis 
solution was added to the plug. The samples were incubated at 37°C for 4 hours then the 
lysis solution was removed. Proteinase K solution (1.0 ml) was added and then the 
plugs were left in this solution at 56°C for at least 4 hours or overnight. The Proteinase 
K solution was removed and the plugs were washed four times with 10 ml TE buffer 
with gentle shaking. At the end of each hour the TE buffer was removed and 10 ml o f 
fresh TE buffer was added prior to gentle shaking. After the last wash, 1.0 ml TE buffer 
was added to the plugs, at this stage the plugs could be left in the 1.0 ml TE Buffer for 
up to 1 year at 4°C.
The 10X Buffer J solution (specific for the Smal restriction enzyme) was diluted to a 
1:10 dilution with df^O. After the TE buffer was removed from the plugs, 800 pi o f the 
IX Buffer J was added to the plugs and these were equilibrated in the buffer for 1 hour. 
The buffer was removed and 100 pi of IX Buffer J was again added to each plug. Then 
2 to 4 pi o f Smal was added to the plugs in 100 pi Buffer J and the plugs were incubated 
at 25°C overnight. Two litres o f 0.5X TBE (100 ml 10X TBE and 1900 ml df^O) was 
prepared and chilled at 4°C. The casting stand for the gel was set up; the desired comb 
was attached to the comb holder and placed into position in the slots of the casting 
stand. The agarose gel was prepared by adding 1.6 g agarose to 160 ml 0.5X TBE and 
melted in a microwave.
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oven. Approximately 100 ml o f agarose was poured into the casting stand for a 
thickness of approximately 5 to 6 mm and the gel was allowed to cool and solidify at 
room temperature for 30 min, then the comb and comb holder were carefully removed. 
The plugs were removed from the 25°C incubator and with the use of the spatula each 
plug was modified to the size of the well in the gel. Using the spatula the sample plugs 
were gently pressed into the bottom of the wells. Two wells were left free for the 
standards the lambda DNA ladders. Each well was filled with low melting point 
agarose, at a concentration equal to that of the gel and then allowed to solidify for 10 to 
15 min.
The casting platform was placed at the centre o f the contour clamped homogenous 
electrophoresis (CHEF-DR III) electrophoresis cell. The CHEF-DR III cell was levelled 
at each o f the feet at each comer and then a levelling bubble placed on the casting 
platform. The platform was removed after levelling and the frame was positioned in the 
cell by placing the two pins into the bottom set of holes in the floor o f the cell. 2.0 to 2.2 
L o f the chilled 0.5X TBE was poured into the cell and then the CHEF-DR III power 
module was switched on. The variable speed pump was adjusted to circulate the buffer 
at approximately 0.75 L/ min (a setting o f approximately 70 on the pump regulator) in 
order to remove bubbles from the system. A constant flow rate was then maintained at a 
setting that did not disturb the cell and the attached cooling module was set at 14°C.
The following PFGE settings were set up for the run:
• Block 1: Initial switch time 5s, final switch time 15s, run time lOh.
• Block 2: switch time 15s, final switch time 60s, mn time 13h.
The Volts/ cm (6.0V/ cm) and the angle (120°) were set and then the programme was 
started. The current was maintained at range of 115 to 135mA by draining (in order to 
reduce a high current) or adding more buffer (in order to elevate a low current). After 
the run was completed the gel was removed from the cell and the gel was slid off the 
platform and placed in 400 ml d ^ O  into which 20 pi or 4 drops o f 0.5 pg/ ml ethidium 
bromide were pipetted and the gel was left to stain for 20 to 30 min with gentle shaking. 
The solution was then poured into a bottle containing an ethidium bromide 
decontamination bag. The gel was de-stained by placing it into 400 ml o f dH 20 with 
gentle shaking for 1 to 3 hours. The gel was removed from the water and visualisation
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and imaging of the PFGE patterns was done with the BIO-RAD Molecular Imager Gel 
Doc XR system and the Quantity One 4.6.3 Basic software.
2.18.2 spa typing
The spa typing technique involved an initial amplification o f a sequence comprising 
polymorphic X region within the spa gene with the Ridom Bioinformatics (Ridom 
GmbH, Wurzburg, Germany) on-line protocol, termed the DNA Sequencing of the spa 
gene (www3.ridom.de/doc/Ridom_spa_sequencing.pdf). The PCR was performed in the 
BIO-RAD DNA Engine Tetrad 2 Thermal cycler as (see Table 2.4).
The PCR products were resolved in a 2% agarose gel by electrophoresis with IX TAE 
buffer at 110V for 40 min and were visualised with SYBR safe under UV illumination. 
The spa PCR products were then purified and prepared in duplicate for DNA 
sequencing of the forward and reverse sequences. Alignment of the sequences was done 
with the Clustal X 1.81 and BioEdit alignment tools and identification o f the repeats 
within the sequences was done manually. The definition of the spa types was done via 
the on-line Ridom spa server (http://spaserver2.ridom.de) and novel spa types were 
verified by on-line submissions o f the forward and reverse sequence chromatograms.
Table 2.4. Oligonucleotides o f the spa PCR_______________________________________
Label_________ Oligonucleotide sequence (5’-3’)___________Position________Reference_____________
spal 113F TAAAGACGATCCTTCGGTGAGC 1113-1092° (http://www.ridom.de/)
jpal514R  CAGCAGTAGTGCCGTTTGCTT 1534-1514° (http://www.ridom.de/)
aS.aureus JO 1796 (http://www.ridom.de/) 
The spa PCR method
Singleplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi Si 95°C / lOmin
spa 1113F 200nM S2 95°C / 45s
spa 1514R 200nM 60°C / 45s
Genomic DNA 1.0 pi 72°C / lm in
Make up to 25 pi with Nuclease free water Repeat cycle S2 35 times
S3 72°C / lOmin
Hold at 4°C
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2.18.3 Typing of the Staphylococcal Chromosome Cassette mec elements
The characterisation of the Staphylococcal Chromosome Cassette mec (SCC/wec) 
elements was performed with two multiplex PCRs. The first was the Milheirico et al. 
(2007b) PCR which involves the amplification of nine SCC/wec-specific loci and the 
mecA gene for the identification of SCCmec types I to V (see Table 2.5).
The second typing method comprised two separate multiplex PCR methods by Kondo et 
al. (2007) i.e. MPCR-1 and MPCR-2 which were developed for detection o f the 
different ccr and mecA gene classes respectively. The MPCR-1 method includes 
oligonucleotides for the amplification of loci in ccrABl, ccrAB2, ccrAB3, ccrAB4 and 
ccrC, whereas the MPCR-2 method includes oligonucleotides for the amplification of 
loci in the class A, class B and class C2 mec gene complexes (see Table 2.6).
For all methods 1 pi of purified genomic DNA was transferred into 24 pi o f the PCR 
reaction mix and the reaction was performed in the DNA Engine Tetrad 2 Thermal 
cycler. The Sensimix was retained for the Milheirico et al. (2007) and MPCR-1 
methods. However with the MPCR-2 method large PCR products ranging from 804bp 
to 2827 bp were generated, so the Expand High Fidelity PCR kit which amplifies 
products up to 10 kb was used (Roche, Hertfordshire, UK). For the Expand High 
Fidelity PCR system the PCR cycling conditions were set up according to the 
manufacturer’s instructions. The recommended elongation times were: 45 sec for up to 
0.75 kb, 1 min for 1.5 kb, 2 min for 3 kb, 4 min for 6 kb and 8 min for 10 kb and a final 
extension step o f 7 min.
The multiple PCR products were resolved in a 2% agarose gel by electrophoresis in IX 
TAE buffer at 100V for 50 min. Visualisation and imaging o f the products was done 
with the BIO-RAD Molecular Imager Gel Doc XR system and the Quantity One 4.6.3 
Basic software.
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The adapted M ilheirico et al. (2007b) method
M ultiplex PCR (M aster Mix) PCR cycle
Sensimix No R e f 12.5 pi Si 95°C / lOmin
kdp¥\ 200 nM S2 95°C / 30s
kdpRl 200 nM 53°C / 30s
CIF2 F2 400 nM 72°C / lmin
CIF2R2 400 nM Repeat cycle S2 30 times
RIF5 F10 400 nM S3 72°C / 4min
RIF5 R13 400 nM Hold at 4°C
SCCmecIII J1F 400 nM
SCCwecIIIJlR 400 nM
SCCmecV J1F 400 nM
SCCmecV J1R 400 nM
mecl P2 800 nM
mecl P3 800 nM
dcs F2 800 nM
dcs R1 800 nM
mecA P4 800 nM
mecA P7 800 nM
ccrB2 F2 800 nM
ccrB2 R2 800 nM
ccrC  F2 800 nM
ccrCR2 800 nM
Genomic DNA
Make up to 25pi with Nuclease 
free water
1.0 pL
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The MPCR-1 and MPCR-2 methods
MPCR-1 (M aster Mix) PCR cycle
Sensimix 12.5 pi SI 95°C / lOmin
mAl 100 nM S2 94°C / 2min
mA2 100 nM 57°C / lmin
a 1 100 nM 72°C / 2min
a 2 100 nM Repeat cycle S2 30 times
a 3 100 nM S3 72°C / 2min
p c 100 nM Hold at 4°C
a 4.2 100 nM
p 4.2 100 nM
y R 100 nM
y F 100 nM
Genomic DNA
Make up to 25pl with Nuclease free water
1.0 pi
MPCR-2 (M aster Mix) PCR cycle
Make up to 25pl with Nuclease free water SI 94°C / 2min
Expand High Fidelity Buffer (10X) without MgCl2 2.5 pi S2 94°C / 2min
MgCfe (25mM) 3.0 pi 58°C / lm in
PCR Grade Nucleotide Mix 0.5 pi 72°C / 3 min
m l6 100 nM Repeat cycle S2 30 times
IS7 100 nM S3 72°C / 7min
IS2(iS-2) 100 nM Hold at 4°C
mA7 100 nM
Expand High Fidelity Enzyme Mix 0.375 pi
Genomic DNA 1.0 pi
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2.19 Amplification of rem nant of SCCmec sequence, attL to attR
Amplification of a sequence spanning from the left chromosome-SCCraec junction 
{attL) to right chromosome-SCC/wec junction (ctf/R) was attempted with forward 
primers that were located upstream of attL and a reverse primer located in orjX. The 
PCR methods and the oligonucleotides that were used were developed by Katayama et 
al. (2000) and Jansen et al. (2006) (see Table 2.7). An oligonucleotide termed cR2 
served as the reverse primer and the oligonucleotides termed cL l, E3 and E4 served as 
the forward primers. These aligned to regions upstream of attL in the following 
published sequences:
i) CL1-AB033763: SC Cmec type 1/ NCTC10442, SCC mec type IV D86934 and 
SCCmec type IVb/ AB063173.
ii) E3- SCC mec type IVc/ AB096217; SCC mec type II/ BX571856
iii) E4- SCCmec type IVa/ JCSC1968
Purified genomic DNA (lp l)  and the Expand High Fidelity PCR kit were used for the 
reactions which were performed as singleplex PCRs i.e. cLl and cR2, E3 and cR2, and 
E4 and cR2. They were performed in the BIO-RAD DNA Engine Tetrad 2 Thermal 
cycler at different annealing temperatures i.e. the E4 and cR2; E3 and cR2 PCRs were 
performed at 56°C whereas the cLl and cR2 PCR was performed at 53°C. The PCR 
products were resolved in a 1% agarose gel with electrophoresis in IX TAE buffer at 
100V for 50 min. Visualisation and imaging of the products was done with the BIO­
RAD Molecular Imager Gel Doc XR system and the Quantity One 4.6.3 Basic software. 
The products were purified, sent for DNA sequencing and the DNA sequences were 
aligned and assessed with the ClustalX 1.81 and the BioEdit sequence alignment tools.
Table 2.7. Oligonucleotides for the amplification o f the sequence spanning from attL to 
orfX_________________________________________________________________________
Label O ligonucleotide sequence (5’-3 ’) P osition R eferen ce
cLl ATTTAATGTCCACCATTTAACA 4 6 0 7-4628a Katayama et al., 2000
E3 TTTTGCTGTTTTTATCACCATATTGAA 6434-6460" Jansen et al., 2006
E4 AATTT ACC AG AC AGCCTGGTGC 836-857  b Jansen et al., 2006
cR2 AAACGACATGAAAATCACCAT 5 8 1 2 2 -5 8 1 0 2 a Jansen et al., 2006
aSCCmec type II/ D86934; bSCCmec type IVa/ AB063172; dSCCmec type IVc/ AB096217
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The attL-orflCYCR method
M aster M ix P C R  cycle
M ake up to 25p l with N uclease free water SI 94°C  /  2m in
Expand High Fidelity Buffer (10X ) without M gC l2 2.5 pi S2 94°C /  30s
M gC l2 (25m M ) 3.0  pi 53°C /  30s*
PCR Grade N ucleotide M ix 0.5 pi 72°C  /  8min
cL l or E4 or E3 200 nM Repeat cycle S2 30 tim es
cR2 200 nM S3 72°C /  7min
Expand High Fidelity Enzym e M ix 0.375 pi H old at 4°C
G enom ic D N A 1.0 pi
*PCRs with oligonucleotides E4 and cR2; E3 and cR2, were performed at annealing temperature 56°C, 
whereas cLl and cR2 was performed at 53°C
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2.20 Antibiotic susceptibility testing
Susceptibility testing o f S. aureus was performed with the oxacillin and cefoxitin disc 
diffusion assays and the BD Phoenix automated microbiology system. These were 
performed and interpreted according to the British Society for Antimicrobial 
Chemotherapy (BSAC) version 9.1 methods for antimicrobial susceptibility testing. 
Pure cultures which were prepared on CBA plates and incubated at 37°C for 24 hour 
were used for testing and bacterial suspensions were prepared in 5 ml o f sterile dF^O to 
a 0.5 McFarland turbidity. Ready-to-use Columbia Salt Agar (CSA) plates (90 mm) 
with 2% NaCl (Oxoid, UK) and Iso-Sensitest media were used for the oxacillin and 
cefoxitin disc diffusion assays respectively.
2.20.1 Oxacillin disc diffusion assay
A sterile straight wire was used to touch a single colony and it was suspended in 2.0 ml 
o f sterile dE^O. A sterile loop was used to transfer a 5 pi aliquot of the bacterial 
suspension onto the surface o f the CSA plate and sterile cotton tipped swabs were used 
to spread the isolate in three directions over the quarter section o f the plate. Then, using 
sterile tweezers, a 1 pg oxacillin disc (Oxoid) was placed firmly on the dried surface o f 
the inoculated plate. Each plate accommodated four lp g  oxacillin discs without the 
overlapping of inhibition zones. Within 15 min o f disc application the plates were 
incubated aerobically at 30°C for 24 hours,. Zone diameters were measured in good 
light and also examined for colonies within zones, if  colonies within zones were 
considered contaminants the isolate was re-tested. For the lp g  oxacillin disc tests the 
sizes o f the inhibition zones were interpreted as following: >15 mm susceptible and <14 
mm resistant (see Table 2.8).
Table 2.8. Zone diameter breakpoints for S. aureus oxacillin and cefoxitin disc
diffusion tests
Antibiotic
Zone diameter (mm)
Disc Resistant Susceptible
Oxacillin
Cefoxitin
lp g  <14 >15 
lOpg <21 >22
(http://www.bsac.org.uk/_db/_documentsWersion_9.l_March_2010_final.pdf)
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2.20.2 Cefoxitin disc diffusion assay
A sterile straight wire was used to touch a single colony and to suspend it in 2.0 ml 
sterile dE^O. In order to obtain semi-confluent growth, a sterile 5 pi loop was used to 
transfer an aliquot o f the bacterial suspension of the test isolate, onto the surface of the 
Iso-Sensitest agar plate and sterile cotton tipped swabs were used to spread the isolate in 
three directions over the plate. With sterile tweezers the 10 pg cefoxitin disc was placed 
firmly on the dried surface o f the inoculated plate, two discs were accommodated per 
plate. Within 15 min of disc application the plates were incubated aerobically strictly at 
35°C for 18 to 20 hours. Zone diameters were measured in good light and examined for 
colonies within zones e.g. for contaminants. A light haze o f colonies may reflect the 
growth o f hyper-producers o f P-lactamase. For the 10 pg cefoxitin disc tests the sizes of 
the inhibition zones were interpreted as following: >22 mm susceptible, <21 mm 
resistant (see Table 2.8).
2.20.3 BD Phoenix automated microbiology system
The following BD Phoenix reagents and components were provided for susceptibility 
testing:
1) BD Phoenix PMIC/ID-67 gram positive panels, closures and an inoculation support
2) Phoenix ID broth for identification
3) Phoenix AST broth for antimicrobial susceptibility test
4) Phoenix AST indicator solution
5) BD PhoenixSpec™ Nephelometer
Prior to taking turbidity readings the BD PhoenixSpec™ Nephelometer was calibrated 
with prepared Phoenix 0.25 or 0.5 or 1.0 McFarland solutions. A panel was placed on 
an inoculation support with the ports of the panels at the top and the pad at the bottom. 
A Phoenix ID Broth tube was labelled with the specimen number and a single colony 
was aseptically selected with the tip o f a sterile cotton swab (polyester swabs 
prohibited) and suspended in the broth. The tube was capped, vortexed for 
approximately 5 sec and allowed to rest for several seconds to allow the air bubbles to 
surface. The tube was inserted into the nephelometer and the turbidity/density readings 
were calculated by the instrument; a range o f 0.5 to 0.6 is acceptable. If the density of 
the suspension was low, more o f the selected colony was added, the suspension was re-
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vortexed and re-read to confirm that the correct density had been achieved. The 
bacterial suspension in the ID broth had to be used within 60 min o f preparation. The 
Phoenix AST indicator solution for gram positive panels was allowed to attain room 
temperature. A Phoenix AST broth was labelled with the specimen number and one 
drop o f the indicator solution was added to the AST broth. The AST broth was inverted 
(not vortexed) and the indicator solution was returned to 2 to 8°C as soon as possible. 
Using a pipette and sterile tips, 25pl o f the standardised inoculated ID broth was 
transferred to the AST broth and the tube was capped and inverted a few times. Several 
seconds were allocated for air bubbles to surface and it was gently tapped to aid 
elimination of bubbles. The ID tube inoculum was poured into the open port o f the ID 
side of the panel and the inoculated AST broth was poured into the open port o f the 
AST side. Panels were inoculated within 30 min after inoculation of the AST broth. The 
ports were capped and the panel was left on the inoculation support, to allow the 
flowing suspension to fill the wells sufficiently, this was indicated by the pad at the 
bottom of the panel turning blue. Inoculated ID tubes could be retained for optional 
purity checks. Using a sterile loop a small drop from the inoculum was recovered and 
spread on a fresh CBA plate. The plate was incubated at 37°C for 24 hours and then 
verified as a pure culture. The used ID and AST broth tubes were capped and discarded 
in a biohazard sharps disposal container. The panels were logged in and loaded into the 
BD Phoenix instrument as per instructions in the BD Phoenix System user’s manual.In 
the instrument panels were continuously incubated at 35°C and tested every 20 min: on 
the hour; at 20 minutes past the hour and again at 40 min, for up to 16 hours (Phoenix 
panels are read only by the instrument and cannot be read manually). Results were 
viewed on a computer and printed from an external printer connected to the instrument. 
On the report, the identification of the organism with a probability percentage and MICs 
of antimicrobial agents (interpreted according to BSAC criteria) were displayed (see 
Table 2.9 for the oxacillin and cefoxitin MIC breakpoints).
Table 2.9. MIC breakpoints for oxacillin and cefoxitin susceptibility testing o f S. 
aureus
Antibiotic
MIC breakpoint (mg/L)
Resistant Susceptible <
Oxacillin
Cefoxitin
>2 <2 
>4 <4
(http://www.bsac.org.uk/_db/_documents/Version_9.l_March_2010_final.pdf)
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2.20.4 Testing for inducible macrolide-lincosamide-streptogramin B resistance in 
S. aureus
Inducible macrolide-lincosamide-streptogramin B (MLSb) resistance was investigated 
with the dissociated test (D-test) in S. aureus isolates which were susceptible to 
clindamycin but resistant to erythromycin (see Table 2.10). An IsoSensitest plate was 
inoculated with 5 pi of the suspension of the test isolate, to give a semi-confluent 
growth. After the plate had dried a 5pg erythromycin disc and a 2pg clindamycin disc 
were placed 1.5 cm apart at the centre of the plate and these were then incubated at 
37°C for 18 to 20 hours. Isolates that had no zones of inhibition with erythromycin but 
exhibited a blunted edge at the inhibition zone of the clindamycin disc were considered 
to have inducible MLSB resistance (see Figure 2.1).
Table 2.10. M LSb resistance: interpretation of susceptibility testing results
R< 16m m ; S> 20m m  
Int. 17-2 0m m
R< 22m m ; S> 26m m  
Int. 23-25m m
Interpretation
E rth rom ycin  (5pg) C lindam ycin  (2p g)
S S Isolate susceptible to both erythromycin 
and clindamycin
R R Isolate resistant to both erythromycin and 
clindamycin (constitutive M L S B resistance)
R S Isolate may have inducible M L S b 
resistance, confirm with D-test
R-resistance; S-susceptible; Int-intermediate
Bhmted growth
Figure 2.1. D-test result showing blunted zone of inhibition around the clindamycin 
disc signifying inducible MLSB resistance
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C hapter Three
A com parison of the real-tim e PCR results and the reported clinical microbiology 
laboratory  results of Staphylococcus aureus clinical isolates
3.0 Introduction
Accurate detection o f methicillin resistance in Staphylococcus aureus isolates is 
essential for the initiation o f infection control measures and the implementation o f 
effective therapy. The gold standard is the detection of the mecA gene by PCR however 
due to technical and financial constraints, molecular assays are infrequently 
implemented in clinical microbiology laboratories. Routinely, phenotypic assays which 
incorporate culture based identification and antibiotic susceptibility assays are 
performed but the variable expression o f methicillin resistance poses challenges for 
these methods. MRSA exhibit heterogeneous or homogeneous expression o f methicillin 
resistance whereby the heterogeneous strains comprise subpopulations o f cells with 
different degrees o f methicillin resistance. The majority o f cells have low-level 
resistance and only a low frequency of cells have high level resistance. Conversely, in 
homogenous strains the majority o f cells express high level resistance constitutively 
(Tomasz et al., 1991). The heterogeneous MRSA can express low methicillin resistance 
or methicillin susceptible phenotypes, therefore the application of phenotypic tests such 
as disc diffusion tests can result in the misidentification o f mecA positive strains as 
MSSA. Additional challenges include certain mecA negative S. aureus strains which 
exhibit minimum inhibitory concentrations (MICs) close to the breakpoint for oxacillin 
resistance. Often they are hyper producers o f penicillinase and are referred to as 
borderline oxacillin resistant S. aureus (BORSA). Although these strains are mecA 
negative they can be misidentified as MRSA with phenotypic assays. S. aureus isolates 
with these types o f atypical resistance phenotypes often generate discrepant results with 
diagnostic assays and present ongoing challenges for accurate identification o f MRSA.
For the purposes o f this study the mecA and femAsA real-time PCR methods were 
performed as a reference method for the identification o f MRSA. The objective was to 
perform the reference method on 561 S. aureus wound isolates and to compare these 
real-time PCR results to the reported results o f the Public Health Wales (PHW) 
Microbiology Abertawe Bro Morgannwg (ABM) Laboratory.
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3.1 Results
3.1.1 Com parison of PCR and reported PHW  microbiology results
Five hundred and sixty one S. aureus clinical isolates were collected from the PHW 
Microbiology ABM Laboratory from April 2007 to September 2007. These were 
originally isolated from wound swab specimens and were collected as cultures on Iso- 
Sensitest agar, a medium used for antimicrobial susceptibility testing. By real time PCR 
the S. aureus femA  gene {femAsA) was detected in all 561 isolates. A real-time PCR for 
the detection o f the S. epidermidis femA  gene (femAsf) was also performed in order to 
verify that the clinical isolates were not S. epidermidis and this gene was not detected in 
any o f the isolates. One hundred and thirty seven (24.4%) isolates were mecA positive 
i.e. MRSA and 424 (75.6%) were mecA negative i.e. MSSA. The reported PHW 
Microbiology ABM Laboratory results were retrieved from the computerised data 
management system and out o f the 137 mecA positive S. aureus only 122 were reported 
as MRSA. In addition one of the 424 mecA negative S. aureus was also reported as a 
MRSA. Furthermore in three cases S. aureus isolates were not reported at all but 
coagulase negative staphylococci (CoNS) were reported in two cases and a different 
bacterial species was reported in one case (see Table 3.1).
In total sixteen discrepancies were observed between the PCR results and the reported 
results in the PHW Microbiology ABM Laboratory system (see Table 3.2). In twelve 
cases MSSA was reported and in the case o f isolate 2 the MSSA was co-identified with 
an S. epidermidis. In two cases MSSA were not reported at all rather, S. epidermidis, 
Acinetobacter species and B. cereus were reported in the case o f isolate 1 whereas only 
S. epidermidis was reported for isolate 13. For isolate 12 a Staphylococcus sp. was not 
reported at all and only a Streptococcus species was reported. In the remaining case of 
isolate 16, MRSA, anaerobes and Corynebacterium were reported in the laboratory 
system (see Table 3.2).
Table 3.1. Comparison o f real-time PCR results and reported PHW Microbiology ABM 
Laboratory results of 561 clinical isolates_________________________________________
Real-time PCR femAsA femASE mecA Other
POS NEG POS NEG POS NEG
561 0 0 561 137 424 0
PHW Microbiology ABM Staphylococcus species Other
Reported results S. aureus CoNS MRSA MSSA
558 2 123* 435 1
*n=123 includes the 122 MRSA and the mecA negative isolate reported as a MRSA
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Table 3.2. Discrepancies between the PCR results and the reported PHW Microbiology 
ABM Laboratory results o f sixteen S. aureus isolates_______________________________
No. Isolate PCR Reported PHW  Microbiology ABM Laboratory results
mecA femAsA Interp. Staphylococcus
species
Other bacteria isolated from  
same specimen
1. 113 015 Pos Pos MRSA S.epidermidis Acinetobacter, B. cereus
2. 122 126 Pos Pos MRSA MSSA, S. epidermidis
3. 124 051 Pos Pos MRSA MSSA —
4. 129 103 Pos Pos MRSA MSSA —
5. 176 065 Pos Pos MRSA MSSA —
6. 186 079 Pos Pos MRSA MSSA —
7. 189 009 Pos Pos MRSA MSSA —
8. 192 020 Pos Pos MRSA MSSA —
9. 205 092 Pos Pos MRSA MSSA —
10. 206 006 Pos Pos MRSA MSSA —
11. 208 506 Pos Pos MRSA MSSA —
12. 219 066 Pos Pos MRSA None Streptococcus species
13. 228 027 Pos Pos MRSA S.epidermidis --
14. 229 015 Pos Pos MRSA MSSA -
15. 241 132 Pos Pos MRSA MSSA —
16. 225 124 Neg Pos MSSA MRSA Anaerobes, Corynebacterium
Key: id.-identification; Interp.- Interpretation; -- no bacteria isolated
3.1.2 Comparison of the PCR results and results of susceptibility testing with disc 
diffusion tests and the BD Phoenix automated microbiology system
The lpg  oxacillin and 10pg cefoxitin disc diffusion tests were performed on the sixteen 
isolates according to BSAC version 9.1 methods for antimicrobial susceptibility testing 
criteria. Eleven o f the isolates were resistant to oxacillin with no zone o f inhibition 
whereas isolates 7, 9 and 10 showed clear susceptibility to oxacillin, exhibiting 
inhibition zone diameters o f 23 mm, 20 mm and 20 mm respectively. They also 
depicted susceptibility in the repeat oxacillin disc test (see Table 3.3). One unusual 
isolate (8) depicted a zone o f 15mm (the breakpoint for susceptibility) and then 10mm 
(exhibiting resistance) in the repeat test. Isolate 16 which was reported as an MRSA in 
the PHW Microbiology ABM Laboratory system also showed susceptibility to oxacillin 
and had zone diameters o f 22 mm and 21mm in the duplicate tests (see Table 3.3).
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In contrast to the oxacillin disc test, all sixteen isolates exhibited resistance to cefoxitin, 
with thirteen isolates displaying no zone of inhibition. Isolates 7 and 8 exhibited zones 
o f 12 mm and 14 mm respectively, indicating resistance to cefoxitin and also there was 
a light haze of colonies within the zones o f inhibition. Isolate 16 was more unusual 
because with the cefoxitin test it depicted inhibition zones o f 20 mm and 21 mm 
(breakpoint for resistance), indicating tentative methicillin resistance however it had 
exhibited clear susceptibility with the oxacillin disc test.
With the BD Phoenix, fourteen isolates had MICs o f >4 mg/L and >8 mg/L for oxacillin 
and cefoxitin respectively, thus were reported methicillin resistant. These included 
isolate 8 which had depicted ambiguous ‘susceptible/ resistant’ results with the lpg  
oxacillin assay and then clear resistance with the lOpg cefoxitin assay (see Table 3.3). 
However isolate 7 had MICs of <lmg/L and <2mg/L for oxacillin and cefoxitin 
respectively and isolate 16 had MICs o f 0.5 mg/L and 4 mg/L for oxacillin and cefoxitin 
respectively. These MICs clearly signified susceptibility to oxacillin and cefoxitin and 
thus these isolates were identified as a MSSA with the BD Phoenix. These two isolates 
presented two fascinating cases because although isolate 7 was mecA positive and 
isolate 16 was mecA negative by PCR, they both depicted similarly discordant results 
with the phenotypic susceptibility testing methods i.e. methicillin susceptibility with the 
1 pg oxacillin disc diffusion test and the BD Phoenix versus methicillin resistance with 
the 10 pg cefoxitin disc diffusion assay (see Table 3.3).
3.1.3 Clinical history associated with the isolates with discrepant results
The clinical history o f the patients from whom the sixteen isolates were identified was 
retrieved from the PHW Microbiology ABM Laboratory data management system, for 
the investigation of previous or later identification o f MRSA (see Table 3.4). In the 
PHW Microbiology ABM Laboratory if a MRSA isolate is identified from a patient >3 
months after a former MRSA isolate has been identified, the latter is considered a new 
MRSA isolate. Therefore the duration of time that elapsed before a MRSA isolate was 
reported from a similar clinical specimen, was assessed for all sixteen isolates. For 
isolates 1, 7, 9, 10 and 13, there were no prior (or subsequent) MRSA reports for the 
respective patients, although in these cases few or no further organisms o f any type 
were isolated from the patients previously or afterwards (see Table 3.4 and 3.5).
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Table 3.4. Bacteria identified prior or post the isolates with discrepant assay results
No. Isolate Date of result Associated infection Bacteria reported
110 024 20/04/ 2007 Wound swab A. baumannii, B. cereus
1. 113 015* 22/04/ 2007 Fracture o f  femur. Groin oozing, infected S. epidermidis, B. cereus,
A. baumannii
114 030 24/04/ 2007 Pus S. epidermidis, A. baumannii
(Patient deceased)
313 006 09/11/2006 Wound swab S. aureus
2. 122 126* 02/05/ 2007 Post ascitic drain S. aureus, S. epidermidis,
123 019 02/05/ 2007 Ascitic drain MRSA
203 003 22/07/ 2007 Ascitic drain MRSA
709 226 23/07/ 2007 Ascitic drain MRSA
703 317 26/07/ 2007 Screening swab MRSA
721 773 25/10/2007 Screening swab MRSA
3. 124 051* 04/05/2007 Post operation sternal wound infection S. aureus
128 022 05/05/2007 Wound swab MRSA
128 051 08/05/2007 Sternal swab MRSA
133 003 14/05/2007 Wound swab MRSA
156 028 05/06/2007 Wound swab MRSA
163 004 12/06/2007 Sternal swab MRSA
166 001 15/06/2007 Wound swab MRSA
109 235 18/04/2007 Screen: all swabs MRSA pos MRSA
128 297 07/05/2007 ScreenrHairline, nasal, axillae-MRSA pos MRSA
4. 129 103* 09/05/2007 Wound: graft failure to finger S. aureus
739 658 11/02/2008 Screen: Throat- MRSA pos MRSA
5.
150 372 
717 036 
176 065*
736 286 
703 589
30/05/2007
18/06/2007
26/06/2007
18/01/2008
12/03/2008
Screening swab-throat positive for MRSA 
Screening swab-throat positive for MRSA 
Infection o f hip post operation incision 
Screening swab
Screening swab-throat and umbilicus
MRSA 
MRSA 
S. aureus 
MRSA 
MRSA
166 054 15/06/2007 Wound swab amputation site MRSA
177 023 26/06/2007 Exit site:chronic renal failure on 
haemodialysis
MRSA
6. 186 079* 05/07/2007 Stump suture line S. aureus, Coliform
191 146 10/07/2007 Wound swab MRSA
225 013 11/08/2007 Wound swab MRSA
232 024 20/08/2007 Wound swab MRSA
711 846 06/09/2007 Screening swab MRSA
166 001 15/06/2006 Skin swab S. aureus
7. 189 009* 08/07/2007 Nasal swab S. aureus
189 010 08/07/2007 Thigh swab S. aureus, Streptococcus 
groupA
*Isolates with PHW Microbiology ABM Laboratory and PCR discrepant results.
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Table 3.4 continued. Bacteria identified prior or post the isolates with discrepant assay
results
No. Isolate Date of result Associated infection Bacteria isolated
8.
183 151
192 020*
310 027 
835 930 
819 543
02/07/2007
11/07/2007 
05/11/2007 
18/07/2008 
21/08/2008
Patient Type 1 Diabetic infected finger
Infected amputation site o f finger 
Infected amputated-serous fluid 
Eye swab 
Eye swab
S. aureus, Streptococcus
groupB
S. aureus
S. aureus
MRSA
MRSA
200 042 19/07/2007 Skin swab, infected eczema S. aureus
9. 205 092* 24/07/2007 Pre septal cellulitis S. aureus
10. 206 006* 25/07/2007 Face swab-weeping lesion to face S. aureus
700 388 04/07/2007 Screening swab MRSA
186 056 05/07/2007 Rheumatoid patient- foot ulcer MRSA
702 538 20/07/2007 Foot swab MRSA
11. 208 506* 27/07/2007 Left thigh wound S. aureus
236 0 16 23/08/2007 Odorous wound on foot MRSA
236 502 24/08/2007 Ankle swab MRSA
(Patient deceased)
071 261 11/03/2007 Screening swab MRSA
116 035 24/04/2007 Pressure sore on heel MRSA
184 057 02/07/2007 Ulcer swab MRSA
12. 219 066* 07/08/2007 Pressure sore, left heel not healing Streptocccus species
13. 228 027* 16/08/2007 Infected belly button S. epidermidis
14. 229 015* 17/08/2007 Wound to left leg S. aureus
298 020 25/10/2007 Hip swab: hardened black lump on leg S. epidermidis
338 050 04/10/2007 Hip swab- long standing wound S.aureus, Anaerobes
808 061 13/04/2008 Hip swab MRSA
(Patient deceased)
151 102 31/05/2007 Eye swab MRSA
172 001 21/06/2007 Eye swab MRSA
701 918 16/07/2007 Screening swabs MRSA
15. 241 132* 29/08/2007 Chronic conjunctivitis S. aureus
722 593 31/10/2007 Screening swabs MRSA
347 054 12/12/2007 Conjunctival swab MRSA
016 102 16/01/2007 Wound discharge MRSA
082 525 23/03/2007 Right leg ulcer MRSA
103 501 13/04/2007 Discharging ulcer MRSA
117 509 27/04/2007 Right leg ulcer MRSA
16. 225 214* 13/08/2007 Discharging ulcer MRSA
304 073 30/10/2007 Right leg ulcer MRSA
*Isolates with PHW Microbiology ABM Laboratory and PCR discrepant results.
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Table 3,5. Duration o f time before MRSA reported in the sixteen cases
MRSA reported from same clinical specimen No. of cases
< lday 2
< 1 week 1
1 month 1
2 months 1
8 months 1
MRSA reported from different clinical specimen
6 - 8  months 3
No further clinical isolates reported 5
Total cases 15*
*Isolate 16 not included as it was reported as an MRSA in the laboratory system
In five cases (isolates 2, 3, 6, 11 and 15) MRSA strains were reported within three 
months from clinical specimens similar to those o f the isolates with the discrepant 
results and in three cases the MRSA had been reported within a week. In the case of 
isolate 2, even though MSSA had been reported, an MRSA was reported from a 
replicate clinical specimen (123019) collected on the same date (see Table 3.5 and 3.4). 
Therefore in these cases it seems the MRSA strains which were possibly initially missed 
were subsequently identified fairly quickly from the same wound infections. However 
in the case o f isolate 14, an MRSA was reported approximately eight months after the 
isolate with the discrepant results, thus it would have been considered a new MRSA 
isolate even though it may have been a persistent strain which was not previously 
identified in the same wound infection. In three cases (isolates 4, 5 and 8) it seems 
MRSA may have been completely missed in earlier infections, as they were reported six 
to eight months after the isolate with the discrepant results but from different types of 
clinical specimens: no MRSA from finger wound versus MRSA in throat swab; no 
MRSA from hip infection versus MRSA in screening swab and no MRSA in finger 
amputation versus MRSA in eye swab (see Table 3.4 and 3.5).
Isolate 16 was the only case in which an MRSA was reported in the laboratory system 
but conversely the isolate was identified as a MSSA by PCR (see Table 3.4). It was 
reported from a patient with an apparent history o f MRSA reports, including 
approximately three months prior and two months after isolate 16 was reported.
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3.4 Discussion
In this study fifteen (10.9%) o f 137 mecA positive S. aureus isolates were reported as 
MSSA, S. epidermidis or Streptococcus species and one (0.24%) of 424 mecA negative 
S. aureus isolates was reported as MRSA in the PHW Microbiology ABM 
Microbiology Laboratory data management system. These clinical isolates were initially 
identified from wound swabs and the factors that could have contributed to the 
discrepancies between the reported microbiology laboratory results and the PCR results 
are discussed below.
Infected wounds are often polymicrobial sites in which both pathogenic and commensal 
bacteria are present, the latter are often skin microflora i.e. S. epidermidis, 
Corynebacterium, Propionibacterium  and micrococci. Streptococcus species may also 
be present even though these are usually commensal bacteria o f the mouth and upper 
respiratory tract and less often found on the skin (Bowler et al., 2001). The presence o f 
these bacteria could lead to the misidentification o f the actual pathogenic 
microorganism(s). Similarly in the fifteen cases whereby MRSA were identified by 
PCR but not reported in the laboratory system, this may have been because the MRSA 
were present in the original wound swabs but were then missed in the polymicrobial 
cultures in subsequent media. However in twelve cases, only one bacterial isolate was 
reported in the laboratory system, indicating that either there was misidentification 
during initial testing or typographical errors occurred during the entering o f results.
In the PHW Microbiology ABM Microbiology Laboratory wound swabs are cultured 
with selective media: Columbia Colimycin Nalidixic acid (CNA) agar, Cystine Lactose 
Electrolyte Deficient (CLED) agar and Neomycin media (with a metronidazole 5pg 
disc) for the identification o f fastidious anaerobic bacteria. The ‘Staph latex’ test for the 
detection o f clumping factor or protein A and the DNAse test are performed on colonies 
depicting S. aureus morphology. Antibiotic susceptibility testing is subsequently 
performed on S. aureus isolates with the 1 pg oxacillin disc diffusion assay, two panels 
of antibiotics or with the BD Phoenix automated microbiology system.
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CNA agar is a blood-based media for the isolation o f Gram-positive microorganisms 
from polymicrobial clinical samples. It supports the growth o f staphylococci, 
haemolytic streptococci and enterococci and contains colistin and nalidixic acid to 
inhibit the growth o f Proteus, Klebsiella, Pseudomonas species, Enterobacteriaceae and 
other gram negative bacteria (http://www.bd.com/resource.aspx?IDX=8969). On this 
media S. aureus typically grow as large, cream or yellow colonies, exhibiting beta- 
haemolysis. However, a limitation o f using CNA plates is that streptococci e.g. S. 
pyogenes also grow as white colonies (though they are smaller) and typically exhibit (3- 
haemolysis (Bessen, 2009). Although coagulase-negative staphylococci (CoNS) 
generally do not depict haemolysis, they also have similar colony morphology (usually 
they grow as smaller colonies) to S. aureus. Therefore there is a possibility that based 
on colony morphology and subjective interpretation, MRSA isolates on CNA agar could 
be misidentified as S. epidermidis or Streptococcus species in the case of isolates 1,12 
and 13.
However, on CLED agar the typical growth of S. aureus is more distinct because they 
are lactose fermenters (growing as deep yellow colonies) and produce acid via the 
fermentation process. Bromthymol blue which is incorporated in the media serves as a 
pH indicator and the presence o f acid lowers the pH and changes the blue-green colour 
of the media to yellow. S. epidermidis do not ferment lactose and grow as pale yellow to 
white colonies thus the media retains its blue-green colour due to the absence of acid 
(,http://www.bd.com/resource.aspx?IDX=8967). Although streptococci are lactose 
fermenters they do not grow sufficiently on CLED media. It is unlikely that the distinct 
growth of S. aureus on CLED plates could have been mistaken for a S. epidermidis or 
Streptococcus species.
Following the identification of colonies with S. aureus characteristic morphology, tests 
for the detection o f DNase and coagulase production are performed to distinguish S. 
aureus from CoNS species. Coagulase is an S. aureus enzyme which is excreted 
extracellularly and causes the clotting o f rabbit plasma, and traditionally tube tests were 
commonly employed for detection o f this enzyme. However there are some rare S. 
aureus strains which do not express coagulase including a bacteraemia isolate described 
by Olver et al. (2005) which was a EMRSA-15 strain, a common strain in the UK
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(Olver et al., 2005, Fukuda et al., 2002, A1 Obaida et al., 1999, Mackay et al., 1993). In 
addition, due to the long duration of the coagulase tube tests, these are seldom used in 
clinical laboratories and alternatively rapid slide agglutination assays for the detection 
o f other S. aureus specific factors i.e. clumping factor and protein A are performed as 
identification tests. In the PHW Microbiology ABM Microbiology Laboratory the 
Prolex™ Staph Latex kit is used for the rapid identification o f S. aureus and it 
comprises buffers containing latex particles which have been sensitized with human 
fibrinogen which is bound by clumping factor or IgG which is bound by protein A (van 
Griethuysen et al., 2001). However there are rare S. aureus strains that do not express 
protein A, furthermore false-negative results are possible with slide tests due to the 
expression o f capsular polysaccharides by certain MRSA strains; usually these are 
capsular serotypes 5 and 8, which mask clumping factor and protein A. To circumvent 
this further agglutination tests have been developed which also include antibodies 
against the capsular polysaccharides (van Griethuysen et al., 2001). Therefore it is 
possible that the initial slide agglutination results may have been negative in the cases 
o f isolate 1 and 13, thus these isolates were subsequently reported as S. epidermidis.
Methicillin resistance in heterogeneous MRSA strains is notoriously difficult to identify 
unambiguously with phenotypic susceptibility tests because these often depict 
methicillin susceptible or low resistance phenotypes (Hososaka et al., 2007, Katayama 
et al., 2001, Weller, 1999). In this study isolate 7 was an ideal example o f this 
phenomenon, as it was mecA positive by PCR but exhibited methicillin susceptibility 
with the phenotypic tests i.e. the oxacillin (1 pg) disc diffusion test and the BD Phoenix. 
Therefore it is highly likely that this isolate was reported as a MSS A in the PHW 
Microbiology ABM Microbiology Laboratory system because it exhibited the same 
phenotype in the original oxacillin lpg  disc diffusion test. Two further mecA positive 
isolates (9 and 10) depicted methicillin susceptibility with the oxacillin disc diffusion 
test and one isolate (8) had tentative resistance. Based solely on this test, these four 
isolates would be regarded MSSA strains and likewise it is possible that in the original 
oxacillin disc tests, the inhibition zones o f these isolates portrayed susceptibility to 
methicillin and thus they were reported as MSSA isolates in the PHW Microbiology 
ABM Microbiology Laboratory system. In contrast isolate 16 was mecA negative by 
PCR but was reported as a MRSA isolate. Non-mecA mediated resistance i.e. mutations
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in the binding site o f native PBPs or hyperproduction o f p-lactamase can cause 
borderline oxacillin resistance phenotypes in S. aureus strains (BORSA) (Croes et al., 
2009, Skinner et al., 2009, Khorvash et al., 2008, Balslev et al., 2005, Keseru et al., 
2005). Interestingly even though isolate 16 displayed methicillin susceptibility with the 
oxacillin disc diffusion test and the BD Phoenix it exhibited borderline methicillin 
resistance with the cefoxitin disc diffusion test. So it is possible that this mecA negative 
isolate is a BORSA strain which is a hyper producer o f penicillinase and in the original 
oxacillin test it may have depicted resistance, resulting in this isolate being reported as a 
MRSA isolate.
The expression of methicillin resistance is also affected by the test conditions i.e. NaCl 
concentration in the test medium, temperature o f incubation and the size o f inoculum 
(Prere et al., 2006, Brown et al., 2005, Brown, 2001a). In the BSAC version 9.1, March 
2010 antimicrobial susceptibility testing methods, it is stated that a heavy inoculum 
density can result in reduced inhibition zones whereas a light inoculum density can 
result in increased inhibition zones. Even time delays (more than 15 minutes) with 
plates at room temperature after application o f the discs and the high stacking of plates 
in incubators can result in unequal distribution o f heat and increased zones o f inhibition. 
However the possibility o f these factors having occurred on fifteen occasions in the 
PHW microbiology laboratory is unlikely. The detection of methicillin resistance with 
oxacillin disc tests has been shown to be improved when 2% NaCl is added to the 
medium and when the incubation temperature is lowered to 30°C (Berger-Bachi and 
Rohrer, 2002, Madiraju et al., 1987). The BSAC version 9.1, March 2010 antimicrobial 
susceptibility testing methods state the use o f Columbia salt agar (CSA) or Mueller 
Hinton agar containing 2% NaCl and incubation at 30°C for 24 hours for oxacillin disc 
diffusion testing o f staphylococci. However some S. aureus strains i.e. the EMRSA-16 
strain are sensitive to salt and may be inhibited by increased NaCl concentrations 
(Bruins et al., 2007). In this study when the lp g  oxacillin disc diffusion test was 
performed on the isolates, methicillin resistance was detected in eleven o f the fifteen 
mecA positive S. aureus isolates, demonstrating that the NaCl concentration in the CSA 
media did not inhibit the expression o f methicillin resistance in these isolates and so this 
is an unlikely underlying cause o f these isolates being reported as MSSA in the 
laboratory system.
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With the 10 pg cefoxitin disc diffusion test, all fifteen isolates depicted methicillin 
resistance including the one mecA negative isolate, illustrating one case o f non 
specificity with this assay. Two o f the isolates i.e. 7 and 8, had a light haze of colonies 
within the zones o f inhibition with the cefoxitin test, a typical feature o f heterogeneous 
MRSA, whereby the colonies growing up to the cefoxitin disc are the population with 
high methicillin resistance and those growing further from the disc are the population 
with lower levels o f methicillin resistance (Cauwelier et al., 2004). This implied that the 
cefoxitin test was more accurate in detecting methicillin resistance in these 
heterogeneous strains than the oxacillin test, whereby isolate 7 depicted susceptibility 
and isolate 8 had ambiguous results. The results o f this study seemingly support data 
from other studies that suggests the cefoxitin test is more sensitive than the oxacillin test 
for detection o f methicillin resistance in S. aureus. However the number of isolates 
(n=16) evaluated in this study was low and a larger collection o f MSSA and MRSA 
isolates is required for a more comprehensive evaluation o f the diagnostic performance 
o f these tests.
Nevertheless several studies investigating methicillin resistance in S. aureus isolates 
generally indicate that cefoxitin assays have higher sensitivities and specificities than 
oxacillin disc tests (see Table 3.6) (Broekema et al., 2009, Junkins et al., 2009, Roisin et 
al., 2008, Andrews et al., 2005, Skov et al., 2005, Skov et al., 2003, Felten et al., 2002). 
Whereas moxalactam has been shown to be more sensitive than both cefoxitin and 
oxacillin for the detection of methicillin resistance in CoNS species (Pupin et al., 2007). 
Currently cefoxitin rather than oxacillin is recommended for disc diffusion tests by the 
Clinical and Laboratory Standards Institute (CLSI) and the Swedish Reference Group 
for Antibiotics (Swenson et al., 2009). However in the UK, as stated in the BSAC 
version 9.1, March 2010 methods for antimicrobial susceptibility testing, both oxacillin 
and cefoxitin discs are permitted for detection of methicillin resistance in S. aureus.
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With broth dilution assays CLSI recommends the use of either oxacillin or cefoxitin for 
detection of mecA -mediated resistance in S. aureus. Manufacturers of the BD Phoenix 
and Vitek 2 automated susceptibility testing systems, which use microdilution assays, 
have adapted these systems to optimize detection of mecA mediated resistance by 
including both oxacillin and cefoxitin (Junkins et al., 2009). The in-built expert systems 
within the instruments interpret any S. aureus isolate that expresses MICs depicting 
resistance to either cefoxitin or oxacillin as methicillin resistant (Junkins et al., 2009, 
Mencacci et al., 2009).
In this study, with the BD Phoenix fourteen o f the fifteen mecA positive isolates had 
MICs o f >4mg/L and >8mg/L to oxacillin and cefoxitin respectively, showing clear 
resistance to both o f these antibiotics and were identified as MRSA. However isolate 7 
had very low MICs, depicting susceptibility to both oxacillin (<lmg/L) and cefoxitin 
(<2mg/L) and was identified as a MSSA. This isolate is clearly a low level resistance 
MRSA and so it is highly likely that a methicillin susceptible result was attained during 
the original testing o f  this isolate. Another interesting mecA positive S. aureus was 
isolate 8 because whereas most isolates depicted clear resistance to oxacillin (>4mg/L) 
and cefoxitin (>8mg/L), this isolate had MICs o f 4 mg/L and 8 mg/L respectively. 
These MICs are merely one 2-fold dilution higher than the BSAC resistance breakpoints 
and it is generally held that the precision of a dilution susceptibility test method is plus 
minus one 2-fold dilution (Prakash et al., 2008). So it is possible that isolate 8 could 
have exhibited MICs depicting susceptibility on previous testing and was thus reported 
as a MSSA isolate.
Even though MRSA were not reported in fifteen o f the sixteen cases evaluated in this 
study, in five cases (isolates 2, 3, 6, 11 and 15) MRSA strains were subsequently 
reported within three months and in three cases within a week. This relatively rapid 
detection o f MRSA (from similar clinical specimens) after former isolates were reported 
as MSSA isolates supports the likelihood that MRSA were probably initially 
misidentified as MSSA isolates.
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The retrospective evaluation o f the reported PHW Microbiology ABM Laboratory 
results is an apparent limitation o f this study and it is difficult to conclusively determine 
the causes o f the discrepancies between these reported results and the mecA PCR 
results. However by repeating the oxacillin, cefoxitin and BD Phoenix susceptibility 
tests, it was evident that there were a few heterogeneous MRSA strains and a MSSA 
isolate with borderline methicillin resistance. These isolates constitute atypical MRSA 
and MSSA strains which could have exhibited susceptible phenotypes and a resistance 
phenotype in the original microbiology laboratory tests, thus contributing to the 
observed discordant reported and PCR results. Therefore this study also helps to 
highlight the limitations o f exclusively using phenotypic susceptibility tests for the 
detection o f methicillin resistance in S. aureus. Even though the conditions of these tests 
have been modified and optimised to facilitate the accurate detection of mecA-mediated 
resistance the misidentification o f heterogeneous MRSA and BORSA strains is still 
possible. Therefore the molecular detection o f the mecA gene i.e. by PCR which is the 
gold standard method, is the optimal method for the conclusive detection o f methicillin 
resistance in S. aureus.
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Chapter Four
Molecular characterisation of methicillin resistant Staphylococcus aureus isolates
4.0 Introduction
4.01 Pulsed field gel electrophoresis and spa typing
The typing o f S. aureus isolates enables the discrimination o f strains based on their 
phenotypic or genetic characteristics. In addition the application of typing methods 
enables the discernment o f the clonal relatedness o f strains which is valuable in 
outbreak investigations and in long-term evolutionary studies. Molecular techniques are 
increasingly employed and pulsed field gel electrophoresis (PFGE) is the gold standard. 
However, spa typing has also become a widely used technique. PFGE involves an initial 
digestion o f the chromosomal DNA with a restriction endonuclease and the fragments 
are subsequently resolved with electrophoresis whereby the direction o f the current is 
changed periodically. The resultant PFGE patterns are representative DNA fingerprints 
of each strain. However, since mutations modify nucleotide sequences consequently 
they can affect PFGE patterns. For instance a single nucleotide change may produce a 
novel restriction site in a sequence and this may cause the loss o f a larger fragment and 
the gain o f two smaller ones in the PFGE pattern (three changes in the pattern). Since 
PFGE rapidly indexes genetic variation closely related strains can exhibit dissimilar 
patterns within a short period. Therefore criteria have been developed for the visual 
analysis o f PFGE patterns and for discerning the relatedness of strains (see Table 4.1) 
(Tenover et al., 1995).
The spa gene encodes protein A, a cell wall associated protein in S. aureus. Within the 
3' coding region o f spa there is a variable-number tandem repeat region referred to as 
the X-region. This region comprises 21-27 bp repeat sequences which have extensive 
polymorphism due to point mutations, duplications and insertions. The spa typing 
method involves the amplification and DNA sequencing o f the polymorphic X-region 
(Koreen et al., 2004, Harmsen et al., 2003, Shopsin et al., 1999). The identified repeat 
sequences are assigned an alpha or numerical code and the order of these defines the 
spa type o f the strain (see Figure 4.1) (Harmsen et al., 2003). An online spa server 
developed and maintained by Ridom GmbH includes a database containing current spa 
types and the associated epidemiological information (Harmsen et al., 2003).
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Table 4.1. Criteria for interpreting PFGE patterns (Tenover et al., 1995)
Category No. of genetic No. of fragm ent In terpretation
__________________ differences differences__________________________________
Indistinguishable 0 0 Belong to single clone
Closely related 1 2-3 Belong to single clone
Possibly related 2 4-6 Possibly belong to single clone
Different > 3  > 7  Unrelated strains
s E D A B C
GAGGAAGACAACAACAAGCGTGGT- AAAGAAGACGGCAACAAACCTGGT- AAAGAAGACAACAAGAAACCTGGT 
08 16 13
0 8 - 1 6 - 1 3  spa type t026
Figure 4.1. A schematic diagram of the spa gene. Boxes indicate sequences encoding: 
S, signal sequence; A-D, immunoglobulin G binding regions; E, sequence homologous 
to A-D; X, region comprising 21-26 bp repeats (Shopsin et al., 1999).
4.02 SCCmec  typing
The typing of SCCmec elements is integral to the characterisation and nomenclature of 
MRSA strains. Several SCC mec elements (type I to VIII) have been described in 
MRSA and the discrimination of these is based on the detection of loci which are 
specific to the respective elements. The Milheirico et al. (2007b) method is a multiplex 
PCR assay which incorporates the detection of mecA as the internal control and the 
detection o f nine additional loci for the characterisation o f SCCmec types I to V. For 
instance, both SCCmec type I and II harbour mecA and dcs but pis  is specific to 
SCC mec type I, whereas ccrB2, kdp, mecl are specific to S CCmec type II (see Figure 
4.2). The loci are amplified with specific primers resulting in PCR fragments of 
different sizes. These are resolved in an agarose gel and the banding patterns are 
specific to the respective elements (see Table 4.2).
The characterisation o f the ccr and mec complexes harboured by SCCmec elements is 
an alternative means o f typing these elements. Kondo et al. (2007) developed a SCC mec 
typing method which includes a multiplex PCR method, MPCR-1 which comprises 
primers specific for five ccr types: types 1 to 5 (ccrC) and mecA (included as an internal 
control) (see Figure 4.3 and Table 4.3).
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Figure 4.2. Diagrams of the SCCmec type I and II elements and the loci detected by the 
Milheirico et al. (2007b) SCCmec typing method in these elements
Table 4.2. PCR fragment sizes of the Milheirico et al. (2007) method for SCCmec types 
I to V (Milheirico et al., 2007b)_________________________________________________
Loci Size(bp) S C C m ec l SCC/wecII SCCmecIII S C C m e c W S C C m ecV
p is 495bp +
ccrC 449bp +
III- J3 414bp +
V - J1 377bp +
dcs 342bp + + +
ccrB 2 31 lbp + +
kdp 284bp +
III-J1 243bp +
m e c l 209bp + +
m ecA 162bp + + + + +
No. of fragments 3 5 4 3 3
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The Kondo et al. (2007) SCCmec typing method also includes another multiplex PCR 
termed MPCR-2 which includes primers for the detection of three different classes of 
mec complexes: class A, B and C2. The PCR fragments are resolved in an agarose gel 
and the ccr types and mec classes are identified by virtue of the expected fragment sizes 
(see Figure 4.3 and Table 4.3).
J1 J2
SCCmecll
>  4
m e c R I
J3
ccrA2B2
Tn 554_______
me c l  | mecA puB110tfcs
T f ,Type 2 
ccr gene com plex
Type 1 - ccrAlBl 
Type 2 - ccrA2B2 
Type 3 - ccrASBS 
Type 4 - ccrA4B4 
Type 5 - ccrC
Class A 
mec gene complex
Class A 
Class B 
Class C
H }  rtpj
IS 431
T herefore SC Cmec elements types are term ed:
SCCwec type I or 1B 
SCCwec type II or 2A 
SCCwec type III or 3A 
SCCwec type IV or 2B 
SCCrnec type V or5C2 5C1 
SCCmec type VI or 4B
Figure 4.3. Diagram of SCC mec type II and the different ccr types and mec classes 
harboured in the MRSA I to VI strains
Table 4.3. PCR fragment sizes of ccr and mec loci of SCCmec type I to VI elements 
with MPCR-1 and MPCR-2 assays (Kondo et al., 2007)____________________________
Loci Size(bp) SCC/wccI SCC/wecII SCCmeclll SCC/wccIV SCC m ec\
MPCR-1 (IB) (2A) (3A) (2B) (5C)
mecA 286bp + + + + +
ccrAlBl 695bp +
ccrA2B2 937bp + +
ccrA3B3 1791bp +
ccrA4B4 1287bp (+)
ccrC 518bp +
MPCR-2
mecA-mecl 1963bp + +
mecA-\S1272 2827bp + +
mecA-\S431 804bp +
(+) SCC/wecVI which contains ccrAB4 has been described which is structurally similar to SCCmecIV
1 0 2
4.03 Subtyping of the SCC mec type IV elements
The definition o f SC Cmec subtypes is based on variations in the J-regions (Jl, J2 and 
J3) o f the elements. The type IV element is the most variable and subtypes IVa, IVb, 
IVc, IVd, IVE, IVF and IVg have been described in MRSA; recently Milheirico et al. 
(2007a) have also described an additional subtype IVh in the EMRSA-15 strain HAR22. 
Several subtyping methods have been developed including the MPCR-3 method by 
Kondo et a l (2007) and a method by Milheirico et al. (2007a). These are multiplex 
PCR assays which discriminate SCCmec type IV subtypes based on variations in the J l-  
region.
Table 4.4. PCR fragment sizes o f SC Cmec type IV subtypes with the Milherico et al. 
(2007a) and MPCR-3 methods__________________________________________________
SCC mec type IV 
Subtypes
PCR fragment sizes 
Milheirico et al. (2007a) MPCR-3
IVa 278 bp 458 bp
IVb 336 bp° 726 bp
IVc 483 bp* 259 bp
IVd 575 bp 1,242 bp
IVE 483 bp*
IVF 336 bp"
IVg 792 bp
IVh 663 bp
ccrB (internal control) 203 bp
° Jl region of IVb and IVF is highly similar; J l region of IVc and IVE is highly similar
The MPCR-3 method involves four primer pairs which are specific for subtypes IVa, 
IVb, IVc and IVd, whereas the Milherico et al. (2007) method is more comprehensive 
and involves seven pairs o f primers which are specific for the IVa, IVb, IVc, IVd, IVE, 
IVF, IVg and IVh subtypes (see Table 4.4). One o f the primer pairs is for the 
amplification o f an internal region in ccrB2 which is characteristic of the SCCmec type 
IV and serves as an internal control. Both methods similarly identify IVa, IVb, IVc and 
IVd subtypes but the primer sets are specific for different open reading frames in the J l-  
regions.
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The objective o f this study was to determine the genetic characteristics o f 137 MRSA 
clinical isolates with the following molecular typing techniques: PFGE, spa typing and 
the Milheirico et al. (2007b) SCCmec typing method. The MPCR-1 and MPCR-2 
assays were performed on indefinite results and subtyping of the SCC mec type IV 
elements was performed with the Milheirico et al. (2007a) and the MPCR-3 methods.
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4.1 Results
4.1.1 Pulsed Field Gel Electrophoresis
The pulsed field gel electrophoresis (PFGE) method was successfully performed on all 
o f the MRSA clinical isolates (n=T37) and a total o f 22 patterns including six unique 
PFGE patterns were resolved with this assay. The PFGE patterns were compared to 
those o f the EMRSA-15 and EMRSA-16 reference strains and 130 of the 137 isolates 
exhibited patterns that were comparable to these strains. Sixty-one of the isolates had 
PFGE patterns which were identical or had a 1-band difference to the EMRSA-15 
reference strain, their patterns were designated EMRSA-15 and EMRSA-15i 
respectively (see lane 1 to 4 in Figure 4.4 and Table 4.5). Forty-three isolates had PFGE 
patterns with 2 to 3 band differences to the EMRSA-15 reference strain and these were 
termed EMRSA-15.1 to EM RSA -15.l.li (see lane 5 to 13 in Figure 4.4 and Table 4.5). 
Sincd these isolates had a <3 band difference to the EMRSA-15 reference strain this 
signified that they were closely related to this strain according to the Tenover et al. 
(1995) criteria. Eighteen isolates had patterns which were more variable to the EMRSA- 
15 reference strain but collectively they had 4 to 6 band differences and they were 
termed EM RSA-15.l.lii to EMRSA-15.4 (see lane 13 to 23 in Figure 4.4 and Table 
4.5). According to the Tenover et al. (1995) criteria isolates with up to a 6-band 
difference belong to a single clone, therefore in total 122 (89.5%) of the 137 MRSA 
isolates belonged to the EMRSA-15 clone (see Table 4.4).
Eight o f the MRSA clinical isolates had PFGE patters that were comparable to the 
pattern o f the EMRSA-16 reference strain. Two isolates had patterns which were 
identical and the remaining six isolates exhibited patterns that were termed EMRSA-16i 
(n=5) and EMRSA-16ii (n=l) (see lane 24, 25, 26 in Figure 4.4 and Table 4.5). These 
patterns had a <3 band difference to the EMRSA-16 reference strain and according to 
the Tenover et al. (1995) criteria, this indicated that they were closely related to this 
strain. Therefore in total eight (5.8%) o f the 137 MRSA isolates belonged to the 
EMRSA-16 clone (see Table 4.4). Seven (5.1%) isolates depicted a total o f six unique 
PFGE patterns, two isolates o f these isolates exhibited an identical pattern. These were 
not comparable to the patterns of the other MRSA isolates and had >6 band difference 
to the EMRSA-15 and EMRSA-16 reference strains.
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Table 4.5. PFGE characteristics of the MRSA clinical strains (n=137)
PFGE pattern No. of band differences No. of isolates PFGE group
EMRSA-15
EMRSA-15 0
122 (89.1%)
30 A
EMRSA-15i 1 31 A
EMRSA-15.1 2 8 A
EMRSA-15.1i 3 26 A
EMRSA-15.1.1 2 3 A
EMRSA-15.1. li 3 6 A
EMRSA-15.1.lii 4 3 A
EMRSA-15.1.2 4 1 A
EMRSA-15.1.3 4 1 A
EMRSA-15.2 5 4 A
EMRSA-15.2i 6 2 A
EMRSA-15.3 6 6 A
EMRSA-15.4 4 1 A
EMRSA-16
EMRSA-16 0
8 (5.8%)
2 B
EMRSA-16i 2 5 B
EMRSA-16ii 2 1 B
Unique 01-06 >6 7 (5.1%) C to H
Total 137
This signified that the seven isolates with the unique patterns did not belong to the 
EMRSA-15 or EMRSA-16 clones and their patterns were termed: Unique-01 (n=T) 
Unique-02 (n=l), Unique-03 (n=l), Unique-04 (n=l), Unique-05 (n=l) and Unique-06 
(n=2) (see lane 27 to 30 in Figure 4.4 and Table 4.5). Based on the closely related or 
unique patterns the MRSA clinical isolates (n=137) were demarcated into eight PFGE 
groups (PFG), these were allocated by clustering isolates with PFGE patterns that had 
up to 6-band differences. Therefore the 122 clinical isolates that exhibited the EMRSA- 
15 related PFGE patterns were placed into PFG-A and the eight isolates that exhibited 
the EMRSA-16 related PFGE patterns were placed into PFG-B. The seven isolates that 
had unique patterns were placed into six groups i.e. PFG-C (n=l), PFG-D (n=l), PFG-E 
(n=l), PFG-F (n=l) and PFG-G (n=l) and PFG-H (n=2) (see Table 4.5).
106
<C/3
Pi
r-
o
m  PJ 
7  \r ^
■iNss
3
; . | S
l iki
h
1H
t
S
1n
<u
i f  7
p
D
• - T  C N  
►VO
PJ
PJ
I I IJD X> JD PO 44Pc; 44 Pi 44 44
m o m O in O
ON CN N" mi KCO on ^t ON O' OnCO (N CN 1—1
I
x>44
in
OO
o
►rsl m 
co
Tf
<N
co
<uo
p<D1—
,<1/
T3
"O
p
cd
X>
O
o
Z
<00
cd
PJI
co
<00
cd
PJi
C N
<D
P
cd
e  ' «  <  — 00
2  s
z  ^• co m ^
1«—I o
^  SPJ JS
<u £  
P  I
iH < 
. „  C/3 — Oi
§
PJm
• 03
Z  ^<u in  00 ^
p  <  « 00 ,U CcC
?S ^-a p.) 
P  <u
=  C/32 *“ c H  <L)
^  > CP U T3
'S . ^
P  ^  — 1
O  C N
«  C/3^  <uC/3 r- .22 Kt 
C d  ^ J
9 dC/3
'" "  cd
cd - d  o  1/5
■p <U
• P  o
u g
< £  00Cd E 
r- "T
CO <  — 00
- O  ■<—
< '00
Pi ©
S  "  w g
c dC N
< 3 ^  C N
— mi
a/ <£ 
P 00 
«  Cd
• ON m _
5=*
C/3
^  03 *—i O
I  §
° < c f
ON <
p I  
i2 S
• -  ^  — r~
<u PJ
r— (L>
"* s<u 3Cd ,—*
E p
E J$
p
5  5 
E 
w ^  O  <  p- Z 
a- Q
T f  cd
■d^ -O 
0/ p
3on
NO
in
a> .>c ^cd C/3^  csi
in PJI
. T^)
Eo
t da,
<
oo
d
S
p ji'O(N
(D
Ccd
C3
c x
cd PJ CNino —; mi
<
C/3
Q i
PUi
m
CN
a>
o o
<D
<
C/3cd
S
p j
■^tCN
a)
E
a /
w
D -
<
C/3
cd
s
p p
no"CN
i
■xfCN
(U
p
cd
■ J
m
o
3
. ?
P
D
OCO
<u
p
cd
NOo
I
<D
3cr
OnCN
<D
P
cd
CN
O i
<D3
O ’
P
D
oo"
CN
<u
p
cd
O i<L>3
.ST
’ p
D
O '"
CN
(UP
cd
£
4>
cd
S P
a>3
a "
P3
<u
^ p
<4-.
0
l-l3
i2
oCO
1
CN
<u
p
cd
J
4.1.2 spa typing
The genetic background o f the MRSA clinical isolates (n=137) was further investigated 
by performing spa typing on 49 selected isolates, including 35 isolates that represented 
diverse EMRSA-15 PFGE patters, all eight isolates with the EMRSA-16 PFGE patterns 
and six isolates representing the unique PFGE patterns. The spa typing method had 
excellent typeability except in one case where the amplification o f the spa target 
sequence was unsuccessful with the isolate exhibiting the unique-05 PFGE pattern. In 
the remaining 48 isolates a total o f fourteen spa types were attained, seven (t022, t032, 
t379, t879, t910, t4185, and t4424) were depicted by the selected EMRSA-15 strains 
(n=35). The majority exhibited spa type t032 (n=20). The remaining EMRSA-15 strains 
depicted spa types: t022 (n=5), t379 (n=l), t879 (n=l), t910 (n=4), t4185 (n=l) and 
t4424 (a new spa type, n=3) (see Table 4.6a). In comparison to spa type t032, these spa 
types were related variants exhibiting deletions o f repeat(s) or nucleotide substitution(s) 
i.e. t022 has a deletion of repeat r23 in comparison to t032, whereas t379 and t910 have 
apparent deletions o f more than one repeat i.e. r31-r29-rl7 and r31-r29-rl7-r25-rl7 
respectively (see Table 4.6a). The spa type t879 does not have deletions o f repeats but 
has r20 in a position where r23 is present in t032. Similarly t4424 has r31 present in a 
location where r23 is present in t032. The spa type t4185 has both deletions o f repeats 
and the presence of r l6  where r23 is present in t032. The sequences of the r20, r31 and 
r l6  repeats in t879, t4424 and t4185 have nucleotide substitution(s) distinguishing them 
from the sequence o f r23.
The tO 12 (n=2) and tOl 8 (n=6) spa types were depicted by the eight strains which 
belonged to the EMRSA-16 clone, these two spa types differed by the absence o f the 
r24 repeat unit in t012. The five isolates with unique PFGE patterns had diverse spa 
types: t l 38, t359, t437, t878 and t l 778, which were different to those depicted by the 
EMRSA-15 and EMRSA-16 clinical strains. In addition spa typing was performed on 
MRSA strains which have been previously epidemic in the UK i.e. EMRSA-1 to 
EMRSA-17 strains (see Table 4.6b). These EMRSA strains exhibited the tOOl, t009, 
tOl 8, t025, t037, t051, tl90  and tl94  spa types. None o f these spa types were exhibited 
by the unique clinical MRSA isolates, signifying that these were not related to the 
EMRSA-1 to EMRSA-17 strains (see Table 4.6b).
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Correlation between the PFGE patterns and spa types was highly variable, especially 
with the EMRSA-15 strains. Four o f the thirteen EMRSA-15 patterns were exclusively 
represented by t032 but in contrast the EMRSA-15 and EMRSA-15.li  patterns were 
represented by three spa types i.e. t022, t032 and t910 and t022, t032 and t4185 
respectively. The remaining EMRSA-15 patterns were represented by variable pairs of 
spa types. Similarly, with the EMRSA-16 strains the EMRSA-16i pattern was 
represented by spa types t012 and tOl 8 (see Table 4.6a).
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4.1.2.1 Cluster analysis of the spa types
^018 |—j ^012
cluster 2
Figure 4.5. Minimum spanning trees generated with Ridom StaphType software. 
Circles represent respective spa types and the central circle depicts the spa type defined 
as the founder of the cluster i.e. t379 for spa-CC379. Note: no founder defined for 
cluster 2. Numerical values on branches represent the similarity (distance) between the 
respective spa types and the founder or between the spa types where there is no founder.
Cluster analysis of the spa types was performed with the Ridom StaphType version
1.5.2.1 software, using the Based Upon Repeat Pattern (BURP) algorithm. It excluded 
spa types that were shorter than five repeats and placed spa types in clusters if costs 
were < 4. Two clusters: spa-CC319, cluster 2 and six singletons were generated. Cluster 
spa-CC379 comprised spa types: t022, t032, t379, t879, t9 10 and t4424, implying that 
all the isolates that exhibited these spa types were genetically related. Whereas cluster 2 
comprised spa types: tO 12 and tO 18 again implying that the isolates with these spa types 
were genetically related. There were six singletons: t l 38, t359, t437, t878,11778, t4 185 
and these implied that the isolates with these spa types were considered to be 
genetically unrelated to the other isolates (see Figure 4.5).
spa-CC319
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4.1.3 D iscrim inatory power of PFGE and spa typing and concordance of results
The discriminatory power o f PFGE and spa typing was investigated by determining the 
number of types and groups (or BURP clusters with spa typing) generated with the 
selected isolates. In total the isolates (n=48, one untypeable with spa typing) were 
represented by 21 PFGE patterns versus fourteen spa types (see Table 4.7). The thirty- 
five EMRSA-15 strains were characterised by thirteen PFGE patterns in comparison to 
seven spa types (t022, t032, t379, t879, t910, t4185 and t4424) by typing (see Table 
4.7). The eight EMRSA-16 strains were characterised by three PFGE patterns and two 
spa types (tOl2 and tOl 8). The five isolates with the unique PFGE patterns similarly had 
five diverse spa types ( t l38, t359, t437, t878 and tl778). This indicated that on a types 
level the PFGE method was more discriminatory than spa typing for the EMRSA-15 
and EMRSA-16 strains.
Table 4.7. Comparison o f PFGE and spa typing results of 41 clinical MRSA strains
Typing Assay EMRSA-15 (n=35) EMRSA-16 (n=8) Unique (n=5) Total (n=48)
PFGE patterns 13 3 5 21
PFGE groupsb 1 1 5 7
spa type 7 2 5 14
spa-BURP 2 1 5 8
Key: PFGE typesa-strains differing by <3bands 
PFGE groupsb- strains differing by <6 bands.
113
spa  c luster PF G
t359 Singleton H
t437 Singleton D
1878 Singleton F
t1778 Singleton E
t138 Singleton C
1018 C luster 2 B
1012 C luster 2 B
14185 Singleton A
1379 CC379 A
1910 CC379 A
1879 CC379 A
14424 CC379 A
tO 32 CC379 A
tO 22 CC379 A
0.25 0.20 0.15 0.10 0.05 0.00
Figure 4.6. Dendrogram showing the genetic relatedness o f spa types and correlation 
with PFGE groups. Generated with the Mega IV software, clustering by unweighted- 
pair group method using average linkages. At a cutoff of 0.05 (arbitrarily selected) two 
clusters and six singletons were evident.
Congruence between PFGE groups and spa clusters was investigated by comparing the 
strains assigned to the PFGE groups and those within the spa BURP clusters. The eight 
EMRSA-16 strains were clustered into one group by both assays i.e. PFG-B by PFGE 
and cluster 2 by spa BURP analysis (see Table 4.6). However the EMRSA-15 (n=35) 
strains were demarcated into one group (PFG-A) by PFGE but with s/?<ar-BURP analysis 
they were demarcated into two clusters. Most o f the spa types (t022, t032, t379, t879, 
t910, t4185 and t4424) were clustered into spa-CCZ19 but the t4185 spa type was 
defined as a singleton (see Figure 4.6). This spa type was represented by one isolate 
which exhibited the EMRSA-15.li PFGE pattern. Therefore by PFGE it was 
characterised as closely related to the EMRSA-15 clone but by spa typing it was 
defined as unrelated to the EMRSA-15 strains (see Figure 4.6). With regards to the 
isolates depicting unique PFGE patterns, all o f these were demarcated into individual 
groups with PFGE and singletons by s/^-BURP analysis. In summary, PFGE grouping 
and spa BURP analysis were comparable for the EMRSA-16 and unique strains but the 
latter was slightly more discriminatory than PFGE grouping for the EMRSA-15 strains.
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4.1.4 SCCmec typing
SCCmec typing was performed on the MRSA clinical isolates (n=137) to determine the 
types o f SC Cmec elements contained in these isolates and the following MRSA 
reference strains were also included: NCTC10442 (SCCmec type I); N315 (SCCmec 
type II), 85/2082 (SCCmec type III), JCSC1978 (SCCmec type IVb) and WIS (SCCmec 
type V). With the Milheirico et al. (2007b) method all of the isolates (n=122) with the 
EMRSA-15 related PFGE patterns and four o f the seven isolates with unique PFGE 
patterns exhibited the three expected SCC mec type IV fragments (mecA, 162 bp; ccrB2, 
311 bp and dcs, 342 bp), therefore these were defined as MRSAIV strains (see Table 
4.8 and lane 4 in Figure 4.7). The eight isolates with the EMRSA-16 related PFGE 
patterns exhibited all o f the SCC mec type II fragments {mecA, 162 bp; ccrB2, 311 bp; 
dcs, 342 bp; kdp, 284 bp and mecl, 209 bp) thus these isolates were defined as MRS All 
strains (see Table 4.8 and lane 2 in Figure 4.7). The remaining three isolates had unique 
PFGE patterns and they exhibited the mecA fragment (162 bp) but only had one 
additional fragment which was comparable in size to the expected ccrC fragment (449 
bp). However unlike the MRSAV WIS reference strain the three isolates (termed isolate 
7, 8 and 151) did not depict the fragment for the J1 -region o f SCCmec type V (377 bp) 
(see Table 4.8 and lane 5 in Figure 4.7). Furthermore in the banding pattern produced 
by the MRSAIII 85/ 2082 strain, the SCCmec type III-J3 fragment (414 bp) had similar 
electrophoretic mobility as the ccrC fragment o f the MRSAV strain (see lane 3 and 5 in 
Figure 4.7). These results had several possible interpretations for isolates 7, 8 and 151:
i) The three isolates contained SCCmec type V elements that lacked the target 
sequence in the J1 region (377 bp).
ii) The three isolates contained SCCmec type III elements that lacked the target 
sequences in m ecl (209 bp) and the J 1 region (243 bp).
iii) The three isolates had atypical SCCmec elements that contained ccrC  but did 
not contain the other loci o f currently published SCC mec elements.
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500bp-
400bp-
300bp-
200bp-
-449bp (ccrQ  
-377bp (SCCwecV-Jl)
M62bp ( m e c A )
Figure 4.7. Milheirico et al. (2007b) SCCmec typing PCR product patterns for MRSA 
reference strains in a 2% agarose gel. M, lOObp molecular marker; lane 2, MRSAI; lane 
3, MRSAII; lane 4, MRSAIII; lane 5, MRSAIVb and lane 6, MRSAV.
Table 4.8. SC Cmec typing results of MRSA isolates (n=137) with Milheirico et al. 
(2007b) method_________________ _____________________________________________
Locus Size 11 (2A)
SCC mec types 
IV (2B) V (5C2)
pis 495bp
ccrC 449bp +
SCC/w£cIII-J3 414bp
SCCm ecV- J1 377bp none?
dcs 342bp + +
ccrB2 31 lbp + +
kdp 284bp +
SCCm ^cIII-Jl 243bp
m ecl 209bp +
mec A 162bp + + +
Total num ber of clinical isolates 8 126 3
none?-expected product not amplified
The SCC mec typing method was repeated using the respective Milheirico et al. (2007b) 
primer sets of the SCCmec type III and V elements in separate PCRs and the MRSAIII 
85/ 2082 and MRSAV WIS strains were included in the repeat assays. Like the 
MRSAV reference strain isolates 7, 8 and 151 generated the mecA and the ccrC 
fragments with the respective PCR assays but unlike the MRSAV reference strain they 
still did not exhibit the SCCmec type V-Jl fragment (see Table 4.9). The three isolates 
did not produce fragments with the PCR assays that amplified specific sequences in 
SCCmec type III element (see Table 4.9). Whereas the MRSAIII 85/ 2082 reference 
strain produced the mec A, mecl and S CCmec type III-J1 fragments but it did not exhibit 
the 414 bp fragment for the targeted SCCmec type III-J3 sequence located between 
Tn554 and orjX  (see Figure 4.8).
1 1 6
Table 4.9. Results of singleplex PCR assays for loci in SCCmec type III and V for 
MRSAIII, MRSAV, isolate 7, 8 and 151 with MPCR-1 and MPCR-2 assays___________
Locus Size M RSAIII MRSAV Isolate 7 Isolate 8 Isolate 151
ccrC 449bp + + + + +
SCCm<?cIII-J3 414bp none?
SCCmecV- J1 377bp +
SCCw<?cIII-Jl 243bp +
m ecl 209bp +
mecA 162bp + + + + +
none?-e\pected product not amplified
ccr A 3
Tn 554 'FT n554
IS431 mtIS4 i l VmtcRi\
mecl
mecl {209bp) III-J1 (377bp)III-J3 region (414bp) mecA (162bp)
SCCmec type III
Figure 4.8. Structure of SC Cmec type III (strain 85/ 2082) showing target sites of the 
Milheirico et al. (2007) typing method (IWG, 2009).
This MRSAIII 85/ 2082 strain also generated the ccrC fragment (449 bp) because it 
harbours a composite SCCmec element which comprises a SCCMercury element which 
contains the ccrC gene and a SCCmec type III element (see Table 4.9 and Figure 4.8). 
The results of the singleplex PCR assays suggested that isolates 7, 8 and 151 were 
probably not MRSAIII strains because they did not produce any of the specific 
fragments however, since they also lacked the SC Cmec type V-J fragment they could 
not be conclusively defined as MRSAV strains. Therefore the MPCR-1 and MPCR-2 
assays were performed to determine the ccr types (types 1 to 5) and mec classes (classes 
A, B and C2) harboured by these isolates. The MRSAIII 85/ 2082 strain exhibited the 
ccrA3B3 (1791 bp) and mecA-mecI (1963 bp) fragments with MPCR-1 and MPCR-2 
respectively (see lane 3 in Figure 4.9a and b; see Table 4.10). This showed that it 
contained the class A mec complex and the type 3 ccr complex which are typical o f the 
SCC mec type III (3 A) element. Once again it also depicted the ccrC fragment (518 bp) 
(see lane 3 in Figure 4.9a). With the MPCR-1 assay isolates 7, 8 and 151 also produced 
the ccrC fragment but with MPCR-2 only isolates 7 and 8 exhibited the mecA-\S431 
(804bp) fragment whereas isolate 151 did not generate any fragments (see lane 5 in 
Figure 4.9a and b; see Table 4.10).
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2000bpH
lOOObpJ
750bp—
500bp-J
lOOObp
750bp
500bp250bp
Figure 4.9. PCR product patterns for ccr types with MPCR-1 (a) and mec classes 
MPCR-2 (b). Lane M, lkb molecular marker; lane 1, MRSAI; lane 2, MRSAII; lane 3, 
MRSAIII; lane 4, MRSAIVb; lane 5, MRSAV.
Table 4.10. MPCR-1 and MPCR-2 results of MRSAIII, MRSAV, isolate 7, 8 and 151
M PC R -1 ccr  type
m ec A c c r A lB l
286bp 695bp
ccrA 2B 2
937bp
ccrA 3B 3  
1791 bp
ccrA 4B 4  ccrC  
1287bp 518bp
M R SA III + + + 3 & 5
M R SA V + + 5
Isolate 7 + + 5
Isolate 8 + + 5
Isolate 151 + + 5
M PC R -2 m ec  class
m ecA -m ecI m ecA -lS 1 2 7 2 m ecA -lS 4 3 1
1963bp 2827bp 804bp
M R SA III + A
M R SA V + C2
Isolate 7 + C2
Isolate 8 + C2
Isolate 151 none? ?
/?0/7e?-expected product not amplified
The carriage of mecA-\S431 by isolates 7 and 8 indicated that these isolates harboured 
the class C2 mec complex and the MPCR-1 results indicated that they contained the 
type 5 ccr complex (ccrC). Since the MRSAV/ WIS strain also contains the type 5 ccr 
complex and the class C2 mec complex, this suggested that isolates 7 and 8 were 
MRSAV (5C2) strains. However, the results of isolate 151 were more ambivalent 
because it harboured ccrC  but it did not generate any fragments with the MPCR-2 assay 
so its mec class could not be confirmed and consequently the SCCmec type of this 
isolate remained undefined.
1 1 8
The lack o f amplification o f the SCCmec type III-J3 fragment with the 85/ 2082 strain 
was further investigated by assessing the locations o f the primers on the sequence of 
this strain. The Milheirico et al. (2007) method is an update o f an assay originally 
developed by Oliveira and de Lencastre (2002) and it retains most o f the original primer 
pairs, including RJF5 F10 (forward primer) and RJF5 R13 (reverse primer) which were 
developed for the amplification o f a sequence in the J3 region o f SCCmec type III. 
However, although the RIF5 F10 sequence is identical in both methods the RIF5 R13 
sequence is different, but the expected product size is stated as 414 bp in both methods 
(see Table 4.11). In both studies the MRSA ANS46 strain was used in the optimisation 
o f the methods. This strain contains a SCCmec element which is identical to the 
SCCmec type III (AB037671) element in the MRSAIII 85/ 2082 strain. In the SCCmec 
type III/ AB037671 sequence the location o f the RIF5 R13 sequence as stated in the 
Milheirico et al. (2007b) method, is located much further downstream o f the original 
reverse primer in the Oliveria and de Lencastre (2002) method and when analysed in 
silico resulted in a 2,983 bp fragment (see Table 4.11). However, when the RIF5 R13 
sequence as stated in the Oliveira and de Lencastre (2002) method was analysed in 
silico on SCCmec type III/ AB037671 sequence it resulted in an expected 414 bp 
product (see Table 4.10). The same results were attained with two further published 
SCCmec type III sequences i.e. AF422696 (HU25 strain) and AF047089 (85/ 3097 
strain) (see Table 4.11).
Table 4.11. Primers for the SC Cmec type III-J3 region of the Milheirico et al. (2007b) 
and Olivera and Lencastre. (2002) methods________________________________________
SCC mec typing method Primer Primer sequence (5’-3’) Location Size
Oliveira et al. (2002) RIF5F10
RIF5R13
TTCTTAAGTACACGCTGAATCG
GTCACAGTAATTCCATCAATGC
59573-59594°
59986-59965° 414bp
Milheirico et al. (2007b) RIF5F10 
*RIF5 R13
TTCTTAAGTACACGCTGAATCG 
ATGGAGAT GAATT ACAAGGG
59573-59594°
62556-62537° ~2.9kb?
Milheirico et al. (2007b) ccrC  F2 
ccrC  R2
GT ACT CGTT AC AAT GTTT GG 
ATAATGGCTTCATGCTTACC
60662-60643°
60214-60223° 448bp
a AB037671/ SC Cmec type III (85/2082)
*AF422696/ SCC mec type III (HU25): RIF5 F10, 894-915 & *RIF5 R13, 3877-3858 
*AF047089/ SC Cmec type III (85/ 3097): RIF5 F10, 21370-21391 & *RIF5 R13, 24354-24335
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It is highly likely that in the multiplex format, the fragment in the banding pattern of 
MRSA III 85/2082 which was assumed to be the SCCmec type III-J3 fragment (414 bp) 
was actually the ccrC  fragment (449 bp) since this strain harbours this gene. This is 
supported by the location o f the ccrC primers on the AB037671/ SCC mec type III 
(85/2082) sequence which result in a 448 nucleotide sequence (see table 4.10). 
Therefore with the Milheirico et al. (2007b) method the lack o f amplification o f the 
SCC mec type III-J3 fragment with the MRSAIII 85/2082 strain was probably due to the 
unusual location o f the RIF5 R13 reverse primer which results in an unanticipated larger 
PCR product (approximately 2.9 kb). Such a large PCR product would not have been 
amplified under the PCR conditions of the multiplex and singleplex PCRs that were 
performed in this study.
In summary the SC Cmec typing results indicate that out o f the 137 MRSA isolates, 126 
(92.0%) contained S CCmec type IV (2B), 8 (5.8%) contained SCC mec type II (2A) and 
2 (1.5%) contained SC Cmec elements which were related to the S CCmec type V (5C2) 
element o f the MRSA WIS strain. However the SCCmec element harboured in one 
isolate (0.7%) remained undefined as it was not typeable with the typing methods 
employed in this study.
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4.1.5 Subtyping of SCCmec type IV elements
One hundred and twenty-six MRSA isolates were found to contain the SC Cmec type IV 
element and these comprised 122 isolates with EMRSA-15 related PFGE patterns 
(n=122) and four isolates with unique PFGE patterns. The Milheirico et al. (2007a) and 
the MPCR-3 methods were performed to determine the specific subtypes harboured by 
these isolates. The following MRSA reference strains were also included in these 
investigations: MRSAIVb/ JCSC1978 (SCCmec type IVb), MRSAIVc/ MR108 
(SCCmec type IVc) and the EMRSA-15 reference strain. A PVL-positive USA300 
clinical isolate was used as the MRSAIVa control (attained from the Specialist 
Chemotherapy Reference Unit, Cardiff, UK and identification and genotyping results 
presented in chapter 7).
With the MPCR-3 method the USA300 isolate, the MRSAIVb and MRSAIVc reference 
strains exhibited the expected PCR fragments i.e. IVa (458 bp), IVb (726 bp) and IVc 
(259 bp) respectively. Similarly with the Milheirico et al. (2007a) methods these strains 
depicted the IVa (278 bp), IVb (336 bp) and IVc (483 bp) fragments (see lanes 1, 2 and
3 in Figure 4.10a and b). However the EMRSA-15 reference strain did not produce any 
products with either o f the two methods (see lane 8 in Figure 4.10a and b). Subtyping of 
the clinical isolates (n=126) was largely unsuccessful and only four produced PCR 
fragments (isolates 9, 10, 150 and 152). Interestingly these four had all depicted unique 
PFGE patterns. With the MPCR-3 method isolates 9, 10 and 152 exhibited the IVa PCR 
fragment (458 bp) and isolate 150 depicted the IVd PCR fragment (1, 242bp) (see lanes
4 to 7 in Figure 4.10a). With the Milheirico et al. (2007a) assay the ccrB2 PCR product 
(203bp) was depicted by all o f the clinical isolate (n=126), this served as an internal 
control for isolates containing a SCC mec type IV or type II elements. However, only 
isolate 150 which had exhibited the IVd PCR fragment with the MPCR-3 method once 
again produced a IVd fragment (575 bp) with the Milheirico et al. (2007a) assay, 
whereas isolates 9, 10 and 152 did not produce the expected IVa fragments (see lane 4, 
5, 6 and 7 in Figure 4.10b).
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(a)
ISOObp
lOOObp—
700bp—
500bp-
300bp
200bp-
(b)
M l  2 3 4  5 6 7 8 _ M  1 2 3 4 5 6 7 S^^BBB ~203bp(g^g)
Figure 4.10. PCR products of MRSA reference strains and four clinical isolates.
(a) MPCR-3 method. Lane M, lOObp molecular marker. Lane 1, USA300 clinical 
isolate; lane 2, MRSAIVb; lane 3, MRSAIVc; lane 4, isolate 150; lane 5, isolate 9; lane 
6, isolate 10; lane 7, isolate 152; lane 8, EMRSA-15 reference strain.
(b) M ilheirico et al. (2007a) method. Lane M, lOObp molecular marker. Lane 1, 
USA300 clinical isolate; lane 2, MRSAIVb; lane 3, MRSAIVc; lane 4, isolate 150; lane 
5, isolate 9; lane 6, isolate 10; lane 7, isolate 152; lane 8, EMRSA-15 reference strain.
In summary the MRSAIVb, IVc reference strains and a MRSAIVa clinical isolate were 
successfully subtyped with the two methods employed in this study however, the 
EMRSA-15 reference strain was not typeable with either of the methods. Similarly out 
of the 126 MRSA isolates that contained the SCCmec type IV elements, the 122 isolates 
with the EMRSA-15 related PFGE patterns did not generate any PCR products. Only 
the four isolates with unique PFGE patterns were subtyped with variable success i.e. 
isolate 150 was a IVd strain whereas isolate 9, 10 and 152 were possible IVa strains.
4.1.6 Detection of the arginine catabolic mobile element
Carriage of the arginine catabolic mobile element (ACME) was detected by 
amplification of the arcA locus located in ACME. It was detected in only two (isolate 
14 and 68) of the MRSA clinical isolates (n=137). Both of them were EMRSA-15 
strains and carried SC Cmec type IV elements. Isolate 14 exhibited the EMRSA-15.1.2 
PFGE pattern and the t032 spa type whereas isolate 68 exhibited the EMRSA-15i PFGE 
pattern {spa typing not done on this isolate). The arc A -ACME PCR products of the two 
clinical isolates were sequenced and aligned to the crrcM-ACME sequence of the 
FPR3757/ USA300 strain (accession number CP000255.1). The sequence of isolate 68 
was identical to the USA300 sequence whereas the sequence of isolate 14 had two point 
mutations (see Figure 4.11).
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4.1.7 Antibiotic susceptibility testing of selected MRSA clinical isolates
Antibiotic susceptibility testing was performed with the BD Phoenix on the two ACME- 
positive isolates (14 and 68) and since these isolates had depicted EMRSA-15 related 
PFGE patterns eleven additional clinical isolates which had also exhibited an EMRSA- 
15 PFGE pattern but were ACME negative were also tested. Susceptibility testing was 
also performed on seven isolates with EMRSA-16 related patterns and the seven 
isolates which had unique PFGE patterns. The EMRSA-15 and EMRSA-16 laboratory 
reference strains were also included in these investigations. The EMRSA-15 and 
EMRSA-16 reference strains were largely susceptible to non p-lactam antibiotics, 
showing resistance to ciprofloxacin only (see Table 4.12). Similarly the two ACME- 
positive isolates and all o f the other EMRSA-15 clinical isolates were also resistant to 
this antibiotic and largely susceptible to other non p-lactam antibiotics. For instance 
very few were resistant to tobramycin (n=2) and clindamycin (n=T) and a variable 
number were resistant to erythromycin (n=6) and trimethoprim (n=4). Only one 
EMRSA-15 clinical isolate (75) was also resistant to gentamicin and mupirocin. 
However even though the EMRSA-16 reference strain was largely susceptible to non p- 
lactam antibiotics, there was an apparent trend o f multiple antibiotic resistance amongst 
the EMRSA-16 clinical isolates (see Table 4.12). These seven isolates were extensively 
resistant to clindamycin (n=6), erythromycin (n=6), trimethoprim (n=7) and surprisingly 
mupirocin (n=6), with two isolates (144 and 145) exhibiting resistance to high level 
mupirocin. There was more variation within the seven unique isolates, three were 
completely susceptible to non p-lactam antibiotics, whereas the remaining four isolates 
were largely resistant to trimethoprim (n=4) and erythromycin (n=3). (As previously 
discussed in chapter 3, isolate 7 had multiple antibiotic resistance but it was susceptible 
to oxacillin).
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In the PHW Microbiology ABM Laboratory isolates that are identified from a patient 
within three months are considered to be the same strain. So consecutive isolates from 
the same patients within this period were identified from MRSA isolates o f this study 
(n=137) and fifteen pairs and two triplicate isolates were identified. This enabled an 
assessment o f any possible genotypic changes within this period, in most cases the 
consecutive isolates had the same PFGE pattern, spa type and SCCmec type (see Table 
4.13).
Table 4.13. Genotypic data o f MRSA isolates identified from consecutive (<3 months)
Isolate ID. PHW result date PFGE spa type SCC mec ACME
46 30-Apr-07 EMRSA-15i not done IV neg
61 22-May-07 EMRSA-15i not done IV neg
2 02-May-07 EMRSA-15.2 not done IV neg
135 02-May-07 EMRSA-15.2 not done IV neg
3 04-May-07 EMRSA-15i not done IV neg
52 08-May-07 EMRSA-15i not done IV neg
57 14-May-07 EMRSA-15i not done IV neg
97 04-May-07 EMRSA-15.H not done IV neg
102 25-Jun-07 EMRSA-15.1i not done IV neg
53 09-May-07 EMRSA-15 not done IV neg
62 26-Jun-07 EMRSA-15 not done IV neg
144 13-May-07 EMRSA-16 t018 II neg
145 16-May-07 EMRSA-16 tOl 8 II neg
143 13-May-07 EMRSA-16i t012 II neg
146 16-May-07 EMRSA-16i t012 II neg
129* 15-May-07 EMRSA-15.1.H t032 IV neg
108* 2 7-Jun-07 EMRSA-15.1i t032 IV neg
63* 22-Jun-07 EMRSA-15 not done IV neg
83* 08-Aug-07 EMRSA-15i not done IV neg
103 25-Jun-07 EMRSA-15.1 not done IV neg
107 27-Jun-07 EMRSA-15.1 not done IV neg
114 24-Jul-07 EMRSA-15.1 not done IV neg
64 02-Jul-07 EMRSA-15i t022 IV neg
12 07-Aug-07 EMRSA-15i not done IV neg
111 10-Jul-07 EMRSA-15.1i not done IV neg
115 27-Jul-07 EMRSA-15.1i not done IV neg
67 17-Jul-07 EMRSA-15i not done IV neg
85 08-Aug-07 EMRSA-15i not done IV neg
71 20-Jul-07 EMRSA-15i not done IV neg
90 24-Aug-07 EMRSA-15i t032 IV neg
9 24-Jul-07 Unique-06 t359 IVa? neg
10 25-Jul-07 Unique-06 not done IVa? neg
77 01-Aug-07 EMRSA-15 not done IV neg
81 06-Aug-07 EMRSA-15 not done IV neg
149 08-Aug-07 EMRSA-16i tOl 8 II neg
147 2 8-Aug-07 EMRSA-16i tOl 8 II neg
*PFGE different but by <3 bands, so same clone (same spa type); PHW- PHW Microbiology ABM Laboratory
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Figure 4.12. Different PFGE patterns exhibited by consecutive isolates identified from 
a single patient within one and a half months. Isolates 63 and 83 identified from one 
patient and isolates 129 and 103 identified from another patient.
However in two cases, there was some variability in the PFGE pattern i.e. isolates 129 
and 108 were identified approximately one and half months apart but they exhibited the 
EM RSA-15.l.li and EMRSA-15.H PFGE patterns respectively (see Table 4.13 and 
Figure 4.12). These only had a 2-band difference, indicating that they were closely 
related and were probably the same strain furthermore their spa types were identical. 
Similarly isolates 63 and 83 were also identified approximately one and a half months 
apart and they depicted the EMRSA-15 and EMRSA-15i patterns. These only had a 1- 
band difference, indicating that they were closely related and were probably the same 
strain (see Table 4.13 and Figure 4.12).
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4.2 Discussion
In this study 137 MRSA clinical isolates were collected from the PHW Microbiology 
ABM Laboratory from April 2007 to September 2007. These isolates were successfully 
typed with the PFGE typing method and twenty two patterns were resolved. One 
hundred and twenty-two (89.1%) isolates were determined to be EMRSA-15 strains, 
eight (5.8%) isolates were determined to be EMRSA-16 strains and seven (5.1%) were 
diverse MRSA strains. PFGE is renowned for its high discriminatory power however, 
EMRSA-15 and EMRSA-16 clones have highly conserved macro-restriction PFGE 
patterns. For instance Goering et al. (2008) observed that approximately 50% of 
EMRSA-15 and 30% of EMRSA-16 strains from Scotland are indistinguishable by 
PFGE (Holmes et al., 2010, Shore et al., 2010, Goering et al., 2008). Similarly in this 
study only thirteen PFGE patterns were resolved from the 122 EMRSA-15 strains and 
30/122 (24.6%) strains had patterns that were identical to the EMRSA-15 reference 
strain. So even though this technique effectively identified two clones in this study, 
these results suggest that it had a limited capacity to discriminate EMRSA-15 and 
EMRSA-16 subtypes. The possible implication of this is that in geographical areas 
where these clones are endemic it may be difficult to identify and monitor specific 
subtypes which may be more predominant and have higher transmissibility within 
hospitals or the community (Holmes et al., 2010, Shore et al., 2010, Goering et al., 
2008, Cookson et al., 2007). So it would be valuable to employ alternative or additional 
techniques that have the further capacity to discriminate these widely disseminated 
clones (Ghebremedhin et al., 2007).
The EMRSA-15 clone belongs to the ST22-MRSA-IV lineage and various techniques 
have been developed to address the limited discriminatory power o f PFGE with regards 
to the discrimination of ST22-MRSA-IV strains. These include methods based on the 
amplification and sequencing of variable number tandem repeat (VNTR) such as spa 
typing, dru typing and multi locus VNTR analysis (Holmes et al., 2010, Shore et al., 
2010, Goering et al., 2008, Nahvi et al., 2001). The dru typing method involves the 
sequencing o f a hyper variable non-coding region located between mecA and IS437 in 
SCCmec elements. This region comprises repeat sequences which vary in composition 
and quantity in different strains. The analysis and assignment of dru types is performed 
with a software and there is an on-line database that provides defined dru types.
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This method has been investigated by Shore et al. (2010) and Goering et al. (2008) as 
an alternative to PFGE for the discrimination o f  EMRSA-15 strains. Goering et al. 
(2008) investigated EMRSA-15 (n=47) and EMRSA-16 (n=57) strains from hospitals in 
Scotland from 1998 to 2005. The EMRSA-15 and EMRSA-16 strains exhibited 13 and 
12 dru types respectively and although there were highly prevalent types which were 
commonly present in all o f the hospitals, they were also able to identify some minor 
EMRSA-15 and EMRSA-16 dru types that were specific to certain geographical 
regions. They suggested that this method may have the potential to trace specific 
subtypes of otherwise indistinguishable EMRSA-15 and EMRSA-16 strains. Shore et 
al. (2010) compared the efficacy o f dru typing with PFGE and spa typing for the 
discrimination o f ST22-MRSA-IV strains (n=173) from Ireland. In total, they attained 
26 pulsed field types (patterns with <3 band differences) and found that these could be 
placed into only four pulsed field groups (<6 band differences). Almost all o f their 173 
strains (n=168, 97%) belonged to one pulsed field group (PFG-01) which was 
comparable to this study whereby all the EMRSA-15 strains belonged to one pulsed 
field group (PFG-A). When they performed dru typing, PFGE and spa typing 
individually on the PFG-01 strains, PFGE was the most discriminatory method followed 
by dru typing. They also evaluated pair-wise combinations o f the three typing methods 
and determined that dru typing and PFGE provided the most discriminatory 
combination method. However they recommended the combination of all three methods 
for an enhanced discrimination of the ST22-MRSA-IV strains. Although dru typing is 
not as widely used as PFGE or spa typing, it involves the same techniques as spa 
typing, such as the amplification and sequencing o f a single VNTR locus. Therefore in 
clinical laboratories or reference laboratories that already perform DNA sequencing- 
based typing methods, the implementation o f this technique would not require 
additional expertise or gravely increase testing costs (Shore et al., 2010).
Holmes et al., 2010 performed two related techniques which are based on the 
amplification and analysis o f seven VNTR loci, namely the MLVF and the MVLA 
methods. The former involves the resolution of the PCR fragments in a gel whereas the 
latter requires DNA-sequencing of the amplified VNTR regions and the assignment of a 
numerical profiles with a specific software. They compared MVLF and MVLA to 
PFGE for the discrimination o f EMRSA-15 (n=41), EMRSA-16 (n=20) and MRSA 
(n=24) strains with variable PFGE patterns. They also evaluated 29 EMRSA-15 strains
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with indistinguishable PFGE patterns which were from two different outbreaks (Holmes 
et al., 2010). Amongst the strains with the variable patterns, they found MVLF to be 
comparable to PFGE for discriminating the EMRSA-15 strains but less discriminatory 
with the EMRSA-16 strains. With the indistinguishable EMRSA-15 strains, the MVLF 
and MVLA methods resolved seven and six subtypes respectively and they were able to 
identify the distinct EMRSA-15 subtypes that caused the outbreaks with both assays 
(Holmes et al., 2010). Since the MVLA and MVLF techniques are more rapid than 
PFGE and the MVLF method was found to be comparable to PFGE, Holmes et al. 
(2010) recommended this method for hospital outbreak investigations.
In this study, the 137 MRSA clinical isolates were from wound swabs and 94.9% (130/ 
137) were collectively EMRSA-15 and EMRSA-16 strains. This suggests that the 
molecular epidemiology o f MRSA isolates from wound infections is dominated by 
these two clones. These results concur with the results o f surveillance studies in 
England and Wales which have shown that HA-MRSA infections in these regions are 
extensively caused by the EMRSA-15 and EMRSA-16 clones (Boakes et al., 2010, 
Ellington et al., 2010c, Khandavilli et al., 2009, Johnson et al., 2005). Studies by Shore 
et al. (2010) and Goering et al. (2008) have shown that these clones are also highly 
prevalent in Ireland and Scotland and have outcompeted former dominant strains. The 
majority (122/137, 89.1%) o f the isolates belonged to the EMRSA-15 clone and less to 
the EMRSA-16 clone (8/137, 5.8%). These proportions were comparable to the results 
by Rollason et al. (2008) for MRSA isolates from skin and soft tissue infections of non­
hospitalised patients in the West Midlands region. They found that EMRSA-15 
accounted for 87% of the isolates whereas EMRSA-16 accounted for 8% (Rollason et 
al., 2008). Furthermore, Ellington et al. (2010) investigated UK bacteraemia isolates 
from the year(s) 2001 to 2007 and found that EMRSA-15 and EMRSA-16 consistently 
accounted for 95% of the MRSA isolates. However the proportions o f EMRSA-16 
declined from 21.4% in 2001 to 9% in 2007, whereas the proportion of EMRSA-15 
accounted for 85% of MRSA in 2007. They postulated that the decline of EMRSA-16 
preceded a subsequent decline in cases of MRSA bacteraemia (Ellington et al., 2010c).
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The spa typing assay is a widely used S. aureus typing tool and is variably comparable 
to PFGE (Grundmann et al., 2010, Petersson et al., 2009, Faria et al., 2008, Golding et 
al., 2008, Mellmann et al., 2008, Strommenger et al., 2008, Strommenger et al., 2006, 
Harmsen et al., 2003, Oliveira et al., 2001, Shopsin et al., 1999). In this study forty nine 
isolates were selected for spa typing, thirty-five of which depicted various EMRSA-15 
PFGE patterns. The most prevalent spa type o f the EMRSA-15 strains was t032, which 
is characteristic o f the EMRSA-15 clone and the other spa types exhibited by the 
EMRSA-15 strains were close variants o f this spa type (t022, t379, t879, t910, t4185 
and t4424) (http://spaserver2.ridom.de/spatypes.shtml) (Grundmann et al., 2010, 
Khandavilli et al., 2009, Soliman et al., 2009). The t012 and tOl8 spa types which are 
characteristic o f the EMRSA-16 clone were depicted by the eight isolates with 
EMRSA-16 related patterns. This indicated that within the selected clinical isolates the 
spa typing method successfully characterised EMRSA-15 and EMRSA-16 strains. 
However one isolate was not typeable with the spa typing method because amplification 
o f the spa target sequence was not successful. This may be due to either mutations in 
the primer binding sites or the possible lack of this gene in this particular isolate (Baum 
et al., 2009, Strommenger et al., 2008). Furthermore strains that contain spa sequences 
comprising a few repeats i.e. <3 repeats cannot be included in the cluster analysis of spa 
types, so to a certain extent these are also non-typeable. These cases are rare but 
indicate a limitation of the typeability capacity o f the spa typing method in S. aureus.
In comparison to PFGE, spa typing was found to be much less discriminatory for the 
EMRSA-15 strains (n=35) i.e. thirteen PFGE patterns versus seven spa types. In 
addition a specific spa type was not confined to a particular PFGE pattern which 
implied that spa types were not consistent predictors o f PFGE patterns. Nonetheless, 
there was congruence in the clustering o f strains into PFGE groups (isolates with <6 
band difference) and s/ra-BURP clusters. The EMRSA-15 strains and EMRSA-16 
strains were demarcated into distinct clusters with both methods and the strains in the 
groups were largely the same. However one EMRSA-15 strain exhibited the t4185 spa 
type which was defined as a singleton. In comparison to the spa types o f the other 
EMRSA-15 clinical strains (t022, t032, t379, t879, t910, t4185 and t4424) the t4185 spa 
type has deletions o f several consecutive repeats (r31-r29-rl7-r31-r29-rl7-r25) and 
possibly this was an underlying cause of this spa type being defined as a singleton by 
5/?<3-BURP cluster software. These results were comparable to those o f several studies
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which have demonstrated that although spa typing tends to be slightly less 
discriminatory than PFGE the spa clusters are highly concordant with PFGE groups 
(isolates exhibiting patters with <6 band difference). In addition ^ar-BURP clusters are 
highly concordant with MLST clonal complexes (Shore et al., 2010, Petersson et al., 
2009, Vindel et al., 2009, Faria et al., 2008, Golding et al., 2008, Mellmann et al., 2008, 
Strommenger et al., 2008, Cookson et al., 2007, Strommenger et al., 2006, Harmsen et 
al., 2003, Oliveira et al., 2001, Shopsin et al., 1999). One study included 1681 S. aureus 
clinical isolates and the discriminatory capacity o f a multi-locus VNTR analysis 
(MVLA) method involving eight loci was compared to spa typing and PFGE (Schouls 
et al., 2009). The spa typing and MVLA methods are based on similar principles which 
involve the amplification and DNA sequencing or fragment size analysis o f loci 
containing polymorphic repeat regions. Except in spa typing only one VNTR locus is 
analysed whereas with MVLA several VNTR loci are analysed. In the study by Schouls 
et al. (2009) the S. aureus clinical isolates (n=1682) had been submitted to a national 
institute for public health in the Netherlands from 2005 to 2007. All o f the isolates were 
typeable with the MVLA method and a total o f 511 MVLA types were represented in 
the 1681 isolates, these were then clustered into eleven MVLA complexes. Diversity 
indices were determined to evaluate the discriminatory power o f the MVLA method, 
spa typing and PFGE, which showed that the MVLA method was comparable to PFGE 
whereas spa typing was less discriminatory than both o f the methods (Schouls et al., 
2009). On a grouping level there was congruence between most o f the spa-chxstQrs and 
the eleven MVLA complexes except, in two cases whereby two o f the MVLA 
complexes were included in one .spar-cluster. This demonstrated that at a grouping level 
the spa typing method is still less discriminatory than MVLA. In addition, there was 
strong agreement between the MLST clonal complexes and MVLA complexes which 
indicates that the MVLA method may be a suitable typing tool for long-term 
evolutionary studies o f S. aureus (Schouls et al., 2009). The inclusion o f several VNTR 
loci in MVLA methods, as opposed to one locus in spa typing, also reduces the 
probability o f strains being un-typeable. In another study diverse S. aureus clinical 
isolates (n=198) collected from hospitals in the 1980s from nineteen countries of 
Europe, Latin America and USA were evaluated with spa typing, PFGE and MLST 
assays (Faria et al., 2008). Statistical tests were applied in order to quantify the levels of 
diversity and congruence between molecular techniques for the collection as a whole 
and also for the MRSA (n=l 16) and MSSA (n=82) separately. Even though spa type(s)
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could predict PFGE type(s) with 92% probability for the MSSA, the probability was 
markedly reduced to 40% for the MRSA (Faria et al., 2008). PFGE typing was found to 
be more discriminatory than spa typing for the collection as a whole and for the MRSA 
but with the MSSA isolates PFGE and spa typing had comparable discriminatory power 
(Faria et al., 2008). In a further study a collection o f 98 S. aureus isolates termed the 
Harmony collection had been collected from eleven European countries in the 1980s 
and these isolates were analysed with spa typing, MLST and PFGE (Cookson et al., 
2007). The collection o f isolates had been previously used in the EU Harmony Project 
which involved the standardisation of the PFGE protocol for European countries 
(Cookson et al., 2007). The spa typing method had a similar discriminatory capacity as 
PFGE and the groupings of strains with the three methods exhibited a high level of 
concordance (Cookson et al., 2007). In the study by Hallin et al. (2007) S. aureus 
strains (n=217) were selected from the Belgian staphylococci reference laboratory. The 
collection included representative strains of the major Belgian HA-MRSA clones and 
some sporadic strains with diverse PFGE patterns. These were selected from national 
surveillance programmes which had occurred from 1992 to 2003 (Hallin et al., 2007). In 
contrast to the afore-mentioned studies, the spa typing method had slightly more 
discriminatory power than PFGE.
The molecular characterisation o f isolates in this study and the results o f the afore­
mentioned studies suggest that spa typing is generally less discriminatory than PFGE 
particularly for MRSA strains. However, in terms o f practicality this method is 
advantageous because it is easier to perform than the intricate PFGE protocol: also the 
universal nomenclature o f spa types and the on-line database allows an accessible 
source of epidemiological data world-wide. Since the clustering o f spa types is highly 
concordant with MLST clonal complexes this indicates that this method has the added 
advantage o f potentially being an adequate typing tool for long-term epidemiology 
investigations. Both PFGE and spa typing can be affected by inter-genomic 
recombination events but these events are rare in S. aureus. However they are more 
effectual in spa typing because a large chromosomal replacement during a 
recombination event may include the spa locus (Hallin et al., 2007, Koreen et al., 2004). 
This results in strains o f the same clonal lineage depicting unrelated spa types. For 
instance Robinson and Enright (2004) demonstrated that the ST239-MRSA-II/ Brazilian 
clone evolved by the homologous recombination of a 557-kb fragment from the ST30
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chromosome into the ST8 genetic background (Robinson and Enright, 2004). Thus 
approximately 20% of the ST239 chromosome is identical to the ST30 genetic 
background and 80% is identical to the ST8 genetic background. Interestingly with the 
MLST method ST239 strains are clustered into the CC8 clonal complex which harbours 
the ST8-MRSA-IV/ USA300 clone however, with spa typing these strains typically 
exhibit the t037 spa type which is affiliated to the CC30 clonal complex which harbours 
the ST30-MRSA-IV/ Southwest Pacific clone (Strommenger et al., 2006). These 
discrepancies can be resolved by spa typing being performed in combination with an 
additional genotyping typing assay (Golding et al., 2008, Hallin et al., 2007, Koreen et 
al., 2004). Although MLST is the optimal assay for the definition o f MRSA lineages or 
clones, it may be financially impractical in high volume studies. The combination of 
s/?tf-BURP typing and PFGE has been shown to be less expensive and similarly 
effective.
Approximately 92% of the isolates in this study carried SCCmec type IV elements, 
these included all of the EMRSA-15 strains (n=122) and four diverse strains. This 
indicates that although the SCCmec type IV element was extensively found in strains 
with EMRSA-15 genetic background it was not restricted to this genetic background. 
This element is the smallest (21-24 kb) o f the currently defined SCCmec types (I to 
VIII- 28 to 67kb) and its small size is thought to award it the advantage o f high 
transmissibility within different genetic backgrounds o f staphylococci (Deurenberg and 
Stobberringh, 2008, Hanssen and Sollid, 2006, Ito et al., 2004). In contrast the SCCmec 
type II element was less prevalent and found in only eight isolates in the present study. 
The carriage of larger SCCmec elements (II and III) is hypothesized to come at a fitness 
cost to MRSA which may include a lower growth rate and this may contribute to the 
higher prevalence of MRSAIV strains in the community and their increasing prevalence 
in hospital environments (Deurenberg and Stobberringh, 2008, de Sousa and de 
Lencastre, 2003, Okuma et al., 2002). Similarly the carriage o f the SC Cmec type IV 
element may also confer these selective advantages to the EMRSA-15 clone and 
contribute to its higher prevalence in the UK in comparison to EMRSA-16. For three of 
the 137 MRSA isolates in this study, the characterisation of the SCCmec elements was 
more ambiguous. Isolates 7 and 8 had an element that was putatively identified as 
SCC mec type V due to the lack o f detection o f a sequence upstream of the hsdM, S, R 
genes in the J1 region o f SC Cmec type V. Whereas for isolate 151, although the ccrC
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gene was identified, the mec class was not confirmed. These results were not enough to 
unambiguously identify the element as a SCC mec type V since the ccrC  gene has been 
found in other elements e.g. the composite element (SCCA/ercwo/SCCraecIII) in the 
MRSA 85/ 2085 strain and in MSSA isolates by Shore et al. (2008) (Shore et al., 2008, 
Chongtrakool et al., 2006). Chongtrakool et al. (2006) carried out a larger study 
comprising 615 strains from 11 Asian countries and similar to the present study they 
used primers which were specific for the different ccr types and mec classes in MRSA. 
The majority o f their isolates carried SCC mec type III (3A) and II (2A) elements but 
they also had five isolates that were non-typeable. Three had type ccrA2B2 but an 
unidentifiable mec class whereas two had ccr genes which were non-typeable. 
Interestingly they also found that one isolate with a type II (2A) element and fifteen 
with type 2B (IV) elements also harboured ccrC  but they were not able to verify that the 
gene was actually located in the SC Cmec elements. This indicates that despite the 
development of comprehensive typing assays their accuracy remains dependent the 
current published SCC mec sequences. However the discovery o f these has not been 
exhausted and novel elements may arise from the recombination of currently defined 
elements.
Attempts to sub-type the 126 clinical isolates that harboured the SCCmec type IV 
element were largely unsuccessful even though the MRSAIVa, IVb and IVc reference 
strains were successfully sub-typed with both o f the PCR methods that were employed 
in this study (Kondo et al., 2007, Milheirico et al., 2007a). Out o f the 126 clinical 
isolates that were investigated 122 were EMRSA-15 strains whereas the remaining four 
were strains that had unique PFGE patterns and spa types. Interestingly, there was a 
clear disparity in the sub-typing results, as only the four unique clinical strains were 
successfully sub-typed whereas all o f the EMRSA-15 strains remained non-typeable, 
including the laboratory EMRSA-15 reference strain. The two sub-typing assays that 
were used in this study comprised primers that were specific for sequences in the J l-  
regions o f the published SCCmec type IV elements. The Milheirico et al. (2007a) assay 
was specifically included because the HAR22 strain, a prototypic EMRSA-15 strain 
was included in the development of the method. This strain had not produced any 
fragments with PCR methods for the amplification of the J1-region o f SCCmec types 
IVa to IVg elements. So they sequenced the SCCmec element harboured by the strain 
and compared it to published type IV sequences. It had almost 100% homology in the
136
mec, ccr and J2 and J3-regions, however, the J1-region was different to other type IV 
elements. This region was homologous to the Jl-region o f the PL72 strain, a SCC mec 
sporadic variant which was originally isolated from a Polish hospital (Milheirico et al., 
2007a). Consequently they regarded the element as a novel type IV sub-type and 
defined it as IVh. In their study five EMRSA-15 strains from Portugal and one ST254- 
MRSA strain from Greece contained the novel IVh sub-type. In this study, the 
magnitude of EMRSA-15 strains that were non-typeable with this method is surprising 
but it is not altogether incomprehensible. The EMRSA-15 strain that was used by 
Milherico et al., 2007a could not be sub-typed with a comprehensive set o f primers that 
were specific for Jl-regions in a diverse array o f type IV subtypes i.e. IVa, IVb, IVc, 
IVd, IVE, IVF and IVg. This implies that there is a certain novelty in the Jl-region o f 
EMRSA-15 strains and perhaps more heterogeneity in other EMRSA-15 strains. The 
prototype strain that they used had a Jl-region that was homologous to a sporadic Polish 
strain, so it is not unlikely that the Jl-region may be rare or restricted to a subset o f 
EMRSA-15 strains in specific geographical locations. Possibly the EMRSA-15 strains 
from other geographical regions including the strains from the epidemiological setting 
o f this study may have a different Jl-region in their SC Cmec type IV elements. 
Certainly the identification o f novel SCCmec subtypes has not been exhausted and this 
is shown by the discoveries of MRSA isolates with non-typeable elements in other 
studies (Berglund et al., 2009, Hanssen and Sollid, 2007, Rossney et al., 2007).
In this study the arginine catabolic mobile element (ACME) element was detected in 
two EMRSA-15 strains suggesting that it is rare in wound MRSA isolates from the 
epidemiological setting o f this study. However, the ACME element is frequently present 
in coagulase-negative staphylococci such as S. epidermidis and S. haemolyticus and 
these are considered to be the reservoir for these elements (Miragaia et al., 2009, Pi et 
al., 2009). In S. aureus, ACME is consistently harboured by methicillin resistant 
USA300 strains depicting the USA300-0114 PFGE pattern. It is speculated that it has a 
contributory role in bacterial colonisation o f the human skin and mucosal surfaces 
(Miragaia et al., 2009, Diep et al., 2006). It was initially identified by Diep et al. (2006) 
in a multidrug resistant US A300 FPR3757 strain and it was presumed that it was 
restricted to the USA300-0114 genetic background. The EMRSA-15 clone belongs to 
the ST22-MRSA-IV lineage whereas ACME positive US A300 strains belong to the 
ST8-MRSA-IVa lineage. Thus the detection o f ACME in this study, presents the first
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documented detection of ACME in specifically the EMRSA-15 genetic background. It 
has also been detected in other lineages. For instance Ellington et al. (2008) investigated 
its prevalence in MRSA (n=203) of diverse genetic backgrounds in England and Wales 
and detected ACME in seventeen strains. Most of the strains belonged to the ST8- 
MRSA-IVa (USA300) lineage, several were STl-MRSA-TVa strains and one MRSA 
was a ST97-MRSA-V strain. This also showed a relatively low prevalence o f this 
element in UK MRSA isolates (Ellington et al., 2008). Earlier Goering et al. (2007) had 
investigated 214 S. aureus isolates from strain collections of the Centres for Disease 
Control and Prevention in the USA. They had detected ACME in all 82 ST8-MRSA- 
IVa strains, six ST5/ USA100 strains and also in two MSSA strains. The MSSA 
belonged to the ST8 lineage and depicted a PFGE pattern that was closely related (1 
band difference) to the USA300-0114 pattern. They hypothesized that these were 
previously methicillin resistant USA300 strains which had undergone a precise excision 
of SCCmecIVa. Later, Diep et al. (2008) performed molecular analysis o f ACME 
elements from diverse genetic backgrounds, i.e. ST8-MRSA-IVa, ST5-MRSA-H and 
ST59-MRSA-IVa and showed that these were distinct ACME allotypes. The ACME 
element in the US A300/ ST8-MRSA-IVa strains harbours two gene clusters, arc 
(encodes arginine deiminase pathway) and opp3 (encodes oligopeptide permease) which 
are homologues o f genetic elements linked with pathogenesis in group A Streptococcus 
species. However the ACME elements in the ST5 and ST59 strains harboured the arc 
cluster but were deficient o f the opp3 cluster (Diep et al., 2008b).
In this study the ACME element was detected in only two o f the 122 EMRSA-15 strains 
and these isolates carried non-subtypeable SCCmec type IV elements. The eight 
EMRSA-16 clinical strains containing SC Cmec type II elements and the seven diverse 
MRSA isolates with SCC mec type IV or V elements did not contain the ACME 
element. Since 89.1% of the MRSA isolates in this study were characterised as 
EMRSA-15 strains this suggests that the prevalence o f the ACME element was low in 
the EMRSA-15 genetic background. It seems like the ACME element is almost 
exclusively present in the USA300 clone and rarely present in other genetic 
backgrounds (Diep et al., 2008b, Goering et al., 2007). However it is possible that this 
element is frequently transferred to diverse S. aureus genetic backgrounds but remains 
largely unnoticed because these genotypes have minimal selective advantage in the 
respective epidemiological settings and thus remain less prevalent than the US A3 00
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clone. Furthermore the SCCmec type IVa element is typically carried by USA300 
strains and the ACME element is located adjacent to this element in the US A3 00 
chromosome. In rare cases it has been identified in isolates harbouring SCC mec type V 
or SCCmec type II elements (Diep et al., 2008b, Goering et al., 2007). It is likely that 
the infrequent detection of ACME in this study was because the SCCmec type IVa 
element was not carried by most o f the MRSA isolates o f this study. Since ACME is 
located adjacent to SCCmec it is hypothesized that it is reliant on the recombinase genes 
o f this element for integration and excision from the S. aureus chromosome. It is 
possible that the SCCmec type IVa element may contribute to an enhanced stabilisation 
of ACME in the US A300 genetic background in comparison to other types o f SCC mec 
elements in other MRSA strains.
In the UK the early 1990’s saw the emergence of the EMRSA-15 and EMRSA-16 
strains (Johnson et al., 2005) which were very successful at spreading between hospitals 
in England. Almost twenty years later these two clones continue to be the dominant 
MRSA strains in England and Wales (Ellington et al., 2009). The PFGE and spa typing 
results o f this study undoubtedly concur with this phenomenon and illustrate a sustained 
predominance o f the EMRSA-15 and EMRSA-16 strains in the molecular epidemiology 
o f wound isolates from Southwest Wales. This implies that these two strains have some 
selective epidemiological advantage in this area and population, over other HA-MRSA 
clones i.e. Archaic clone, ST250-MRSA-I; the Brazilian/ Hungarian clone, ST8-MRSA- 
III; the Iberian clone, ST247-MRSA-I; the New York / Japan clone ST5-MRSA-H and 
the Paediatric clone, ST5-MRSA-IV (Deurenberg and Stobberringh, 2008).
In conclusion, in this study 137 MRSA isolates were characterised as EMRSA-15 
(n=122), EMRSA-16 (n=8) and unique MRSA strains (n=7). Most of the isolates 
(n=126) contained SC Cmec type IV whereas fewer isolates harboured the SCC mec type 
II element (n=8). Two isolates harboured elements which were affiliated to the SCCmec 
type V type element and one isolate had an element which was non-typeable. The 
accurate and rapid identification o f MRSA isolates is vital for infection control and the 
performance o f diagnostic tests that are able detect diverse MRSA strains with a high 
level of accuracy is essential.
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C hapter Five
Optim isation of three SCCmec-orJX PCRs
5.0 Introduction
The mecA PCR is the gold standard assay for detection of methicillin resistance and 
duplex assays detecting mecA and a S. aureus specific gene e.g. nuc, femA, femB  or 
Sa442 have been described for the identification of MRS A from clinical isolates (Costa 
et al., 2005, Francois et al., 2003, Jonas et al., 2002, Reischl et al., 2000b, Vannuffel et 
ah, 1995). However these assays are limited as MRSA detection cannot be conclusively 
inferred from clinical specimens harbouring diverse staphylococci i.e. methicillin- 
resistant coagulase-negative staphylococci and methicillin-susceptible S. aureus 
(MSSA) because these could generate false positive results.
The mecA gene is located on the SCC/wec element which comprises characteristic 
genetic features: the mec and ccr complexes and regions outside of these, termed J 1, J2 
and J3. In the S. aureus chromosome, SCCmec integrates specifically at attB, a site 
located at the 3 ’ end of orjX. The chromosomal extremities at the left and right 
junctions are termed attB-L  and <sr//B-R, whereas the SCCmec extremities are termed the 
<3tfSCC-L and attSCC-R (see Figure 5.1). The junction of the right extremity of 
SCC mec and the S. aureus specific orjX  locus, provides a surrogate marker for MRSA 
detection (Cuny and Witte, 2005, Hagen et al., 2005, Huletsky et al., 2004). However 
there are diverse SCCmec types I-VIII and the sequences downstream of mecA differ by 
varying degrees (Zhang et al., 2009, Berglund et al., 2008, Oliveira et al., 2006, Ito et 
al., 2004, Ito et al., 2003, Ma et al., 2002). In SCCmec type I, II, IVa, IVb and IVc, the 
sequence is highly similar but it is different and longer in SCC mec type III (Huletsky et 
al., 2004, Oliveira and de Lencastre, 2002) (see Figure 5.2).
J1 J2 J3
o/rB-L
ccrAB
mecRI 
mecl i mecA
forward oligonucleotide 
affB-R
o r /X
atiSCC-L t
IS 431
ccr  gene com plex mec gene complex
aflSCC-R
reverse oligonucleotide
Figure 5.1. Schematic diagram of a SCCmec element showing general locations of 
oligonucleotides for SCCmec-orjXamplification (Katayama et al., 2000)
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Figure 5.2. Schematic diagrams of SCCmec types I-IV (Deurenberg et al., 2007)
This necessitates that SCCmec-orJX amplification methods demonstrate the capacity to 
detect diverse SCCmec types. In 2004 the concept of MRSA detection by amplification 
of the SCCmec-orJX junction was published by Huletsky et al. (2004), subsequently two 
additional studies were published by Hagen et al. (2005) and Cuny and Witte (2005) 
and these were advocated for use in routine clinical testing. The Huletsky et al. (2004) 
and Hagen et al. (2005) methods are multiplex systems, comprising one forward 
oligonucleotide for the detection of SCC mec type I, II, IVa, IVb, IVc, an additional one 
for SCCmec type III and one reverse nucleotide in orjX. Three additional forward 
oligonucleotides were designed in the Huletsky et al. (2004) study, for the detection of 
eleven MRSA strains which were initially undetected. The Cuny and Witte (2005) 
method employs only one forward oligonucleotide and a reverse oligonucleotide in orfX  
for the detection of SCCmec type I to V elements.
The objective of this study was to compare the three SCCmec-orjX amplification 
methods developed by Cuny and Witte (2005), Hagen et al. (2005) and Huletsky et al.
(2004) for the detection of MRSA in a collection of 561 S. aureus isolates. They are 
referred to as: PCR-A for the Huletsky et al. (2004) method, PCR-B for the Hagen et al.
(2005) method and PCR-C for the Cuny and Witte (2005) method. The methods were 
optimised with reference strains prior to comparative analysis.
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5.1 Results
5.1.1 Effects of the modified PCR annealing temperatures on the detection 
of reference strains and clinical isolates
The bacterial reference strains employed in this study were: NCTC10442 (SCC/wec type 
1/ accession number AB033763); N315 (SCCmec type II/ accession number D86934) 
and 85/2082 (SCCmec type III/ accession number AB037671), as described by Ito et al. 
(2001). MRSA strains: CA05 (SCCmec type IVa/ accession number AB063172) and 
JCSC1978 or 8/6-3P (SCCmec type IVb/ accession number AB063173) as described by 
Ma et al. (2002). MR108 or 81/108 (SCCmec type IVc/ accession number AB096217) 
as described by Ito et al. (2003) and WIS or JCSC3624 (SCCmec type V/ accession 
number AB121219) as described by Ito et al. (2004). The Oxford MSS A reference 
strain and two clinical MSSA isolates were also included as negative controls.
Initially the annealing temperatures were maintained at those stated in the original 
published methods: 60°C for PCR-A, 56°C for PCR-B and PCR-C. At these conditions 
MRSAI to IVa,b,c strains were successfully amplified with the PCR-A and PCR-B 
methods and the MSSA isolates were not amplified (see Table 5.1). Thus the initial 
conditions were retained for these two methods. Similarly with the PCR-C method, 
MRSAI to IVa,b,c strains were also amplified and no MSSA were amplified. The 
MRSAV strain (SCCmecV/AB121219/WIS) had also been included in the original 
method and was successfully amplified. Even though the same strain was employed in 
this study amplification was not achieved on repeated attempts at 56°C and 55°C (see 
Table 5.1). Amplification was only achieved when the annealing temperature was 
reduced to 54°C and the total number o f PCR cycles was extended from 45 to 50 cycles. 
However the average Ct value (Ct=38) o f the MRSAV strain was considerably higher 
than average Ct value (Ct=28) of the MRSAI to IVa,b,c strains. At these conditions the 
MSSA isolates were also amplified (average Ct value o f 40) (see Figure 5.3), so for 
subsequent PCR-C runs an annealing temperature of 55°C was maintained and the 
Oxford MSSA reference strain, included as the negative control, also served as a cut-off 
for possible amplifications with high Ct values. Therefore if  the Oxford MSSA strain 
was amplified, all isolates that were amplified at Ct values equal to or greater than the Ct 
value o f the Oxford strain were considered to have negative results i.e. not MRSA. If 
the Oxford strain was not amplified, all amplified isolates were considered to have 
positive results i.e. were considered MRSA.
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Figure 5.3. Amplification curves of MRSAI, II, III, IVa, IVb, IVc verses MR.SAV and 
MSSA with PCR-C at annealing temperature of 54°C
5.1.2 Alignment of oligonucleotides on SCC/nec sequences
To determine the probable cause of the late amplification of the MRSAV WIS strain 
and the MSSA isolates, a search of the location of the PCR-C oligonucleotides on 
published SCCmec sequences was performed with a National Centre for Biotechnology 
Information (NCBI) BLAST search tool. The forward oligonucleotide (5*- 
TATGATATGCTTCTCC-3’) aligned precisely to SCCmec type II and IV sequences 
but with SC Cmec type I and III there was one mismatch and with S CCmecV, there were 
two mismatches (see Table 5.2). In AB033763/SCCwecI, the thymidine to adenine 
(T—>A) substitution at position nine from the 3’ end, presents an internal T:T mismatch, 
whereas with AB037671/SCCwec type III the thymidine to cytosine (T—>C) substitution 
presents an internal T:G mismatch. In SCCmecV sequences the two T ^ C  substitutions, 
present two internal T:G mismatches. Evidently the forward PCR-C oligonucletide also 
aligned to two MSSA sequences: AP009351/ S.aureus Newman and AJ938182/ S. 
aureus RF122, with sequences identical to the SCCmec type V sequences (see Table 
5.2).
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T a b le  5.2. PCR -C  forw ard oligonucleotide on SC C m e c  type I to V  sequences
Accession num ber and SC Cmec type Sequence Position
PCR-C forward oligonucleotide TATGATATGCTTCTCC -
D86934 (SCCwecII)/ N 315 TATGATATGCTTCTCC 57641 - 57656
AB063172 (SCCmecIVa)/ CA05 TATGATATGCTTCTCC 25210-25225
AB063173 (SCCmecYVb)/ JCSC1978 TATGATATGCTTCTCC 21207-21222
AB033763 (SCCmecI)/ NCTC10442 TATGATAAGCTTCTCC 38855 - 38870
AB037671 (SCCmeclll) TATGATACGCTTCTCC 67782 - 67797
AB121219 (SCCm ecVy WIS TATGATACGCCTCTCC 892 - 877
AB478780 (SCCmecV)/ JCSC 5952 TATGATACGCCTCTCC 42073 - 42058
AP009351 (S. aureus Newman) TATGATACGCCTCTCC 34392 - 34377
AJ938182 (S. aureus RF122) TATGATACGCCTCTCC 34166-34151
A comparison o f the location of the oligonucleotides o f all three SCCmec-orJX assays 
on the SCCmec type I to IVa sequences was also conducted. Within the sequences of 
SCC mec type I, II and IV, the forward oligonucleotides o f PCR-A and PCR-B are 
located in close proximity and they overlap in the sequence o f SCCmec type III (see 
Figure 5.4). These oligonucleotides are also located upstream o f the SCCmec-orfX 
junction, in contrast to the PCR-C forward oligonucleotide which is located at the 
SCCmec-or/Xjunction, partially overlapping into orjX.
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The MRSAV WIS reference strain was not amplified with the PCR-A and PCR-B 
methods. In order to verify that this was not due to possible suboptimal test conditions, 
the location o f the forward and reverse oligonucleotides of these methods on the 
SCCmec type V/AB121219 sequence o f the MRSAV WIS strain was investigated with 
the NCBI BLAST search tool. Since the PCR-A and PCR-B methods are both multiplex 
PCRs, all o f the forward primers were investigated and none o f these aligned to the 
SCC mec type V/ A B121219 sequence. However the reverse primer did align to a 
location in orfX  (see Table 5.3). Nevertheless since none o f the forward primers aligned 
to the sequence, the amplification o f a PCR product was not feasible. This demonstrated 
that the oligonucleotides o f the PCR-A and PCR-B methods were not specific for the 
amplification o f the MRSAV WIS SCCmec type V sequence. On the other hand the 
oligonucleotides o f the PCR-A and PCR-B methods did align to two other SCC mec type 
V sequences (see Table 5.3):
i) SCCmec type V (5C1)/ AB373032, carried by the JCSC6082 strain
ii) SCCmec type V/ AB478780, carried by the JCSC5952 strain.
However on these sequences both the forward and reverse primers were located in orjX. 
Therefore because the forward primer was located in orjX  and not at the right extremity 
of SCC mec, a PCR product from these strains would be non-specific as it would be an 
orflCsequence and not the required SCCmec-orfiCsequence (see Table 5.3).
Table 5.3. PCR-A and PCR-B oligonucleotides on SCCmec type V sequences
Strain Accession number/ SCCm ec type Oligonucleotide Position Locus
MRSAV WIS AB121219/SCCmec type V (5C2) PCR-A DM11 (reverse) 
PCR-B DM5 (reverse)
742-760
664-681
orfX
JCSC60823 AB373032/ SCC mec type V (5C1) PCR-A DM7 (forward) 
DM11 (reverse)
681-653
459-477
orfX
PCR-B DM4 (forward) 
DM5 (reverse)
668-652
381-398
orjX
JCSC5952b AB478780/ SCC mec type V PCR-A DM7 (forward) 
DM11 (reverse)
857-829
635-653
orjX
PCR-B DM4 (forward) 
DM5 (reverse)
844-828
557-574
orfX
a JCSC6082 MRSA strain described by Berglund et al., 2008
b JCSC5952 MRSA strain (Japanese CA-MRSA) sequence submitted from unpublished work.
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5.1.3 PCR efficiency and detection limit of the mecA, femAsA  and SCCmec-orJX 
assays
The efficiency of the PCR assays was determined by generating standard curves from 
serial dilutions (neat to 10°) of a MRSAI suspension and applying the slope of the 
curves to the reaction efficiency formula: [-1 + 10 H slopc)] xlOO. Values of 90-110% 
(slope -3.1 to -3.6) illustrate a doubling of the PCR product at each cycle and a slope of 
-3.322 indicates 100% efficiency. The MRSAI standard curves of the mec A and femAsA 
PCRs had slopes of: -3.8 (81.5%) and -3.1 (110%) respectively (see Figure 5.5a and b). 
The slopes of PCR-A, PCR-B and PCR-C methods were: -3.75 (84.79%), -3.76 
(84.48%) and -3.54 (91.64%) respectively, indicating that the femA  and PCR-C assays 
had the highest efficiency (see Figure 5.6a, 5.5b and 5.5c). Colony counts showed that 
the neat suspension of the MRSAI strain had 1.23xl08 CFU/ml and amplification of 
MRSAI was achieved up to the 10° dilution for the three SCCmec-orJX methods. Since 
2 pi was used as the template for the PCRs, this corresponded to a detection limit of 2.5 
CFU/reaction for the three methods.
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Figure 5.5. Standard curve of MRSAI with the mecA and JemASA PCR assays
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Figure 5.6. Standard curve of MRSAI with PCR-A, PCR-B and PCR-C
149
5.2 Discussion
The three SCCmec-orJX assays PCR-A, PCR-B and PCR-C, successfully detected 
MRSAI, II, III, IVa,b,c reference strains, which was comparable to the results attained 
in the original assays (Cuny and Witte, 2005, Hagen et al., 2005, Huletsky et al., 2004). 
The MRSAV WIS strain had also been detected in the original study o f PCR-C but in 
this study the initial attempts to amplify this strain were unsuccessful. At a lower 
annealing temperature the MRSA WIS strain was detected but with the simultaneous 
amplification o f the MSSA isolates, suggesting that the observed amplification was due 
to non specific amplification.
This was further investigated by examining the alignment o f the forward PCR-C 
oligonucleotide to published SCC mec sequences which revealed two T:G mismatches 
within the SCC mec type V (AB121219 and AB478780) sequences. Mismatches can 
hinder efficient binding o f the oligonuceotide to the template and certain mismatches at 
the 3’ end can deter the polymerase from adding nucleotides to the terminus. Notably 
A:G (purine: purine) and C:C (pyrimidinerpyrimidine) mismatches at the 3 ’end, can 
have up to a 100-fold reduction on the PCR product yield (Kwok et al., 1990). However 
in this study, the type and internal location of the T:G mismatches (and also the T:T 
mismatch observed in SCCmec type I) have minimal adverse effect on the amplification 
of the target sequence (Kwok et al., 1990). Nevertheless it is probable that the 
combination o f the initial higher annealing temperatures (56°C and 55°C) and the 
mismatches on the SCCmec type V sequence was initially a deterrent for robust 
amplification. As the conditions were made less stringent by lowering the annealing 
temperature (54°C), amplification of the SCC mec type V target sequence was 
achievable. However the PCR-C forward oligonucleotide also aligns to published 
MSSA sequences: AP009351/ S.aureus Newman and AJ938182/ S. aureus RF122, 
indicating that the PCR-C method could also result in the amplification o f these MSSA 
strains. Similarly it is highly likely that the detection o f MSSA isolates in this study was 
due to the amplification o f homologous PCR-C target sequences in these isolates. The 
presence o f the PCR-C target sequences in MSSA strains casts some uncertainty on the 
suitability o f this assay for the exclusive detection of MRSA strains in clinical 
specimens. Furthermore in this study the template DNA was maintained at a relatively 
standard concentration i.e. 2-3 colonies of the isolates were consistently used in
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preparation o f the template DNA. Therefore in the PCR-C assay the late Ct values could 
be discerned as positive or negative results based on the Ct value of the negative 
control. However in clinical specimens the concentration o f the target DNA is variable 
and it may be difficult to make a clear distinction between the results.
The MRSAV WIS reference strain was also not detected with the PCR-A and PCR-B 
methods. An evaluation o f the location o f the oligonucleotides on the SCCmec type V/ 
A B121219 sequence demonstrated that none o f the forward oligonucleotides o f these 
two methods aligned to this sequence and thus amplification was not feasible. However 
there was some indication that non-specific amplification o f a sequence in orfX  was 
possible with two other MRSAV strains, the JCSC6082 strain and the JCSC5952 strain. 
The sequence o f the latter strain was submitted to GenBank from unpublished work and 
the strain seems to be a Japanese CA-MRSA strain whereas, the former strain was 
originally isolated in Sweden, a country with a very low prevalence rate of MRSA 
(<1%) (Berglund et al., 2008). Evidently these MRSAV strains appear to be rare so the 
likely occurrence o f their detection amongst UK clinical strains is low. The JCSC6082 
strain harbours a variant SC Cmec type V element and the clinical history o f this strain is 
interesting. It was originally isolated in Sweden in 2002 from the subcutaneous 
abdominal wall abscess o f a previously healthy 42-year-old woman (Berglund et al., 
2008). The abscess was initially considered to be a rare community-acquired infection 
but the patient had undergone abdominal surgery 24 years earlier and within the present 
abscess cavity remnants o f a suture were found (Berglund et al., 2008). Therefore it was 
suspected that the JCSC6082 strain had possibly persisted in dormancy, embedded in a 
biofilm for more than 20 years and was only identified due to the occurrence o f the 
abscess. This unusual strain was found to contain a SC Cmec element with the ccrC  gene 
complex (type 5) and a class C l mec gene complex (Berglund et al., 2008). This was a 
unique combination because even though the ccrC gene is also present in the SCC mec 
type V element o f the MRSAV WIS strain, the class C l mec complex differs from class 
C2 mec complex which is present in the MRSAV WIS strain. In the class C l mec 
complex the orientation of IS431 inserted downstream o f mecA is in the opposite 
orientation to that found in class C2 mec complex. Since the class C l mec had only been 
previously identified in methicillin-resistant Staphylococcus haemolyticus strain SH631 
(Katayama et al., 2001), this was the first description of a class C l mec complex in an 
MRSA strain (Berglund et al., 2008).
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A comparison o f the locations o f the oligonucleotides of the three PCR-A, PCR-B and 
PCR-C assays on published SCCmec type I to IV sequences showed that the 
oligonucleotides o f PCR-A and PCR-B were in close proximity. This suggests that these 
assays could have similar diagnostic capacity. Also the PCR-A and PCR-B 
oligonucleotides are located further upstream of the SCCmec-orfX junction than the 
forward oligonucleotide o f the PCR-C assay. In fact the PCR-C forward oligonucleotide 
is located right at the SCCmec-orJX junction and partially overlaps into orjX. Seemingly 
the oligonucleotides o f PCR-A and PCR-B are better located for the amplification of a 
sequence comprising both the right extremity o f SC Cmec and a region in orjX, whereas 
the location of the PCR-C forward oligonucleotide could potentially enable the 
amplification of a sequence in orfX  alone, causing the amplification o f both MRSA and 
MSSA isolates.
In this study, the initial results indicated that all three SCCmec-orJX assays detected 
MRSAI, II, III, IVa, IVb and IVc strains. However, the amplification o f MSSA isolates, 
the presence of mismatches and the position o f the forward oligonucleotide in published 
SCC mec sequences, questions the adequacy o f PCR-C for robust detection o f MRSA. 
However a more comprehensive evaluation of the diagnostic performance of the PCR- 
A, PCR-B and PCR-C SCCmec-orJX methods was performed with a larger collection of 
S. aureus isolates (n=561) and the results are presented and discussed in chapter 6.
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Chapter Six
The diagnostic performance of three SCCmec-orJX amplification methods
6.0 Introduction
MRSA is endemic in hospitals in the UK and the reduction o f MRSA infections is a 
priority in this country. The UK Health Protection Agency (HPA) voluntary reporting 
surveillance data o f England, Wales and Northern Ireland, has shown a reduction in the 
prevalence o f MRSA over the past decade. In 1999 MRSA accounted for approximately 
37.4% o f S. aureus bacteraemia however by 2008 this rate had reduced to 24.4%. 
Mandatory surveillance data has shown that the rate o f MRSA bacteraemia reports has 
also declined over the past year i.e. for April 2009 to March 2010 the rate was 3.7/
100.000 population, a reduction from 5.7/ 100,000 population in the previous year. 
Furthermore the recent quarterly report showed that in April to June 2010 the rate 
further decreased to 3.3/ 100,000 population
(http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1284473407318).
Individuals who are colonised with MRSA are at greater risk o f contracting infections 
and transmitting MRSA, so it is recommended that patients are screened on or before 
hospital admission (Jeyaratnam et al., 2008b). MRSA screening is performed on clinical 
swabs including nasal, axilla, groin and skin break swabs and it is essential that 
implemented diagnostic tests are accurate, and desirable that they should be rapid, as it 
is postulated that rapid detection will lead to faster implementation o f infection control 
procedures and possibly a reduction in MRSA transmission. However conventional 
laboratory protocols are lengthy i.e. 24 to 72 hours, as they typically involve culture- 
based assays i.e. enrichment broths, selective media and chromogenic media. In 
contrast, PCR tests have shorter execution periods (2-4 hours) and thus they could be 
ideal screening tests (Snyder et al., 2010, Jeyaratnam et al., 2008b, Paule et al., 2007, 
van Hal et al., 2007).
The PCR-A, PCR-B and PCR-C SCCmec-orJX amplification methods discussed in 
chapter 4, could be suitable for MRSA screening as they are rapid (less than two hours) 
and they detect diverse MRSA. However a comprehensive evaluation of the diagnostic 
performance o f the tests has to be undertaken prior to their implementation. In this study 
the three methods were evaluated with pure cultures of S. aureus isolates.
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To hasten the PCR set up stage, crude DNA extracts (supernatant of a heated bacterial 
suspension made from 2-3 colonies suspended in sterile distilled H2 O) were used as the 
template DNA in all the assays.
The definition o f positive and negative results was based on the results o f chapter 4. 
With PCR-A and PCR-B the negative control had been consistently undetected 
therefore all isolates that generated an amplification signal were regarded as MRSA and 
those that did not generate an amplification signal were regarded as MSSA. Since with 
the PCR-C method there was possible late amplification o f MSSA isolates, the Ct value 
o f the negative control was used as the cut off for negative results. Therefore only 
isolates with Ct values less that the Ct value o f the negative control were regarded as 
MRSA whereas those with values greater than Ct value o f the negative control were 
regarded as MSSA.
The objective o f  this study was to compare the diagnostic performance of the PCR-A, 
PCR-B and PCR-C methods by determining the sensitivity, specificity and predictive 
values with a collection of 561 S. aureus isolates. The false negative and false positive 
results were further investigated to determine the probable causes o f these results.
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6.1 Results
6.1.1 The diagnostic perform ance of the SCCmec-orflC  assays
Five hundred and sixty one S. aureus isolates were screened with the reference method 
(mecA, femAsA and femAsE PCRs) and the femAsA gene was detected in all the isolates 
whereas femAsE was not detected in any isolates. The mecA gene was detected in 137 
isolates and undetected in 424 isolates, therefore out o f the 561 S. aureus isolates, 
24.4% were MRSA and 75.6% were MSSA. After the exclusion o f replicate isolates 
from consecutive visits (occurring within 3 months), 118 (22.7%) MRSA and 401 
(77.3%) MSSA were retained for the comparison o f the PCR-A, PCR-B and PCR-C 
methods. The average Ct values o f the MRSA (n=l 18) for the femAsA and mecA PCRs 
were: 19.3 and 21.1 respectively.
Out o f the 118 MRSA, 114 (96.6%) isolates were amplified with the PCR-A method 
and o f the 401 MSSA isolates 394 (98.3%) were not amplified. The values for the PCR- 
B method were identical to those o f the PCR-A method. With the PCR-C method, out of 
the 118 MRSA, 113 (95.8%) were amplified and of the 401 MSSA isolates 392 (97.8%) 
were not amplified (see Table 6.1). The average Ct values o f the MRSA (n=l 18) for the 
PCR-A, PCR-B and PCR-C assays were: 26.4, 28.9 and 30.5 respectively.
Table 6.1. The number o f mecA positive and mecA negative S. aureus isolates detected 
with the three SCCmec-orfX assays.______________________________________________
SCCm ec-orfX  PCR Positive (n=118)
mecA PCR
Negative (n=401)
PCR-A 114(96.6%) 394 (98.3%)
PCR-B 114(96.6%) 394 (98.3%)
PCR-C 113(95.8%) 392 (97.8%)
Table 6.2. Average and median Ct values o f the MRSA (n=l 18) for the PCR assays
PCR Ct values
Av. C t + SD M edian
femAsA 19.3 ± 2 .9 19.8
mecA 21.1 ±3.5 21.6
PCR-A 26.4 ±5 .7 25.7
PCR-B 28.9 ±5 .2 28.9
PCR-C 30.5 ±5.3 30.0
Ct- cycle threshold; Av.-Average; SD- standard deviation
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Even though the results o f the three SCCmec-orJX assays were largely comparable to 
the mecA PCR, there were, apparent discrepancies. Four mec A positive S. aureus 
isolates: 17, 18, 19 and 20 were not amplified with the PCR-A and PCR-B methods. 
Similarly, with the PCR-C method, four mecA positive S. aureus: 21, 22, 18, and 7 were 
not amplified and one additional isolate (isolate 8) had a high Ct value o f 44.6 which 
was regarded as a negative result based on the Ct value (42.6) o f the negative control in 
that particular run. Isolate 18 was not amplified by all three SCCmec-orJX PCRs (see 
Table 6.3). Although the false negative isolates were undetected with the SCCmec-orfX 
assays, their femAsA and mecA PCR Ct values were comparable to the average Ct value 
o f the respective tests i.e. 19.3 and 21.1 (see Table 6.2 and 6.3).
In addition to the false negatives, there were mecA negative isolates which were 
amplified with the three SCCmec-orJXassays. Seven isolates: 23, 24, 25, 26, 27, 28 and 
16 were amplified with PCR-A and PCR-B. With the PCR-C nine mecA negative 
isolates were amplified: 29, 30, 31, 32, 33, 34, 35, 36 and 16 (isolate 16 was amplified 
by all three assays). Isolates 32, 34 and 36 had higher Ct values (41.8, 44.8 and 42.9 
respectively) than the other isolates and based on the Ct value (41.3) o f the negative 
control, they had negative results (see Table 6.4). Nevertheless they were retained for 
the further investigations to determine the cause o f the amplification o f these clinical 
isolates.
Table 6.3. Ct values o f the mecA positive and SCCmec-orJX negative S. aureus isolates 
with the mecA, femAsA PCR and the PCR-A, PCR-B and PCR-C methods____________
Isolate mec A femAsA PCR-A PCR-B PCR-C
17 21.6 22.4 — — 25.6
18* 19.8 18.53 — — —
19 21.4 18.2 — — 29.6
20 22.4 20.2 - — 27.8
21 16.7 21.7 20.6 30.0
22 18.8 23.0 21.8 28.9 —
7 25.6 17.6 25.7 24.8 —
8 15.3 14.1 23.8 30.9 44.6a
— not amplified
♦Isolate 18 not amplified in all three assays
a Isolate 8 was negative with PCR-C because Ct value 44.6 > Ct value (42.4) o f the detected negative 
control in run.
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Table 6.4. Ct values o f the mecA negative and SCCmec-orJX positive S. aureus isolates 
with the mec A, femAsA PCR and the PCR-A, PCR-B and PCR-C methods_____________
Isolate mec A fem A PCR-A PCR-B PCR-C
23 — 24.4 18.6 17.2 —
24 — 19.7 19.6 29.5 —
25 — 21.9 24.6 32.5 —
26 — 22.7 28.3 27.4 —
27 — 13.3 14.6 29.2 —
28 — 25.1 26.0 29.9 —
16* 19.9 25.1 31.4 28.1
29 — 15.3 — — 27.5
30 — 19.8 — — 28.9
31 — 15.1 — — 33.6
32 — 19.0 — — 41.8°
33 — 18.8 — — 33.9
34 — 19.7 — — 44.8"
35 — 16.5 — — 42.9"
36 — 14.9 — — 32.5
♦Isolate 16, amplified in all three assays; — not amplified
"Isolates 32, 34 and 35 negative because Ct values > Ct value (41.3) o f  detected negative control in run.
Table 6.5. Sensitivity, specificity, PPV and NPV values o f SCCmec-orJX PCRs o f 118 
MRSA and 401 MSSA isolates
Perform ance PCR-A PCR-B PCR-C
% Sensitivity (N) 96.6(114) 96.6(114) 95.8(113)
%  Specificity (N) 98.3 (394) 98.3 (394) 97.8 (392)
%  PPV" 94.2 94.2 92.6
%  NPV6 99.0 99.0 98.7
%Sensitivity: [SCCmec-orJX positives / mecA positives] xlOO
% Specifiticity: [SCCmec-orJXnegatives / mecA positives] xlOO 
%PPV°= [True positives/ (True positives + False positives)] xlOO 
%NPVft= [True negatives/ (True negatives + False negatives)] xlOO
The sensitivity results of the PCR-A, PCR-B and PCR-C methods were: 96.6%, 96.6%, 
95.8% and the specificity results were: 98.3%, 98.3% and 97.8% respectively. The 
positive predictive values (PPV) were 94.2%, 94.2% and 92.6% respectively and the 
negative predictive values (NPV) were: 99.0%, 99.0%, and 98.7% respectively. 
Therefore the PCR-A and PCR-B methods had slightly higher diagnostic performance 
results than the PCR-C method (see Table 6.5).
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6.1.2 Investigating the mecA positive and SCCmec-orJX negative isolates
6.1.2.1 Application of purified genomic DNA and effect on Ct values
The SCCmec-orJX false negative isolates were further investigated to determine the 
probable causes of the discrepant results. The initial measure undertaken was to 
ascertain if the lack of amplification was due to PCR inhibitors in the crude DNA 
extracts.
Fresh pure cultures were prepared from a single colony and purified genomic DNA was 
attained with an extraction and purification kit (QIAamp genomic DNAMini Prep, 
Qiagen) and a 1 pi aliquot of the genomic DNA was used (in triplicate) in the repeated 
mecA, femAsA PCRs and the SCCmec-orJX assays. Two MRSA reference strains: 
MRSAH (MRSA252), MRSAIVb (8/6-3P), the MSSA Oxford reference strain and 
three clinical MRSA (37, 38 and 39) which had previously been successfully amplified, 
were included in the repeated runs. With the PCR-A and PCR-B methods the four false 
negative isolates were amplified however there was a distinct disparity between the high 
Ct values of the false negative isolates (ranging within 33.9 -  36.0 cycles) and those of 
the reference strains (ranging within 14.9 - 16.9 cycles) (see Figure 6.1 and Table 6.6). 
In contrast, the Ct values with the mecA and femAsA PCRs were low and comparable to 
those of the MRSA reference and MRSA clinical strains (see Table 6.6).
The presence of PCR inhibitors in the crude extracts was an unlikely cause of the initial 
lack o f amplification because crude extracts were also used with mecA and femAsA 
PCRs and the false negative isolates were amplified at Ct values comparable to those of 
the MRSA reference and MRSA clinical strains (see Table 6.3). The subsequent 
amplification of the false negative isolates suggests that the initial lack of amplification 
was due to a low concentration o f DNA in the crude extracts and the use of a higher 
concentration o f DNA resulted in the amplification o f the isolates. However the 
concentration o f the extracted genomic DNA was not measured before it was used in the 
repeated assays, therefore the disparity o f the Ct values may have been due to higher 
concentrations o f genomic DNA in the PCR reactions of the MRSA reference strain and 
lower concentrations in the reactions o f the false negative isolates.
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Figure 6.1. PCR-A amplification curves o f MRSA reference strains, clinical MRSA 
and false negative MRSA isolates
Table 6.6. Ct values of MRSA reference and clinical strains and the PCR-A and PCR-B 
false negative isolates with use of purified genomic DNA in assays__________________
mec A femAsA PCR-A PCR-B
Isolate Av. Ct ± SD Av. Ct 1 SD Av. Ct 1 SD Av. Ct 1  SD
MRSA II 11.4 ± 0.1 9.3 ±0.2 14.910.2 16.3 1 0 .4
MRSA IVb 12.410.4 8 .9 1 0 .2 15.510.1 16.510.3
Oxford MSSA — 11.010.1 — —
37 (clinical MRSA) 13.1 ±0.3 10.310.2 15.610.8 17.01 1.3
38 (clinical MRSA) 13.910.3 10.910.2 16.910.5 18.010.2
39 (clinical MRSA) 13.010.5 11.510.1 16.41 1.3 17.410.4
False negative isolates
17 12.810.1 10.710.3 33.91  1.0 34 .610 .6
18 12.210.2 10.410.1 34 .910 .8 35 .810 .7
19 12.010.2 9 .910 .1 36 .01  1.0 36 .410 .4
20 13.1 ±0.3 9 .9 1 0 .3 34 .810 .2 35.1 ±0.5
Key: Av.-average; SD-standard deviation; — not amplified
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6.1.2.2 The application of standard  concentrations of genomic DNA and the 
effect on C t values
To investigate if  disparity o f the Ct values o f the MRSA reference strains and false 
negative isolates was due to differences in the template DNA concentrations, a standard 
concentration o f crude and purified genomic DNA was used in the assays. For the crude 
templates, bacterial suspensions were prepared at a standard optical density of 0.3 at 
600 nm and 2 pi of the supernatant was used (in triplicate) in the repeat PCR-A and 
PCR-B assays. For the purified genomic DNA, a concentration o f 20 ng/pl was 
maintained for all the isolates and 1 pi was used (in triplicate) in the repeated PCRs.
With the standardised crude template, the MRSA reference and MRSA clinical strains 
were amplified but the false negative isolates were not amplified. The standard use o f 
20 ng/ pi DNA in the assays once again resulted in the false negative isolates amplified 
at late Ct values in comparison to the MRSA reference and MRSA clinical strains. As 
previously observed with the mecA and femAsA PCRs, the Ct values of the false negative 
isolates were comparable to those o f the MRSA reference and MRSA clinical strains 
(see Table 6.7).
This indicated that the divergent results were not due to variable concentrations of the 
DNA template however they may have been due to the polymorphism of the SCCmec 
right extremity region in MRSA strains and resultant differences in the target sequences.
Table 6.7. Ct values o f MRSA reference strains, three clinical MRSA and four false 
negative isolates with use of 20ng/pl o f DNA template_____________________________
femAsA mecA PCR-A PCR-B
Isolate Av. Ct ± SD Av. Ct ± SD Av. Ct ± SD Av. Ct ± SD
MRSA II 10.8 ± 0 .0 14.5 ±0 .7 14.6 ± 0.2 16.3 ± 0.5
MRSA IVb 10.6 ±0 .0 14.0 ±0.1 15.4 ± 0.2 16.9 ± 0.9
Oxford MSSA 11.0 ± 0.1 — — —
37 (clinical MRSA) 11.6 ± 0.1 13.9 ±0.3 15.1 ±0 .4 16.4 ± 0.1
38 (clinical MRSA) 11.4 ±0 .2 13.5 ±0 .2 14.9 ± 0.2 16.7 ± 0.5
39 (clinical MRSA) 11.2 ± 0.1 13.6 ±0.2 15.1 ± 0.2 16.4 ± 0.4
False negatives
17 11.4 ± 0 .0 13.6 ±0 .2 34.7 ± 0 .8 35.9 ± 0.5
18 11.4 ± 0.1 13.6 ±0 .2 36.6 ± 0.8 37.7 ± 0.6
19 11.2 ±0 .0 13.6 ±0.2 37.2 ± 0.3 38.7 ± 0.7
20 11.1 ±0.1 13.4 ±0.2 35.4 ± 0.4 37.3 ± 0.9
Key: Av.-average; SD-standard deviation; —not amplified
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6.1.2.3 Analysis of the sizes and melting tem peratures of the PCR-A and 
PCR-B amplification fragments
To determine if there were differences in the sizes the PCR fragments of the MRSA 
reference strains and the false negative isolates (17, 18, 19 and 20), the fragments were 
resolved in a 2% agarose gel. The PCR-A fragment size of the four false negative 
isolates was approximately 278 bp and with PCR-B, approximately 400 bp. These sizes 
were comparable to those of the MRSAII and MRSAIVb reference strains with both 
methods (see Figure 6.2a and 6.2b).
A melt analysis of the PCR fragments showed that the melting temperatures (Tm) of the 
fragments of the MRSAII and MRSAIVb reference strains were 80.7°C and 80.5°C 
with PCR-A and 83.2°C and 83.3°C with PCR-B. In the original PCR-B study i.e. by 
Hagen et al. (2005), PCR fragments with Tm values within a ±0.8 range of the positive 
control Tm were considered to be specific amplification products. Similarly in this study 
the Tm values of the PCR fragments of the false negative isolates were within the ±0.8 
range of the MRSAII and MRSAIVb reference strains in both methods (see Figure 6.3).
These results showed that the PCR fragment sizes of the false negative isolates were 
comparable to those of the MRSAII and MRSAIVb reference strains. Furthermore the 
similar Tm values suggested that the sequences of the PCR fragments of the false 
negative isolates were possibly homologous to those of the MRSAII and MRSAIV 
reference strains.
II III IVb 17 18 19 20
(b)
M I II III IV 17 18 19 20
Figure 6.2. PCR fragments of the MRSA reference strains and the false negative 
isolates with PCR-A (a) and PCR-B (b). M, lOObp molecular marker; I, MRSAI; II, 
MRSAII; III, MRSAIII; IV, MRSAIVb; 17- 20, isolates 17, 18, 19 and 20.
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Figure 6.3. Melt curves of the PCR fragments of the MRSA reference strains and the 
false negative isolates of PCR-A (a) and PCR-B (b).
6.1.2.4 Analysis of nucleotide sequences of the false negative isolates
The PCR fragments of the PCR-A and PCR-B false negative isolates were sequenced 
(forward and reverse sequences) and aligned to the sequence of the MRSAIVb reference 
strain. This was performed with a new pair of primers (NB1 and NB2) which flanked 
those of PCR-A and PCR-B in the SCCmec-orJX region. This also enabled the 
assessment of the primer binding sites of the assays for possible primer:template 
mismatches which may have hindered optimal annealing of the primers and caused a 
reduction in the PCR product yield. The MRSAIVb reference strain and three additional 
clinical MRSA isolates (1, 40 and 41), were also included in the NB1-NB2 PCR. With 
this PCR the four false negative isolates were still amplified at higher Ct values (34.6 to 
36.6) in comparison to the MRSA reference and MRSA clinical strains (14.7 to 15.9) 
(see Table 6.8 and Figure 6.4).
The alignment of the fragment sequences showed that the false negative isolates only 
had five nucleotide differences at random locations and there were no nucleotide 
differences within the primer binding sites of the PCR-A and PCR-B methods. This 
showed that the target sequences o f the false negative isolates were homologous to the 
target sequence of the MRSAIVb reference strain. Therefore the differences in the Ct 
values were not due to variable target sequences or primer: template mismatches.
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Table 6.8. Ct values of MRSA reference strains, three clinical MRSA and four false 
negative isolates with NB1 and NB2 PCR.
NB1 -NB2 PCR
Isolate Av. ± SD
MRSAIVb 14.7 ±0.5
1 (clinical MRSA) 16.1 ±0.2
40 (clinical MRSA) 15.9 ± 0.1
41 (clinical MRSA) 15.9 ± 0.1
17 34.6 ±0.1
18 35.7 ±0.3
19 36.4 ±0.4
20 35.4 ±0.4
Key: Av.-average; SD-standard deviation
MRSAIV, EMRSA-15 
& clinical MRSA i
Atypical false j  
negative M RSA/>
0.2
Threshold
10 30 35 455 15 20 25 40 50
_______________________________  Cycle_____________________________________________
Figure 6.4. NB1 and NB2 PCR amplification curves of MRSAIV, EMRSA-15, clinical 
MRSA and false negative isolates
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The results of the previous investigations indicated that the disparity of the Ct values 
was not due to: PCR inhibitors, different PCR fragment sizes, variable target sequences 
or primer: template mismatches. However a hypothetical cause of the atypical results 
could be a SCCmec-orjX associated deletion in the false negative isolates. The deletion 
could be inclusive of the binding sites of the forward primers of PCR-A and PCR-B and 
may occur frequently, resulting in the majority of cells containing the deletion and only 
a minority of cells carrying the complete SCCmec-orJX junction (see Figure 6 .6 ). A low 
prevalence of the complete target sequences in the false negative isolates would result in 
later detection, represented by late Ct values with the PCR-A and PCR-B methods.
The frequency of the complete SCCmec-orJX junction may be postulated from the Ct 
values of the femAsA, mecA PCRs and PCR-A (see Table 6.9). The femAsA gene is 
located in the S. aureus chromosome and thus represents a genome equivalent. A 
femAsA standard curve (Ct versus logio CFU / ml) was generated with a 10-fold dilution 
series of the MRSAI reference strain (presented in chapter 4) and under optimal 
conditions there would be 10-fold increase of genome equivalents every 3.3 cycles. 
With the MRSAIVb reference strain and four false negative isolates the femAsA and 
mecA PCR Ct values were comparable, indicating that the mecA gene was detected in an 
equal number of genome equivalents in both the MRSAIVb strain and the false negative 
isolates (see Table 6.9).
However with the PCR-A there was a 20.1 cycle difference between the Ct value of the 
MRSAIVb strain (Ct 14.7) and the Ct value of the false negative isolate, 17 (Ct 34.7) 
(see Table 6.9). There was a similar difference in the remaining false negative isolates. 
With the assumption that 3.3 cycles represent one logio CFU / ml difference, or a 10- 
fold difference of genome equivalents, 2 0 . 1  cycles would be equivalent to six logio 
CFU/ ml difference or 106 genome equivalents. Therefore it could be estimated that 
with the false negative isolates the PCR-A SCCmec-orjX target sequence was detected 
in as few as 10"6 genome equivalents. This estimated prevalence of a complete SCCmec- 
orjX junction in the false negative isolates could explain the late amplification of these 
isolates in comparison to the MRSA reference strains with PCR-A and PCR-B assays.
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Table 6.9. Ct values of MRSAIVb and the false negative isolates with the femAsA, mecA 
and PCR-A
Isolate
femAsA PCR
Ct values 
mecA PCR PCR-A Cycle difference
MRSAIVb 10.8 14.0 14.6
Isolate 17 11.4 13.6 34.7 20.1
Isolate 18 11.4 13.6 36.6 22.0
Isolate 19 11.2 13.6 37.2 22.6
Isolate 20 11.1 13.4 35.4 20.8
forward primers
deletion
P C R -A  & P C R -B  P C R  C v ____________  ^
reverse primers
Figure 6 .6 . Schematic diagram of proposed deletion inclusive of PCR-A and PCR-B 
forward primer positions at the right extremity of SCCmec
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6.1.2.5 The false negative isolates of the PCR-C method
Five mecA positive S. aureus isolates (isolates 21, 22, 18, 7 and 8 ) were not amplified 
with the PCR-C method. To determine the cause of these results the steps performed for 
the false negative isolates of the PCR-A and PCR-B methods were undertaken. To 
ascertain if PCR inhibitors were present in the crude DNA templates, purified genomic 
DNA attained with an extraction and purification kit was used alternatively (QIAamp 
genomic DNAMini Prep, Qiagen). An aliquot (1 pi) of the purified genomic DNA of 
the false negative isolates was used (in triplicate) in the repeated mecA, femAsA, PCR-C 
assays and the MRSAII and IVb reference strains and three MRSA clinical strains 
which had previously amplified successfully were also included in the repeated tests.
With the use of purified genomic DNA in the repeated PCR-C assay, regrettably the 
MSSA reference strain (negative control) was amplified at much earlier cycles i.e. 
average Ct value, 25.5 (see Table 6.10). This value was greater than the Ct values of the 
MRSAII (20.3), MRSAIVb (20.7) reference strains and MRSA clinical strains (20.9, 
20.6 and 21.2 respectively). Two of the five false negative isolates (isolate 22 and 
isolate 18) were amplified at low Ct values i.e. 20.9 and Ct 21.1 which were lower than 
the value of the negative control and comparable to the values of the MRSA reference 
and MRSA clinical strains however the remaining three isolates: 21, 7 and 8 , were 
amplified at considerably higher Ct values i.e. 34.1, 37.1 and 38.8 respectively (see 
Table 6.10). With the mecA and femAsA PCRs the Ct values of all the false negative 
isolates were comparable to those of the MRSA reference and MRSA clinical strains.
Apart from the apparent amplification of the MSSA reference strain, the results of the 
false negative isolates in the repeated PCR-C assay were reminiscent of the results of 
the PCR-A and PCR-B false negatives. There was a disparity between the lower Ct 
values of the MRSA reference strains, MRSA clinical strains and isolates 22 and 18 
versus the higher Ct values of isolates 21,7 and 8  (see Figure 6.7). Therefore the basis 
of this phenomenon was thought to be similar to the proposed cause of the PCR-A and 
PCR-B false negative Ct results.
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Table 6.10. Ct values of reference strains, clinical MRSA strains and PCR-C false 
negative isolates with use of purified genomic DNA as template in assay
Isolate mecA femAsA PCR-C
Av. Ct ± SD Av. Ct ± SD Av. Ct ± SD
MRSA II 11.4 ±0.1 9.3 ±0.2 20.3 ±0.2
MRSA IVb 12.4 + 0.4 8.9 ±0.2 20.7 ±0.3
Oxford MSSA — 11.0 ± 0.1 25.5 ±0.1
37 (clinical MRSA) 13.1 ±0.3 10.3 ±0.2 20.9 ±0 .6
38 (clinical MRSA) 13.9 ±0.3 10.9 ±0.2 20.6 ±0.2
39 (clinical MRSA) 13.0 ±0.5 11.5 ± 0.1 21.2 ± 0.5
False negatives
21 11.6 ±0.2 9.8 ±0.1 34.1 ±0.2
22 13.0 ±0.2 11.4 ±0.2 20.9 ±0.8
18 12.2 ±0 .2 10.4 ± 0.1 21.1± 0.4
7 14.9 ±0.3 9.0 ±0.3 37.1 ±0 .6
8 13.1 ±0.1 11.0 ±0.3 38.8 ±0.4
Key: Av.- average; SD-standard deviation;—not amplified
Figure 6.7. PCR-C amplification curves of MRSA reference strains, clinical MRSA and 
false negative MRSA isolates
TbresftoW
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6.2 Investigating the mecA negative and SCCmec-orJX positive isolates
6.2.1 Application of purified genomic DNA and effect on Ct values
The PCR-A and PCR-B assays had seven false positives and the PCR-C assay had nine, 
one isolate (isolate 16) was a false positive in all three assays. To ascertain if these 
results were due to contamination of the initial MSSA cultures with MRSA, fresh 
cultures of the MSSA isolates were sub cultured from a single colony. Genomic DNA 
was obtained from the cultures with an extraction and purification kit (QIAamp 
genomic DNAMini Prep, Qiagen) and the mecA, femAsA and SCCmec-orfX PCRs were 
repeated with lp l (in triplicate) of the genomic DNA. The MRSAII, MRSAIVb 
reference strains and two clinical MRSA (37 and 39) were included in the repeat runs.
All of the PCR-A and PCR-B false positive isolates were amplified at Ct values which 
were comparable to the MRSA reference and MRSA clinical strains (see Table 6.11). 
These results illustrated that although these false positive isolates were mecA negative 
they amplified with similar efficiency to the MRSA strains (see Figure 6 .8 ). With the 
PCR-C method, disappointingly the MSSA reference strain once again amplified at low 
cycles i.e. average Ct, 23.0, which was comparable to the Ct values of the MRSA 
reference strains (see Table 6.12). Unlike the Ct values of the PCR-A and PCR-B false 
positives, the Ct values of the PCR-C false positive isolates were more variable. Isolates 
29, 30, 31, 33 and 16 had Ct values which were comparable to the MRSA reference 
strains but the Ct values of isolates 32, 34 and 36 were considerably higher (>30).
Table 6.11. Ct values of the PCR-A and PCR-B false positive isolates when purified 
template was used for the SCCmec-orfXPCRs___________________________________
Isolate femAsA PCR-A PCR-B
Av. Ct + SD Av. Ct + SD Av. Ct + SD
MRSAII 9.3 ± 0.2 14.3 ±0.3 18.7 ±1.5
MRSAIVb 9.2 ±0.1 14.1 ±0.3 19.2 ±0.5
Oxford MSSA 1 1 . 0  ± 0 . 1 — —
37 (clinical MRSA) 1 0 . 8  ± 0 . 2 15.1 ±0.4 19.6 ±0.9
39 (clinical MRSA) 11.5 ±0.2 15.4 ±0.5 20.0 ±0.7
23 13.5 ±0.4 13.5 ±0.6 23.7 ±0.7
24 12.5 ±0.1 12.7 ±0.6 23.0 ±0.4
25 12.3 ±0.3 12.4 ±0.5 2 2 . 0  ± 0 . 6
26 12.9 ±0.2 12.9 ±0.5 22.7 ±1.4
27 12.5 ±0.0 1 2 . 1  ± 1 . 0 22.5 ±0.6
28 12.9 ±0.9 12.9 ±1.0 2 2 . 1  ± 0 . 6
16 1 0 . 6  ± 0 . 2 14.9 ±0.5 18.8 ±0.4
Key: Av.-average; SD-standard deviation; — not amplified;
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Figure 6 .8 . PCR-A amplification curves of MRSAII, MRSAIVb, clinical MRSA and 
PCR-A false positive isolates.
Table 6.12. Ct values of PCR-C false positive isolates when purified template was used 
for the SCCmec-orfiC PCRs
Isolate femAsA 
Av. Ct + SD
PCR-C 
Av. Ct + SD
MRSAII 9.3 ±0.2 19.6 ±0.4
MRSAIVb 9.2 ±0.1 17.2 ±0.3
*Oxford MSSA 11.0 ± 0.1 23.0 ±0.4
37 (clinical MRSA) 10.8 ±0.2 21.0 ± 0.2
39 (clinical MRSA) 11.5 ± 0.2 21.8 ± 0.3
29 10.6 ±0.5 18.6 ± 0.1
30 11.4 ±0.2 18.6 ±0.3
31 11.1 ±0.3 23.0 ±0.2
32 10.9 ± 0.1 32.8 ±0.4
33 10.1 ±0.5 22.9 ±0.2
34 10.3 ±0.3 32.2 ±0.1
35 9.9 ±0.5 25.9 ±0.5
36 9.9 ±0.1 32.0 ±0.5
16 10.6 ±0. 2 18.2 ± 0.7
*Oxford MSSA reference strain amplified with PCR-C assay
The amplification of the PCR-A and PCR-B false positive isolates with purified 
genomic DNA extracted from verified pure cultures indicated that the initial 
amplification of the isolates was credible and the SCC mec-orjX target sequences were 
probably present in these isolates. Unfortunately with the PCR-C method the use of 
purified genomic DNA resulted in robust amplification of the Oxford strain. Even 
though this is a MSSA reference strain, it was implausible to use it as a cut off for false 
positive results and justifiably distinguish the true positive and false positive results.
Threshold
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6.2.2 Analysis of the PCR fragment sizes of the false positive isolates
To ascertain if there were any differences in the PCR fragment sizes of the false 
positives and the MRSA reference strains, the fragments were resolved in a 2% agarose 
gel. Six of the seven (23, 24, 25, 26, 27 and 28) PCR-A false positives had smaller 
fragments (approximately 176 bp) which were comparable to the MRSA I fragment (see 
Figure 6.9a). Isolate 16 which was detected by all three SCCmec-orfX assays had a 
larger PCR fragment (approximately 278 bp) which was comparable to the MRSA II 
and MRSA IVb fragments. With PCR-B the same six false positives had a smaller 
fragment comparable to the MRSA I and MRSA III fragments i.e. 300 bp and 310 bp 
respectively (see Figure 6.9b). Whereas isolate 16 had a larger fragment which was 
comparable to the MRSAII and MRSAIV fragments (400 bp).
400bp_
30 Obi
M  I II III I V  23  24  25  2 6  2 7  2S  16
Figure 6.9. PCR fragments of the MRSA reference strains and the false positive isolates 
with PCR-A (a) and PCR-B (b). M, lOObp molecular marker; I, MRSAI; II, MRSAII; 
III, MRSAIII; IV, MRSAIV; 23-16, isolates 23, 24, 25, 26, 27, 28 and 16.
a) b)
30
25
20
j
1^5
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0
M R S A I - 8 1 .8  
M R S A II - 82 2 
M R S A I I I -8 1 .5  
M R S A IV b  - 82 .0  
Isolate 2 3 - 8 1 . 5  
Isolate 2 4 - 8 1 . 8  
Isolate 2 5 - 8 1 . 8  
Isolate 26 - 81 .8  
Isolate 27  - 81 .7  
Isolate 2 8 - 8 1 . 5  
Isolate 1 6 - 8 2 .0
85
deg.
M R S A I-87 .0  
MRSAII - 85.2 
MRSAIII - 87.0 
Isolate 23 - 86,5 
Isolate 24 - 86 8 
Isolate 25 - 87,0 
Isolate 26 - 86.8 
Isolate 27 - 87.0 
Isolate 28 - 86.5 
Isolate 16 - 85 5
Figure 6.10. Melt curves of the PCR fragments of MRSA reference strain and the false 
positive isolates of PCR-A (a) and PCR-B
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I ll  IV 29 30 31 32 33 34 35 36 16
1
Figure 6.11. PCR fragments and melt curves of the MRSA reference strains and the 
false positive isolates with PCR-C. M, lOObp molecular marker; I, MRSAI; II, 
MRSAII; III, MRSAIII; IV, MRSAIVb; 29-16, isolates 29, 30, 31, 32, 33, 34, 35, 36 
and 16.
The fragments o f all nine PCR-C false positives (29, 30, 31, 32, 33, 34, 35, 36 and 16) 
were of the same size i.e. approximately 400 bp, and were comparable to the fragments 
of MRSA I, II, III and IV reference strains (see Figure 6.10).
Melt curve analyses of the fragments were performed to ascertain if the false positive 
isolates had melting temperatures (Tm) which were comparable to the MRSA reference 
strains. The six PCR-A false positive isolates which had smaller PCR fragments 
comparable to the MRSA I fragment also had Tm values (81.5 to 81.8°C) which were 
within the ±0.8 range of this reference strain (81.8°C) (see Figure 5.10). Similarly the 
same isolates with the PCR-B assay had Tm values (86.5 to 87.0°C) within the ±0.8 
range of the MRSAI and MRSA III Tm values (87.0°C). Isolate 16 which had a larger 
PCR fragment with both assays, exhibited Tm values (82.0°C and 85.5°C) which were 
comparable to the Tm values of the larger sized fragments of the MRSA II and IVb 
reference strains in the PCR-A and PCR-B assays (see Figure 6.10). Since the values of 
the PCR-A and PCR-B false positive isolates were within the ±0.8°C range of the 
respective MRSA reference strains, this strongly suggested that they were specific PCR 
products of the two methods. Conversely, the nine PCR-C false positive isolates were of 
equal size but the Tm values were more diverse and five isolates (32, 33, 34, 35 and 36) 
had Tm values ranging from 81.3 to 82.0°C, these were below the ±0.8°C range o f the 
MRSAII and IVb Tm values (83.7 and 84.0°C respectively), implying that these may 
have been non-specific amplification products (see Figure 6.11).
MRSA D-83.* 
MRSA IVb-84.0 
Isolate 29 - S3 J  
Isolate 30 - 83.5 
Isolate 31-83.0 
Isolate 32 - 81.5 
olate 33 - S2.S - 
Isolate 34-SI.3 
Isolate 35- 82.0 
Isolate 36 - 81.5 
Isolate 16 - 83.3
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6.2.3 Comparison of nucleotide sequences of the false positive isolates to 
published SCCmec sequences 
The PCR fragments of the false positive isolates of the PCR-A and PCR-C assays were 
sequenced and aligned i.e. both the forward and reverse strands (the false positive 
isolates of the PCR-A and PCR-B methods were identical, so only the fragments of the 
PCR-A assay were sequenced). Since the PCR-A false positive fragments were 
comparable to the fragments of MRSAI and MRSAII, the sequences were aligned with 
the SCCmec type I (NCTC10442) and SCCmec type II (N315) sequences.
Six of the seven PCR-A false positives which had the smaller PCR fragments (similar to 
the MRSAI fragment) had identical sequences and they were homologous to the 
SCCmec type I sequence, with only four nucleotide differences (see Figure 6.12). The 
remaining PCR-A false positive (isolate 16) which had the larger fragment size (similar 
to the fragment sizes of MRSAII and MRSAIV) had a sequence which was homologous 
to the SCCmec type II sequence, with only three nucleotide differences (see Figure 
6.12). Surprisingly even though the Tm values of the PCR fragments of the nine PCR-C 
false positive isolates were diverse, the sequences of these isolates were extensively 
homologous to the SCC mec type IVb sequence, with some nucleotide differences at 
random locations in the respective sequences (see Figure 6.13).
The homology between the sequences of the PCR-A and PCR-C false positive isolates 
and the SCCmec type I, II and IVb sequences suggests that the PCR fragments of the 
false positives were not generated by non specific amplification but were due to the 
amplification of SCCmec-orJXassociated sequences within these MSSA isolates.
173
a a a C r t j a a a a
U U U U U U U U U  
H H H H H H H H H  < a a&
u  u  fS 4
g  g
E J S g g g g g g g
g g g g g g g g g
t J B t i e c e e G dCJUUUUUUUU
2 S 2 S S S 2 S 2
o u u u o o o o o
H H H H H H H H H
a a a a a a a a a
C J U C J U U U U U U
u u u u u u u u u
H H H H H H H H H
o u u u o u u u o
' GGBGGGGGG < < < < < & < < <
—  D U D O O O D C I D&&&&&&&&& H H H H H H H H H  UOOOOOOOU u c j u u a a u a u
■UUOOOCJOOO 
H H H H H H H H H  UUUUUUUOU<< ft ft < < & << h h h h h h h h h— a a a a a a a a aUUUUUUOUU
s s s s s s s s s
- O O O O O O O O O
u u u u u u u u u■ ■ H............. ...
"Cj-
g g g g g g g g g
H H H H H H H H HOOUOUOUOO
H H H H H H H H H
C5 U  C5 CD d  8  *B OOOOOOODO 
H H H H H H H H H  
O O O U O O O O O
H H H H H H H H Ha a a a a a a a aOOOOOOOOC3
l l l l l l l l la a a a a a a a aO c j u u u o u u u
H H H H H H H H Ha a a a a a a a a
C J U U U U U U U U
0 0 0 0 0 ( 3 ( 3 0 0UUUUCJUUUU
u u u u u u u u u
u a u o u o u a u
o o u u u a o o u  
0 6 6 6 6 6 6 6 6
3 S 3 3 3 3 S S 3U B U p f: i: B r: U
BBPBPIJBi &Ji
0 0 0 0 ( 3 0 0 0 ( 3
e e e e e e e e e
S 0 S S S S 0 S S  
- g g g g g g g g gu o o o o o o mrp;
Ge GGGGGCS
o o o o o o o o o
E E E E E E E E E
1 I I I I I I I IH H H H H H H H H
- g g g g g g S S g g
o o o o o o o o oa u u u u u u u t j
* g g g g  g g e j g *
H 
- '8
u
u u o u u u u u a
H H H H H H H H  
U U O O O H h  H
o u c j o u o G u
O U O U U U O O U
H H H H H H H H H
< < 
U  U  
H  EJ
a  a
H  Ha <
U  U  
H  H
oo
cn — U U U U C J U U U Uo o o o o o o o o  
H H H H H H H H H
a a a a a a a a a
0 ( 3 0 0 0 0 0 ( 3 0  
H H H H H H H H H
CN EE EE
a  o  o  o  
u  a u  u  u u a u 
u  o  o  o
^ ^ S Su u a u
E E E E Eo o o o o 
u u u u a  
u u a u u  
o o o o o o o o o o
g g g g g
o o o o o o o o o
H H H H H H H H H
O O O O O O O O O
■ U U C J U U U U C J U
H H H H H H H H H
u u u u u u u u u
u u u u u u u u u
r t l r i j r t j r i l r t j r i j r f l r i j r t ;  
■0  ( 3 ( 3 0 0 ( 3 ( 3 0 ( 3
g g g g g g g g gH H H H H H H H H
O O O O O O O O O
E h E E £ E h E £
( 3 0 ( 3 ( 3 ( 3 ( 3 ( 3 ( 3 ( 3
u u u a a u u o o  r«-trar a -ar a tai a a
C N C N C N C N C N C N C O r H C Q
H H H
H H H H H H
(J U u o u (j
(U <U (U <u <u <U
E E E E E E
U a u a CJ U
U VO (J m ^ i n v o r ' o o c j v o u r o ^ m v o r ' o o u v o O
C N C N C N C N C N C N C O iH C O C N C N C N C N C N C N C O r H C / 3
m
I (
c n
s
1=1
<L>
CJ
(V)
5
u
u
C/5
CN
T}-
o
1-H
o
H
u
&
CJ
cu
s
u
u
CO
'O
cd
*
a>
>
•■p
"wo
a
<D
hU  a>
0 *1  £
£  t §o  3 -h
(/) ”7 3  
a>
O  <L> 
d  t 3o  " —I 
CO ( J
‘S 3 °  d
"S j, 
§ 8 
a  g
a  sP  a> 
< £• CQ CN M_l
COv© a> 
^  o
g  ai-l 0>
§D  ^
o o o o o o o o
O O D O U O C I Oo o o o o o o o
4 4 4 4 4 4 4 4o o o o o o o o
^ 'S1 ^ 2; ^ ^
O O O O O O O O
E E E E E E E E
D  O  [J O  O U O Oa o o a o o o o  o o I4i o (4! o 145 o
E E C E E E E e
g  g  «  g
e5 c5H  H  E-i Ho u o < o o o o u u o o
H  H  H  Heg eg C3 egft, ft < ft 
H H H H
S3 S2 S3 S34 4 4 < 
H H H H 0  0  0  4  
U U  U O 
O O  O O 
Eh Eh Eh Eh
53 S3 S3 S34  4  4  4  
H H E-i H
4 4 4 4 4 4 4 4
O O O O O O O O
H H H H H H H H
0  0  0  4  0  0  0
e e e e e e e e
U U U U O U U O
i l i i i i l ls s s s s s s s
H H H H H H H H
O O O O O O O O
H H H H H H H H
5 5 5 3 3 3 3 5
o o o o o o o o o o o o
H h H H  o o o o
H H H H
6 o 6 o
E E E E
H H H
o o 6
H H H H
6 6 6  6 
o  o  o  a u o 
u  u  o  
o  u  a
4  0  0  0o o o o o o o o 
H H H H 
O O O O 
H H H H 
4  4  4  4  
O  O  O O
E E E E
H H H H H
' £ £ 5? £6 6 6 6 o o o o ou u o u oa u u o ou o u u a
6 6 6 6 6 6 6 6
3 3 6 6 6 6 5 3
§ £ £ £ £ £ £ £
6 6 6 6 6 6 6 6
E E E E E E E E
O O O O O O O O
E E E E E E B E
a a a a a a a a
6 6 6 6 6 6 6 6  
4 4 4 4 4  0 4 4
e e e e e e e e
E E E E E E E E
O O O O O O O OH U U H U H H H
4 4 4 4 4 4 4 4
s s s s s s s s
G B c E B e E cH H H H h H H H
5 5 5 2 5 5 2 5
4 4 4 4 S S S 4
E ' F EBEEEE
O O O O O O O O
b e e e e e e e
O O O O O O O O
4 4 4 4 4 4 4 4
O O O O O O O O
O O O O O O O O
4 4 4 4 4 4 4 4
H H H H H H H H
O O O O O O O O
3 5 3 3 3 1 3 3
u u u u u u u u
O O O O O O O O
E E E E E E E E
O O O O O O O O
O O O O O O O O  
• O O O O O O O O
O O O O O O O O
E E E E E E E E
' £ £ £ £ £ £ £ £  6 6 6 6 6 6 6 6  6 6 6 6 6 6 6 6  
e e e e e e e e
0 0 0 0 0 4 0 0  
O O O O O O O O
o  — O O O O O O O O  H —  H H H H H H H H'  - - -  - -  - -  U O O O O O O O
BBBBBE BB
O O O O O O O O
O O O O O O O O
O O I H O O Q O O
O O O O O O O O
E B E E E E E E
e e e e e e e e
3 3 3 5 5 3 3 3
O O O O O O O O
e e e e e e e e
u u u o u o o o
o u u u u o o u
E E E E E E E E
O O O O O O O O
O O O O O O O O
O O O O O O O O
H E - t H H H H H H
6 6 6 6 6 6 6 6
U O O U U U U O
© o u u u u o u
O O O O O O O O
BBBBBE BB
O O O O O O O O  
O O O O O O O O  
O O O O O O O O  
'  '  ‘ ‘ ‘ H ’ '
O O O O O O O O  
O O O O O O O O  
H H H E - t H H H H o
O O O O O O O O  vo —
_ o  o  o  _
6 6 6 6 6 
5 5 5 5 5  .
0 0 0 0 0 0
O O O O O O O O
4 4 4 4 4 4 4 4
O O O O O O O O
H H H H H H E h H
o  . . _ _
O O O O O O O O  
O O O O O O O O  
O O O O O O O O
O O O O O O O O
h h h h h h b h  
4 4 4 4 4 4 4 4  
O O O O O O O O
^ E E E E E E E E
O O O O O O O O  
O O O O O O O O  
O O O O O O O O
Ol f f l O O O O O O  
O O O O O O O O
6 6 6 6 6 6 6 6  
O O O O O O O O  EhHHHHHHEh 
O O O O O O O O  
H H H E - I H H H H  
h H H p H H H no o o o o o o o
m l l e e .
i i i i i i i i4 4 4 4 4 4 4 4
6 6 6 6 ^ 6 6 6
e e e e e E E e
u u o o u u o ©
BBBBBE BB
4 4 4 4 4 4 4 4
BBBBBE BBu o o o o o o o
O O O O O O O O
O O O O O O O O
E E E E E E E EOCDOUOOOO
u o u u u o a a
o u u o u o u u
E E E E E E E E
O O O O O O O O
O O O O O O O O
0 0 0 0 0 0  o oifao o o:H H T* H H H
• 4 4 4 4 4 4 4 4
E E E E E E E E
u u u o u u o o  
a o o a o u o u
O O O O O O O O
E E E E E E E E
4 4 4 4 4 4 4 4  -. — . . .  ^
3 3 0  
3  H
O O O O O O O O
B B B e e C B B
6 6 6 6 6 6 6 6  HHEh H H H H H
a a g a s s s s
O O O O O O O O
ggggggggE E E E E E E E
l l l l l l l l
H H H H H H E h H 
O O O O O O O O
E E E E E E E E
O O O O O O O O
O O O O O O O O
O O O O O O O O
0 0 0
H H H 
4  4  4  
H E-i H0 0 0
H H H
0 0 0
0 0 0
E E E
0 0 0
H H H
fC <c <c 
H H E-i 
O O O  
H H H 
O O O  
O O O
E E E
o  o  
H H 
4  4  
H H 
O  O 
H H 
O O 
O O 
H H 
H Eh
O O O O O O O OHHEhEhHHEhH
6 6 6 6 6 6 6 6E E E E E E E E
O O O O O O O OHHHHE h HHH
4 4 4 4 4 4 4 4
O O O O O O O O
B B B B B B B B
BBBBBE BB
5 5 5 5 5 5 3 5
O O O O O O O O
O O O O O O O O
Eh H E h H E h H H Ho o o o o o o o
Eh H H H H H E h H
O O O O O O O O
O O O O O O O O
E E E E E E E E
H H H E h H E h H E h
H E h Eh Eh Eh Eh Eh Eh
a
u
Q)
E
o
VO O  
H  CO
<u
E
o
a v O H C N i n v o v o O
C N i r o m m m r n H C O
H  
0 
0) 
E 
O 
vo O  
H  CO
6.3 Discussion
6.3.1 Comparison of PCR-A, PCR-B and PCR-C to the original studies
The PCR-A, PCR-B and PCR-C SCCmec-orJX amplification methods had high 
accuracy (sensitivity >95%) in the detection of mecA positive S. aureus in a collection 
of 118 (22.7%) MRSA and 401 (77.3%) MSSA isolates. The original PCR-A method 
was developed by Huletsky et al. (2004) as a real-time PCR with the Cepheid Smart 
Cycler and they evaluated a much larger collection of isolates comprising 1657 MRSA 
and 569 MSSA isolates. A comparison of the results of the present study and the 
original study shows that Huletsky et al. (2004) attained higher sensitivity (98.7% 
versus 96.6%) and PPV results (98.5% versus 94.2%) but lower specificity (95.4% 
versus 98.3%) and NPV results (96.3% versus 99.0%) (see Table 6.13, 1st and 2nd 
column). Even though Huletsky et al. (2004) had a higher PPV result, the number of 
false positives (n=26, 4.6%) was significantly higher (p=0.02) than in this study (n=7, 
1.7%), indicating that in the original study more MSSA isolates were misidentified as 
MRSA. The NPV result of the present study exceeded the result attained by Huletsky et 
al. (2004) and this was most likely due to the lower MRSA prevalence rate in this study 
(22.7% versus 74.4%). The results of the present and original studies illustrate that the 
PCR-A SCCmec-orflC assay has high accuracy for MRSA detection in clinical isolates.
In a later study by Huletsky et al. (2005) the SCCmec-orJX assay was performed on 331 
nasal swabs of which 81 (24.5%) were MRSA positive by the culture method. The 
sensitivity, specificity, PPV and NPV results were 100%, 98.4%, 95.3% and 100% 
respectively, demonstrating particularly high sensitivity and NPV results and suggesting 
that the PCR-A SCCmec-orfiC method retains high accuracy for MRSA detection in 
both clinical isolates and nasal swabs (see Table 6.13, 3rd column).
Table 6.13. Performance results of the PCR-A method in the present study and in the 
Huletsky et al. (2004, 2005) studies____________________________________________
Present study 
S. aureus isolates
Huletsky et al. (2004) 
S. aureus isolates
Huletsky et al. (2005) 
Nasal swabs
Sensitivity 96.6 % 98.7 % 1 0 0 %
Specificity 98.3 % 95.4 % 98.4%
PPV 94.2 % *98.5% 95.3%
NPV 99.0 % *96.3% 1 0 0 %
*Predictive values calculated from sensitivity, specificity, false negative, and false positive results o f
Huletsky et al. (2004)
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The PCR-B method was originally developed by Hagen et al. (2005) as a real-time PCR 
with the Roche LightCycler system and they evaluated 256 clinical isolates comprising 
124 MRSA isolates, similar to the number (n=l 18) evaluated in this study but a lower 
number of MSSA isolates (n=53 versus n=401). They also included 47 methicillin 
resistant-coagulase negative staphylococci (MR-CoNS) and 32 methicillin susceptible- 
coagulase negative staphylococci (MS-CoNS). The Hagen et al. (2005) study had 
higher sensitivity (98% versus 96.6%), specificity (100% versus 98.3%) and PPV 
results (100% versus 94.2%) but the NPV results were comparable in both studies i.e. 
98% versus 99.0% (see Table 6.14, 1st and 2nd column). Their specificity and PPV 
results were faultless indicating the absence of false positive results but this was most 
likely due to the low number of MSSA isolates tested in the study. The overall results of 
the present and original studies indicated a high accuracy of the PCR-B SCCmec-orfX 
assay for MRSA detection in clinical isolates. Hagen et al. (2005) also performed the 
assay on 60 nasal swabs of which 29 (48.5%) were MRSA positive by a culture method. 
Even though the specificity and PPV results remained high, the decline in the sensitivity 
and NPV results, 93% and 94% respectively, indicated a lower accuracy of the assay for 
MRSA detection in nasal swabs and a higher likelihood of false negative results with 
these clinical specimens (see Table 6.14, 3rd column).
A comparison of the original results of the Huletsky et al. (2004) study to those of the 
Hagen et al. (2005) study shows that the respective SCC mec-orjX assays had 
comparable sensitivity results with clinical isolates i.e. 98.7% and 98% respectively (see 
Table 6.13 and 6.14) and similarly in this study, the PCR-A and PCR-B methods had 
identical results. However with nasal swabs, the Huletsky et al. (2005) method (PCR-A) 
had higher sensitivity (100% versus 93%) and NPV results (100% versus 94%) than the 
Hagen et al. (2005) method (PCR-B), suggesting that with nasal swabs the PCR-A 
method is potentially more accurate than the PCR-B method (see Table 6.13 and 6.14).
Table 6.14. Performance results of the PCR-B method in the present study and in the 
Hagen et al. (2005) study____________________________________________________
Present study 
S. aureus isolates
Hagen et al. (2005) 
S. aureus isolates
Hagen et al. (2005) 
Nasal swabs
Sensitivity 96.6 % 98% 93%
Specificity 98.3 % 1 0 0 % 1 0 0 %
PPV 94.2 % 1 0 0 % 1 0 0 %
NPV 99.0 % 98% 94%
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In this study the PCR-C method had the lowest diagnostic performance out of all three 
SCCmec-orpC assays. The original method was developed by Cuny and Witte (2005) as 
a conventional PCR and the fragments were resolved in an agarose gel. The positive 
results were defined by the presence of a band (approximately 400bp) and negative 
results verified by the absence of the band. In this study the method was modified into a 
real-time PCR on the Corbett Rotor-Gene 6000 platform. Cuny and Witte (2005) had 
performed the assay on 330 staphylococci isolates: 100 MRSA, 100 MSSA, 50 MR-& 
epidermidis, 30 MS-S. epidermidis, 30 MR-S. haemolyticus, 10 MR-51, hominis and 10 
MS-51, hominis and they had perfect sensitivity and specificity results (100%). However 
the lower sensitivity (95.8%), specificity (97.8%), PPV (92.8%) and NPV results 
(98.7%) of PCR-C in the present study, suggest that in a larger collection of isolates this 
method does generate false negative and false positive results (see Table 6.15).
In this study the PCR-C method had the lowest PPV result in comparison to the PCR-A 
and PCR-B methods (92.6% versus 94.2% and 94.2% respectively), indicating a higher 
likelihood of false positive results with this method. This was not unexpected as the late 
amplification of MSSA isolates was observed in previous results (presented in chapter 
4). The likely cause of these results is the design and location of the PCR-C forward 
primer, the sequence of the primer is homologous to two published MSSA sequences 
and it overlaps into the orfX sequence (discussed in chapter 4). This concern has been 
highlighted by Kolman et al. (2010), they performed the Cuny and Witte (2005) assay 
on 150 staphylococci isolates: 50 MRSA, 50 MSSA, 25 MR-CoNs and 25 MS-CoNs 
and attained even lower specificity and PPV results i.e. 8 6 % and 77.8% respectively, 
they subsequently excluded the assay from further evaluations (Kolman et al., 2010).
Table 6.15. Results of the PCR-C method in the present study and results of the Cuny 
and Witte (2005) study______________________________________________________
Present study 
S. aureus isolates
Cuny and Witte (2005) 
S. aureus isolates
Sensitivity 95.8 % 1 0 0 %
Specificity 97.8 % 1 0 0 %
PPV 92.6 % 1 0 0 %
NPV 98.7 % 1 0 0 %
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In the present study the template concentration per reaction was kept relatively constant 
by the consistent use of two to three S. aureus colonies in the preparation of the crude 
DNA extracts. Based on the evaluation of the Ct values of the amplified isolates, the 
discrimination of the positive and negative results was possible. However with the use 
of purified genomic DNA a higher concentration of DNA was being added to the PCR 
reactions and this resulted in the robust amplification of both MRSA and MSSA strains 
at similar low Ct values, therefore it was difficult to validly distinguish the true positive 
results from the false positive results with the PCR-C assay. These observed results 
question the suitability of this assay as an MRSA diagnostic test in routine clinical 
analysis. Furthermore in clinical specimens the bacterial load is variable and 
consequently the target sequence concentration may be low, this could also make the 
discrimination of positive and negative results problematic with this assay. However, 
the original method by Cuny and Witte (2005) was implemented as a commercial 
MRSA screening test for nasal swabs, indicating that under certain defined reaction 
conditions undoubtedly this method is a suitable MRSA screening test (Hain 
LifeScience).
6.3.2 The diagnostic performance of SCCmec-orpC assays on clinical swabs
Out of the three SCCmec-orfX assays evaluated the PCR-A and PCR-B methods had the 
best diagnostic performance. However, the high performance is not guaranteed in 
routine MRSA screening swabs due to the lower prevalence rate of MRSA in these 
clinical specimens. Studies by Maudsley et al. (2004), Grundmann et al. (2002) and 
Abadu et al. (2001) conducted in London, Nottingham and Birmingham respectively 
indicate that in the UK the prevalence of nasal carriage of MRSA in the community is 
very low i.e. 0.78%, 0.83% and 1.5% (Maudsley et al., 2004, Grundmann et al., 2002, 
Abadu et al., 2001). Lower prevalence rates will affect the predictive values of the 
SCCmec-orfiC assays i.e. with decreasing prevalence the PPV decreases and the NPV 
increases, thus increasing the likelihood of false positive results (Akobeng, 2006).
The original PCR-A method was the first SCCmec-orfX PCR to be approved as a 
commercial assay for MRSA detection in nasal swabs (BD GeneOhm MRSA test). This 
is a qualitative in vitro real-time PCR for direct detection of MRSA in nasal swabs. It 
involves an initial lysis step, during which the nasal swab is placed directly into the kit 
lysis buffer, then an aliquot of the lysate is transferred to a tube containing a volume of
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the kit PCR master mix and the reaction mix is then placed into the designated 
themocycler i.e. the Cepheid SmartCycler: the PCR takes less than 2 hours. The 
amplified target sequences are detected with hybridisation probes labelled with 
fluorophores, the amplification, detection and interpretation of the results is done 
automatically by the SmartCycler software. Other commercial real-time PCR tests for 
MRSA detection in nasal swabs include the Xpert MRSA (Cepheid) and the 
LightCycler MRSA Advanced test (Roche), these also utilise specific kit reagents and 
require the use of designated thermocyclers (www.cepheid.com/tests-and-reagentsA 
(http://molecular.roche.com). Another assay is the GenoQuick MRSA test (Hain 
LifeScience). Although this is an amplification method, it is not a real-time PCR assay, 
rather it involves the use of a DNA strip coated with specific complementary probes to 
detect the amplified MRSA target sequence and the bound amplified sequence is then 
made visible in a colorimetric reaction (www.hain-lifescience.de/). Further tests include 
GenoType MRSA (Hain LifeScience) for MRSA detection in bacterial cultures, the BD 
GeneOhm StaphSR for the detection of MSSA and MRSA in blood cultures and the 
Xpert MRS A/S A SSTI and Xpert MRS A/S A BC tests (Cepheid) for MRSA detection in 
skin and soft tissue infections swabs and blood cultures respectively.
Several studies have investigated the BD GeneOhm MRSA test (previously termed the 
IDI-MRSA) and other commercial SCCmec-orfiC tests on various screening swabs. 
Those in which the tests were performed directly on nasal swabs with variably low 
MRSA prevalence rates, have a similar trend of results: relatively high (>90%) 
sensitivity and specificity values but disappointingly low PPV values, in certain studies 
the values dropped below 80% (Snyder et al., 2010, Park et al., 2009, de San et al., 
2007, Paule et al., 2007, Zhang et al., 2007, Bishop et al., 2006, Warren et al., 2004) 
(see Table 6.16). In a study by Park et al. (2009) the overall performance of the BD 
GeneOhm MRSA test was notably lower than in the present study (sensitivity 85.8%, 
specificity 77.5%, PPV 72.8% and NPV 93.5%). In the study by Wolk et al. (2009) the 
Cepheid Xpert MRSA test was performed on nasal swabs and despite a MRSA 
prevalence rate of 44%, the results of that study also showed a low PPV result for the 
assay. Nevertheless in most of the studies which used nasal swabs, the NPV (94%- 
1 0 0 %) results were exceptionally high and comparable to the values attained in this 
study with clinical isolates (see Table 6.16).
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Although the BD GeneOhm MRSA test is approved for nasal swabs, several studies 
have investigated the performance of this assay on non-nasal swabs. The results of some 
studies indicate that the sensitivity of the IDI-MRSA and the BD GeneOhm MRSA tests 
is higher with nasal swabs than with swabs from other anatomical sites (de San et al., 
2007, van Hal et al., 2007, Bishop et al., 2006) (see Table 6.16). Conversely, Zhang et 
al. (2007) attained comparable high sensitivity values (>90%) for both rectal and nasal 
swabs with an earlier and newer version of the IDI-MRSA test. However the PPV 
results with the non-nasal swabs were very low for both versions of the test (58.3% and 
61.4%) (see Table 6.16). Overall these results suggest that with non-nasal swabs the 
diagnostic performance of SCCmec-orfiC assays may further decline and false positives 
may be more frequent.
The pooling of screening specimens could reduce the time required for testing and the 
performance of SCC mec-orfiC assays on pooled specimens e.g. nasal swabs, axilla, 
perineum, rectal swabs, has been investigated in some studies. Nulens et al. (2010), 
Wassenberg et al. (2010) and Jeyaratnam et al. (2010) attained lower sensitivity results 
and the PPV results of the Nulens et al. (2010) and Wassenberg et al. (2010) studies 
were particularly low (50.0% and 44.2%) (see Table 6.16) but in both studies the NPV 
values of the assays were remarkably high (99%). Also in these studies the BD 
GeneOhm test was compared to the Cepheid GeneXpert test and although both tests had 
poor sensitivity and PPV results, the BD GeneOhm tests had slightly better results with 
the pooled specimens (see Table 6.16). These results indicate that as with non-nasal 
swabs, the accuracy of SCCmec-orfX assays may decrease with pooled clinical 
specimens also and an increase in the rate of false positive results is likely, thus these 
assays perform more optimally with nasal swabs.
6.3.3 SCC mec-orfiC false negative and false positive results
In this study false negative results were attained with the PCR-A, PCR-B and PCR-C 
SCCmec-orjX assays. Initially these were thought to be due to PCR inhibitors in the 
crude templates however the same isolates were successfully amplified using the crude 
templates in the mecA and femAsA PCR assays. If inhibitors were present these would 
have also hindered amplification in all the PCR assays. Subsequent amplification with 
the SCCmec-orJX assays when purified genomic DNA was used suggested that the 
initial lack of amplification was probably due to lower concentrations of target DNA in
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the crude extracts. Several possible causes of the divergent Ct values of the false 
negative isolates and the MRSA reference strains with the PCR-A and PCR-B methods 
were investigated but a conclusive explanation was not achieved. In fact the sequences 
of these false negative MRSA were homologous to the MRSAIVb reference strain. A 
proposed cause of the unusual results was a deletion within the SCC mec right extremity 
region which was inclusive of the binding sites of the PCR-A and PCR-B forward 
primers. This is not implausible because the SCCmec right extremity sequence is 
adjacent to orjX, the site for the integration and excision of the SCCmec elements. It is 
postulated that the excision of the elements reduces the fitness cost incurred by their 
carriage, so it is possible that under high antibiotic pressure since the excision of an 
entire element may be detrimental, only certain regions may be deleted and the 
proposed deletion may have arisen under such circumstances. Perhaps in the false 
negative isolates there was over-expression of the recombinase genes which mediate the 
excision of the SCCmec element and this may have caused the frequent deletion of the 
regions inclusive of the PCR-A and PCR-B target sequences.
However the location and extent of the proposed deletion was not established in this 
study and several strategies could be implemented to further explore this hypothesis. 
The structural composition of the SCCmec elements contained in the false negative 
isolates could be investigated by DNA hybridisation microarray analysis. A microarray 
could be developed which comprises oligonucleotide sequences that are representative 
of all the open reading frames iprfs) of currently sequenced SCC mec types. The 
analysis of the false negative isolates would enable a comprehensive characterisation of 
the SCCmec elements and also it would allow the identification of orfs that are absent or 
not homologous to currently defined SCC mec types. A whole genome microarray has 
already been developed based on the genomes of seven S. aureus strains belonging to 
different clonal lineages (Lindsay et al., 2006, Witney et al., 2005). This assay could be 
used to determine the genomic differences between the MRSA reference strains and the 
false negative isolates. The target sequences of the SCCmec-orJX amplification methods 
employed in this study are located in the J3-region (mecA to orfX) o f SCCmec type I to 
V elements. The proposed deletion could be investigated by sequencing this region in 
the SCCmec elements of the false negative isolates. This would require the optimisation 
and implementation of long range PCR(s) and DNA sequence analysis of the PCR 
fragments.
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In addition to the false negative results, the SCCmec-orjX assays also generated false 
positive results. Seven MSSA isolates were amplified with PCR-A and PCR-B and nine 
MSSA isolates were amplified with PCR-C. False positive results can arise from the 
amplification of non specific products however this was ruled out because the sequences 
of the false positive PCR fragments aligned to published SCCmec type I, II and IVb 
sequences, indicating that SCC mec-orjX sequences were present in these isolates even 
though the mecA gene was absent. The presence of the SCCmec-orfiC junction in the 
absence of mec A in S. aureus isolates has been described in several studies (Noto et al., 
2008a, Donnio et al., 2005, Wada et al., 1991). Donnio et al. (2005) described the 
presence of a SC Cmec associated remnant, 7.543 l::pUBl 10::ZS43 Indies in tobramycin 
resistant MSSA strains collected from various French hospitals from 1992 to 2002. 
They postulated that the fragment resulted from the partial excision of possibly 
SCCmecIA, II or IVA elements as these carry the pUB770 plasmid which has aadD, the 
gene encoding tobramycin resistance (Donnio et al., 2005). The detection of SCCmec- 
orjX in MSSA can also be caused by the carriage of non-mecA containing SCC 
elements i.e. SCCcapi and SCC4 76 present in certain MSSA strains. The presence of 
SCC/wec-associated DNA, possibly resulting from an excised SCC mec or from an 
integrated non mecA SCC element was subsequently investigated and the results are 
reported and discussed in chapter 7.
Several factors contribute to the excision of SCC mec from the chromosome including 
long-term storage or long-term cultivation in the absence of antibiotic selective pressure 
(van Griethuysen et al., 2005, Deplano et al., 2000, Lawrence et al., 1996). As such van 
Griethuysen et al. (2005) recommended the addition of oxacillin to cryopreservatives to 
enable stabilisation of mecA. In this study the S. aureus isolates were collected as 24 to 
48 hour cultures which were grown on Iso-Sensitest plates and colonies were picked 
from these plates for the PCR tests or isolates were then subcultured (24 hours) onto 
CBA plates for repeat testing. Even though these media are antibiotic free the 
incubation times were not extensive, so these conditions present a low risk for SCCmec 
excision.
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S CCmec-orJX assays are based on the detection of SC Cmec right extremity sequences 
of currently published SCCmec elements. However, the identification of novel elements 
has not been exhausted, thus current assays may prove less optimal for the detection of 
future MRSA strains with novel SCCmec elements. In addition, the presence of 
different MRSA clones or the varying prevalence rates of respective MRSA clones in 
various geographical locations may affect the performance of SCCmec-orJX assays. 
This was observed by Bartels et al. (2009) who evaluated the BD GeneOhm MRSA 
assay against a diverse collection of MRSA which were mainly from Copenhagen, 
Denmark (Bartels et al., 2009). Fifteen percent of MRSA isolates gave false negative 
results and subsequent engagement of the authors with collaborators from BD 
GeneOhm enabled assessment of the sequences of these isolates. This revealed that they 
contained SCC mec right extremity types which could not be detected by the assay. 
Ninety five percent of the undetectable isolates belonged to the ST8 -MRSA-IVa clone 
{spa type t024) which was common in Copenhagen at the time of the study.
The reduction of MRSA infections is a priority in the UK and the rapid but accurate 
detection of MRSA in screening clinical specimens is an integral part of infection 
control. The results of this study indicate that the SCC mec-orjX PCR assays, 
particularly the PCR-A and PCR-B methods have high sensitivity and NPV results and 
therefore they could be attractive tests for MRSA screening programmes. However this 
would require careful consideration of local MRSA prevalence rates as these will affect 
the diagnostic predictive values of the tests. Also the diverse molecular epidemiology of 
MRSA strains in various geographical locations necessitates the inclusion of local 
MRSA strains in the validation process. Nevertheless in spite of the high sensitivity 
results of the SCC mec-orfiC assays it was evident that certain MRSA strains were 
undetected and several MSSA were amplified with these assays. Even though the exact 
cause of these results was not verified in this study, the genotypic characteristics of the 
atypical MRSA and MSSA strains were investigated with molecular typing methods 
and the results are presented in the proceeding chapter.
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Chapter Seven
Molecular characterisation of the SCCmec-orfX false negative and false positive S. 
aureus isolates
7.0 Background
Previously 137 MRSA isolates were characterised by PFGE, spa typing and SC Cmec 
typing and 89.1% (n=122) were EMRSA-15 strains, 5.8% (n=8 ) were EMRSA-16 
strains and 5.1% (n=7) were diverse MRSA strains (results presented in chapter 4) (see 
Table 7.1). The SCCmec typing results demonstrated that out of the 137 MRSA isolates 
92% (n=126) contained SCC mec type IV elements, thus were defined as MRSAIV 
strains and 5.8% (n=8 ) contained SCC mec type II elements, thus were defined as 
MRSAII strains. Of the remaining three isolates, two had elements which were 
provisionally defined as SCCmec type V elements and one isolate had an element which 
was not typeable (results presented in chapter 4).
Three SCCmec-orfX amplification methods: PCR-A, PCR-B and PCR-C had been 
evaluated with MRSA reference strains and demonstrated the capacity to amplify 
MRSAI to MRSAIV reference strains. However when these were performed on 118 of 
the 137 MRSA isolates and 401 MSSA isolates, several MRSA and MSSA isolates 
generated false negative and false positive results (results presented in chapter 6 ). Four 
MRSA isolates: 17, 18, 19 and 20 were not amplified with the PCR-A and PCR-B 
assays and five MRSA isolates: 21, 22, 18, 7 and 8  were not amplified with the PCR-C 
assay (isolate 18 was not amplified in all three assays). Whereas seven MSSA isolates 
were amplified with the PCR-A and PCR-B assays: 23, 24, 25, 26, 27, 28 and 16 and 
nine MSSA isolates were amplified with the PCR-C assay: 29, 30, 31, 32, 33, 34, 35, 36 
and 16 (isolate 16 was amplified in all three assays).
Table 7.1. Genotypic characteristics of 137 MRSA clinical isolates as determined by 
PFGE, spa typing and SC Cmec typing (refer to section 4.1.1 and 4.1.4 in chapter 4)
Clone MRSA (n=137) SCCmec type MRSA (n=137)
EMRSA-15 122 (89.1%) IV 126 (92.0%)
EMRSA-16 8  (5.8%) II 8  (5.8%)
Unique 7 (5.1%) y* 2 (1.5%)
Non-typeable 1 (0.7%)
*SCCmec type V designation was provisional
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Therefore the objective of this study was to examine the genotypic characteristics of the 
MRSA isolates which were not amplified with the PCR-A, PCR-B and PCR-C methods. 
In addition the genotypic characteristics of the false positive MSS A isolates were 
investigated with PFGE and spa typing. The SCCmec typing had been previously 
performed with the Milheirico et al. (2007b) and the MPCR-1 and MPCR-2 typing 
methods (Kondo et al., 2007) (see section 4.02 in chapter 4). In this study these methods 
were also performed on the false positive MSS A isolates to investigate if they contained 
SCCmec associated loci (see Table 7.2 and 7.3).
Table 7.2. Expected PCR fragment sizes of the Milheirico et al. (2007b) method for 
SCCmec types I to V________________________________________________________
Loci Size(bp) SCCmecl SCCmecW SCCmeclW SCCmecYV SCCmecW
pis 495bp +
ccrC 449bp +
III-  J3 414bp +
V- J1 377bp +
dcs 342bp + + +
ccrB2 31 lbp + +
kdp 284bp +
III- J1 243bp +
m ecl 209bp + +
mecA 162bp + + + + +
No. of fragm ents 3 5 4 3 3
Table 7.3. Expected PCR fragment sizes of ccr and mec loci of SCCmec type I to VI 
elements with MPCR-1 and MPCR-2 assays_____________________________________
Loci Size(bp) SCC mecl SCCmecll SCCmeclll SCCmeclV SCC mecW
M PCR-1 (IB) (2A) (3A) (2B) (5C)
mecA 286bp + + + + +
ccrA lB l 695bp +
ccrA2B2 937bp + +
ccrA3B3 179lbp +
ccrA4B4 1287bp (+)
ccrC 518bp +
M PCR-2
mecA-mecI 1963bp + +
mecA-lS1272 2827bp + +
mecA-\S431 804bp +
(+) SCCmecVl which contains ccrAB4 has been described which is structurally similar to SCCwecIV
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7.1 Results
7.1.1 Molecular characterisation of the false negative isolates
7.1.1.1 Pulsed field gel electrophoresis
Pulsed field gel electrophoresis was performed on the four MRSA isolates: 17, 18, 19 
and 20 which were not amplified with the PCR-A and PCR-B assays and the five 
isolates: 21, 22, 18, 7 and 8  which were not amplified with the PCR-C assay (isolate 18 
was not amplified in all three assays).
The PFGE patterns of the four PCR-A and PCR-B false negative isolates were either 
identical or differed by a single band (see identical patterns of 17, 18 and 19, 20 in 
Figure 7.1a). In comparison to the PFGE pattern of the EMRSA-15 reference strain, 
isolates 17 and 18 had a 5-band difference and isolates 19 and 20 had a 6 -band 
difference (see Figure 7.1a). Since these isolates depicted < 6  band differences to the 
EMRSA-15 reference strain this indicated that they were related to this strain, according 
to the Tenover et al. (1995) criteria. The PFGE patterns of isolates 17 and 18 were 
termed EMRSA-15.2 and those of isolates 19 and 20 were termed EMRSA-15.2i.
The PFGE patterns of the PCR-C false negative isolates (21, 22, 18, 7 and 8 ) were 
diverse. Isolate 21 had a 3-band difference to the PFGE pattern of the EMRSA-16 
reference strain whereas isolate 22 had a 3-band difference to the PFGE pattern of the 
EMRSA-15 reference strain, indicating that these isolates were closely related to the 
respective reference strains (see Figure 7.1b). The PFGE patterns of isolate 21 and 22 
were termed EMRSA-16ii and EMRSA-15.H respectively (isolate 18 was related to the 
EMRSA-15 reference strain). The remaining two PCR-C false negative isolates (7 and 
8 ) had PFGE patterns which were dissimilar to the other isolates and the EMRSA-15 
and EMRSA-16 reference strains, indicating that they were unrelated to all of the strains 
(see Figure 7.1b).
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Figure 7.1. PFGE patterns of the false negative isolates (compiled from different gels), 
a. M, lambda DNA Marker; A, EMRSA-15 reference strain; PCR-A and PCR-B 
isolates 17, 18, 19 and 20. b. M, lambda DNA Marker; A, EMRSA-15 reference strain; 
PCR-C isolates 22 and 18; B, EMRSA-16; PCR-C isolates 21, 7 and 8.
7.1.1.2 spa typing of false negative isolates
Isolates 17, 18 and 20 exhibited spa type t4424 whereas 19 depicted spa type t032. 
These spa types are closely related albeit the presence of repeat r31 in t4424 in contrast 
to r23 in t032. The r31 repeat sequence (AAAGAAGATGGCAACAAACCTGGC) 
differs from the r23 sequence (AAAGAAGACGGCAACAAACCTGGC) by one 
nucleotide at position 9. The spa types of the four PCR-A and PCR-B false negative 
isolates were also closely related to the spa type of the EMRSA-15 reference strain 
(t025), indicating that these were EMRSA-15 strains, as previously ascertained by 
PFGE (see Table 7.6). In contrast, the spa types of the PCR-C false negative isolates 
(21, 22, 7, 8 and 18) were more diverse: tO 18, t032, t437,11778 and t4424 respectively. 
The spa types of isolate 22 (t032) and 18 (t4424) were also closely related to the spa 
type of the EMRSA-15 reference strain whereas the spa type of isolate 21 (tO 18) was 
identical to the spa type of the EMRSA-16 reference strain. The unique spa types of 
isolates 7 and 8 showed that these isolates were unrelated to the other isolates and the 
reference strains. Therefore both the PFGE and spa typing results revealed that the four 
PCR-A and PCR-B false negative isolates were EMRSA-15 strains whereas the PCR-C 
isolates were a mixture of EMRSA-15 and EMRSA-16 strains and diverse MRS A 
strains.
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7.1.1.3 SCCmec typing of false negative isolates
The four PCR-A and PCR-B false negative isolates (17, 18, 19 and 20) and the 
EMRSA-15 and EMRSA-16 reference strains were successfully typed with the 
Milheirico et al. (2007b) assay. The four isolates and the EMRSA-15 reference strain 
exhibited all the SCCmec type IV fragments (mecA, 162 bp; ccrB2, 311 bp and dcs, 342 
bp) and were defined as MRSAIV strains (see Table 7.4). The five PCR-C isolates (18, 
21, 22, 7 and 8 ) were more diverse, only isolate 21 exhibited all o f the SCCmec type II 
fragments like the EMRSA-16 reference strain, whereas isolate 22 (and 18) depicted the 
SCC mec type IV fragments, thus these isolates were defined as MRSA II and MRSA IV 
strains. Isolates 7 and 8  exhibited only two of the three SC Cmec type V fragments: ccrC 
(449 bp) and mecA (162 bp) whereas the SCC mec type V J1 fragment was not 
amplified, so they were provisionally defined as MRSAV strains (refer to section 4.1.4). 
With the MPCR-1 and MPCR-2 assays the isolates exhibited the expected SCCmec type 
V fragments: ccrC  (518 bp) and mecA (286 bp) with MPCR-1 and mecA-\S>431 (804bp) 
with MPCR-2. However due to the absence o f the SCC mec type V J1-fragment, these 
isolates could not be conclusively regarded as MRSAV strains (see Table 7.4 and 7.5).
Table 7.4. SCCmec typing results o f PCR-A, PCR-B and PCR-C false negative isolates 
with the Milheirico et al. (2007b) method_________________________________________
mec A
162bp
SCCmec types I to V loci 
m ecl III J1 kdp ccrB2 dcs V- J1 III J3
209bp 243bp 284bp 31lbp 342bp 377bp 414bp
ccrC
449bp
pis Type
495bp
PCR-A and PCR-B false negative isolates
17 + + + IV
18* + + + IV
19 + + + IV
20 + + + IV
PCR-C false negative isolates
21 + + + + + II
22 + + + IV
7 + none + V?
8 + none + V?
* Isolate 18, was a false negative for all three assays; none- expected product not amplified
Table 7.5. Results of isolate 7 and 8 with MPCR-1 and MPCR-2 assays
mec A ccrA lB l ccrA2B2 ccrA3B3 
286bp 695bp 937bp 1791bp 
Isolate 7 and 8 +
ccrA4B4
1287bp
ccrC
518bp
+
mecA-mecJ mecA-\S1272 mecA-lS431
1963bp 2827bp 804bp
Isolate 7 and 8  +
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7.1.1.4 A n tib io tic  su scep tib ility  te s tin g  o f  th e  fa lse  n eg a tiv e  iso la tes
Antibiotic susceptibility testing was performed with the BD Phoenix on all the false 
negative isolates and the EMRSA-15 and EMRSA-16 reference strains. All four PCR-A 
and PCR-B isolates exhibited resistance to the same non p-lactam antibiotics: 
ciprofloxacin, erythromycin, and fusidic acid (see Table 7.6). Even though these isolates 
were determined to be EMRSA-15 strains by PFGE and spa typing, their multiple 
antibiotic resistance profile was in contrast to the EMRSA-15 reference strain which 
was largely susceptible to non p-lactam antibiotics i.e. depicting resistance to 
ciprofloxacin only. The five PCR-C isolates (21, 22, 7, 8  and 18) had variable resistance 
to non p-lactam antibiotics i.e. ciprofloxacin (n=4), erythromycin (n=4), fusidic acid 
(n=2), trimethoprim (n=2) and tetracycline (n=l). Isolates 21 and 22 were determined to 
be EMRSA-16 and EMRSA-15 strains by PFGE and spa typing and exhibited narrow 
resistance profiles similar to the reference strains i.e. resistance to ciprofloxacin (and 
erythromycin). Interestingly, isolate 7 and 8  which had unique PFGE and spa type were 
resistant to more non p-lactam antibiotics than the other isolates. Notably isolate 7 was 
an unusual strain because it was mecA positive by PCR but was oxacillin susceptible 
and was resistant to clindamycin, erythromycin, tetracycline and trimethoprim. Isolate 8  
had resistance to ciprofloxacin, erythromycin, fusidic acid and trimethoprim (see Table
7.6).
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7.1.2 M olecular characterisation of the false positive isolates
7.1.2.1 Pulsed field gel electrophoresis
Seven MSSA isolates were amplified with the PCR-A and PCR-B assays i.e. 23, 24, 25, 
26, 27, 28 and 16 and nine MSSA isolates were amplified with the PCR-C assay i.e. 29, 
30, 31, 32, 33, 34, 35, 36 and 16 (isolate 16 was amplified in all three assays). The 
PFGE patterns o f five (isolates 24, 25, 26, 27 and 28) of the seven PCR-A and PCR-B 
false positive isolates had some degree of similarity i.e. a <6 band difference, indicating 
that these isolates were possibly related (see Figure 7.2a). The PFGE patterns of isolates 
24, 25, 26, 27, and 28 were termed PFGE-l.i, PFGE-l.ii, PFGE-l.iii, PFGE-l.iv and 
PFGE-l.v respectively. In contrast, only two (isolates 31 and 33) o f the seven PCR-C 
false positive isolates exhibited patterns which were identical (termed PFGE-3) whereas 
the remaining five isolates had diverse patterns (>7 band difference), indicating that 
only two of the PCR-C false positive isolates were related and the majority of the 
isolates were unrelated (see Figure 7.2b).
The PFGE patterns of the false positive isolates were different to PFGE patterns of the 
EMRSA-15 and EMRSA-16 reference strains, except for isolate 16 which had <3 band 
difference to the EMRSA-15 reference strain pattern, illustrating that this MSSA isolate 
was closely related to the EMRSA-15 reference strain and the PFGE pattern of isolate 
16 was termed EMRSA-15.1.4 (see Figure 7.1c).
( a )  ( b )
M 23 24 25 26 27 28 29 30 31 32 33 34 35 36
! 9 1 . 0 k b
2 4 2 . 5 k b  - \  
1 9 4 . 0 k b J
1 4 5 . 5 k b  J  
9 7 . 0 k b H  
4 8 . 5 k b J
M A 16
Figure 7.2. PFGE patterns of the false positive isolates (compiled from different gels), 
a. M, lambda DNA Marker; PCR-A and PCR-B isolates 23, 24, 25, 26, 27, and 28. b. 
M, lambda DNA Marker; PCR-C isolates 29, 30, 31, 32, 33, 34, 35 and 36. c. M, 
lambda DNA Marker; A, EMRSA-15 reference strain; isolate 16.
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7.1.2.2 spa ty p in g  o f  fa lse positive  iso la tes
The spa types o f the false positive isolates also revealed that the PCR-A and PCR-B 
isolates were genetically related in contrast to the more diverse PCR-C isolates. The 
five PCR-A and PCR-B false positive isolates (24, 25, 26, 27 and 28) that had exhibited 
PFGE patterns with some degree o f similarity also had identical spa types or closely 
related types. Isolates 25, 26 and 28 had spa type tl27  whereas 24 and 27 had spa types 
tl381 and t559 which were related variants of tl27  (see Table 7.7). The tl381 spa type 
differs from tl27  by the presence o f the terminal r34 sequence 
(AAAGAAGACAACAAAAAACCTGGT) which differs from the rl 3 sequence 
(AAAGAAGACAACAACAAACCTGGT) by one nucleotide at position 15. Whereas 
t559 differs from tl27  by three deleted repeat sequences (rl6-r34-r33). Only the two 
PCR-C isolates (31 and 33) which had identical PFGE patterns had related spa types i.e. 
t216 and t471. These differed by the presence o f repeat r20 in t216 versus r02 in t471. 
The r20 repeat sequence (AAAGAAGACAACAACAAACCTGGC) differs from the 
r02 sequence (AAAGAAGACAACAAAAAACCTGGC) by one nucleotide at position
15.
T a b le  7.7 Genotypic characteristics o f false positive isolates by PFGE and spa tying
P C R -A  a n d  P C R -B  fa lse p o sitiv e  iso la tes
Iso la te P F G E  p a t te rn spa ty p e spa re p e a t
23 PFGE-2 tl 778 26-23-21-17-13-34-16-34-33-13
24 PFGE-l.i tl 381 07-23-21-16-34-33-34
25 PFGE-l.ii tl27 07-23-21-16-34-33-13
26 PFGE-l.iii tl27 07-23-21-16-34-33-13
27 PFGE-l.iv t559 07-23-21- - - -13
28 PFGE-l.v tl27 07-23-21-16-34-33-13
16* EMRSA-15.1.4 t0 2 2 26-23-13-23-31 -29-17-31 -29-17-25-17-25-16-28
P C R -C  fa lse  p o s itiv e  iso lates
Iso la te P F G E  p a t te rn spa ty p e spa re p e a t
31 PFGE-3 t216 04-20-17-20-17-31-16-34
33 PFGE-3 t471 04-02-17-20-17-31-16-34
29 Unique t3 11 26-23-17-34-20-17-12-17-16
30 Unique t089 04-33-31-12-16-34-16-12-33-34
32 Unique t917 09-02-16-34-13-13-17-34-16-34
34 Unique t587 14-12-23-02-02-34-34
35 Unique t091 07-23-21 -17-34-12-23-02-12-23
36 Unique tOO 8 11-19-12-21-17-34-24-34-22-25
* Isolate 16, false positive of all three PCR-A, PCR-B and PCR-C assays
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7.1.2.3 SC C w tfc ty p in g  o f fa lse  p o sitiv e  iso la tes
The amplification o f MSSA isolates with the PCR-A, PCR-B and PCR-C SCCmec-orJX 
assays indicated the presence o f the right SCC/wec-chromosome junction, attR. Despite 
the lack o f mec A, the detection o f attR in these isolates suggested the possible presence 
o f SCC elements (elements lacking mecA) or remnant SCCmec elements resulting from 
an imprecise excision. The Milheirico et al. (2007b), MPCR-1 (ccr complex) and 
MPCR-2 {mec complex) typing assays were performed to detect any SCCmec 
associated loci in the isolates. Only four (isolates 16, 29, 30 and 35) yielded PCR 
fragments and the mec A fragment was not exhibited in any of the isolates. With the 
Milheirico et al. (2007b) assay, only isolate 16 yielded a single 342 bp fragment 
corresponding to the expected size o f the dcs fragment which is present in SCC mec 
types I, II and IV, no further fragments were attained with the other typing assays (see 
Figure 7.3a). Isolates 29, 30 and 35 (PCR-C false positive isolates) yielded a single 
fragment with the MPCR-1 assay but none with the Milheirico et al. (2007) and MPCR- 
2  assays:
i) Isolate 29 - 1 287 bp fragment (ccrAB4), see 29 in Figure 7.3b.
ii) Isolate 30 - 695 bp fragment (ccrAB 1), see I and 30 in Figure 7.3b.
iii) Isolate 35 - 518 bp fragment (ccrC), see V and 35 in Figure 7.3b.
To verify that the fragments were not non-specific amplification products resulting from 
the multiplex PCR procedures, the assays were repeated independently using single 
pairs o f primers for ccrAB 1, ccrAB4, ccrC and dcs respectively. MRSA reference 
strains containing SCC mec types I (NCTC10442), IVb (JCSC1978) and V (WIS) were 
also included as positive controls for the amplification o f ccrABl, dcs and ccrC 
respectively. An MRSA strain containing a SCC mec type VI which harbours ccrAB4 
was not available, thus the expected size (1 287 bp) of the ccrAB4 fragment was used 
for verification. Isolates 16, 29, 30 and 35 yielded the same results as initially observed 
and it was concluded that the PCR fragments were due to specific amplification of 
existing SCCmec associated sequences harboured in these isolates:
i) 342 bp fragment (dcs) - see IVb and 16 in Figure 7.4
ii) 1 287 bp fragment (ccrAB4) - see 29 in Figure 7.4
iii) 695 bp fragment {ccrABl) -  see I and 30 in Figure 7.4
iv) 518 bp fragment {ccrC) -  see V and 35 in Figure 7.4
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a)
M I II III IVb V 16
b)
M I II III IVb V 29 30 35
500bp-
300bp-
200bp-
2 u0 0 bp-
lOOObp-
500bp-
2 0 0 bp-
-ccr.-L34'-12S bp
-£,cr.l5/~695bp 
-ccrC-5 ISbp
■wer.4'2S6bp
Figure 7.3. PCR fragments of the SCCmec typing assays in MRSA reference strains 
and false positive isolates, (a) Milheirico et al. (2007) fragments. M, lOObp molecular 
marker; I, II, III, IVb, V- MRSAI, MRS All, MRSAIII, MRSAIVb, MRSAV; 16, isolate
16. (b) MPCR-1 fragments M, lkb molecular marker; I, II, III, IVb, V- MRSAI, 
MRSAII, MRSAIII, MRSAIVb, MRSAV; isolates 29, 30, 35.
1 5 0 0 b p  
lOOObp 
7 0 0 b p  
5 0 0 b p
3 0 0 b p
M l l V b V
B ■
-ccrA34 ~ 1 2 S  bp
-ccrABi ~ 6 9 5 b p  
■ccrC - 5 1  Sbp
- dcz' ' 3  4 2 bp
Figure 7.4. PCR fragments of the MPCR-1 assay in MRSA reference strains and false 
positive isolates. M, lOObp molecular marker; I, IVb, V- MRSAI, MRSAIVb and 
MRSAV; Isolates 35, 30, 16 and 29.
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7.1.2.4 Investigation of SCC mec associated DNA in false positive isolates
SCCmec elements integrate at attB which is located at the 3’ terminus o f orfX. This site 
comprises a conserved 15 bp sequence (TTATGATACGCCTC) which is duplicated at 
the other end of the element during insertion, thus generating direct repeats which flank 
the left and right ends (see Figure 7.6). Degenerate inverted repeats are also formed at 
the left and right SC Cmec boundaries, thus the left and right chromosome-SCCmec 
junctions are characterised by direct (attB-L and attB-R) and inverted repeats and are 
referred to as atiL  and attR  respectively (see Figure 7.5 and 7.6). When the element is 
excised the attB site is reconstituted in the chromosome and the ends o f the SCC mec 
element combine forming a circular version of the element (Wang and Archer, 2010, Ito 
et al., 2004, Ito et al., 2001).
The further detection o f ccrABl, ccrAB4, ccrC and dcs in the four MSSA isolates, 
implied the possible presence of SCC elements (elements lacking mecA) or remnant 
SCCmec elements and this was investigated by undertaking efforts to amplify the 
sequence from the left to the right SCCmec-chromosome junctions (see figure 7.5). 
Three respective forward primers located upstream o f attB-L  in MRSAI, II, IVa, IVb, 
IVc strains and a single reverse primer (cR2) located in orjX  (Jansen et al. 2006, 
Katayama et al. 2000) were employed for this study and the MRSAI, II, MRSAIVb and 
MRSAIVc reference strains were also included. A long range high fidelity PCR kit 
(Roche) was used, the fragments were resolved in a 1% agarose gel and then sequenced.
i) Forward primer, cLl {attB-L o f MRSAI, II and IVb) and reverse primer cR2
ii) Forward primer, E3 {attB-L o f MRSAIVc) and reverse primer cR2
iii) Forward primer, E4 {attB-L o f MRSAIVa) and reverse primer cR2
F ’ prim er (cL l, E3 or E4)
i_i* //
anB-L aoSCC-L 
attL
Figure 7.5. A schematic diagram o f the left {attL) and right {attR) SCCmec- 
chromosome junctions and the locations o f the forward and reverse primers (Katayama 
et al., 2 0 0 0 ).
attR
<iffSCC-R gtztB-R
T
R ’ prim er (cR2)
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Regrettably the attempts to amplify the sequence spanning from attL to attR  were 
largely unsuccessful and no PCR fragments were obtained with the PCR-A and PCR-B 
false positive isolates and the MRSA reference strains (including isolates 16, 29, 30 and 
35 which had previously yielded the dcs, ccrAB4, ccrABl and ccrC fragments). Three 
o f the nine PCR-C isolates (32, 34 and 36) yielded relatively small fragments:
i) Isolate 32: approximately 600 bp fragment with E4 and cR2 primers
ii) Isolates 34, 36: approximately 550 bp fragment with cLl and cR2 primers
The complete SCCmec type I to V elements are considerably large (ca. 20-60 kb) thus 
the failed amplification o f a PCR fragment in the MRSAI, II, IVb and IVc reference 
strains was plausible as the PCR assay employed in this study had an amplification limit 
o f 10 kb. Therefore it is also likely that in the false positive isolates, in which no 
fragment was attained, a SCC element or remnant SCC mec may have been present but it 
was larger than lOkb and thus the PCR conditions were inadequate for successful 
amplification of the entire sequence.
The small fragments o f isolate 32, 34 and 36 (600 bp, 550 bp and 550 bp respectively), 
implied that either the attB site did not contain SCCmec associated sequences or that the 
existent sequences were short. The amplified fragments were sequenced and the 
sequences were compared to published ones in Genbank with the NCBI BLAST 
programme. Those of isolates 34 and 36 (549 nucleotides) were highly similar albeit 
five nucleotide differences and they were homologous (99%) to a region (nucleotides 
33685 to 34232) in the S. aureus Newman DNA/ AB009351 (see Figure 7.7). This 
region comprised attB and the sequences upstream and downstream of this site. Notably 
the S. aureus Newman strain does not harbour SCC mec or SCC elements and so this 
also indicated that isolates 34 and 36 did not contain SCCmec remnant sequences or 
SCC elements. However the sequences o f isolate 34 and 36 were also homologous 
(99%) to two regions in the NCTC10442, N315, and JCSC1978 MRSA strains which 
harbour AB033763/ SCC mec type I, D86934/ SC Cmec type II and AB063173/ S CCmec 
type IVb, respectively. Furthermore the sequence o f isolate 32 (597 nucleotides) was 
homologous to two regions in the CA05 and WIS MRSA strains (99% and 96% 
homology respectively) which carry the AB063172/ SCC mec type IVa and A B121219/ 
SCC mec type V elements (see Figure 7.8).
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4
The sequences o f isolates 32, 34 and 36 were homologous to sequences outside of the 
SCCmec elements which did not include the terminal inverted repeats or other 
characteristic SC Cmec loci which are internally located in the elements e.g. 
recombinase genes {ccrAB or ccrC). For instance in the AB063172/ SCCmec type IVa 
sequence, the first 129 nucleotides o f the isolate 32 sequence aligned to a region 
upstream of the left chromosome-SC Cmec junction, extending up to the end of attB-L 
and nucleotides 130 to 597 aligned to a region downstream o f the right SCCmec- 
chromosome junction (see CA05/AB063172/ SC Cmec type IVa in Figure 7.9). In 
SCCmec type V, nucleotides 20 to 128 o f isolate 32 aligned to a sequence upstream of 
the left chromosome-SCCmec junction, extending up to the end o f attB-L  and 
nucleotides 129 to 597 aligned to the sequence downstream of the right SCCmec- 
chromosome junction (see WIS/AB121219/ SCCmec type V in Figure 7.9). Similar 
results were observed with isolates 34 and 36, the sequences aligned to regions 
exclusively outside of the left and right junctions o f SC Cmec type I, II and IVb 
elements (see AB033763/ SCC mec type I and D86934/ SCC mec type II in figure 6A.12, 
since the sequences o f isolate 34 and 36 aligned to identical positions, only isolate 34 is 
shown in Figure 7.9).
Even though attB-L  was detected, the lack o f detection o f inverted repeats indicated that 
the left and right boundaries of SCC mec were not present in isolate 32, 34 and 36. 
These results indicate that the sequences o f isolates 32, 34 and 36 (597 nt, 545 nt and 
545 nt respectively) do not harbour remnant SCCmec or SCC elements rather they 
comprise an unoccupied attB site and the sequences upstream and downstream of this 
site. The sequences of isolates 34 and 36 are homologous to the attB site and adjacent 
sequences o f the S. aureus Newman MSSA strain. The alignment of the sequences to 
regions outside of the SC Cmec elements in the MRSA strains (NCTC10442, N315, 
CA05, JCSC1978 and WIS) suggests that isolates 32, 34 and 36 contain attB and 
adjacent sequences which are also homologous to the attB and adjacent sequences of 
certain S. aureus strains which subsequently acquired SCCmec types I (AB033763), II 
(D86934), IVa (AB063172), IVb (AB063173) and V (AB121219) elements (see Figure
7.6).
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6
The lack of detection of any remnant SCC mec sequences in isolates 32, 34 and 36 is 
seemingly contradictory to initial results which showed that these isolates were 
amplified with the PCR-C SCCmec-orfiC assay, which is based on the detection o f the 
right SCC/wec-chromosome junction. It was previously shown (presented in chapter 5) 
that the PCR-C forward primer had up to two mismatches to enable the detection of 
SCC mec types I, III and V however consequently there were identical regions in two 
published MSSA strains i.e. the S. aureus Newman and S. aureus RF122 strains (see 
Table 7.8). This indicated that this method could potentially amplify both MRSA and 
MSSA strains. Evidently the target sequences for the PCR-C primers were also present 
in isolates 32, 34 and 36 demonstrating that the amplification o f these clinical MSSA 
isolates was not due to the presence o f a remnant SCCmec-orfiC junction but rather 
chromosomal sequences which contain the PCR-C primer binding sites (see Figure 7.7, 
7.8 and Table 7.8).
Table 7.8. PCR-C forward primer binding site in sequences of SCCmec type I, III, V 
and MSSA strains
Accession num ber / SCCmec type Sequence Position
PCR-C forward oligonucleotide TATGATATGCTTCTCC --
AB033763 (SCCmecI)/NCTC10442 T AT GAT A AGCTT CT CC 38855 -38870
AB037671 (SCC/wecIII) T AT GAT A CGCTT CTCC 67782 - 67797
AB121219 (SCCmecV)/ WIS T AT GAT ACGCCTCTCC 892 - 877
AP009351 (S. aureus Newman) T AT GAT ACGCCT CTCC 34392 - 34377
AJ938182 (S. aureusRF\22) T AT GAT ACGCCTCTCC 34166-34151
Isolate 32 (clinical isolate, this study) T AT GAT ACGCCT CTCC 116-131 (figure 7.8)
Isolate 34 (clinical isolate, this study) T AT GAT ACGCCT CTCC 68 - 83 (figure 7.7)
Isolate 36 (clinical isolate, this study) T AT GAT ACGCCT CTCC 68 - 83 (figure 7.7)
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7.1.2.5 A n tib io tic  su scep tib ility  te s tin g  o f  th e  fa lse  positive  iso la tes
Antibiotic susceptibility testing was performed with the BD Phoenix on all the PCR-A, 
PCR-B and PCR-C false positive isolates and collectively the isolates were resistant to 
penicillin and all except one were resistant to trimethoprim (see Table 7.7). Only three 
isolates (23, 26 and 29) exhibited resistance to >3 classes o f non p-lactam antibiotics: 
isolate 23 was resistant to ciprofloxacin, erythromycin, fusidic acid and trimethoprim; 
isolate 26 was resistant to ciprofloxacin, fusidic acid, tetracycline and trimethoprim; 
isolate 29 was resistant to ciprofloxacin, erythromycin, and trimethoprim. The 
remaining isolates had narrow resistance profiles and only a few were resistant to 
erythromycin (n=2 ), ciprofloxacin (n=l), fusidic acid (n=l) and gentamicin (n=l).
The clinical history o f the patients from whom the fifteen isolates were identified was 
investigated in order to ascertain if  MRSA isolates had been previously or later reported 
from the same patients. The information was retrieved from the Public Health Wales 
(PHW) Microbiology ABM Laboratory data management system (see Table 7.9). In 
thirteen o f the fifteen cases there were no previous or later reports o f MRSA from the 
patients and in six of these cases, there seemed to be no prior or later submissions of 
wound specimens to the PHW microbiology lab. However in two cases i.e. isolate 16 
and 25, MRSA had been reported in the PHW microbiology data management system. 
In the case of isolate 16, it had been reported as an MRSA and there was considerable 
history (ten months) o f intermittent reports of MRSA from the patient, including about 
four months prior and two months after isolate 16 was reported. In the case of isolate 
25, an MRSA isolate was reported from the patient 5 months after isolate 25 was 
reported.
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7.2 Discussion
The SCCmec-orfXjunction presents an ideal genetic marker for methicillin resistance in 
S. aureus and the amplification of this junction signifies detection o f MRSA. However, 
eight MRSA and fifteen MSSA isolates had false negative and false positive results 
with PCR-A, PCR-B and PCR-C SCCmec-orJX amplification assays and this provided 
an opportunity to determine the genotypic characteristics o f these atypical clinical 
isolates by performing PFGE, spa tying and SCCmec typing assays.
Both PFGE and spa typing revealed that five o f the eight false negative MRSA isolates 
(isolate 17, 18, 19, 20 and 22) were EMRSA-15 strains which harboured the SCCmec 
type IV element whereas isolate 21 was an EMRSA-16 strain which contained the 
SCCmec type II element. EMRSA-15 and EMRSA-16 are dominant hospital acquired 
MRSA clones in the UK therefore these results imply that despite the capacity o f the 
PCR-A, PCR-B and PCR-C methods to detect diverse MRSA strains, certain local 
endemic strains may be undetected with these assays (Rollason et al., 2008, Johnson et 
al., 2005). The two remaining isolates (7 and 8 ) were PCR-C false negative isolates 
which were unrelated to EMRSA-15 and EMRSA-16 reference strains. These isolates 
contained SCC mec elements that seemed to have some similarity to the S CCmec type V 
element harboured in the MRSAV WIS reference strain (refer to section, 4.1.4 in 
chapter 4). Previously it had been observed the PCR-C assay did not robustly amplify 
the MRSAV WIS strain (results presented in chapter 5) thus it is likely that isolates 7 
and 8  were not adequately amplified due to the carriage o f an SCCmec element which is 
similar to the one contained in the MRSAV WIS strain.
On the other hand with the PCR-A and PCR-B methods isolates 7 and 8  were 
successfully amplified even though the MRSAV WIS strain had not been amplified 
with both assays. A previous examination of the primer sequences o f these methods 
demonstrated that they were not specific for the SC Cmec type V/ AB121219 element 
contained in this strain (refer to section 5.1.1, chapter 5). Therefore this further suggests 
that the SCCmec elements harboured in isolates 7 and 8  may be similar but not identical 
to the S CCmec type V element of the MRSAV WIS strain.
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SCCmec-associated loci i.e. dcs, ccrABl, ccrAB4 and ccrC, were detected in four (16, 
29, 30 and 35) of the fifteen false positive MSSA isolates. The detection o f SCC mec 
associated DNA in MSSA isolates has also been described in several other studies 
(Bartels et al., 2009, Shore et al., 2008, Donnio et al., 2007, Rupp et al., 2006, Donnio et 
al., 2005, Corkill et al., 2004, Huletsky et al., 2004). Although the dcs locus 
(downstream constant segment) was detected in isolate 16, it is typically located 
downstream of mecA and closely mapped to orfX  in SCCmec types I, II and IV 
(Oliveira and de Lencastre, 2002, Oliveira et al., 2000). The detection of dcs in MSSA 
strains has also been described by Shore et al. (2008), Donnio et al. (2007, 2005) and 
Corkill et al. (2004). Since the MSSA in these studies had genetic backgrounds which 
were indistinguishable to prevalent local HA-MRSA strains, the authors concluded that 
the MSSA had emanated from the local HA-MRSA strains. Similarly in this study, the 
PFGE pattern and spa type o f isolate 16 (EMRSA-15.1.4 and spa type t022) indicated 
that it was closely related to the EMRSA-15 reference strain. Therefore it is likely that 
isolate 16 resulted from the imprecise excision of a SCC mec type IV element from a 
local EMRSA-15 strain and consequently a fragment containing the dcs locus remained 
in this isolate. Since dcs is typically just upstream of orjX, it is plausible that the 
remnant fragment constituted the right SCCmec-orfiC junction and resulted in the 
detection of isolate 16 by the PCR-A, PCR-B and PCR-C assays. In the studies by 
Shore et al. (2008) and Donnio et al. (2007) they were able to confirm that the dcs locus 
was located in SCC mec fragments in the MSSA isolates with various PCR and DNA 
sequencing experiments. Disappointingly in this study attempts to amplify possibly 
existent SCCmec remnants were unsuccessful and thus the actual location of dcs and the 
other detected loci i.e. ccrABl, ccrAB4 and ccrC  was not established.
The integration and excision of SCC mec type I to V elements is mediated by site- 
specific recombinases which are encoded by ccr gene complexes located within 
SCCmec. Non-mecA SCC elements contained in certain S. aureus strains e.g. SCCcqpl, 
SCC4 7 6  also contain recombinase genes and it is postulated that these genes have the 
same role in these elements (Hanssen and Sollid, 2006). The ccrABl locus which was 
detected in isolate 30, is typically located in SCC mec type I elements carried by MRSA 
I strains. However, Corkill et al. (2004) detected ccrABl in MSSA clinical isolates 
which were fusidic acid-resistant and these had been isolated from patients with 
bacteraemia, initially caused by fusidic acid-resistant MRSA. They ascertained
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indistinguishable genetic backgrounds of the MSSA and MRSA and concluded that the 
MSSA emanated from the MRSA. It is tempting to draw similar implications in this 
study and assume that the ccrABl in isolate 30 resulted from a previous excision of a 
SCCmec type I element from a MRSA I strain or from the presence of a non mecA SCC 
element. However the location o f this locus with respect to SCCmec-orfX right junction 
could not be established and thus these propositions cannot be verified.
The detection o f ccrAB4 in isolate 29 was performed with oligonucleotides by Kondo et 
al. (2007) based on the ccrAB4 sequence o f the HDE288 strain. This is a prototypic 
strain o f a dominant paediatric MRSA clone in Portugal which was subsequently re­
defined as MRSA VI due to the novelty o f the recombinase genes harboured in the 
SCC mec element o f this strain (Oliveira et al., 2006). However, subsequently Shore et 
al. (2008) also identified the ccrAB4 gene in several MSSA isolates. The gene was 
located in chromosomal regions outside of residual fragments of SCCmec type II 
variants and it was 100% homologous to ccrAB4 harboured in SCC-CI, a composite 
island in the S. epidermidis ATCC 12228 strain. Another ccrAB4 allotype has been 
identified in MRSA clinical isolates containing the SCCmecNl element, identified in 
intravenous drug users in Switzerland (Ender et al., 2007). These studies indicate that 
there are various ccrAB4 allotypes in diverse staphylococci genetic backgrounds and 
they are not restricted to intact or residual SC Cmec elements. Thus the detection of 
ccrAB4 in isolate 29 does not necessarily imply that this isolate emanated from a MRSA 
strain because it is possible that ccrAB4 is innate to the chromosome o f this isolate.
A single MSSA (isolate 35) isolate yielded a PCR product for ccrC which is typically 
located in the SC Cmec type V element. The detection o f ccrC in MSSA has been 
described by Chlebowicz et al. (2010). They identified isogenic MRSA and MSSA 
isolates o f the ST398 lineage (a veterinary clone) in a mother and child who suffered 
from pneumonia and an umbilicus infection, respectively. Interestingly the generation 
o f the MSSA isolate was not from the excision o f the SCCmec but rather from the loss 
o f the mecA gene complex during recombination o f two ccrC allotypes within the 
SCC mec type V element o f the MRSA strain (Chlebowicz et al., 2010). In this study no 
other SCC mec type V loci were detected in the isolate 35, thus it is unlikely that a 
significant fragment o f the SCC mec type V element was present in this isolate.
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Five of the false positive MSSA isolates in this study had similar PFGE patterns 
(termed PFGE-l.i, PFGE-l.ii, PFGE-1.iii, PFGE-l.iv and PFGE-l.vi) and spa types 
which were close variants o f spa type tl27. However collectively the fifteen false 
positive isolates were genetically diverse and were also unrelated to the local HA- 
MRSA clones i.e. EMRSA-15 and EMRSA-16. This variability and the detection o f the 
different SCCmec associated loci i.e. dcs, ccrABl, ccrAB4, ccrC, could suggest that 
independent excision events in diverse MRSA genetic backgrounds may have occurred 
and yielded these MSSA isolates. However there is greater diversity o f SCCmec loci i.e. 
ccr allotypes in coagulase-negative staphylococci (CoNS) and these species are thought 
to harbour the SCCmec reservoir. Even though the specific mechanism o f transfer 
between strains is not well understood, it is postulated that S. aureus acquire SCCmec 
and SCC like elements from CoNS species (Garza-Gonzalez et al., 2010, Ruppe et al., 
2009, Hanssen and Sollid, 2007). So it is also likely that the MSSA isolates in this study 
could have acquired the SC Cmec associated loci from CoNS strains and not necessarily 
from MRSA.
Several attempts to determine the extent o f presumed SCC mec remnants in the false 
positive MSSA isolates were largely unsuccessful and only three isolates yielded PCR 
products which were actually the unoccupied attB  site and adjacent sequences to this 
site. It is possible that for the remaining twelve false positive isolates the anticipated 
remnant SC Cmec sequence exceeded the 10 kb amplification limit of the assay and 
were not adequately amplified. However it is also possible that the failure of 
amplification was due to non specificity o f the forward oligonucleotides. The ones used 
in this study were designed from sequences in the N315/ MRSA II, CA05/ MRSA IVa, 
JCSC1978/ MRSA IVb and MR108/ MRSAIVc strains. However Noto et a l  (2008) 
examined the attB site and adjacent sequences in 42 diverse MSSA isolates and several 
MRSA including COL/ MRSAI and MRSA252/ MRSA II and they found that the 
sequences upstream of the attB are heterogeneous in S. aureus srains (Noto et al., 
2008b). Therefore it is likely that the target sequences o f the forward oligonucleotides 
were not present in the twelve false positive MSSA isolates o f this study.
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MSS A originating from multi-antibiotic resistant MRS A have been shown to retain the 
initial resistance to non (3-lactam antibiotics (Shore et al., 2008, Donnio et al., 2005, 
Corkill et al., 2004). Donnio et al. (2005) verified that prevalent tobramycin resistant 
MSS A strains in French hospitals had originated from a dominant tobramycin resistant 
MRSA clone. Similarly Shore et al. (2008) and Corkill et al. (2004) also showed that 
MSSA emanating from gentamicin and fusidic acid resistant clinical MRSA strains, 
retained these resistance phenotypes after the SCCmec excision. Ellington et al. (2010) 
have shown that the dominant UK HA-MRSA strains: EMRSA-15 and EMRSA-16, 
have a narrow resistance profile and similarly in this study the EMRSA-15 and 
EMRSA-16 reference strains were largely susceptible to non p-lactam antibiotics, 
except to ciprofloxacin. Most o f the false positive MSSA isolates were also susceptible 
to non p-lactam antibiotics except for two isolates which were resistant to >3 non (3- 
lactam classes of antibiotics. Nevertheless because the genotypes o f most of the isolates 
were unrelated (except isolate 16) to the EMRSA-15 and EMRSA-16 reference strains 
this strongly suggests that they did not originate from these UK HA-MRSA strains. In 
addition a comparison o f the spa types o f these isolates to those o f the UK EMRSA-1 to 
14 strains (see Table 4.6b in chapter 4) demonstrated that they were unrelated, 
suggesting that they did not originate from these HA-MRSA strains either. Thirteen of 
the fifteen false positive isolates were from patients without previous or later reports of 
MRSA isolates and this also supports the notion that these MSSA isolates probably did 
not emanate from MRSA strains.
However isolate 16 is particularly interesting because like the EMRSA-15 reference 
strain this MSSA isolate was resistant to ciprofloxacin and the additional consideration 
o f the genotypic characteristics i.e. detection o f the SCCmec-orJX right junction and 
dcs, the PFGE pattern and t022 spa type, persuasively imply that isolate 16 was 
previously an EMRSA-15 strain which subsequently underwent partial excision of the 
SCCmec type IV element. For the purposes o f this study S. aureus cultures were 
collected from the PHW Microbiology ABM Laboratory on Iso-Sensitest media which 
had been used for susceptibility testing. Therefore the collection of the cultures may 
have occured 24 to 48 hours after completion o f the tests. It is possible that at the time 
o f collection from the patient and testing at the microbiology laboratory, isolate 16 
contained the complete element but at some time point leading up to the mecA and
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SCCmec-orJXFCR testing in this study, excision of the element occurred. It would have 
been possible to verify this by genotyping both the original cultures and the 
cryopreserved stocks subsequently prepared in this study. However this was not 
possible because the original Iso-Sensitest cultures were not retained and the cultures 
prepared from both of the stocks o f isolate 16 i.e. cryopreservation beads and glycerol 
stocks, were mecA negative.
Despite the robust capacity o f the PCR-A, PCR-B and PCR-C SCCmec-orJX assays for 
MRSA detection, a total of six EMRSA-15 and EMRSA-16 strains were undetected 
with these assays and two MRSA V strains were specifically undetected with the PCR- 
C assay, indicating that if  these assays are implemented as routine MRSA screening 
assays certain local endemic strains may remain undetected. However this may be an 
infrequent occurrence because the prevalence o f false negative results in this study was 
relatively low (3.4% to 4.2%, presented in chapter 5). The fifteen MSSA isolates which 
were detected with the three SCCmec-orfiC assays were extensively genetically diverse, 
indicating that a specific MSSA genetic background was not the underlying cause o f the 
false positive results. However these results do highlight that the amplification of the 
SCCmec-orfXjunction does not provide absolute verification o f MRSA presence.
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C h a p te r  E ig h t
M o lecu la r ep idem io logy  o f  P a n to n -V a le n tin e  L eu k o c id in -p o sitiv e  S. aureus iso lates
8.0 In tro d u c tio n
The pathogenicity of S. aureus is affiliated to its expression o f diverse virulence factors. 
These have various functions which enable strains to colonise host tissues and evade 
innate host defence mechanisms (DeLeo et al., 2009, Foster, 2005, Rooijakkers et al., 
2005). Recognition and phagocytosis by neutrophils and other phagocytes are critical 
defence strategies against invading microorganisms. However, S. aureus strains express 
toxins and phenol soluble modulin peptides which form pores in the cytoplasmic 
membrane o f targeted immune cells and cause subsequent lysis o f these cells (Foster, 
2005, Voyich et al., 2005). The alpha toxin is the archetype o f a family o f pore forming 
beta-barrel toxins that cause lysis o f different cell types including monocytes, platelets 
and erythrocytes (DeLeo et al., 2009, Foster, 2005, Valeva et al., 1997). Other members 
o f this family include bi-component toxins e.g. gamma toxin, leukocidin D/ E, the 
Panton Valentine-Leukocidin (PVL) and a PVL-like leukocidin M/ F (Foster, 2005). 
The PVL toxin mainly causes the lysis o f neutrophils and tissue necrosis. However ot- 
toxin and y-toxin are present in virtually all S. aureus strains whereas PVL is only 
expressed in 2 to 3% of strains (Loffler et al., 2010, Otto, 2010, Clark, 2008). 
Nevertheless certain S. aureus strains which carry PVL genes have caused extensive 
morbidity. For instance in the 1950’s and 1960’s the PVL-positive phage type 80/ 81 
strain was highly prevalent in the UK and caused severe infections in both the 
community and hospitals (Ellington et al., 2010a). The recent emergence o f CA-MRSA 
strains and the high prevalence of certain clones e.g. the USA300 clone in the USA is a 
public health concern. Several studies have demonstrated that the leading CA-MRSA 
clones have certain common genetic features e.g. carriage of SCCmec type IV or V 
elements and PVL genes. Furthermore certain clones such as USA300 and MW2 have 
been implicated in fatal infections like necrotising pneumonia and this has prompted the 
suggestion that PVL may have a role in the virulence o f CA-MRSA strains (Ito et al., 
2008, Hageman et al., 2006, Soderquist et al., 2006, CDC, 1999).
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In the UK it has been demonstrated that the prevalence o f PVL-positive S. aureus 
strains is relatively low at 1.6% - 4.9% and that these strains are polyclonal (Ellington et 
al., 2010b, Ellington et al., 2009, Otter et al., 2009, Holmes et al., 2005). However this 
information has been primarily obtained from investigations on isolates submitted to the 
UK Staphylococcus Reference Unit in Colindale. Since reference laboratories primarily 
receive selected isolates the results may not be a true representation of the epidemiology 
of PVL-positive S. aureus strains in the UK community. So in order to attain a more 
comprehensive insight it would be informative to also investigate the molecular 
epidemiology of unselected clinical isolates which are submitted to diagnostic 
laboratories as these may be more representative o f the epidemiology in the community.
Therefore the objective o f this study was to determine the prevalence of PVL genes in 
consecutive wound swab S. aureus isolates (n=519) from the PHW Microbiology ABM 
Laboratory (PHW-ABM). Genotyping o f the isolates was conducted with the following 
molecular typing methods: PFGE, spa typing, SCCmec typing and detection of the 
ACME element by PCR. Furthermore the molecular epidemiology of these PVL- 
positive isolates was compared to a second collection o f PVL-positive S. aureus isolates 
(n=61) from a reference laboratory, the Specialist Antimicrobial Chemotherapy Unit 
(SACU) in Cardiff.
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8.1 R esu lts
8.1.1 P rev a len ce  o f P V L  genes in  P H W -A B M  S. aureus iso lates
The prevalence o f PVL genes in 519 S. aureus isolates (MRSA n=118 and MSSA 
n=401) was investigated by real-time PCR and these were detected in a total o f nineteen 
isolates (3.7%). Out of the 118 MRSA isolates two (1.7%) were PVL-positive in 
comparison to seventeen (4.2%) o f the 401 MSSA (see Table 8.1). However there was 
no significant difference between the prevalence o f PVL in MRSA and MSSA isolates 
(p>0.05; two-tailed Fishers exact test).
T ab le  8.1 Prevalence o f PVL genes in clinical MSSA and M RSA
Iso la te P V L -p o sitiv e P V L -n eg a tiv e T o ta l
M R S A 2 (1.7%)’ 116(98.3%) 118
M SSA 17 (4.2%)* 384 (95.8%) 401
T o ta l 19 (3.7%) 500 (96.3%) 519
*(p>0.05; two-tailed Fishers exact test)
8.1.2. A na lysis  o f p a tie n t d em o g ra p h ics  a n d  c lin ica l in fec tio n s asso c ia ted  w ith  
P V L -p o sitiv e  S. aureus iso lates
Demographic data of the S. aureus isolates (n=519) was retrieved from the PHW 
Microbiology ABM Laboratory data management system and the gender or age data 
was not available in four cases. More than half (51.4%; 265/515) o f the S. aureus 
isolates were identified in individuals who were more >61 years o f age (see Table 8.2). 
Whereas 21.2% (109/515) were identified from individuals within 41 to 60 years; 
16.3% (84/515) were from individuals of 21 to 40 years and the least number of isolates 
(11.1%; 57/515) were identified from individuals who were <20 years o f age (see Table
8.2). There were significantly more PVL-positive S. aureus (11.9%; 10/84) identified in 
the young adult age-group (21 to 40 years) than from all o f the individuals (2.1%; 
8/374) who were >41 years o f age (p=0.0003; two-tailed Fishers exact test). This 
indicated that PVL-positive S. aureus were more associated with young adults than with 
older patients.
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Table 8.2. Patient demographics o f PVL-positive and negative S. aureus (n=519). 
MRSA (n=l 18) and MSSA (n=401) _____________________________
Age Gender Pathogen
(years) PVL-positive PVL-negative PVL-pos / neg PVL-pos
MRSA MSSA MRSA MSSA No. (%)
61+ Male 1 2 39 79
Female 0 0 40 104 3/ 262
41 to 60 Male 0 1 1 0 41
Female 0 4 13 40 5/104 8  (2 .1 %)*
21 to 40 Male 0 5 7 38
Female 1 4 3 26 10/74 10(11.9%)*
0  to 2 0 Male 0 0 1 31
Female 0 0 2 23 0 /5 7 0  (0 .0 %)
“TOTAL 2 16 115 382 18/497 18
*(p=0.0004; two-tailed Fishers exact test); "Gender or age data not available: PVL-positive MSSA (n=l); PVL- 
negative MRSA (n=l); PVL-negative MSSA (n=2)
Information on the clinical infections associated with the S. aureus isolates was 
retrieved from the specimen forms that were attached to the clinical samples, However, 
in 226 cases the information was not specific. Based on the available information more 
isolates (n=140) were identified from mild purulent skin infections e.g. abscesses, ulcers 
and boils, than from device-related/ surgical infections (n=72) and other infections 
(n=81). A statistically significantly higher number o f PVL-positive S. aureus isolates 
were associated with mild purulent skin infections (8 .6 %, 12/140) than all o f the other 
types o f infections (1.8%; 7/379) (p=0.0008; two-tailed Fishers exact test) (see Table 
8.3).
An additional collection o f sixty-one PVL-positive S. aureus isolates was obtained from 
the Specialist Antimicrobial Chemotherapy Unit (SACU). Based on the available 
information a significantly higher number of isolates were associated with purulent skin 
infections, particularly abscesses (44.3%; 27/61) as compared to the other infections 
(p=0.006; two-tailed Fishers exact test) (see Table 8.4). This was comparable to the 
clinical data associated with the PVL-positive S. aureus isolates from the PHW 
Microbiology ABM Laboratory (PHW-ABM).
220
Table 8.3. C linical infections associated w ith the PV L-positive S. a u r e u s  from  PH W -
ABM
In fec tio n P V L  positive P V L  neg a tiv e T o ta l
Abscess, ulcer, boil, folliculitis 
cysts and nodule 1 2  (8 .6 %)* 128 (91.4%) 140
O th e r  in fec tio n s
Medical device related 
& surgical related 1 71 72
Screening swab (eye, groin) 
and other (i.e. infected nail, 
ear)
2 79 81
Not specified- wound swabs 
(arm, leg, abdominal, bum)
4
7(1.8%)*
2 2 2
372 (98.2%)
226
379
Total 19 500 519
*(/?=0.0008; two-tailed Fishers exact test)
T a b le  8.4. Clinical infections associated with the PVL-positive S. aureus from SACU
In fec tio n N o. (% )
Abscesses
Boils
Cellulitis
S u b to ta l
14 (23.0%)
8  (13.1%)
5 (8.2%)
27 (44.3% )*
O th e r  in fec tio n s
Necrosis
Ear discharge, pacemaker, fever, otalgia, screen 
Wound swab (site unknown)
S u b to ta l
Clinical details not available
2 (3.3%)
7 (11.5%)
3 (4.9%)
12 (19.7% )* 
22 (36.0%)
Total 61
*(p=0.006; two-tailed Fishers exact test)
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8.2 Molecular characterisation of the PVL-positive S. aureus
A comparison of the molecular epidemiology of the nineteen PVL-positive isolates
from PHW Microbiology ABM Laboratory (PHW-ABM) and the SACU PVL-positive 
isolates (n=61) was conducted by performing the following assays: mecA PCR, PFGE, 
spa typing, SCCmec typing and detection of the arginine catabolic mobile element 
(ACME) by PCR. There was a significantly higher prevalence of mecA-positive S. 
aureus (57.4%; 35/61) in the SACU isolates in comparison to PHW-ABM mecA- 
positive S. aureus isolates (10.5%, 2/19) (p=0.0004; two-tailed Fishers exact test) (see 
Table 8.5).
Table 8.5. PVL-positive MRSA and MSSA in SACU (n=61) and PHW-ABM (n=19)
____________________ isolates___________
PHW-ABM SACU
*MRSA 2 (10.5%) 35 (57.4%)
MSSA 17(89.5%) 26(42.6%)
Total 19 61
*(p=0.0004; two-tailed Fishers exact test)
8.2.1. Pulsed Field Gel Electrophoresis of the PVL-positive MRSA
PFGE was successfully performed on the PVL-positive MRSA (n=37) isolates (PHW- 
ABM, n=2; SACU, n=35) and thirteen patterns were resolved. Isolates with patterns that 
had <6 band differences were defined as clones, in accordance with the Tenover et al. 
(1995) criteria. The majority (n=16, 43.2%) of the 37 MRSA isolates exhibited the Al 
pattern and one isolate had the A li pattern which had 2-band differences to the former 
(see Figure 8.1). The Al pattern was identical to the PFGE pattern (USA300-0114) of 
two USA300 reference strains (FPR3857 and SF8300 strains), signifying that 16 
(43.2%) of the 37 PVL-positive MRSA were USA300 strains. The patterns termed B l, 
Cl and D1 were displayed by five (13.5%; 5/37), four (10.8%; 4/37) and two (5.4%; 
2/37) isolates respectively (see Figure 8.1).
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M 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 M
291 kb —I 
2 4 2 .5 k b  —
14 5 .5 k b —
4 8 .5 k b —|
' ■------------' A l i  A l  v------- *------- ' B l i  Cl  C l i  '— •— ' v— *— '  ----------- ------------ '
Al  B1 E MRS A- 15  D1 Unique
Figure 8.1. PFGE patterns of twenty SACU PVL-positive MRSA. Lane M, lamda DNA 
marker; lane 1 to 6, Al and A li; lane 7 to 10, B1 and B li; lane 11 and 12, Cl and C li; 
lane 13 and 14, EMRSA-15a and EMRSA-15b; lane 15 and 16, D l; lanes 17 to 20 
unique.
Figure 8.2. PFGE patterns of EMRSA-15 reference strain 
and two SACU PVL-positive MRSA with similar patterns 
(different gels). Lane M, lamda DNA marker; lane 1 and 
2, EMRSA-15 reference strain; lane 3, EMRSA-15a 
pattern; lane 4, EMRSA-15b pattern.
Two isolates exhibited patterns which were similar to the PFGE pattern of the EMRSA- 
15 reference strain (see Figure 8.2). However these had >7 band difference to the 
pattern of the EMRSA-15 reference strain, so the isolates were provisionally affiliated 
to this clone and the patterns were termed EMRSA-15a and EMRSA-15b (see Figure
8.2). The remaining eight (21.6%) isolates had unique PFGE patterns. In summary, five 
clones were evident in the PVL-positive MRSA (n=37), the USA300 clone was the 
most prevalent (43.2%), followed by the B1 (13.5%) and Cl (10.8%) clones, whereas 
the Dl and EMRSA-15 clones were less prevalent. Notably these clones were 
exclusively present in SACU isolates (n=35) as the two PHW-ABMU PVL-positive 
MRSA had unique patterns.
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8.2.2. spa typing of the PVL-positive MRSA
The PVL-positive MRSA (n=37) isolates were successfully typed with the spa typing 
method except for one isolate in which amplification of the targeted sequence was not 
successful. Eighteen spa types were exhibited by the 36 PVL-positive MRSA and the 
prevalent spa types were: t008 (n=12); t044 (n=4); t002 (n=3) and tl27 (n=2) (see Table
8.6). There were also spa types which were evidently closely related to the former types 
albeit single nucleotide differences or the deletion or insertion of spa repeats such as, 
t024, tl 578, tl 624 and t2743 are close variants of spa type t008.
Therefore within the PVL-positive MRSA isolates (n=36): 17 (47.2%) exhibited spa 
type t008 and closely related variants; five (13.9%) had spa type t044 and a closely 
related variant (t4725); four (11.1%) had spa type t002 and a closely related variant 
(t311) and two (5.6%) isolates depicted tl27. The spa types t005 and t223 were also 
closely related, differing by the absence of one repeat unit (rl7) in t223.
Correlation between the spa typing results and the PFGE patterns was evident and 
sixteen isolates which exhibited the t008 spa type or close variants (t024, t l 578, tl624, 
t2743) displayed the USA300-0114 PFGE pattern (see Table 8.6). The five isolates with 
the t044 and t4724 spa types exhibited the B1 PFGE pattern and the three isolates with 
the t002 spa type all had the Cl PFGE pattern. Interestingly, the isolate which was not 
typeable with the spa typing method exhibited a PFGE pattern (C 1.1) which had a <6 
band difference to the Cl pattern (see Table 8.6). The two isolates depicting spa type 
tl27 exhibited the Dl pattern and the isolates with the t005 and t223 spa types depicted 
the EMRSA-15a and EMRSA-15b patterns. However, there were two discrepancies 
between PFGE and spa typing. One isolate with the t008 spa type had a pattern that was 
markedly different (>7 band difference) to the USA300 PFGE pattern (see Table 8.6). 
Also one isolate with the t311 spa type, a close variant of t002 had a PFGE profile that 
was unrelated to the Cl PFGE pattern (see Table 8.6).
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8.2.3. SCCmec typing of the PVL-positive MRSA
The SCCmec typing was successfully performed on all of the 37 PVL-positive MRSA 
isolates and the majority (n=36) of the isolates carried the SCCmec type IV element. 
One isolate contained a SCCmec element that was putatively regarded as a type V (as 
previously discussed in chapter 4) (see Table 8.6). The sub-typing of the isolates (n=36) 
with the SCCmec type IV elements was also performed and they contained: type 
SCCmec type IVa (n=25), IVc (n=10) and IVd (n=l), two isolates contained type IV 
elements which were not sub-typeable with this method (see Table 8.6).
All of the sixteen isolates with the USA300 PFGE pattern and spa type t008 and close 
variant spa types, t024, tl578, tl624, t2743 contained SC Cmec type IVa (see Table
8.6). The one isolate with the t008 spa type and a unique PFGE pattern harboured 
SCCmec type IVc. The five isolates with the B1 PFGE pattern and spa type t044/14725 
also contained SCCmec type IVc (see Table 8.6). Similarly the three isolates with the 
Cl PFGE pattern and the t002 spa type also had and SCC mec type IVc but the isolate 
with t311 spa type (a closely related variant of t002) and a unique PFGE pattern 
contained SCCmec type IVa (see Table 8.6). The two isolates depicting the Dl PFGE 
pattern and spa type tl27 both contained SCCmec type IVa. The two isolates that had 
the EMRSA-15a and b harboured different SCCmec type IV subtypes i.e. type IVa and 
IVc.
8.2.4. Detection of the arginine catabolic mobile genetic element
The eighty PVL-positive S. aureus (MRSA n=37, MSSA n=43) were screened for the 
arginine catabolic mobile element (ACME) by amplification of the arcA gene of ACME 
(arcA-ACME) with PCR. The ACME element was only detected in the sixteen of the 80 
PVL-positive S. aureus isolates, which exhibited the USA300 PFGE pattern, the t008 
spa type (or closely related t024, t l 578, t l 624 and t2743 spa types) and the SCCmec 
type IVa element (see Table 8.6). The two USA300 reference strains (FPR3857 and 
SF8300 strains) were also arcA-KCME positive.
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8.2.5. Pulsed Field Gel Electrophoresis of the PVL-positive MSSA
With the 43 PVL-positive MSSA isolates (SACU n=26; PHW-ABMU, n=17) eighteen 
PFGE patterns were resolved. These included patterns that were related (<6 band 
difference) to those exhibited by the MRSA isolates: Al (A l.li and A l.lii), Cl (C l. 1 i 
and C l.lii) and Dl (D l.li and D l.lii) respectively. Other patterns that were evident 
were termed FI to J l, EMRSA-15c, EMRSA-15d and there were also unique patterns 
(see Table 8.7). The most prevalent pattern was HI (and several related patterns) which 
were exhibited by ten (23.3%; 10/43) of the isolates. Four (9.3%; 4/43) isolates had 
patterns (A l.li and A l.lii) that were related to the PFGE pattern of the USA300 strains 
(see Table 8.7).
8.2.6. spa typing of the PVL-positive MSSA
A diverse array of spa types (n=30) were exhibited by the 43 PVL-positive MSSA and 
there was no particular spa type which was clearly predominant over other types. The 
largest groups contained four MSSA isolates which exhibited the tl 59 and t314 spa 
types respectively and three MSSA isolates depicted the t021 and t211 spa types 
respectively (see Table 8.7).
8.3. 5/nz-BURP analysis of the PVL-positive S. aureus isolates (n=80)
The genetic relatedness of the eighty PVL-positive S. aureus isolates was investigated 
with the j/w-BURP analysis using the Ridom StaphType version 1.5.2.1 software. The 
spa types that were shorter than five repeats were excluded and spa types were placed in 
clusters if costs were < 4 (see Figure 8.3 and 8.4)
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Table 8.7. Genotypic characteristics of the SACU and PHW-ABM MSSA isolates
(n=43)
spa type spa repeat_____________________________No.__________PFGE_________Location______
tl 59 14-44-13-12-17-17-23-18-17 4 HI & H l.ii ABMU & SACU
tl62 14-44-12-17-17-23-18-17 1 H l.i SACU
t645 14-44-13-12-17-23-18-17 1 H l.ii ABMU
tl425 14-44-13-12-17-17 1 HI SACU
t3204 14-44-13-12-17-17-23-23-18-17 1 H l.i SACU
15448 14-44-13-12-17-17-22-18-17 2 H l.i SACU
Subtotal 10 (23.3%)
t314 08-17-23-18-17 4 (9.3%) J1 & Jl.i ABMU & SACU
t021 15-12-16-02-16-02-25-17-24 3 G1 ABMU
t2271 15-12-16-16-02-25-17-24-24 2 G l.l SACU
t6186 (new) 15-12-16-02-16-02-24-24-24-17 2 11 SACU
Subtotal 7 (16.2%)
t019 08-16-02-16-02-25-17-24 1 FI SACU
tl 38 08-16-02-25-17-24 1 FI SACU
Subtotal 2 (4.7%)
t211 11-19-12-12-21-17-34-24-34-22-25 3 A l.l i i SACU
tl635 11-19-12- 21-17-34-25 1 A l . l i SACU
Subtotal 4 (9.3%)
t002 26-23-17-34-17-20-17-12-17-16 1 C l.lii ABMU
tl 05 26-23-17-34-17-20-17-17-16 1 C l.l i SACU
Subtotal 2 (4.7%)
tOO 5 26-23-13-23-31-05-17-25-17-25-16-28 1 EMRSA-15d ABMU
t891 26-23-13-23-31-05-17-25-17-25-28 1 EMRSA-15c ABMU
tl 869 26-23-34-23-31-05-17-25-17-25-16-28 1 EMRSA-15c SACU
Subtotal 3 (7.0%)
t345 26-23-13-21-17-34-34-33-34 1 Unique SACU
t4363(new) 26-23-13-21-17-34-34-24-33-34 1 Unique ABMU
Subtotal 2 (4.7%)
spa type spa  repeat PFGE
t084 07-23-12-34-34-12-12-23-02-12-23 1 Unique ABMU
tl60 07-23-21-24-33-22-17 1 D l . l i SACU
tl 77 26-23-21-16-34-33-13 1 D l.l i i SACU
tl 89 07-23-12-21-17-34 1 Unique ABMU
t903 26-22-19-17-17-20-17-12 1 Unique ABMU
t917 09-02-16-34-13-13-17-34-16-34 1 Unique ABMU
t2393 07-12-21-17-13-13-13-34-33-34 1 Unique SACU
t3011 08-23-16-13-17-34-16-34 1 Unique ABMU
t4791 07-56-16-33-31-57-21-12 1 Unique ABMU
Subtotal 9 (20.8%)
Total 43
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The performance of sp^-BURP cluster analysis on the 80 PVL-positive S. aureus 
isolates demonstrated that eight spa clusters were evident, whereby CC002, CC005, 
CC008, CC159, CC275 were so termed to reflect the postulated ancestral strain of the 
cluster e.g. spa type t002 for CC002 (see Figure 8.3 and 8.4). The remaining clusters 
were defined as cluster 6, cluster 7 and cluster 8 as no ancestral strain was postulated by 
the software. Thirteen spa types were regarded as singletons which indicated that they 
were unrelated to the other PVL-positive S. aureus isolates i.e. t084, 1160, 1189, t202, 
t3 14, t437, t903, t9 17, 11635, t2393, t3011, t4791, t6 187. The t026 spa type which was 
exhibited by one MRSA isolate was excluded from the cluster analysis as it had less 
than five repeats.
tl 869
t005
# t2 2 3
t891
t3204 t645tl 59
CC159
t211
ID
tl 578
t008I
t024 tl 624 
CC008
t2743
t6186
tl 38tO 19
CC2"5
t311 t002 tl 05
• -----□  • ------0  •
CC002
t4363
»  •  t345
tl77  tl 27 
•  #
Cluster 6
Cluster
t4725 t044
Cluster S
Figure 8.3. Minimum spanning trees generated with Ridom StaphType software. 
Circles represent respective spa types and the central circle depicts the spa type 
defined as the founder of the cluster i.e. t005 for spa-CC005. Numerical values on 
branches represent the similarity (distance) between the respective spa types and the 
founder or between the spa types where there is no founder.
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8.4 Genotypes and antibiotic resistance profiles of PVL-positive S. aureus
M R S A  ( n = 3 " ) M S S A  ( n = 4 3 )
Unique to M SSAUnique to M RSA Common to both
108-MRSA-IYi 
17(46% ) 
v (CSA300) /
Ict008
C luster 8
5(14% )
CC002
t002-MRSA-IVc ' 
4(11%) ;
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Miscellaneous
CC 275
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Figure 8.5. Prevalence of PVL-positive MRSA and MSSA isolates within spa-BURP 
clusters (Blue-MRSA, yellow-MSSA).
The s/?tf-BURP cluster analysis demonstrated the genetic relatedness of the isolates but 
the MRSA (n=37) and MSSA (n=43) were distributed within the clusters in different 
proportions (see Figure 8.5). Cluster 7 and CC159 contained only PVL-positive MSSA 
whereas cluster 8 comprised only PVL-positive MRSA strains. The genotypic 
characteristics and the antibiotic resistance profiles of the PVL-positive MRSA and 
MSSA strains within each cluster were further examined.
231
8.4.1 Genotypes and antibiotic resistance profiles of PVL-positive MRSA (n=37)
8.4.1.1 Cluster CC008
The t008 and related spa types were grouped into spa cluster CC008 which comprised 
both MSSA and MRSA (see Figure 8.5). This was the most prominent cluster of the 
PVL-positive MRSA (n=37) comprising seventeen (46.0%; 17/37) MRSA isolates (see 
Table 8.8). The core genotype expressed by the sixteen USA300 strains was t008-(or 
closely related spa types)-MRSA-IVa. Antibiotic susceptibility testing was performed 
with the BD Phoenix and the majority of the strains were resistant to trimethoprim 
(n=12) and erythromycin (n=ll).  Eight were resistant to tobramycin and a few were 
resistant to ciprofloxacin (n=3) and co-trimoxazole (n=2). The remaining MRSA isolate 
depicted the t008 spa type but had a unique PFGE pattern, was ACME negative, carried 
a SCC mec type IVc element and was only resistant to trimethoprim.
8.4.1.2 Cluster 8
Cluster 8 exclusively contained MRSA and it comprised five (13.5%; 5/37) isolates 
with spa types t044 and t4725, they had the t044/ t4725-MRSA-IVc genotype and had 
the same B1 PFGE pattern. All five MRSA strains were resistant to tobramycin and 
trimethoprim but had variable resistance to tetracycline (n=4) and fusidic acid (n=3) 
(see Table 8.8).
8.4.1.3 Cluster 6
Two (5.4%; 2/37) MRSA and one MSSA (depicting spa type tl77) were contained 
within cluster 6 and the two MRSA isolates exhibited the tl27-MRSA-IVa genotype 
and the Dl PFGE pattern (see Figure 8.5). Both of the MRSA isolates were resistant to 
fusidic acid and trimethoprim but only one was resistant to tobramycin (see Table 8.8).
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8.4.1.4 Cluster CC002
The CC002 cluster comprised spa types depicted by both MSSA and MRSA and a total 
o f four (10.8%; 4/37) MRSA isolates were contained in this cluster (see Figure 8.5). 
Three isolates had identical t002-MRSA-IVc genotypes, the Cl PFGE pattern and were 
susceptible to all classes of non p-lactam antibiotics, except for one isolate which was 
resistant to trimethoprim. The other MRSA isolate had spa type t311 which is highly 
similar to t002 but it had a unique PFGE pattern and harboured the SCC mec type IVa 
element. Unlike the former three isolates it had multiple antibiotic resistances i.e. 
tetracycline, trimethoprim and co-trimoxazole (see Table 8.8).
8.4.1.5 Cluster CC005
Cluster CC005 comprised spa types exhibited by both MRSA and MSSA and the two 
(5.4%; 2/37) MRSA displaying t005-MRSA-IVc and t223-MRSA-IVa genotypes were 
included in this cluster (see Figure 8.5). They exhibited the EMRSA-15a and EMRSA- 
15b PFGE patterns respectively and both isolates were resistant to tobramycin, 
trimethoprim and co-trimoxazole. However the t223-MRSA-IVa isolate was also 
resistant to gentamicin whereas the t005-MRSA-IVc isolate was also resistant to 
erythromycin and clindamycin (inducible) (see Table 8.8).
8.4.1.6 Cluster CC275
Two (5.4%; 2/37) MRSA strains with t019-MRSA-IVd and t275-MRSA-IV«/ 
genotypes were contained in cluster CC275 which comprised both MRSA and MSSA 
(see Figure 8.5). However the t019 spa type appeared to be remotely related to the t275 
spa type, the putative ancestral spa type of the cluster. It has a single nucleotide 
substitution in the first repeat: r08 versus rl5  in spa type t275 and exhibits several 
deletions and insertions of repeats. Both of the MRSA isolates were largely susceptible 
to non p-lactam antibiotics with only the t275-MRSA-IV«/ isolate being resistant to 
fusidic acid (see Table 8.8).
8.4.1.7 Miscellaneous
Four (13.5%; 4/37) MRSA had diverse spa types (t026, t202, t437 and t6187) and 
PFGE patterns. Only the t437-MRSA carried a SCCmec type V element whereas the 
other three isolates harboured SC Cmec type IVa elements. These diverse isolates also 
had different antibiotic resistance profiles (see Table 8.8).
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8.4.2 Genotypes and antibiotic resistance profiles of PVL-positive MSSA (n=43)
8.4.2.1 Miscellaneous
Unlike the MRSA isolates which comprised a relatively low prevalence of isolate with 
diverse spa types (10.8%; 4/37), twelve (27.9%; 12/43) MSSA isolates were not 
included in any of the spa clusters and they exhibited the following diverse spa types: 
t084, tl 60, tl 89, t314 (n=4), t903, t917, t2393, t3011, and t4791. They showed variable 
resistance to trimethoprim (n=5), tetracycline (n=4), erythromycin (n=2), clindamycin 
(inducible) (n=2), co-trimoxazole (n=2), tobramycin (n=l), fusidic acid (n=l) (see 
Table 8.9).
8.4.2.2 Cluster CC159
The CC159 cluster only comprised ten MSSA isolates (23.3%; 10/43) (see Figure 8.5) 
and these were characterised by the t l 59 spa type and closely related variants (tl62, 
t645 tl425, t3204 and t5448) and similar HI, Hl.i or Hl.ii PFGE patterns. They were 
extensively resistant to trimethoprim (n=8) but had variable resistance to erythromycin 
(n=4) and clindamycin (inducible) (n=4). A few isolates were resistant to tobramycin 
(n=3), tetracycline (n=2) and co-trimoxazole (n=2) (see Table 8.9).
8.4.2.3 Cluster CC275
Cluster CC275 extensively comprised MSSA isolates (20.9%; 9/43) and only two 
MRSA isolates (see Figure 8.5). The MSSA exhibited the t021 or related spa types 
(t019, t l 38, t2271 and t6186) and the FI, G l, Gl.ii and II PFGE patterns. Two of the 
MSSA with the t019 and t l 38 spa types and had identical FI patterns which were 
remotely related (7 band difference) to the Gl pattern. The nine MSSA were extensively 
resistant to trimethoprim (n=5) but had variable resistance to tobramycin (n=2), 
ciprofloxacin (n=l), tetracycline (n=l), gentamicin (n=l), fusidic acid (n=l) and co- 
trimoxazole (n=l) (see Table 8.9).
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S.4.2A Cluster CC008
In contrast to the MRSA where a considerable number (46.0%; 17/37) of isolates 
belonged to the CC008 cluster, only four (9.3%; 4/43) MSSA belonged to this cluster 
(see Figure 8.5). Three MSSA with spa type t211 and one isolate with spa type tl635 
had similar PFGE patterns (Al.i and Al.ii) which were related (<6 band difference) to 
the USA300 pattern. However, in contrast to the t008-MRSA-IVa isolates, these MSSA 
were largely susceptible to non P-lactam antibiotics, three were resistant to 
erythromycin (n=3) and only one was also resistant to trimethoprim (see Table 8.9).
8.4.2.5 Cluster CC005
Cluster CC005 comprised three (7.0%; 3/43) MSSA isolates with the t005, t891, tl 869 
spa types and the EMRSA-15c PFGE pattern. The isolates with the t005 and t891 spa 
types were resistant to gentamicin, tobramycin, trimethoprim and co-trimoxazole, 
whereas the MSSA depicting tl 869 was only resistant to tobramycin (see Table 8.9).
8.4.2.6 Cluster CC002
Cluster CC002 comprised two (4.7%; 2/43) MSSA exhibiting spa types t002 and tl05 
and the Cl. l i i  and Cl . l i  PFGE patterns. These were largely susceptible to non P-lactam 
antibiotics, both having resistance to trimethoprim and one also resistance to 
tobramycin (see Table 8.9).
8.4.2.7 Cluster 7
Cluster 7 exclusively comprised two (4.7%; 2/43) MSSA isolates with the t345 and 
t4363 spa types. Even though these isolates had related spa types i.e. t4363 differed 
from t345 by one inserted repeat, they had unrelated PFGE patterns. They also had 
different resistance; the t345-MSSA isolate was resistant to trimethoprim and co- 
trimoxazole whereas the t4363-MSSA isolate was susceptible to all non P-lactam 
antibiotics (see Table 8.9).
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8.4.2.8 Cluster 6
Only one (2.3%; 1/43) MSSA isolate was contained in cluster 6 which also comprised 
two MRSA with the tl27-MRSA-IVa genotype. The one MSSA isolate had the t l 77 
spa type which was highly similar to tl27 albeit one nucleotide difference in the first 
repeat. It had a Dl. l i i  PFGE pattern which was similar (<6 band difference) to the Dl 
pattern of the tl27-MRSA-IVa isolates. Furthermore the tl27-MRSA-IVa isolates and 
the tl77-MSSA were similarly resistant to fusidic acid and trimethoprim (see Table 
8.9).
8.5 A comparison of the genotypes of the PVL-positive S. aureus isolates from 
PHW-ABM versus the PVL-positive S. aureus isolates from SACU
The eighty PVL-positive S. aureus isolates were composed of two collections: 
unselected consecutive isolates (n=19) from PHW-ABM and isolates (n=61) referred to 
SACU from microbiology laboratories across Wales. The molecular epidemiology of 
these isolates was compared by assessing the s/?a-clusters represented in both 
collections. The PHW-ABM isolates were distributed into five of the eight clusters i.e. 
CC002 (n=l), CC005 (n=2), CC159 (n=5), CC275 (n=4) and cluster 7 (n=l) and six 
isolates had diverse genotypes. The SACU isolates were distributed into all of the eight 
clusters and CC008 was the most prominent (see Table 8.10 and Figure 8.6). This 
indicated that both collections of PVL-positive S. aureus isolates were polyclonal. Five 
clusters: CC002, CC005, CC159, CC275 and cluster 7 were common to both collections 
of isolates. Notably the CC008 genotype was significantly more prevalent in the SACU 
isolates (p=0.002), whereas the prevalence differences of the other genotypes between 
the two strain collections were not statistically significant (see Table 8.10 see Figure
8.6).
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Table 8.10. Distribution of PHW-ABM (n=19) and SACU (n=60) PVL-positive S. 
aureus in the eight sprt-BURP clusters___________________________________________
PHW-ABM SACU
Cluster Total MRSA MSSA Total MRSA MSSA a/?-value
CC008 0 21 (35.0%) 17 4 p= 0.002
Cluster 6 0 3 (5.0) 2 1 p=  1.000
Cluster 8 0 5 (8.3%) 5 0 /?=0.332
CC002 1 (5.2% ) 0 1 5 (8.3%) 4 1 p=1.000
CC005 2 (10.5%) 0 2 3 (5.0%) 2 1 /?=0.588
CC159 5 (26.3%) 0 5 9 (15.0%) 0 9 /?=0.302
CC275 4 (21.1%) 1 3 7 (11.7%) 1 6 p= 0.205
Cluster 7 1 (5.3%) 0 1 1 (1.8%) 0 1 /?=0.421
Misc. 6 (31.6%) 1 5 6 (10.0%) 3 3 p=0.086
Total 19 2 17 60* 34 26
"p-values by two-tailed Fishers exact test; *one MRSA not typeable with spa typing; Misc- 
miscellaneous*
P H \\
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Figure 8.6. A comparison of clonal complexes according to s/?a-BURP analysis of 
PVL-positive S. aureus from (n=61) and PHW-ABM (n=19) (Blue-MRSA, yellow- 
MSSA).
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8.6. Susceptibility testing of the PVL-positive S. aureus isolates
Susceptibility testing was performed with the BD Phoenix on the PVL-positive S. 
aureus isolates (n=80) and the majority (n=51, 63.8%) were resistant to trimethoprim 
(see Table 8.11). There was extensive resistance to tobramycin (n=29, 36.3%), 
erythromycin (n=22, 27.5%) and variable resistance to tetracycline and co-trimoxazole 
(n=14, 17.5%) respectively. There was low resistance to fusidic acid (n=10, 12.5%), 
gentamicin (n=4, 5.0%) and ciprofloxacin (n=4, 5.0%). The dissociation test (D-test) 
was performed on the erythromycin resistant isolates (n=22) according to the BSAC 
version 9.1, March 2010 methods for antimicrobial susceptibility testing. This revealed 
that eight isolates (36.3%) had inducible resistance to clindamycin and one had 
constitutive resistance to clindamycin (see Table 8.11). Apart from the evident 
statistically significant difference in the prevalence of methicillin resistance between the 
PHW-ABM and SACU isolates, most differences in resistance to non P-lactam 
antibiotics were not statistically significant. There was a statistically significant higher 
number of PHW-ABM isolates which were resistant to tetracycline (42.1% versus 
9.8%) and gentamicin (15.8% versus 1.6%) (p<0.05: two-tailed Fishers exact test) (see 
Table 8.11).
Table 8.11. Antibiotic resistance of PVL-positive S. aureus (n=80)
Antibiotic All (n=80) SACU (n=61) PHW-ABM (n=19)
Oxacillin 45.0% (36) 57.4% (35) 5.3% (1)*
Gentamicin 5.0% (4) 1.6% (1) 15.8% (3)*
Tobramycin 36.3% (29) 41.0% (25) 21.1% (4)
Erythromycin 27.5% (22) 29.5% (18) 21.1% (4)
Clindamycin0 1.3% (1) 0.0% (0) 5.3% (1)
Clindamycin1 10.0% (8) 8.2% (5) 15.7% (3)
Tetracycline 17.5% (14) 9.8% (6) 42.1% (8)*
Trimethoprim 63.8% (51) 67.2% (41) 52.6% (10)
Co-trimoxazole 17.5% (14) 14.8% (9) 26.3% (5)
Ciprofloxacin 5.0% (4) 4.9% (3) 5.3% 0 )
Fusidic acid
* r^\ r\ r ,__ . 'i _ i
12.5% (10) 14.8%• c __ .• (9)
5.3% 0 )__ • i • , ,
* /K 0 .0 5 ;  two-tailed Fishers exact test; Clindamycin -constitutive resistance; Clindamycin- inducible 
resistance.
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8.7. Discussion
In this study 519 consecutive unselected wound swab S. aureus isolates were collected 
from the PHW Microbiology ABM Laboratory from April 2007 to September 2007. By 
real-time PCR, PVL genes were detected in 3.7% (n=19) of these isolates This 
prevalence rate was comparable to the results of a previous investigation on S. aureus 
isolates (n=515) which had been submitted to the UK Staphylococcus Reference Unit 
(SRU) in 2002 (Holmes et al., 2005). In the latter study a subset of every tenth isolate 
received was tested for PVL genes by PCR and a prevalence rate of 1.8% was 
determined. A second collection of 470 isolates was used to determine the distribution 
of PVL genes in different types of staphylococcal infections and 23 (4.9%) were PVL- 
positive. The majority of these isolates (n=15) (p<0.00005) were associated with skin 
and soft tissue infections (SSTIs): abscesses (n=7), cellulitis (n=3), skin lesions (n=3) 
and boils. The remaining isolates were from cases of pneumonia, bum infections, 
bacteraemia and scalded skin syndrome. PVL was not detected in the isolates from 
deep-seated infections e.g. endocarditis, osteomyelitis (Holmes et al., 2005). This was 
similar to the present study whereby a significantly (p=0.0008) higher number of the 
PVL-positive isolates were associated with purulent skin infections as opposed to other 
types of wound infections (see section 8.1.2). However, in the present study the clinical 
information was not very specific in several cases and so the classifications of infection 
types for the isolates may have been less robust than in the study by Holmes et al. 
(2005).
In a later study the prevalence of PVL-positive strains in consecutive bacteraemia 
isolates which were submitted to the UK Staphylococcus Reference Unit in 2005 was 
investigated and only four of the 244 isolates (1.6%) harboured PVL genes (Ellington et 
al., 2007). This suggests that PVL-positive S. aureus are not a significant cause of 
bacteraemia in the UK. In a recent study the prevalence rate of PVL was investigated in 
390 consecutive unselected S. aureus strains isolated from clinical specimens submitted 
to the Royal Free Hampstead NHS Trust in North London (Shallcross et al., 2009). In 
the overall collection 12.6% (n=49) of the isolates harboured PVL genes however, a 
higher prevalence rate (22.6%) was determined in strains isolated from SSTIs and in 
wound infection isolates the rate was 9.2%. In addition the PVL prevalence rate in the 
wound infection isolates (9.2%) was considerably higher than the prevalence rate 
(3.9%) determined in the wound swab isolates of the present study.
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However similar to the present study the PVL-positive S. aureus isolates (n=49) from 
the study by Shallcross et al., 2009, were predominantly MSSA isolates (n=44) whereas 
only five of the isolates were MRSA (Shallcross et al., 2009). From quantitative 
statistical analysis of their clinical data they determined that certain factors were 
independently associated with PVL including: increased duration of hospital stay, male 
gender (which they attributed to increased body hair which may predispose to infection) 
and SSTIs. However, it is debatable if these factors are truly specific to PVL-positive 
strains since they appear to be characteristic features of S. aureus infections in general.
In another study DNA microarrays were used to characterise 155 S. aureus strains 
isolated from nasal swabs of asymptomatic carriers from Saxony Germany (Monecke et 
al., 2009). The microarrays covered 332 target sequences corresponding to distinct 
genes, including virulence genes, antimicrobial resistance markers, superantigens, 
exotoxins, SCCmec, capsule and agr group typing markers. Within the 155 S. aureus 
isolates PVL was detected in one MSSA isolate (0.65%) and mecA was detected in three 
isolates (1.94%), indicating that the prevalence of methicillin resistance and PVL is low 
in S. aureus strains from asymptomatic carriers of Saxony, Germany (Monecke et al., 
2009). However in an earlier study carried out in the same geographical region 30% of 
100 S. aureus strains isolated from SSTIs including abscesses and chronic soft tissue 
infections harboured PVL genes. This indicated a greater association of PVL with S. 
aureus strains isolated from SSTIs rather than asymptomatic nasal carriage (Monecke et 
al., 2009, Monecke et al., 2007). A comparison of the PVL prevalence rate in S. aureus 
strains isolated from nasal swabs of healthy individuals and strains isolated from 
infections was also undertaken in a study conducted in Rotterdam, the Netherlands 
(Melles et al., 2006). In a collection of 1033 S. aureus strains isolated from nasal swabs 
of healthy children (<19 years) and adults (>55yeas) the mecA gene had not been 
identified in any of the isolates, which is indicative of the low MRSA prevalence rate in 
the Netherlands (Melles et al., 2006). Eight hundred and ninety two isolates selected 
from the same collection were used to evaluate the prevalence of PVL in carriage and 
invasive isolates (146 S. aureus strains isolated from blood cultures). Five (1.6%) PVL- 
positive S. aureus strains were identified in the carriage group and three (2.1%) blood- 
culture S. aureus isolates carried PVL genes. However a significantly higher (p<0.0001) 
prevalence rate of PVL (38.9%; 7/18) was reported in 18 strains isolated from SSTIs 
such as abscesses (Melles et al., 2006).
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This was comparable to prevalence rates reported in an earlier study conducted in 
Strasbourg, France (Prevost et al., 1995). In the latter study low PVL prevalence rates 
were reported in 31 nasal carriage S. aureus isolates (0%) and 69 blood culture isolates 
(1.4%) but a higher PVL prevalence rate (23.2%) was reported in 246 S. aureus strains 
which had been isolated from cutaneous infections such as abscesses, furunculosis, 
folliculitis and paronychia (Prevost et al., 1995)
In summary the results of the present study and afore-mentioned studies indicate that 
the prevalence rate of PVL-positive S. aureus is relatively low in the UK and these 
strains are largely methicillin susceptible (Shallcross et al., 2009, Holmes et al., 2005). 
Furthermore the PVL-positive S. aureus strains are extensively associated with purulent 
SSTIs such as abscesses in contrast to invasive infections such as bacteraemia 
(Ellington et al., 2010a, Shallcross et al., 2009, Monecke et al., 2009, Melles et al., 
2006, Prevost et al., 1995). This is markedly different to the situation in the USA where 
it has been reported that the prevalence of the USA300 clone, a PVL-positive CA- 
MRSA is accounting for 59% (range 15% to 74%) of SSTIs among patients seeking 
treatment at accident and emergency departments across USA cities (Edelsberg et al., 
2009).
In this study it was evident that PVL-positive MRSA isolates (n=37) were polyclonal 
and by spa-BURP analysis belonged to eight clusters: CC002, CC005, CC008, CC159, 
CC275, cluster 6, 7 and 8. The majority of the MRSA isolates (n=16, 43.2%) belonged 
to the USA300 clone which constituted the CC008 spa cluster. Other prominent clusters 
were cluster 8 (n=5, 13.5%) and CC002 (n=4, 10.8%) which comprised strains 
exhibiting the t044-MRSA-IV and t002-MRSA-IV genotypes. Previous studies and the 
epidemiological information associated with spa types in the on-line Ridom SpaServer 
Ihttp://spaserver2.ridom.de/spatvpes.shtml) have demonstrated that these genotypes are 
characteristic of the European (ST80-MRSA-IV) and USA800 (ST5-MRSA-IV) clones 
respectively (Deurenberg and Stobberringh, 2008, Larsen et al., 2008, Strommenger et 
al., 2006). The less prominent clusters were cluster 6, CC005 and CC275 which were 
characterised by strains with the following core genotypes: tl27-MRSA-IV; t005- 
MRSA-IV and t019-MRSA-IV. The latter are typically exhibited by strains in the ST1, 
ST22 and ST30 lineages which harbour the USA400 (ST1-MRSA-IV), EMRSA- 
15/Bamim (ST22-MRSA-IV) and Southwest Pacific clones (ST30-MRSA-IV)
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respectively (Deurenberg and Stobberringh, 2008). Therefore these results indicate that 
in addition to the USA300 clone, representative strains of other established CA-MRSA 
clones such as the European, USA800, USA400 and the South-West Pacific clones 
were present.
Other studies have also illustrated the polyclonal epidemiology of PVL-positive MRSA 
isolates in the UK (Ellington et al., 2010b, Ellington et al., 2009, Otter et al., 2009, 
Holmes et al., 2005). These studies include an investigation of 275 PVL-positive MRSA 
isolates from England and Wales which were submitted to the SRU from 2005 to 2006. 
The isolates belonged to eight MLST clonal complexes: CC1, CC5, CC8, CC22, CC30, 
CC59, CC80 and CC88 and the majority belonged to CC80 (32.0%), CC8 (25.5%) and 
CC30 (17.8%) which were characterised by the following genotypes: t044-MRSA-IVc, 
t008-MRSA-IVa and t019-MRSA-IV typical of the European, USA300 and South-West 
Pacific clones (Ellington et al., 2009). This indicated that in contrast to the present 
study, strains related to the European clone were predominant (32% versus 13.5% in 
this study) whereas USA300 strains were less prevalent (25.5% versus 43.2% in this 
study). In another study the molecular epidemiology of 76 PVL-positive MRSA isolates 
with multiple antibiotic resistance, submitted to the SRU from 2005 to 2008 was 
investigated (Ellington et al., 2010b). These isolates belonged to six MLST clonal 
complexes: CC1, CC8, CC22, CC59, CC80 and CC5 however, unlike the previous 
study the CC80 (14.5%) and CC8 (9.2%) lineages were less prevalent and the majority 
of isolates belonged to CC1 (n=29, 38.2%). Interestingly, the latter lineage was 
characterised by strains exhibiting spa type t657 and the SCCmec type VII element. It 
was established that most of those strains were associated with travel to the Bengal Bay, 
mainland India or family links to these regions (Ellington et al., 2010b). Otter et al.
(2009) compared PVL-positive MRSA isolates (n=71) from a hospital in England and a 
hospital in New Haven Connecticut, USA (n=43). They observed marked differences in 
the molecular epidemiology of the two collections. The UK isolates displayed more 
genetic diversity and belonged to several s/?<2 -BURP clusters affiliated to the following 
MLST lineages: ST1, ST5, ST8, ST22, ST59, ST80, ST88 and ST97. The majority 
belonged to the ST1 lineage (n=27, 38%) and only 5.6% of the isolates belonged to the 
ST8 lineage which contained strains with the USA300 PFGE pattern and spa type t008. 
In contrast, only two lineages, ST8 and ST59 were represented in the USA isolates and 
65.1% of the strains belonged the ST8 lineage (Otter et al., 2009).
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Collectively these results demonstrate the polyclonal epidemiology of the PVL-positive 
MRSA isolates in the UK. Certain lineages were commonly identified across the 
respective studies, including the ST80-MRSA-IV (European clone), ST1-MRSA-IV 
(Midwest/US A400), ST5-MRSA-IV (USA800) and ST8-MRSA-IV (USA300) 
lineages. However in contrast to the present study the US A300 strains were not 
predominant in the previous studies (Ellington et al., 2010b, Ellington et al., 2009, Otter 
et al., 2009, Holmes et al., 2005). The differences in the prevalence rates may be due to 
a variety of factors which affect the endemicity, transmissibility and dissemination of 
strains such as genetic background of the strains, patient demographics (including age, 
gender, ethnicity, socio-economic factors), travel history and environmental factors 
(Otter et al., 2009). It is possible that the unusual higher rate of USA300 strains in the 
present study was associated with travel to the USA where these strains are highly 
prevalent. However, this could not be verified due to limited patient history information.
Twenty-eight percent of the PVL-positive MSSA isolates in this study (n=43) had 
diverse genotypes which were not affiliated to any of the ^pa-BURP clusters and the 
remaining isolates belonged to seven of the eight clusters. This indicated the MSSA 
strains were more genetically diverse than the MRSA isolates. The CC159 (23%; 10/43) 
and CC275 (21%; 9/43) spa-BURP clusters were the predominant genotypes in the 
MSSA isolates. The former was characterised by strains exhibiting the tl 59 spa types 
(and closely related variants). This genotype was absent in the MRSA and suggesting 
that although it may be a successful PVL-positive MSSA lineage it remains unreceptive 
to SCCmec elements in this local epidemiological setting. The spa type t l 59 is 
associated with the ST121 lineage which has been extensively associated with MSSA 
rather than MRSA in several studies in different countries like the UK, Denmark, 
China, Cambodia and Thailand (Chheng et al., 2009, Gomes et al., 2006, Holmes et al., 
2005) (http://spaserver2.ridom.de/spatvpes.shtmlT The CC275 genotype was 
characterised by tOl 9, t021 and tl38 spa types which are associated with the ST30 
lineage which harbours the Southwest Pacific CA-MRSA clone (ST30-MRSA-IV) 
(http://spaserver2.ridom.de/spatvpes.shtmn. Therefore these results indicated that the 
majority of the PVL-positive MSSA isolates in this study were affiliated to the ST121 
and ST30 lineages. In a recent study the molecular epidemiology of two collections of 
PVL-positive S. aureus strains from two different geographical regions was compared 
by microarray analysis (Monecke et al., 2007). One collection comprised 30 PVL-
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positive S. aureus strains which had been identified from 100 consecutive isolates 
received at a university hospital in Dresden, Saxony, Germany (Monecke et al., 2007). 
These were predominantly MSSA strains (MSSA n=27; MRSA n=3) and had been 
isolated from SSTIs including abscesses, chronic soft-tissue infection, complicated 
acne, furunculosis and paronychia. The second collection comprised 18 PVL positive 
MSSA strains isolated from abscesses which had been submitted to the SRU in the UK, 
over a 2-year period (2004 to 2006) (Monecke et al., 2007). Even though the collections 
were from two different countries, in both collections the majority of the isolates 
belonged the ST121, ST30 and ST22 clonal lineages (Monecke et al., 2007). This was 
comparable to the present study whereby the CC159 and CC275 spa clusters, associated 
with the ST 121 and ST30 lineages respectively, were predominant in the PVL-positive 
MSSA isolates. Since the UK strains in the former study had been collected from 2004 
to 2006 and the isolates in the present study were collected from April 2007 to 
September 2007, this suggests that the ST121 and ST30 lineages remained predominant 
in UK PVL-positive MSSA strains from 2004 to 2007.
In the present study the CC005 s/ra-cluster genotype was present to the MSSA (7.0%; 
3/43) and MRSA (5.5%; 2/37) isolates but was less prevalent in both sets of isolates. 
These PVL-positive strains exhibited the t005, t223 spa types (and related variants t891 
tl 869) and PFGE patterns that were similar to the EMRSA-15 reference strain. The 
t005 spa type is affiliated to the ST22 lineage which harbours the EMRSA-15/Bamim 
clone (t032-MRSA-IV) a predominant PVL-negative HA-MRSA clone in the UK. It is 
postulated that the PVL-negative t032 strains and the PVL-positive t005 strains evolved 
independently from the ancestral ST22-MSSA lineage (Boakes et al., 2010). Initially 
the t032-MRSA-IV HA-MRSA clone evolved from a PVL-negative ST22-MSSA 
ancestral strain and then the t005-MRSA-IV clone evolved separately after the ancestral 
strain acquired PVL genes (Boakes et al., 2010). Though the t005-MRSA-IV and t032- 
MRSA-IV genotypes are closely related, the latter genotype is evidently advantaged in 
UK hospital settings but apparently remains unreceptive to bacteriophages which carry 
PVL genes, whereas the t005-MSSA/ MRSA genotype seems to provide a more 
selective advantage in community settings (Boakes et al., 2010).
In the UK several studies have been performed on PVL-positive S. aureus isolates that 
have been submitted to reference laboratories (Boakes et al., 2010, Ellington et al.,
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2010b, Ellington et al., 2010a, Ellington et al., 2009, Ellington et al., 2007). However 
these isolates may not sufficiently represent the epidemiology of PVL-positive strains of 
a geographical region as they are often selected based on various underlying factors and 
this may influence the selection of particular genotypes. On the other hand other studies 
have investigated the prevalence and molecular epidemiology of PVL-positive isolates 
submitted to routine clinical laboratories for diagnostic purposes (Otter et al., 2009, 
Rollason et al., 2008, Rossney et al., 2007). In the present study in order to achieve a 
more comprehensive view of the molecular epidemiology of PVL-positive isolates a 
direct comparison of the unselected PHW-ABMU isolates (n=19) and isolates referred 
to SACU (n=61) was performed. Interestingly even though both collections of isolates 
were from Wales, they were markedly different and this was initially indicated by the 
high prevalence rate of methicillin resistance (57.4%; 35/61) in the SACU isolates in 
contrast to the PHW-ABM isolates which were essentially methicillin susceptible 
(89.5%; 17/19). These results are interesting because some of the world-wide 
established CA-MRSA clones are PVL-positive and so it may be presumed that PVL- 
positive strains are predominantly methicillin resistant. Certainly solely based on the 
results of the SACU isolates this also appears to be the case, however, the results of the 
unselected isolates contradict this and imply that PVL-positive isolates in Southwest 
Wales are predominantly MSSA strains. The PHW-ABM and SACU isolates were both 
polyclonal but the existing clones differed in their composition and prevalence rates. A 
distinct difference was the predominance of USA300 strains (26.2%) in the SACU 
isolates (n=61) and yet these strains were completely absent in the unselected PHW- 
ABM isolates. Similarly cluster 8 (8%) and cluster 6 (5%) which were associated with 
the European and USA400 clones were present in the SACU isolates but absent from 
the unselected PHW-ABM isolates. Actually 32% (6/19) of PHW-ABM isolates had 
spa types which were not associated with any of the spa-BURP clusters indicating that 
these were from unrelated genetic backgrounds. The remaining thirteen isolates (68%; 
13/19) were represented by five different spa-BURP clusters which were also present in 
the SACU isolates. These results indicate that despite the high prevalence of established 
CA-MRSA strains, particularly the USA300 clone in the SACU isolates, these were 
absent in unselected isolates from PHW-ABMU. Accordingly this may also imply that 
these clones are infrequent in the PVL-positive S. aureus strains of the Southwest Wales 
region.
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In this study the majority of the PVL-positive S. aureus isolates were resistant to 
trimethoprim (63.8%; 51/80) and a variable number of isolates were resistant to 
tobramycin (36.3%; 29/80) and erythromycin (27.5%; 22/80). Furthermore 10% percent 
of the isolates had inducible clindamycin resistance and one had constitutive resistance. 
Several isolates were also resistant to tetracycline (17.5%; 14/80) and co-trimoxazole 
(17.5%; 14/80). However antibiotic resistance profiles could not be specifically 
affiliated to particular clones in this study. For instance resistance to fusidic acid, 
tetracycline and neomycin has been previously identified as the typical resistance 
profile for the European clone (ST80-MRSA-IV) (Ellington et al., 2009). However in 
this study this profile was not restricted to the t044-MRSA-IV isolates and strains in 
other clusters e.g. CC002, cluster 6 and CC275 also exhibited resistance to fusidic acid, 
tobramycin and tetracycline. These results support the growing concern that multiple 
antibiotic resistance is increasingly exhibited by PVL-positive CA-MRSA strains 
(Higuchi et al., 2010, Ellington et al., 2010b, Coombs et al., 2006).
The UK Health Protection Agency has recommended susceptibility to ciprofloxacin as a 
putative marker for CA-MRSA (Ellington et al., 2010a, Ellington et al., 2010b). In this 
study ciprofloxacin resistance was detected in 5% (n=4) of the eighty isolates; these 
included three US A300 strains (SACU isolates) and one MSSA strain (PHW-ABM 
isolate) which depicted the t021-MSSA genotype. Since the leading CA-MRSA clones 
are PVL-positive, this suggests that ciprofloxacin susceptibility is still a relatively good 
marker for PVL-positive MRSA. However Ellington et al. (2010b) observed 
ciprofloxacin resistance in PVL-positive MRSA strains belonging to several clones in 
the UK i.e. ST1, ST5, ST80, ST22 and ST8. Consequently they suggested that the 
utility of ciprofloxacin susceptibility as a marker is diminishing. Markers based on 
antibiotic resistance or susceptibility may be disingenuous because the acquisition of 
resistance by bacteria is dynamic especially under a selective environments.
The UK Health Protection Agency (HPA) 2008 report - ‘Guidance on the diagnosis and 
management of PVL-associated Staphylococcus aureus infections in England, 2nd 
edition’ - recommends the administration of clindamycin for the treatment of moderate 
SSTIs caused by PVL-positive MSSA. For PVL-positive MRSA the combination of 
rifampicin with either doxycycline, fusidic acid, trimethoprim or clindamycin is 
recommended. The results of this study showed a high prevalence of trimethoprim
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resistance thus suggesting that this drug may be largely ineffective for the treatment of 
SSTIs caused by PVL-positive S. aureus in Wales. The observed variable resistance to 
tetracycline (17.5%; 14/80) suggests that the utility of this class of antibiotics i.e. 
doxycline may also be diminishing. Clindamycin is recommended for severe infections 
by PVL-positive MSSA e.g. deep seated infections and osteomyelitis and has also been 
shown to have some effectiveness in necrotising pneumonia (in combination with 
vancomycin). In this study 10% of the isolates expressed inducible clindamycin 
resistance and one had constitutive resistance, which suggests the possible 
ineffectiveness of this drug in some cases of severe infections. The low resistance to 
fusidic acid, ciprofloxacin, gentamicin and complete susceptibility of all isolates to 
rifampicin, vancomycin, daptomycin, mupirocin and linezolid indicates that these drugs 
remain effective against PVL-positive S. aureus infections in Wales.
In conclusion, this study has been informative as it has enabled the determination of the 
prevalence of PVL-positive strains in Southwest Wales and furthermore granting some 
insight into the molecular epidemiology of these strains in Wales. The results were 
comparable with previous findings in that they indicated that the prevalence rate of 
PVL-positive S', aureus remains low (3.9%). However contrary to an observed high 
prevalence rate of methicillin resistance in isolates that were submitted to the SACU 
reference laboratory, the results of the unselected isolates from PHW Microbiology 
ABM Laboratory suggest that PVL-positive S. aureus strains in Southwest Wales are 
largely represented by genetically diverse MSSA strains.
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Chapter Nine
Identification of Staphylococcus aureus isolates by matrix-assisted laser desorption 
ionization time-of-flight (MALDI-TOF) mass spectrometry
9.0 Introduction
S. aureus is a significant pathogen which typically causes various skin and soft tissue 
infections e.g. abscesses and boils, but can also cause severe infections like bacteraemia 
and necrotising pneumonia. Of particular concern are MRSA strains which are 
associated with increased morbidity and are prevalent in hospital settings in many 
countries world-wide. The implementation of infection control measures is essential for 
the prevention of dissemination of MRSA strains and rapid diagnosis is an integral part 
of infection control. A plethora of phenotypic and molecular diagnostic methods have 
been developed for the identification of S. aureus e.g. conventional culture-based 
phenotypic tests, PCR and sequencing-based methods. In addition mass spectrometry 
has been widely used for the analysis of micro-organisms and the characterisation of 
proteins and peptides. In recent years several studies have demonstrated the capacity of 
matrix-assisted laser desorption ionization time-of-flight (MALDI-TOF) mass 
spectrometry for the identification of bacterial isolates to species level e.g. 
staphylococci, enterobacteria, non-fermentative gram negative rods, listeria, 
pneumococci and anaerobes (Szabados et al., 2010b, Dubois et al., 2009, Nagy et al., 
2009, Rajakaruna et al., 2009, Seng et al., 2009, Barbuddhe et al., 2008, Grosse- 
Herrenthey et al., 2008, Williamson et al., 2008, Carbonnelle et al., 2007).
The flexibility, speed and accuracy of the MALDI-TOF MS assay are key factors in its 
increasing popularity in routine clinical analysis. Either intact bacteria (bacterial 
colonies) or bacterial extracts may be used in the simple set-up procedure which 
involves an initial co-crystallization step of the sample with a radiation-absorbing 
matrix followed by exposure to laser radiation. The resulting ions are directed into a 
flight tube and the time taken by respective ions to arrive at the detector is measured and 
converted to a mass to charge ratio (m/z) (Marvin et al., 2003). This yields a spectrum 
consisting of a series of protein peaks recorded in a mass-to-charge ratio of 2,000 to
20.000 m/z (Dubois et al., 2009, Bittar et al., 2009, Carbonnelle et al., 2007, Jackson et 
al., 2005, Keys et al., 2004).
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The discriminatory capacity of the MALDI-TOF method at a subspecies level and its 
application as a typing technique is a current area of interest and recently Wolters et al.
(2010) demonstrated its potential to discriminate five MRSA lineages e.g. CC5, CC8, 
CC22, CC30 and CC45. Other studies have demonstrated its potential as a typing tool 
for EMRSA-15 and EMRSA-16 strains, Salmonella enterica and Streptococcus species 
(Wolters et al., 2010, Lartigue et al., 2009, Dieckmann et al., 2008, Walker et al., 2002, 
Edwards-Jones et al., 2000). This method has also been applied for the discrimination of 
antibiotic resistant and susceptible strains and the detection of virulence factors in 
bacteria e.g. Panton Valentine-Leukocidin (PVL) in S. aureus (Bittar et al., 2009, 
Majcherczyk et al., 2006, Du et al., 2002, Walker et al., 2002, Edwards-Jones et al., 
2000). However this particular application remains debatable as other studies have 
questioned the stability and reproducibility of previously identified mass ion peaks 
which were recommended as biomarkers for antibiotic resistance or virulence factors 
(Szabados et al., 2010a, Rajakaruna et al., 2009).
In this study S. aureus clinical isolates (n=137) had previously been determined as 
MRSA by using mecA and femAsA real-time PCR methods (results presented in chapter 
3). The isolates were further characterised by PFGE, spa typing and SCCmec typing and 
the following strains were identified: EMRSA-15 (n=122), EMRSA-16 (n=8) and 
unique MRSA strains (n=7) (results presented in chapter 4). By s/?a-BURP analysis 37 
PVL-positive MRSA isolates were shown to belong to eight genotypes including the 
USA300 clone and the t044-MRSA-IV genotype which has been affiliated with the 
European clone. The objective of this study was to explore the MALDI Biotyper 2.0 
System (Bruker Daltonics) with bacterial extracts of S. aureus isolates (n=137), to 
determine the diagnostic sensitivity of the method and to investigate the potential of this 
method for the discrimination of MRSA strains.
2 5 2
9.1 Results
9.1.1 Identification of S. aureus isolates with MALDI-TOF MS method
The generated mass spectra profiles of the respective S. aureus isolates (n=137) were 
automatically analysed by the MALDI Biotyper 2.0 software (Bruker Daltonik, Bremen, 
Germany). The spectra comprised mass ion peaks of varying intensity (see y-axis in 
Figure 9.1) over a broad range of 2000 to 20000 m/z (see x-axis in figure 9.1). The 
assay proved reproducible as shown by high intensity peaks repeatedly present in six 
replicates of the respective extracts (see Figure 9.1).
* 124 002VO_C10\1\1SUn, "Baseline su b t"
* 124 002\0_C12\1\1SUn, "Baseline su b t"
* 124 002\0_C7M\1 SUn, "Baseline su b t"
* 124 002\0_C8\1\1SLin, "Baseline s u b t’
* 124 002V0_C911MSUn, "Baseline su b t"
2000 6 0 0 0 8 0 0 0 10000 120004 0 0 0 1 4 0 0 0 1 6 0 0 0 1 8 0 0 0
Figure 9.1. Mass spectra of six replicates of a bacterial extract of a single S. aureus 
isolate
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The mass ion peaks were automatically evaluated against reference spectra profiles in 
the MALDI Biotyper 2.0 database and log scores were generated based on the 
classification of results into four categories: a log score of >2.3 indicates a highly 
probable species identification, a log score of <2.299 and >2.0 indicates secure genus 
identification, probable species identification, a log score value of <1.999 and >1.7 
indicates probable genus identification, and a log score of <1.699 indicates no reliable 
identification. The isolates (n=137) had been previously identified as S. aureus with the 
femAsA real-time PCR and with the MALDI-TOF method all of the isolates were 
correctly identified at species level, illustrating that the assay had 100% diagnostic 
sensitivity. The mean log score value was 2.47 (standard deviation 0.04), the median log 
score value was 2.48, the lowest and highest log score values were 2.29 and 2.56 
respectively. The mass spectra profile of a randomly selected S. aureus clinical isolate 
(isolate 39) was compared to that of the S. epidermidis strain 1457 and by visual 
comparison there were clear differences between the profiles of the two isolates (see 
Figure 9.2). Within the range of 2000 to approximately 7000 m/z, there was a higher 
peak density of mass ions in the spectra of the S. aureus isolate in contrast to the S. 
epidermidis isolate.
S. epidermidis 1457
Isolate 39
JLl jj*-j ujJbJ ^  LuLjL^-JuL-_jJtL^
Figure 9.2. Raw mass spectra o f S. epidermidis isolate, 1457 (top) and S. aureus isolate, 
39 (bottom).
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Further evaluation of the proportion of mutual mass ion peaks versus unique mass ion 
peaks between the two isolates was carried out by assessing a graphical representation 
generated by the software, as seen in Figure 9.3.a. The green, yellow and red colour 
coding enables identification of mass ion peaks which do or do not match between the 
compared spectra. A comparison of the peaks of the S. aureus isolate 39 and the S. 
epidermidis strain 1457 revealed that the majority of peaks of the S. aureus were not 
present in the S. epidermidis strain (all the peaks of the S. epidermidis strain 1457 are 
depicted in blue and unmatched peaks are depicted in red, see Figure 9.3a). However a 
few peaks were coded in yellow which depicted mass ions that were mutual to both the 
S. aureus and S. epidermidis strains, an indication of the presence of staphylococcal 
genus-specific mass ions (see Figure 9.3a). A subsequent comparison of the peaks of 
two S. aureus strains: isolate 39 (an EMRSA-15 clinical isolate) and the EMRSA-15 
reference strain showed that a majority of mass ion peaks were shared by both isolates 
(peaks depicted in green, see Figure 9.3b) and a few peaks were unique to the each 
strain (peaks depicted in red, see Figure 9.3b).
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9.2 Investigating the potential of MALDI-TOF to discriminate EMRSA-15 and 
EMRSA-16 strains
A comparison of the mass spectra of the EMRSA-15 reference strain and two clinical 
EMRSA-15 strains (isolate 39 and 40) and the EMRSA-16 reference strain and two 
clinical EMRSA-16 strains (isolate 21 and 145) was conducted. There were two high 
intensity peaks (approximately 2000m/z and 7000m/z) which were noticeably present in 
the spectra of the reference and clinical strains, thus representing two common S. aureus 
species-specific mass ions (see Figure 9.4a). However the profiles of the EMRSA-16 
reference and clinical isolates 21 and 145 had a higher peak density within the range of 
2000 to approximately 7000 m/z, illustrating the presence of mass ions which were 
specific to these particular strains but absent in the EMRSA-15 strains (see lower three 
rows in Figure 9.4a).
According to the Tenover et al. 1995 criteria, isolates with PFGE patterns that are 
indistinguishable or that have a <3 band difference are considered closely related and 
belong to a single clone, whereas those with >6 band difference are unrelated. As seen 
in Figure 9.4b isolates 39 and 40 had PFGE patterns with a <3 band difference strains to 
the EMRSA-15 reference strain, signifying that they were strains of this clone. 
Similarly the mass spectra of these two clinical isolates were very similar to the 
EMRSA-15 reference strain (see first three rows in Figure 9.4a). Likewise by PFGE the 
clinical isolates 21 and 145 had patterns which signified that they belonged to the 
EMRSA-16 clone and similarly they had mass spectra profiles which were comparable 
to the EMRSA-16 reference strain. These results suggested that the MALDI-TOF 
method has the capacity to generate S. aureus strain-specific mass ions. Similarly, 
isolates which were designated as EMRSA-15 and EMRSA-16 strains by PFGE, 
exhibited profiles with the MALDI Biotyper 2.0 system which were highly similar to 
the EMRSA-15 and EMRSA-16 reference strains, respectively. This illustrated that 
there was congruence between the two methods and indicated the possibility of 
applying the MALDI-TOF Biotyper 2.0 system as a typing assay for S. aureus.
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9.3 The potential of MALDI-TOF method as a typing tool for S. aureus isolates
To investigate the potential typing capacity of the MALDI-TOF assay the following S. 
aureus clinical isolates belonging to four different clones as previously determined by 
PFGE and spa typing analysis were randomly selected:
• EMRSA-15 clone: clinical strains (n=14) termed EM 15a to EM15n
• EMRSA16 clone: clinical strains (n=7) termed EM 16a to EM16g
• USA300 clone: clinical strains (n=7) termed USA300a to USA300g
• t044-MRSA-IV clinical strains (n=3) termed EUa to EUc
In this study the bacterial extracts were spotted on the target plate six times, so each 
isolate was run in six replicates. Using the MALDI-TOF Biotyper 2.0 software the six 
replicate mass spectra of each respective isolate were compiled into a single main 
spectra profile (MSP) for each. Cluster analysis with the MALDI Biotyper software was 
then performed on the MSPs of the isolates. The EMRSA-15 and EMRSA-16 reference 
strains were also included in the analysis. Initially the analysis was performed on six 
EMRSA-15 (EM 15a to EM15f) and six EMRSA-16 (EM 16a to EM16f) strains and 
these were distributed separately into two distinct clusters in the generated dendrogram 
(see Figure 9.5a). Therefore the clusters defined by the MALDI Biotyper 2.0 system 
were congruent with EMRSA-15 and EMRSA-16 clones as defined by PFGE and spa 
typing, indicating that this method has the potential to distinguish two S. aureus clones.
Six USA300 strains (USA300a to USA300f) were then assessed together with the 
previous EMRSA-15 and EMRSA-16 strains. In the dendrogram two clusters were 
evident at a distance level of 500 (arbitrarily selected). The six USA300 strains were 
designated into one cluster but two EMRSA-15 strains (EM 15c and EM15f) were also 
included in this cluster (see Figure 9.5b). The remaining four EMRSA-15 strains and all 
six EMRSA-16 strains were designated into the second cluster. At a distance level of 
400 three clusters were evident, one cluster contained only EMRSA-15 strains (EM 15a, 
d and e) but there were discrepancies in the other two clusters. One cluster contained all 
of the EMRSA-16 strains and one EMRSA-15 (EM 15b) strain whereas the other 
comprised all of the USA300 strains and two EMRSA-15 strains (EM 15c and f) (see 
Figure 9.5b). Therefore with a larger collection of strains in which three clones were 
represented, cluster analysis by the MALDI Biotyper 2.0 software had less correlation 
to PFGE.
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Figure 9.6. Dendrogram by MALDI Biotyper 2.0 software illustrating cluster analysis 
of S. aureus strains belonging to the EMRSA-15, EMRSA-16, US A300 clones and the 
t044-MRSA-IVgenotype.
Cluster analysis with the MALDI Biotyper 2.0 software was also performed on the raw 
spectra of strains belonging to four clones: EMRSA-15, EMRSA-16, USA300 and 
strains with the t044-MRSA-IV genotype which is associated with the European clone. 
In the generated dendrogram there was evident discrimination of the strains according to 
the four clones and the EMRSA-16 and EMRSA-15 strains were designated into 
separate clusters. However at a cut-off distance level of 500 (arbitrarily selected) the 
USA300 and the t044-MRSA-IV strains constituted a single cluster. Interestingly the 
EMRSA-15 and EMRSA-16 strains are predominant UK HA-MRSA strains whereas, 
the US A300 strains and the t044-MRSA-IV strains are PVL-positive strains which are 
predominantly associated with community-acquired infections. This suggested that the 
MALDI Biotyper 2.0 software had the potential to discriminate four MRSA clones and 
the defined clusters were largely concordant with the clones as defined by PFGE and 
spa typing (see Figure 9.6).
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9.4 Discussion
In this study the MALDI Biotyper 2.0 System was applied to bacterial extracts of 137 S. 
aureus clinical isolates and all of the isolates were correctly identified at species level, 
demonstrating 100% diagnostic sensitivity of the assay. These results are comparable to 
previous studies in which collections of S. aureus and coagulase-negative staphylococci 
were evaluated and identified with excellent accuracy (Szabados et al., 2010b, Dubois et 
al., 2009, Carbonnelle et al., 2007). However lower diagnostic sensitivity values have 
been attained in some recent studies including one study which used MALDI-TOF for 
the analysis of 95 S. aureus isolates and the MicrobeLynx software for the processing of 
the data (Rajakaruna et al., 2009). The isolates were initially analysed with a 2005 
reference database and four isolates were misidentified as Streptococcus pyogenes, S. 
haemolyticus, S. epidermidis and S. warneri. In a subsequent analysis using an updated 
2006 reference database containing additional S. aureus reference spectra, the 
previously misidentified isolates were correctly identified as S. aureus isolates. In 
another study the MALDI Biotyper 2.0 System was used on a collection of diverse 
bacterial species (n=1660) including anaerobic bacteria and 95.4% of the isolates were 
correctly identified (Seng et al., 2009). Similar to the afore-mentioned study, 2.8% of 
the isolates had been misidentified due to the lack of representative spectra in the 
reference database. This illustrates that despite the advantageous speed of the MALDI- 
TOF assay, the diagnostic performance is dependent on an accurate and comprehensive 
reference database because strains which lack representative spectra will not be 
identified.
The typing of S. aureus has revealed existing HA-MRSA and CA-MRSA clonal 
lineages which are endemic in certain geographic regions or have disseminated 
internationally. Currently molecular typing techniques are largely employed for the 
characterisation of isolates e.g. pulsed field gel electrophoresis (PFGE), multi locus 
sequence typing and spa typing. PFGE is the gold standard because of its excellent 
discriminatory power in short-term epidemiology but this technique is laborious and 
inter-laboratory comparison of data is problematic mainly due to methodological 
variations. Therefore the development of alternative discriminatory typing assays with 
an added advantage of speed is desirable. In this study the MALDI Biotyper 2.0 System 
demonstrated the potential to discriminate S. aureus strains. A visual comparison of the 
mass spectra profiles of the EMRSA-15 (n=3) and EMRSA-16 strains (n=3) revealed
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mass-ion peaks which were specific to the respective strains. The application of cluster 
analysis with the MALDI Biotyper 2.0 software to a modest collection of strains (n=14) 
resulted in the clear demarcation of EMRSA-15 and EMRSA-16 strains into two 
separate clusters. This indicated that the two MRSA clones could be distinguished with 
this technique however, subsequent analysis of three or four clones was less precise.
When strains belonging to three clones: EMRSA-15 (n=6), EMRSA-16 (n=6) and 
USA300 (n=6) were analysed two clusters were apparent but one comprised a mixture 
of EMRSA-15 (n=2) and all of the EMRSA-16 strains, whereas the second contained 
two EMRSA-15 and all of the USA300 strains. This implied that increased strain 
diversity and a higher number of strains affected the discriminatory capacity of the 
method and it exhibited reduced correlation to PFGE typing. When the raw spectra of 
strains belonging to four clones were evaluated there was an encouraging indication of 
the discrimination of the four clones. The EMRSA-15, EMRSA-16 strains were 
demarcated into separate clusters however the USA300 and t0440-MRSA-IV strains 
were demarcated into a single cluster. Notably the strains of the latter clones were 
segregated within the single cluster indicating that to some extent the strains were 
distinguished by the software. Nevertheless their demarcation into a single cluster 
indicated that the software recognised a degree of relatedness and this implied that there 
were mass ion peaks which were common to both of the MRSA clones. Interestingly in 
contrast to the EMRSA-15 and EMRSA-16 strains, the USA300 and t0440-MRSA-IV 
strains harboured genes for Panton-Valentin Leukocidin and they are regarded as CA- 
MRSA clones whereas the former are HA-MRSA clones. It is possible that the mass ion 
peak for the PVL toxin may have been one of the distinguishing markers between the 
afore-mentioned HA-MRSA and CA-MRSA clones however, this was not verified in 
this study. In this study the cluster analysis was done on MSPs which had been 
compiled from replicate raw mass spectra profiles. The mass ion peaks were 
reproducible across the replicate spectra however, these were not normalised to 
minimise any spectra: spectra variations. The latter may have caused slight shifts in the 
sizes of the mass ion peaks and it is possible that these may have contributed to the 
ambiguity of the results.
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Recently a more succinct discrimination of five major HA-MRSA genotypes was 
demonstrated with the MALDI-TOF assay (Wolters et al., 2010). The raw mass spectra 
profiles were normalised with the FlexAnalysis software and analysed with the MALDI 
BioTyper 2.0 Software. Twenty-five MRSA clinical isolates which were previously 
identified as belonging to the CC5, CC8, CC22, CC30 and CC45 genotypes were 
analysed and although there were many mass ion peaks which were commonly present 
in all of the genotypes, thirteen mass ion peaks between the 2500 to 7734 m/z range 
distinguished the five genotypes (Wolters et al., 2010). Based on the presence or 
absence of the thirteen mass peaks 60 additional MRSA isolates could be classified into 
fifteen MALDI-TOF types. Subsequent cluster analysis of the peak profiles of the 
fifteen MALDI-TOF types was largely concordant to the five HA-MRSA genotypes 
except for four isolates which belonged to ST80, ST15, ST88 and ST1 clonal lineages 
which were demarcated into a cluster affiliated to the CC5 HA-MRSA genotype 
(Wolters et al., 2010). This study successfully demonstrated a preliminary typing 
application of the MALDI-TOF technique which is robust and rapid for the 
discrimination of five MRSA genotypes.
The rapid detection of methicillin resistance in S. aureus isolates is essential in routine 
clinical diagnosis and several studies have identified mass ion peaks which could be 
used as potential methicillin resistance markers with the MALDI-TOF method. 
Edwards-Jones et al. (2000) applied the MALDI-TOF assay to MRSA (n=7) and MSSA 
(n=7) strains and were able to discriminate the MRSA from MSSA by visual 
comparison of the spectra. In a follow-up study they employed the SPSS for Windows 
version 8.0 statistics package to distinguish EMRSA-15 and EMRSA-16 strains based 
on the peak sizes of mass ions generated with a MALDI-TOF system (Walker et al., 
2002, Edwards-Jones et al., 2000). Similar results were also attained by Du et al. (2002) 
and they demonstrated that the MALDI-TOF and the use of the MicrobeLynx software 
could distinguish MRSA and MSSA strains. They performed a cluster analysis of the 
mass spectra of 76 S. aureus clinical isolates and in the generated dendrogram three 
clusters were evident, two of which largely contained MRSA and one containing only 
MSSA strains. Nevertheless five false positives (MSSA demarcated in an MRSA 
cluster) were observed in their study. However in a recent study which also used the 
MALDI-TOF and the MicrobeLynx software, attempts to identify mass ion peaks which
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could discriminate MRSA and MSSA strains in 134 S. aureus isolates was unsuccessful 
(Rajakaruna et al., 2009).
In another study involving 81 S. aureus isolates two peaks at 4448 m/z and 5302 m/z 
were recommended as potential markers for the presence of the PVL toxin (Bittar et al., 
2009). However in a later study the two recommended peaks were detected in 104 
MRSA isolates irrespective of the presence of PVL (Szabados et al., 2010a). 
Consequently it has been emphasized that prior to the recommendation of certain peaks 
as biomarkers the stability and reproducibility o f the peaks needs to be verified because 
they may become less precise as more wild-type isolates are evaluated (Rajakaruna et 
al., 2009). In support of this assertion Rajakaruna et al (2009) demonstrated that the 
mass spectra profiles of the same isolates grown on different media can be different. 
This was demonstrated in the case of an S. aureus isolate grown on Columbia blood 
agar (CBA) and Chocolate agar (CHOC). Although the composition of CBA and CHOC 
media is similar except for the presence of lysed blood in the latter, the mass spectra 
profiles of the S. aureus isolate exhibited striking differences (Rajakaruna et al., 2009). 
This served to show that different growth culture conditions can affect the expression of 
proteins and consequently the mass spectra profiles. The reproducibility of results with 
the MALDI-TOF method is important and efforts have been undertaken to standardise 
the different stages constituting the preparatory and analysis protocols, including 
bacterial growth conditions, extraction procedures, the concentration of the matrix 
solution and the MALDI settings (Jackson et al. 2005). This is essential as the 
performance of a standardised method across different studies could better facilitate the 
identification of stable peaks which can be applied in the typing of strains or used as the 
markers for the identification of diverse antibiotic or virulence factors in S. aureus.
The results of this study indicate that the MALDI Biotyper 2.0 system is a robust 
method for the identification of S. aureus and these results are consistent with the 
findings of previous studies (Szabados et al., 2010b, Dubois et al., 2009, Carbonnelle et 
al., 2007). There was an encouraging indication of the typing potential of this assay and 
a preliminary capacity to discriminate MRSA clones, however a more comprehensive 
study involving a larger collection of isolates and more scrupulous processing of the 
data is required for the verification of these results and possibly the development of a S. 
aureus typing method with excellent discriminatory power.
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10.0 Conclusion
MRSA are a leading cause of hospital acquired infections (HAIs) in the UK and in 
many countries world-wide. In clinical diagnosis the accurate identification of MRSA is 
vital because the misidentification of MRSA as MSSA could have adverse clinical, 
therapeutic, and emotional effects on the patient and increased financial repercussions 
on the healthcare system. Therefore it is essential that implemented diagnostic tests 
have excellent diagnostic sensitivity, specificity and are rapid, as this could reduce the 
misidentification of MRSA, facilitate faster implementation of infection control 
procedures thereby possibly reducing MRSA transmission, and lead to earlier 
implementation of definite antimicrobial therapy with improved outcomes. Individuals 
who are colonised with MRSA are at greater risk of contracting infections and 
transmitting MRSA, so it is recommended that the screening of patients occurs before 
or during hospital admission. Screening is performed primarily on nasal swabs and also 
on swabs from different anatomical sites i.e. axilla, groin and skin breaks.
The Public Health Wales (PHW) Microbiology ABM Swansea laboratory is the 
diagnostic laboratory for Abertawe-Bro Morgannwg University Health Board with three 
major acute hospitals (approximately 1570 beds) serving a population of approximately 
350000. ABM University Health Board has multiple secondary and tertiary services 
including haematology with regional bone-marrow transplant centre, neonatal ICU sub­
regional centre, cardiac surgery, and the Welsh Centre for Bums and Plastic Surgery. In 
this high volume clinical laboratory, methicillin susceptibility testing is based on 
conventional phenotypic methods including the 1 jig oxacillin disc diffusion assay and 
the BD Phoenix automated microbiology system which incorporates both oxacillin and 
cefoxitin for methicillin susceptibility testing. However these laboratory protocols are 
lengthy i.e. 24 to 72 hours, whereas PCR tests have shorter execution times (2 hours) 
and are generally more sensitive. Therefore the implementation of a PCR assay would 
facilitate the reduction of the turn-around times of results and provide higher accuracy 
in the detection of methicillin resistance in S. aureus. In light of the priority to reduce 
MRSA in hospital-acquired infections in the UK, the rationale of this research was to 
evaluate PCR assays which could be potentially implemented as MRSA screening tests 
in the PHW Microbiology ABM Laboratory in lieu of the currently used phenotypic 
assays in order to facilitate the reduction of turn-around times and increase the accuracy 
of MRSA identification from clinical specimens. However despite the accuracy and
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speed of a candidate PCR assay, clinical laboratories are constrained within financial 
and technical limitations. Therefore in addition to an investigation of the diagnostic 
performance of a candidate assay, the financial and technical implications of 
implementing a recommended assay would also require meticulous review.
The term methicillin resistant specifically refers to strains that carry the mecA gene 
whereas methicillin susceptible refers to strains that do not carry this gene. Accordingly 
the detection of mecA by real-time PCR is the gold standard as this provides 
unequivocal identification of methicillin resistance, whereas the detection of resistance 
to oxacillin and/ or cefoxitin is a surrogate method for the detection of mecA which is 
based on the interpretation of zone diameters or MIC results which are within ranges 
established for methicillin resistance. These assays are based on the assumption that the 
transcription of mecA is strongly induced by these antibiotics and the expression of 
PBP2a directly results in high MICs or narrow (or absent) inhibition zones representing 
methicillin resistance. However there are multiple factors which are involved in the 
regulation of mecA expression and these may result in some MRSA strains exhibiting 
susceptible phenotypes in vitro. In addition non-mecA mediated oxacillin resistance i.e. 
mutations in the binding site of native PBPs or the hyperproduction of penicillinase can 
cause borderline oxacillin resistance phenotypes in mecA-negative S. aureus strains 
(BORSA). Therefore in contrast to the direct detection of the mecA gene by PCR, 
oxacillin or cefoxitin susceptibility tests are not unequivocal methods for the detection 
of wec^-mediated methicillin resistance, as they can result in the misidentification of 
mecA-positive strains as methicillin susceptible or mecA-negative strains as methicillin 
resistant. This hypothesis was examined in chapter 3, by investigating sixteen 
discrepancies between the mecA real-time PCR results and the reported results of the 
PHW Microbiology ABM Laboratory for 137 mecA-positive and 424 mecA-negative 
wound swab S. aureus isolates.
Out of the sixteen discrepancies, twelve of the 137 mecA-positive S. aureus isolates had 
been reported as MSS A and one of the 424 mecA-negative S. aureus had been reported 
as an MRSA. On repeating the lpg  oxacillin disc diffusion assay and antibiotic 
susceptibility testing with the BD Phoenix, eleven of the mecA-positive S. aureus were 
clearly resistant to oxacillin but interestingly three mecA-positive S. aureus isolates 
exhibited methicillin susceptible phenotypes and one isolate had a borderline methicillin
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resistant phenotype. Evidently these cases illustrated the misidentification of MRSA as 
MSSA and ambiguous results with the antibiotic susceptibility assays. The mecA- 
negative S. aureus isolate displayed methicillin susceptibility with the oxacillin disc 
diffusion test and the BD Phoenix but exhibited borderline methicillin resistance with 
the cefoxitin disc diffusion test. This indicated that the mec,4-negative isolate was a 
possible BORSA strain which was subsequently misidentified as a MRSA and this 
represented the misidentification of an MSSA as an MRSA with antibiotic susceptibility 
assays.
An assumption of this study was that the collection of 561 clinical isolates for real-time 
PCR testing had initially been confirmed as S. aureus with the identification tests used 
in the PHW Microbiology ABM Laboratory i.e. an agglutination slide test for clumping 
factor or protein A and the DNase test. Furthermore the subsequent detection of the 
femAs. aureus gene by real-time PCR confirmed that all of the 561 isolates were S. aureus. 
However the audit of the PHW Microbiology ABM Laboratory reported results showed 
that in three of the sixteen discrepant cases, S. aureus had not been reported but rather S. 
epidermidis were reported in two cases and in the third case a Streptococcus species, 
respectively. The reporting of S. epidermidis or Streptococcus species may have been 
due to errors made during the entering of the results into the computerised data system. 
Alternatively S. aureus isolates may have indeed been misidentified with the initial 
phenotypic assays as it is possible for the morphology of S. aureus colonies to be 
misidentified as S. epidermidis or Streptococcus species on certain selective media like 
Columbia Colistin Nalidixic Acid media. Furthermore there are rare S. aureus strains 
that do not express protein A and they would exhibit negative results with protein A 
agglutination slide tests resulting in them being misidentified as coagulase-negative 
staphylococci (CoNS). False-negative results are also possible due to the expression of 
capsular polysaccharides by certain MRSA strains which mask clumping factor and 
protein A. Even though the reason for the reporting of S. epidermidis or Streptococcus 
species was not conclusively determined, these cases provided further examples of the 
possible misidentification of S. aureus isolates with assays that are based on the 
detection of phenotypic markers rather than the direct detection of the S. aureus specific 
genetic determinants with PCR assays.
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A limitation of this study was that the initial phenotypic tests conducted at the PHW 
Microbiology ABM Laboratory and the PCR assays were not done concurrently. 
Therefore the initial cultures on the selective media, the results of the identification tests 
and the oxacillin disc diffusion tests could not be immediately re-evaluated. As a result 
the analysis of the initial phenotypic results was based on an audit of the final reported 
results. Nevertheless, this study highlighted the limitations of exclusively using 
phenotypic susceptibility tests for the detection of mecA-mediated methicillin resistance 
in S. aureus. By repeating the oxacillin, cefoxitin and BD Phoenix susceptibility tests, it 
was evident that there were several MRSA strains and one MSSA isolate with 
borderline methicillin resistance. These represent atypical strains which could be 
misidentified with oxacillin and cefoxitin susceptibility tests. Therefore the molecular 
detection of the mecA gene by PCR is the optimal method for the conclusive detection 
of methicillin resistance in S. aureus and the implementation of this assay in the PHW 
Microbiology ABM Laboratory could facilitate a reduction in the misidentification of 
mecA-positive or mecA-negative S. aureus isolates.
Duplex PCR assays detecting mecA and a S. aureus specific gene e.g. nuc, femA, femB 
or Sa442 have been described for the identification of MRSA from clinical isolates. 
However mecA is not exclusively carried by MRSA, it is also carried by methicillin 
resistant-CoNS (MR-CoNS) species. Since CoNS species such as S. epidermidis, S. 
haemolyticus are common contaminants of non-sterile clinical specimens (e.g. screening 
swabs and wound swabs) these could generate false positive results with the duplex 
PCR assays. Therefore these PCRs are limited to pure clinical isolates or specimens 
from normally sterile sites such as blood cultures. The PHW Microbiology ABM 
Laboratory receives a variety of clinical specimens from both sterile and non-sterile 
sites therefore the performance of a PCR assay that provides conclusive identification of 
MRSA from all specimen types is essential. The mecA gene is located on the SCCmec 
element which integrates at a S. aureus specific locus termed orfX within the 
chromosome. Theoretically the amplification of the junction of the SCCwec right 
extremity and orjX provides an ideal marker for MRSA in both clinical isolates and 
non-sterile clinical specimens. MRSA detection by the amplification of the SCCmec- 
orfX junction was a method initially published by Huletsky et al. (2004) and 
subsequently two additional methods were published by Hagen et al. (2005) and Cuny 
and Witte (2005). These three SCCmec-orJX PCR methods represented candidate tests
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that could be implemented in the PHW Microbiology ABM Laboratory as in-house 
MRSA screening tests which could be performed on both clinical isolates and non- 
sterile clinical specimens. Subsequent to the initial publication of the three SCCmec- 
orfiCYCR. methods, a commercial kit termed the BD GeneOhm MRSA test based on the 
Huletsky et al. (2004) method was approved for MRSA diagnosis in nasal swabs. For 
the purposes of this study, a direct evaluation of the diagnostic performance of the BD 
GeneOhm MRSA test on a collection of nasal swabs was considered, however 
commercial tests are financially costly in a high volume laboratory, whereas an in-house 
MRSA screening test is more economically sustainable. Therefore the evaluation of the 
three original SCCmec-orfX methods as candidate in-house MRSA screening tests was 
pursued in this study.
The disadvantage of the SC Cmec-orfX junction as a surrogate methicillin resistance 
marker is that unlike the mecA gene which is highly conserved in MRSA strains, there 
are diverse SC Cmec types (I to VIII) and there is polymorphism at the SCCmec right 
extremity sequence which forms the junction with orfX. For instance the SCCmec types 
I, II, IV have similar right extremity sequences whereas SCCmec type III and V have 
different sequences. Even though this can be circumvented by the development of 
multiple forward primers which are specific to multiple SCCmec elements, the failure to 
detect novel SC Cmec elements remains a possibility. For instance, when the three 
SC C mec-orflC assays were published in 2004 and 2005, the forward primers were 
specific for target sequences in the right extremity of published SCCmec types I to V 
sequences. However SCC mec types VI, VII and VIII were later described and the 
discovery of further novel SCC mec elements has not been exhausted, consequently 
former SC Cmec-orfX assays would be obsolete. Therefore this presents the underlying 
problem of possible false negative results with some MRSA strains. In addition several 
SCC elements lacking mecA have been described in certain S. aureus strains e.g. 
SC C 4 7 6 , SCCcapl, SCCHg, SCCfur. These elements have characteristic features of 
SCC mec elements i.e. carriage of a ccr gene complex, integration at orfX and flanking 
direct repeats. Therefore the amplification of the junction of the right extremity of these 
elements and orfX could generate false positive results with SCCmec-orfX PCR assays. 
Furthermore the imprecise excision of a SCC mec element may result in the deletion of 
mec A and other structural components of the element but a remnant of the SC  Cmec-
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orfX junction may remain. This may also generate false positive results with a mecA- 
negative S. aureus strains which harbour these remnants.
Therefore although SCCmec-orfiC PCR assays are theoretically ideal assays for the 
identification of MRSA, they can generate false negative results with mec A- positive S. 
aureus strains harbouring novel SCCmec elements and false positive results with mecA- 
negative S. aureus strains harbouring remnant SCC mec-orjX sequences. This hypothesis 
was investigated in chapter five and six by performing three SCC mec-orfX assays re- 
termed the PCR-A, PCR-B and PCR-C methods on 118 (22.7%) MRSA and 401 
(77.3%) MSSA clinical isolates. The mecA PCR was used as the reference method and 
the diagnostic performance of the PCR-A, PCR-B and PCR-C methods was evaluated 
by determining the sensitivity, specificity and predictive values. The MRSA isolates 
with false negative results were investigated for novel SCC mec elements and the MSSA 
isolates with false positive results were investigated for remnant SCC mec-orfX 
sequences, SCC mec associated DNA or possible SCC elements.
In comparison to the mecA PCR the sensitivity results of the PCR-A, PCR-B and PCR- 
C methods were: 96.6%, 96.6%, 95.8% and the specificity results were: 98.3%, 98.3% 
and 97.8% respectively. The positive predictive values (PPV) were 94.2%, 94.2% and 
92.6% respectively and the negative predictive values (NPV) were: 99.0%, 99.0%, and 
98.7% respectively. Out of the three SCCmec-orJX assays the PCR-A and PCR-B 
methods had the best diagnostic performance. Nevertheless, the high performance is not 
guaranteed in routine screening swabs due to the lower prevalence rate of MRSA in 
these clinical specimens. Studies by Maudsley et al. (2004), Grundmann et al. (2002) 
and Abadu et al. (2001) conducted in London, Nottingham and Birmingham 
respectively indicate that in the UK the prevalence of nasal carriage of MRSA in the 
community is very low i.e. 0.78%, 0.83% and 1.5%. Lower prevalence rates would 
affect the predictive values of the SC Cmec-orfX assays because with decreasing 
prevalence rates even though the NPV increases, the PPV decreases, increasing the 
probability of false positive results. Furthermore in this study 2 to 3 colonies of the 
isolates were consistently used in preparation of the template DNA therefore the 
template DNA was maintained at a relatively standard concentration. However in 
clinical specimens the concentration of the target DNA is variable and lower 
concentrations at the detection limit could reduce the sensitivity of the assays when
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performed on clinical specimens. Therefore despite the excellent diagnostic 
performance of the PCR-A and PCR-B methods on clinical isolates, further studies are 
necessary in order to conclusively advocate either of the methods as ideal MRSA 
screening tests for the PHW Microbiology ABM Laboratory. An important future study 
would be an evaluation of the diagnostic performance of these methods on a collection 
of nasal swabs. In addition a comparative analysis of the diagnostic performance and the 
financial costs (reagents, consumables and training of technical staff) of these methods 
versus the commercial BD GeneOhm MRSA test on the collection of nasal swabs 
would also be valuable. The BD GeneOhm MRSA test has only been approved for nasal 
swabs, however MRSA screening often includes swabs from other anatomical sites, 
therefore it would also be valuable to evaluate these methods versus the BD GeneOhm 
MRSA test on a collection of diverse screening swabs either tested separately or pooled.
Four (3.4%) MRSA isolates generated false negative results with the PCR-A, PCR-B 
assays and five (4.2%) were false negatives with PCR-C. Seven (1.7%) MSSA isolates 
generated false positive results with the PCR-A, PCR-B assays whereas nine (2.2%) 
were false positive with PCR-C. Molecular typing of the MRSA isolates with PFGE and 
spa typing demonstrated that the PCR-A and PCR-B false negative isolates were 
genetically related to the EMRSA-15 HA-MRSA clone. This indicated the false 
negative isolates were local endemic strains which were misidentified with the PCR-A 
and PCR-B SCC mec-orfX assays. Although the prevalence of the false negative strains 
was low, the misidentification of these EMRSA-15 subtypes could lead to selection of 
these clones and they would become prevalent through failure to implement infection 
control measures. This is a further factor to be considered prior to the possible 
implementation of either method as MRSA screening tests in lieu of currently 
performed phenotypic tests in the PHW Microbiology ABM Laboratory.
The reason for the lack of amplification of the false negative MRSA was proposed to be 
a frequent deletion of a sequence in the SCC mec-orjX junction which included the 
primer binding sites of the SCCmec-orfX assays. Alternatively a possible inversion of 
the right extremity sequence of SCCmec may have also caused the lack of amplification 
of the SCCmec-orjX sequence. However these proposals could not be verified within 
the duration of this study. In the future this hypothesis could be investigated by 
performing a Southern blot hybridisation assay following Smal-PFGE, with a probe
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spanning from mecA to orjX which could be designed from the SCC mec type IV 
sequence of the published EMRSA-15 genome. The false negative isolates, an EMRSA- 
15 reference strain and several previously successfully amplified clinical EMRSA-15 
strains could be included to ascertain if the size of the Smal fragment containing the 
SCC mec element varies between the false negative isolates. Alternatively, a long-range 
PCR for the amplification of a fragment spanning from mecA to orfiC could be 
performed. Then the mecA-orfX PCR fragment could be sequenced and compared with 
the nucleotide sequences of published SCC mec sequences in order to locate the position 
of the proposed deletion or other mutations in the sequence of the false negative 
isolates.
The typing of S. aureus strains facilitates the determination of the local epidemiology of 
strains, investigations of outbreaks, the transmission of clones and the evolutionary 
history of this bacterial species. Multi Locus Sequence Typing (MLST) has been 
fundamental to the current understanding of the clonal structure of S. aureus, revealing 
that it comprises ten dominant human lineages (CC1, CC5, CC8, CC12, CC15, CC22, 
CC25, CC30, CC45 and CC51) and additional minor lineages (Lindsay, 2010, Feil et 
al., 2003, Enright et al., 2002, Enright et al., 2000). These are referred to by their clonal 
complex (CC) numbers which are defined by the clustering of the sequence types (ST) 
with an electronic algorithm which is Based Upon Related Sequence Types (e-BURST). 
MRSA clones are described by their STs and the SCCmec elements i.e. ST22-MRSA- 
IV (EMRSA-15), ST8-MRSA-IV (USA300 clone). Furthermore their names may also 
give reference to the geographical regions where they are or were highly prevalent, their 
pulsed field gel electrophoresis (PFGE) pattern or where they have caused the most 
severe infections e.g. Midwest clone/ ST1-MRSA-IV, European clone/ST80-MRSA-IV. 
Interestingly even though there are ten dominant human S. aureus clonal lineages, a 
select number of lineages harbour established HA-MRSA clones (CC5, CC8, CC22, 
CC36 and CC45) which have become the leading cause of MRSA infections worldwide. 
The major HA-MRSA clones which belong to these lineages include the: Archaic 
(ST250-MRSA-I/ CC8); Brazilian (ST239-MRSA-III/ CC8); Hungarian (ST239- 
MRSA-III/ CC8); Iberian/ EMRSA-5 (ST247-MRSA-I/ CC8); New York/ Japan (ST5- 
MRSA-II/ CC5); Paediatric/ USA800 (ST5-MRSA-IV/ CC5); Southern Germany 
(ST228-MRSA-I/ CC5); EMRSA-2/ USA500 (ST8-MRSA-IV/ CC8); EMRSA-3 (ST5- 
MRSA-I/ CC5); EMRSA-15 (ST22-MRSA-IV/ CC22) and EMRSA-16/ USA200
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(ST36-MRSA-II/ CC36). Apart from MLST, the clonal lineages can be determined with 
alternative techniques such as DNA microarray analysis and spa typing. DNA 
microarray analysis is a hybridisation method which enables the investigation of the 
expression of diverse genes and the genome structure of tested isolates. Whole genome 
DNA microarrays have been shown to be comparable with MLST for the determination 
of clonal lineages (Lindsay et al., 2006). Similarly with spa typing, the clustering of spa 
types as determined by the BURP algorithm has also been shown to be comparable to 
MLST clonal lineages. The PFGE technique is highly discriminatory and has been 
traditionally used for the typing of S. aureus strains. However it rapidly indexes genetic 
variation so even though it is excellent for outbreak investigations and local 
epidemiological studies it is not suitable for long-term epidemiology investigations. 
Even though MLST is the ideal technique for the characterisation of the respective S. 
aureus clonal lineages it involves multi-locus PCRs and DNA sequencing which is 
financially costly to conduct on a large collection of strains. Similarly DNA microarray 
analysis is a robust technique for the determination of clonal lineages and it generates a 
wealth of data of gene prevalences, however in this study the equipment and expertise 
for PFGE typing, spa typing and SCCmec typing were available in-house and so these 
techniques were performed for the typing of the MRSA isolates.
Interestingly amongst the diversity of HA-MRSA clones world-wide, in the UK HA- 
MRSA infections are extensively caused by the EMRSA-15 and EMRSA-16 clones 
(Boakes et al., 2010, Ellington et al., 2010c, Khandavilli et al., 2009, Johnson et al., 
2005). These clones have consistently accounted for approximately 95% of consecutive 
nosocomial bacteraemia MRSA isolates collected from 2001 to 2007 for a BSAC 
Bacteraemia Surveillance programme (Ellington et al., 2010c, Johnson et al., 2005, 
Moore and Lindsay, 2002). In addition studies by Shore et al. (2010) and Goering et al. 
(2008) in Ireland and Scotland have demonstrated that these clones have outcompeted 
former dominant strains and are currently the predominant HA-MRSA strains in these 
regions. In this study the 561 S. aureus wound isolates (MRSA, n=137; MSSA, n=424) 
were collected from April 2007 to September 2007 from the PHW Microbiology ABM 
Laboratory. Since the EMRSA-15 and EMRSA-16 clones have consistently constituted 
95% of bacteraemia MRSA isolates in the UK from 2001 to 2007, accordingly these 
clones would similarly constitute a significant proportion of MRSA wound isolates 
from the Southwest Wales region within the same period. This hypothesis was
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investigated in chapter 4, by typing of the 137 MRSA wound swab isolates which had 
been collected from April 2007 to September 2007 with the PFGE, spa typing and 
SCCmec typing methods.
Out of the 137 MRSA isolates, 122 (89.1%) MRSA isolates were determined to be 
EMRSA-15 strains, eight (5.8%) were determined to be EMRSA-16 strains and seven 
(5.1%) were diverse MRSA strains. Therefore the EMRSA-15 and EMRSA-16 strains 
collectively accounted for 94.9% (130/ 137) of the wound swab isolates, illustrating that 
the molecular epidemiology of MRSA wound isolates is indeed dominated by these two 
clones. The majority (89.1%) of the MRSA isolates belonged to the EMRSA-15 clone 
and less to the EMRSA-16 clone (5.8%). These proportions were comparable to the 
results by Rollason et al. (2008) for MRSA isolates from skin and soft tissue infections 
of non-hospitalised patients in the West Midlands region. They found that EMRSA-15 
accounted for 87% of the isolates whereas EMRSA-16 accounted for 8% (Rollason et 
al., 2008). The results of this study concur with previous studies which indicate that the 
EMRSA-15 and EMRSA-16 clones have some selective advantage over other HA- 
MRSA clones, which enables them to be more successful at surviving, colonising and 
spreading in the hospitals within the UK (Moore and Lindsay, 2002). This is thought to 
be due to a combination of the virulence factors expressed by the EMRSA-15 and 
EMRSA-16 clones and host factors (Moore and Lindsay, 2002). An investigation of the 
factors(s) facilitating the dominance of the EMRSA-15 and EMRSA-16 in the UK 
would require a comprehensive study investigating a wide range of diverse virulence 
factors expressed by these clones in comparison with other HA-MRSA clones and an 
evaluation of host factors which may also have a role in the dominance of these clones. 
The genome of the MRSA252/ EMRSA-16 strain (accession number BX571856) has 
been published and comparative genomics of EMRSA-15 is currently underway 
(http://www.sanger.ac.uk/resources/downloads/bacteria/staphvlococcus-aureus.html) 
(Holden et al., 2004). Therefore a comparative analysis of their genomes with other 
published HA-MRSA genomes would also grant insight into the success of these clones 
in the UK.
In the 1990s, community associated-MRSA (CA-MRSA) emerged in patients without 
links to health-care units or hospitals; these have increased in prevalence worldwide 
especially in the USA. However a select number of CA-MRSA clones belonging to
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only five major clonal lineages (CC1, CC8, CC30, CC59 and CC80) are the 
predominant causes of community-associated MRSA infections world-wide (DeLeo et 
al., 2010, Lindsay, 2010). Generally CA-MRSA are associated with skin and soft tissue 
infections (SSTIs) especially abscesses. However in 1997 to 1999 a Midwestern strain 
/MW2 with a pulsed field type termed USA400 (ST1-MRSA-IV/ CC1) was implicated 
in four paediatric deaths in Minnesota and North Dakota. In addition the US A300 clone 
(ST8-MRSA-IV/ CC8) has been increasingly implicated in community-acquired 
necrotising pneumonia, indicating that CA-MRSA strains can cause severe invasive 
infections (Hidron et al., 2009, Francis et al., 2005).
The prevalence of CA-MRSA clones varies world-wide, for instance in the USA 
initially both USA400 and US A300 were the dominant CA-MRSA clones. However the 
US A300 clone has become the predominant cause of SSTIs in the community and is 
increasingly a cause of hospital-associated infections (DeLeo et al., 2010). In contrast to 
the USA, in Europe CA-MRSA infections are less prevalent and are characterised by 
clonal heterogeneity (Otter and French, 2010). They have been reported in most 
European countries, including the Netherlands and Nordic countries, which have low 
rates of HA-MRSA (Otter and French, 2010). The most common CA-MRSA strain is 
the European clone (ST80-MRSA-IV/ CC80) but reports of USA300 are increasing. In 
isolates from Norway, collected from 1995 to 2003 from outpatients without any links 
to healthcare facilities, both the US A300 and the European clone were found to be 
prevalent (Hanssen et al., 2005). Similarly in Denmark, the epidemiology of CA-MRSA 
was investigated on a nationwide scale from 1993 to 2004. The isolates were from 
SSTIs in patients outside of hospitals and they extensively belonged to the European 
clone (Larsen et al., 2008). Other established CA-MRSA include the Southwest Pacific/ 
Oceania clone (ST30-MRSA-IV/ CC30) which is postulated to be a descendant of the 
penicillin-resistant 80/81 MSSA clone which was highly prevalent in the 1950’s and 
1960’s. It is prevalent in Australia and has also been reported in Europe and South 
America (DeLeo et al., 2010). The Taiwan clone (ST59-MRSA-Vt / CC59) is the 
predominant CA-MRSA clone in Taiwan and has also been reported in Singapore and 
Malaysia (DeLeo et al., 2010). Other CA-MRSA clones have arisen in Europe, notably 
the ST398-MRSA-V pig-associated clone in the Netherlands and Denmark (Otter and 
French, 2010). The detection of Panton-Valentine Leukocidin (PVL) in USA300 and an 
overwhelming majority of the established CA-MRSA clones led to the speculation that
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PVL has a significant role in CA-MRSA virulence. Even though the direct role of PVL 
is debatable, it is frequently used as a provisional epidemiological marker for CA- 
MRSA (Voyich et al., 2005, Vandenesch et al., 2003). In addition CA-MRSA are also 
characterised by the carriage of the SCCmec type IV or V elements.
Investigations of the molecular epidemiology of CA-MRSA in the UK, specifically 
within the epidemiological setting of this study, Southwest Wales, is essential to 
monitor the transmission of clones and to guide new control initiatives to prevent these 
strains from becoming endemic like the HA-MRSA in the UK. The implications of 
published epidemiological studies seem to suggest that community-associated infections 
are primarily caused by PVL-positive CA-MRSA but this is not a universal trend. In the 
UK, even though the PVL-negative EMRSA-15 and EMRSA-16 clones are a leading 
cause of hospital-acquired infections, MRSA are not a prominent cause of community- 
acquired infections. The prevalence of PVL-positive S. aureus strains is relatively low, 
1.6% - 4.9%, these strains are mainly MSSA and they are polyclonal (Ellington et al., 
2010b, Ellington et al., 2009, Otter et al., 2009, Holmes et al., 2005). In addition PVL- 
positive S. aureus strains are not specifically restricted to community-associated 
infections, they have also been implicated in sporadic hospital-associated outbreaks. For 
instance a PVL-positive MSSA strain was implicated in an outbreak in the maternity 
unit of Derriford hospital, Plymouth, in 2003 (Dyer, 2007). Ten mothers and babies 
were infected and four developed extensive abscesses which needed surgery. In 
September 2006, the PVL-positive ST30-MRSA-IV clone was implicated in an 
outbreak which affected eleven healthcare workers and patients and resulted in the death 
of a nurse and a patient at the University Hospital of North Staffordshire, Stoke-on- 
Trent (Orendi et al., 2010). In December 2006 at the Norfolk and Norwich University 
NHS Trust in East Anglia, a PVL-positive MSSA strain was isolated from six babies in 
a neonatal unit and caused the death of one premature baby (Dyer, 2007).
However published prevalence data and the genetic characterisation of PVL-positive S. 
aureus isolates is primarily from investigations carried out on isolates submitted to the 
UK Staphylococcus Reference Unit. Since reference laboratories primarily receive 
selected isolates this may create a bias for certain clones over others and this may not be 
a true representation of the prevalence and epidemiology of PVL-positive S. aureus 
strains in the UK. In order to attain a comprehensive insight it would be informative to
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investigate the prevalence of PVL genes in unselected consecutive clinical S. aureus 
isolates which are submitted to diagnostic laboratories. This hypothesis was investigated 
in chapter 8, by determining the prevalence of PVL genes by real-time PCR in 
unselected consecutive wound swab S. aureus isolates (n=519) from the PHW 
Microbiology ABM Laboratory (PHW-ABM). Furthermore the molecular 
epidemiology of PVL-positive isolates which have been submitted to a reference 
laboratory could be different to unselected PVL-positive isolates from a diagnostic 
laboratory. This was investigated in chapter 8, by comparing the molecular 
epidemiology of a collection of PVL-positive S. aureus isolates (n=61) from the 
Specialist Antimicrobial Chemotherapy Unit (SACU) in Cardiff which receives isolates 
from microbiology laboratories across Wales and the molecular epidemiology of the 
collection of PVL-positive S. aureus isolates (n=19) from the PHW-ABM laboratory. 
Genotyping of the isolates was conducted by PFGE, spa typing, SCCmec typing and 
detection of the ACME element by PCR. The determination of S. aureus clonal lineages 
was determined by clustering spa types with the BURP algorithm.
By real-time PCR, PVL genes were detected in 3.7% (n=19) of the 519 consecutive 
unselected wound swab S. aureus isolates, only two of the nineteen PVL-positive S. 
aureus were MRSA. This was comparable to the prevalence rate (1.8% to 4.9%) of PVL 
genes in S. aureus isolates (n=515) which had been submitted to the UK 
Staphylococcus Reference Unit (Holmes et al., 2005). The PVL-positive S. aureus 
(n=19) from the PHW-ABM laboratory were distributed into five s/?tf-BURP clusters 
CC002 (n=l), CC005 (n=2), CC159 (n=5), CC275 (n=4) and cluster 7 (n=l), associated 
with the ST5, ST22, ST121 and ST30 lineages and six isolates had diverse genotypes. 
This demonstrated that in the region of Southwest Wales, PVL-positive S. aureus are 
not highly prevalent and they are constituted extensively by polyclonal MSSA and not 
MRSA. The polyclonal nature of the PVL-positive S. aureus was similar to the 
heterogeneity of CA-MRSA strains in mainland Europe but markedly different to the 
situation in the USA where it has been reported that the USA300 clone, accounts for 
59% (range 15% to 74%) of SSTIs among patients seeking treatment at accident and 
emergency departments across USA cities (Edelsberg et al., 2009).
The molecular epidemiology of the unselected consecutive isolates (n=19) from the 
PHW-ABM laboratory and SACU isolates (n=61) showed interesting differences. Even
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though both collections of isolates were from Wales, they were markedly different and 
this was initially indicated by the high prevalence rate of methicillin resistance (57.4%; 
35/61) in the SACU isolates in contrast to the PHW-ABM isolates which were 
essentially methicillin susceptible (89.5%; 17/19). These results are interesting because 
since the leading CA-MRSA clones are extensively PVL-positive, it may be presumed 
that PVL-positive strains are predominantly methicillin resistant. Certainly solely based 
on the results of the SACU isolates this appeared to be the case, however the results of 
the unselected isolates contradict this and imply that PVL-positive isolates in Southwest 
Wales are predominantly methicillin susceptible. Both collections of PHW-ABM and 
SACU PVL-positive S. aureus isolates were polyclonal; however the proportions of 
isolates which belonged to the various S. aureus clonal lineages in both collections were 
variable. A distinct difference was the predominance of USA300 strains (26.2%) in the 
SACU isolates (n=61) and yet these strains were completely absent in the unselected 
PHW-ABM isolates. Similarly cluster 8 (8%) and cluster 6 (5%) which were associated 
with the European and USA400 clones were present in the SACU isolates but absent 
from the unselected PHW-ABM isolates. Actually 32% (6/19) of PHW-ABM isolates 
had spa types which were not associated with any of the s/?tf-BURP clusters indicating 
that these were from unrelated genetic backgrounds. These results indicate that despite 
the presence of established CA-MRSA strains, particularly the US A300 clone in the 
SACU isolates, these were absent in unselected isolates from PHW-ABMU. The 
European clone which is regarded as the prevalent CA-MRSA clone in certain countries 
in mainland Europe, was also notably absent from the PHW-ABM isolates. Accordingly 
this may imply that these clones are infrequent in the PVL-positive S. aureus strains of 
the Southwest Wales region. This suggests that the molecular epidemiology of PVL- 
positive S. aureus in the Southwest Wales region is somewhat unique in comparison to 
mainland Europe and the USA.
This study contributed insights into the molecular epidemiology and prevalence of 
PVL-positive strains in Southwest Wales. The results were comparable with previous 
findings in that they indicated that the prevalence rate of PVL-positive S. aureus 
remains low (3.9%). However contrary to an observed high prevalence rate of 
methicillin resistance in isolates that were submitted to the SACU reference laboratory, 
the results of the unselected isolates from PHW Microbiology ABM Laboratory suggest 
that PVL-positive S. aureus strains in Southwest Wales are largely represented by
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genetically diverse MSSA strains. Differences in the molecular epidemiology and 
prevalence rates of HA-MRSA clones and PVL-positive S. aureus across different 
regions world-wide may be due to a variety of factors which affect the endemicity, 
transmissibility and dissemination of strains. These may include the genetic background 
o f the strains, the virulence genes and accessory genes harboured by strains, patient 
demographics (including age, gender, ethnicity, socio-economic factors), host factors, 
travel history and environmental factors (Otter et al., 2009). For instance it is possible 
that the unusual higher rate o f USA300 strains in the present study in the SACU isolates 
was associated with travel to the USA where these strains are highly prevalent. 
However, this could not be verified due to limited patient history information. 
Nevertheless continual investigations o f the prevalence rates o f HA-MRSA and CA- 
MRSA strains are important for the strategic planning of infection control measures, in 
order to reduce the incidence and transmission o f these strains. Furthermore 
comprehensive genetic characterisation o f these strains is valuable for the further 
understanding o f the epidemiology o f these strains. This will facilitate the identification 
of virulence factors which may be targeted for effective therapeutic strategies.
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